



California Cancer Registry Research Data Dictionary

Revision: March 2021

(Incorporates 2018 data changes)

Prepared By:

California Cancer Reporting and Epidemiologic Surveillance (CalCARES) Program

Institute for Population Health Improvement, UC Davis Health

UCDAVIS
**INSTITUTE FOR POPULATION
HEALTH IMPROVEMENT**



California Cancer Registry Research Data Dictionary

Variable Names by Category

UCDAVIS
INSTITUTE FOR POPULATION
HEALTH IMPROVEMENT

ADMINISTRATIVE

VARIABLE NAME	LABEL / DESCRIPTION
CASEFINDING_STATUS	Casefinding Status
CODPROC	Coding Procedure
FNAME	Name--First
LNAME	Name--Last
MAIDNAME	Name--Maiden
MEDICAREBENEFID	Medicare Beneficiary Identifier
MEDREC1	Medical Record Number-CCR
MIDLNAME	Name--Middle
NOCONTAC	Patient No Contact
PATIENT_ID	Patient ID Number
PAYER	Primary Payer at DX
PAYER2	Pay Source 2
PHONE	Telephone
PROTOCOL	Protocol Participation
RECORD_ORDER	Record Number Recode
SITEFLAG	Reportable Site/Histology Flag
SSNO	Social Security Number
TUMOR_ID	Tumor ID
TYPERP	Type of Reporting Source

California Cancer Registry Data Dictionary



CLINICAL, OTHER

VARIABLE NAME	LABEL / DESCRIPTION
CHRLSON	Charlson Comorbidity Score
COMORBIDCOMPLICATION1-10	Comorbid/Complication 1-10
HEIGHT	Height
SECONDARYDIAGNOSIS1-10	Secondary Diagnosis 1-10
SOURCECOMORBIDITY	Source Comorbidity
TOBACCOUSECIGARETTES	Tobacco Use Cigarettes
TOBACCOUSENOS	Tobacco Use NOS
TOBACCOUSEOTHERSMOKE	Tobacco Use Other Smoke
TOBACCOUSESMOKELESS	Tobacco Use Smokeless
WEIGHT	Weight

California Cancer Registry Data Dictionary



FOLLOW-UP

VARIABLE NAME	LABEL / DESCRIPTION
ADDRCURRENTCOUNTRY	Address Current--Country
CDEATH	Cause of Death
CONADDR	Address Current--No & Street
CONADDR_S	Address Current--Supplemental
CONCITY	Address Current--City
CONSTATE	Address Current--State
CONZIP	Address Current--Postal Code
DATEOFLASTCONTACTFLAG	Date of Last Contact Flag
DATESTAT	Date Cancer Status
DC_FATHERS_SURNAME	DC Fathers Surname
DCBIRTHPL	DC Birthplace
DCFILENO	DC State File Number
DCRACE	DC Race
DCSPANISH	DC Spanish Origin
DCSSNO	DC SSN
DCSTATE	Death File No State
FOLLOWUPCONTACTCOUNTRY	Follow-Up Contact--Country
FUDATE	Date of Last Contact
FUTYPPAT	Follow-Up Last Type Patient
FUTYPTUM	Follow-Up Last Type Tumor
FUYEAR	Year of Last Follow-up or Death
ICDREVISIONNUMBER	ICD Revision Number
SEER_CSDC	SEER Cause Specific COD
SEER_OTHDC	SEER Other COD
STYPEFU	SEER Type of Follow-Up
SURV_DATEDX_RECODE	Survival-Date DX Recode
SURV_DATELC_ACT	Survival-Date Active Follow-up
SURV_DATELC_PSU	Survival-Date Presumed Alive
SURV_FLAG_ACT	Survival-Flag Active Follow-up
SURV_FLAG_PSU	Survival-Flag Presumed Alive
SURV_MON_ACT	Survival-Months Active Follow-up
SURV_MON_PSU	Survival-Months Presumed Alive
TUSTAT	Cancer Status
VITSTAT	Vital Status

GEOGRAPHICAL INFORMATION

VARIABLE NAME	LABEL / DESCRIPTION
BLKGRP00	Census Block 2000
BLKGRP90	Census Block 1990
CENBLOCKGRP2020	Census Block Group 2020
CENSUS00	Census Tract 2000
CENSUS90	Census Tract 1970/80/90
CENSUSBLOCK2010	Census Block 2010
CENSUSCODSYS19708090	Census Coding Sys 1970/80/90
CENSUSTRACT2010	Census Tract 2010
CENSUSTRCERTAINTY2010	Census Tract Certainty 2010
CENTRACT2020	Census Tract 2020
CENTRACTCERT2020	Census Tract Certainty 2020
CENTRD00	Census Tract Certainty 2000
CENTRD90	Census Tract Certainty 1970/80/90
CNTYFIPS	California County FIPS Code
COUNTY	County at DX Reported
COUNTYATDXGEOCODE1990	County at DX Geocode 1970/80/90
COUNTYATDXGEOCODE2000	County at DX Geocode 2000
COUNTYATDXGEOCODE2010	County at DX Geocode 2010
DEN	MSSA 1990, Density
DXSTATEGEO708090	State at DX Geocode 1970/80/90
DXSTATEGEO2000	State at DX Geocode 2000
DXSTATEGEO2010	State at DX Geocode 2010
DXSTATEGEO2020	State at DX Geocode 2020
GISCOORDINATEQUALITY	GIS Coordinate Quality
LATITUDE	Latitude
LONGITUDE	Longitude
MSSAID	Medical Service Study Area Identification Number
MSSANAME	Medical Service Study Area Name
NONRURAL	Rural/Urban Indicator of 1990 MSSA
RANDOM	Random Assignment of Census Tract/Block Group
RESREG	Resident of CCR Reporting Region
RUCA	Rural-Urban Commuting Area
RURALEMSSA90	Rural/Urban Designation of Year 1990 Medical Service Study Areas
RURALEMSSA00	Rural/Urban Designation of Year 2000 Medical Service Study Areas
RURALEMSSA10	Rural/Urban Designation of Year 2010 Medical Service Study Areas

HOSPITAL AND PHYSICIAN

VARIABLE NAME	LABEL / DESCRIPTION
ACOS	ACOS Approved
CASEFIND	Case-finding Source
CLASS	Class of Case
COC_FLAG	CoC Accredited Cancer Program Flag
COCACCREDITEDFLAG	CoC Accredited Flag
DATEADM	Date of 1st Contact
DATEDIS	Date of Inpatient Discharge
DATEIADM	Date of Inpatient Admission
DATEOFINPTADMFLAG	Date of Inpatient Admission Flag
DRATTEND	Physician--Managing
DRFOLLOW	Physician--Follow-Up
DRMEDONC	Physician 4
DROTHER1	Physician Other 1
DROTHER2	Physician Other 2
DRRADONC	Physician 3
DRREF	Physician—Referring
DRSURG	Physician--Primary Surg
HOSPNO	Reporting Facility
NCCN_FLAG	National Comprehensive Cancer Network Flag
NCI_FLAG	NCI-Designated Comprehensive Cancer Center Flag
TYPEADM	Type Admission
VAHOSP	Veteran's Health Administration Facility Flag

PATIENT DEMOGRAPHICS

VARIABLE NAME	LABEL / DESCRIPTION
ADDRATDXCOUNTRY	Address at DX--Country
AGE	Age at Diagnosis
AGECAT	Age Group
BIRTHPLACECOUNTRY	Birthplace--Country
BIRTHPLACESTATE	Birthplace--State
DATEOFBIRTHFLAG	Date of Birth Flag
DCSSN_FLAG	DC SSN Used to Derived Year of Issue
DOB	Date of Birth
DXADDR	Address at DX--No & Street
DXADDR_S	Address at DX--Supplemental
DXCITY	Address at DX--City
DXSTATE	Address at DX--State
DXZIP	Address at DX--Postal Code
HISPSURN	Hispanic Surname on 1980 Census List
HMNGSURN	Hmong Surname Flag
IHSLINK	IHS Linkage Flag
INDUS80	Industry 80
INDUS90	Industry 90
INDUSTRY_CODE	Industry Code
MAIDSURN	Hispanic Maiden Name on 1980 Census List
MARSTAT	Marital Status at DX
NAPIIA	Race--NAPIIA (Derived API)
NHIA	NHIA Derived Hispanic Origin
OCCUP80	Occupation 80
OCCUP90	Occupation 90
OCCUPATION_CODE	Occupation Code
QME	Middle Eastern Surname Flag
RACE1	Race 1
RACE2	Race 2
RACE3	Race 3
RACE4	Race 4
RACE5	Race 5
RACEGROUP	Race/Ethnicity of Patient
RACEME	Race/Ethnicity of Patient with Middle Eastern Category
RELIGION	Religion
SEX	Sex
SPANISH	Spanish/Hispanic Origin
SPANSURN	Computed Ethnicity
SRCSUR	Middle Eastern Surname Source

VIETSURN	Vietnamese Surname Flag
YR_SSNISSUED	Year SSN was Issue

California Cancer Registry Data Dictionary

PROGNOSTIC FACTORS

VARIABLE NAME	LABEL / DESCRIPTION
ADENOIDCYSTICBSLD	Adenoid Cystic Basaloid Pattern
ADENOPATHY	Adenopathy
AFPPOSTORCHRANGE	AFP Post-Orchiectomy Range
AFPPOSTORCHVALUE	AFP Post-Orchiectomy Lab Value
AFPPREINTERP	AFP Pretreatment Interpretation
AFPPREORCHRANGE	AFP Pre-Orchiectomy Range
AFPPREORCHVALUE	AFP Pre-Orchiectomy Lab Value
AFPPREVALUE	AFP Pretreatment Lab Value
ALBUMINPRETXLEV	Serum Albumin Pretreatment Level
ANEMIA	Anemia
BETA2MGPRETXLVL	Serum Beta-2 Microglobulin Pretreatment Level
BILIRUBINPREUNIT	Bilirubin Pretreatment Unit of Measure
BILIRUBINPREVALUE	Bilirubin Pretreatment Total Lab Value
BONEINVASION	Bone Invasion
BRESLOWTHICKNESS	Breslow Tumor Thickness
BSYMPTOMS	B Symptoms
CA125PREINTERP	CA-125 Pretreatment Interpretation
CEAPREINTERP	CEA Pretreatment Interpretation
CEAPREVALUE	CEA Pretreatment Lab Value
CHROMOSOME19QLOH	Chromosome 19q: Loss of Heterozygosity (LOH)
CHROMOSOME1PLOH	Chromosome 1p: Loss of Heterozygosity (LOH)
CHROMOSOME3STATUS	Chromosome 3 Status
CHROMOSOME8QSTAT	Chromosome 8q Status
CREATININEPREUNIT	Creatinine Pretreatment Unit of Measure
CREATININEPREVALU	Creatinine Pretreatment Lab Value
CRMARGIN	Circumferential Resection Margin (CRM)
EXTRAVASCMATRIX	Extravascular Matrix Patterns
FIBROSISSCORE	Fibrosis Score
GESTPROGNOSTINDEX	Gestational Trophoblastic Prognostic Scoring Index
HCGPOSTORCHRANGE	hCG Post-Orchiectomy Range
HCGPOSTORCHVALUE	hCG Post-Orchiectomy Lab Value
HCGPREORCHRANGE	hCG Pre-Orchiectomy Range
HCGPREORCHVALUE	hCG Pre-Orchiectomy Lab Value
HIVSTATUS	HIV Status
IMMUNESUPP	Profound Immune Suppression
INRPROTIME	International Normalized Ratio Prothrombin Time
JAK2	JAK2
KRAS	Prognostic Factors
LDHPOSTORCHRANGE	LDH Post-Orchiectomy Range

California Cancer Registry Data Dictionary



LDHPREORCH RANGE	LDH Pre-Orchiectomy Range
LDHPRETXLEVEL	LDH Pretreatment Level
LDHPRETXVALUE	LDH Pretreatment Lab Value
LDHUPPERNORMAL	LDH Upper Limits of Normal
LN_ITCS	LN Isolated Tumor Cells (ITC)
METHYLATIONO6MGMT	Methylation of O6-Methylguanine-Methyltransferase
MICROVASC DENSITY	Microvascular Density
MITOTICCOUNTUVEA	Mitotic Count Uveal Melanoma
MITOTICRATEMELANO	Mitotic Rate Melanoma
MSI	Microsatellite Instability (MSI)
NCCNIPI	NCCN International Prognostic Index (IPI)
ONCOTYPERISKDCIS	Oncotype DX Risk Level-DCIS
ONCOTYPERISKINVAS	Oncotype DX Risk Level-Invasive
ONCOTYPESCOREDCIS	Oncotype DX Recurrence Score-DCIS
ONCOTYPESCOREINV	Oncotype DX Recurrence Score-Invasive
ORGANOMEGALY	Organomegaly
PERCNTNECROSPOST	Percent Necrosis Post Neoadjuvant
PERINEURALINV	Perineural Invasion
PERIPHBLOODINV	Peripheral Blood Involvement
PSCLERCHOLANGITIS	Primary Sclerosing Cholangitis
RESIDPOSTCYTOREDU	Residual Tumor Volume Post Cytoreduction
SCATCLIN	S Category Clinical
SCATPATH	S Category Pathological
SEERSSF1	SEER Site-Specific Fact 1
ULCERATION	Ulceration

SOCIOECONOMIC INDICATORS

VARIABLE NAME	LABEL / DESCRIPTION
BELOW200	Percent below 200% poverty line in block group, 1988-2005
BELOW200CT	Percent below 200% poverty line in census tract, 1988-2005
BELOW200CTACS2011	Percent below 200% poverty line in census tract, 2006+
BLUECOLR	Proportion 16 yrs+ in block group with blue collar job, 1988-2005
BLUECOLRCT	Proportion 16 yrs+ in census tract with blue collar job, 1988-2005
BLUECOLRCTACS2011	Proportion 16 yrs+ in census tract with blue collar job, 2006+
COLLEGE	Proportion 25 yrs+ in block group with college degree, 1988-2005
COLLECT	Proportion 25 yrs+ in census tract with college degree, 1988-2005
COLLECTACS2011	Proportion 25 yrs+ in census tract with college degree, 2006+
EDINDEX	Average years of schooling in block group, 1988-2005
EDINDEXCT	Average years of schooling in census tract, 1988-2005
EDINDEXACS2011	Average years of schooling in census tract, 2006+
EDINDEXACS2011MOE	Margin of error associated with EDINDEXACS2011
MDINC	Median household income of block group, 1988-2005
MDINCCT	Median household income of census tract, 1988-2005
MDINCCTACS2011	Median household income on census tract, 2006+
MEDRENT	Median gross rent in block group, 1988-2005
MEDRENTCT	Median gross rent in census tract, 1988-2005
MEDRENTCTACS2011	Median gross rent in census tract, 2006+
MEDVALUE	Median value of owner-occupied homes in block group, 1988-2005
MEDVALUECT	Median value of owner-occupied homes in census tract, 1988-2005
MEDVALUECTACS2011	Median value of owner-occupied homes in census tract, 2006+
NOEDUC	Proportion 25+ yrs in block group w/o high school diploma, 1988-2005
NOEDUCCT	Proportion 25+ yrs in census tract w/o high school diploma, 1988-2005
NOEDUCCTACS2011	Proportion 25+ yrs in census tract w/o high school diploma, 2006+
NOJOB	Proportion 16+ yrs in block group who are unemployed, 1988-2005
NOJOBCT	Proportion 16+ yrs in census tract who are unemployed, 1988-2005
NOJOBCTACS2011	Proportion 16+ yrs in census tract who are unemployed, 2006+
QUINYANG	Socioeconomic Status Quintile of Block Group, 2006+
QUINYANGIMPUTED	Socioeconomic Status Quintile of Block Group with Missing Values Imputed, 2006+
QUINYOST	Socioeconomic Status Quintile of Block Group, 1988-2005
YANGRELIABILITY	Reliability of SES Indexes YANGSCL and YANGSCLIMPUTED
YANGSCL	Index of Socioeconomic Status of Block Group, 2006+
YANGSCLIMPUTED	Index of Socioeconomic Status of Block Group with Missing Values Imputed, 2006+
YOSTSCL	Index of Socioeconomic Status of Block Group, 1988-2005

TREATMENT

VARIABLE NAME	LABEL / DESCRIPTION
DATEOFINITIALRXFLAG	Date Initial RX SEER Flag
OTHSUM	RX Summ--Other
RADSEQ	RX Summ--Surg/Rad Seq
RXDATE	Date Initial RX SEER
RXDATEO	RX Date Other
RXDATEOTHERFLAG	RX Date--Other Flag
RXSUMMTREATMENTSTATUS	RX Summ--Treatment Status

TREATMENT, RADIATION

VARIABLE NAME	LABEL / DESCRIPTION
NORAD	Reason for No Radiation
NUMPHASESRTTOVOL	Number of Phases of Rad Treatment to This Volume
PHASEIBEAMTECH	Phase I Radiation External Beam Planning Tech
PHASEIDOSEFRACT	Phase I Dose Per Fraction
PHASEINUMFRACT	Phase I Number of Fractions
PHASEIPRIMTXVOL	Phase I Radiation Primary Treatment Volume
PHASEIRTMODALITY	Phase I Radiation Treatment Modality
PHASEIRTTOLN	Phase I Radiation to Draining Lymph Nodes
PHASEITOTALDOSE	Phase I Total Dose
PHASEIIBEAMTECH	Phase II Radiation External Beam Planning Tech
PHASEIIDOSEFRACT	Phase II Dose Per Fraction
PHASEIINUMFRACT	Phase II Number of Fractions
PHASEIIPRIMTXVOL	Phase II Radiation Primary Treatment Volume
PHASEIIRTMODALITY	Phase II Radiation Treatment Modality
PHASEIIRTTOLN	Phase II Radiation to Draining Lymph Nodes
PHASEIITOTALDOSE	Phase II Total Dose
PHASEIIIBEAMTECH	Phase III Radiation External Beam Planning Tech
PHASEIIIDOSEFRACT	Phase III Dose Per Fraction
PHASEIIINUMFRACT	Phase III Number of Fractions
PHASEIIIPRIMTXVOL	Phase III Radiation Primary Treatment Volume
PHASEIIIRTMODALITY	Phase III Radiation Treatment Modality
PHASEIIIRTTOLN	Phase III Radiation to Draining Lymph Nodes
PHASEIIITOTALDOSE	Phase III Total Dose
RADBSTMOD	Rad Boost RX Modality
RADREGMOD	Rad--Regional RX Modality
RADSUM	RX Summ--Radiation
RTDISCONTEARLY	Radiation Treatment Discontinued Early
RXDATER	RX Date Radiation
RXDATERADIATIONFLAG	RX Date Radiation Flag
TOTALDOSE	Total Dose

TREATMENT, SURGICAL

VARIABLE NAME	LABEL / DESCRIPTION
DATEREGLNDISS	Date Regional Lymph Node Dissection
DATEREGLNDISSFLAG	Date Regional Lymph Node Dissection Flag
DTDEFSURG	RX Date Most Definitive Surgery
DX_STG_SUM	RX SUMM--DX/STG PROC
NNODES	RX Reg LN Examined
NOSURG	Reason for No Surgery
NUMNODESEXAMPARAA	Number of Examined Para-Aortic Nodes
NUMNODESEXAMPELV	Number of Examined Pelvic Nodes
NUMNODESPOSPARAA	Number of Positive Para-Aortic Nodes
NUMNODESPOSPELV	Number of Positive Pelvic Nodes
RXDATEMSTDEFNSRGFLAG	RX Date Most Definitive Surgery Flag
RXDATESURGERYFLAG	RX Date Surgery Flag
RXSUMMSURGICALMARGINS	RX Summ--Surgical Margins
SCOPE	RX Summ--Scope Reg LN Sur
SURGDATE	RX Date Surgery
SURGOTH	Rx Summ--Surg Oth Reg/Dis
SURGPRIM	Rx Summ--Surg Prim Site
SURGRCON	Rx Summ--Reconstruct 1st

TREATMENT, SYSTEMIC

VARIABLE NAME	LABEL / DESCRIPTION
CHEMOSUM	RX Summ--Chemo
DTSYSTEMIC	RX Date Systemic
DTTRANSP	RX Date Transp Endo
HORMSUM	RX Summ--Hormone
IMMUSUM	RX Summ--BRM
RSPNSTONEOADJUVT	Response to Neoadjuvant Therapy
RXDATEBRMFLAG	RX Date BRM Flag
RXDATEC	RX Date Chemo
RXDATECHEMOFLAG	RX Date Chemo Flag
RXDATEH	RX Date Hormone
RXDATEHORMONEFLAG	RX Date Hormone Flag
RXDATEI	RX Date BRM
RXDATESYSTEMICFLAG	RX Date Systemic Flag
RXDATETRANSPLNTENDOCRFLAG	RX Date Transp Endo Flag
RXSUMMSYSTEMICSURSEQ	RX Summ--Systemic Sur Seq
TRANSSUM	RX Summ--Transplnt/Endocr

California Cancer Registry Data Dictionary



TUMOR CHARACTERISTICS / STAGE AT DIAGNOSIS

VARIABLE NAME	LABEL / DESCRIPTION
AJCCED	TNM Edition Number
AMBIGUOUSTERMINOLOGY	Ambiguous Terminology DX
AYARECODE	SEER Site Recode for Adolescents & Young Adults
BASALDIAMETER	Measured Basal Diameter
BEHAVIOR	SEER Behavior Recode for Analysis/WHO 2008
BEYONDCAPSULE	Invasion Beyond Capsule
BRAINMOLMARKERS	Brain Molecular Markers
CS_EXT	CS Extension
CS_LN	CS Lymph Nodes
CS_METS_DX	CS Mets at DX
CS_METS_EVAL	CS Mets Eval
CS_REG_LN_EVAL	CS Lymph Nodes Eval
CS_SITE_SPEC_F1 - CS_SITE_SPEC_F6	CS Site-Specific Factor 1 - CS Site-Specific Factor 6
CS_TS_EXT_EVAL	CS Tumor Size/Ext Eval
CS_TUM_SIZE	CS Tumor Size
CSMETSATDXBONE	CS Mets at DX-Bone
CSMETSATDXBRAIN	CS Mets at DX-Brain
CSMETSATDXLIVER	CS Mets at DX-Liver
CSMETSATDXLUNG	CS Mets at DX-Lung
CSSITESPECIFICFACTOR7 - CSSITESPECIFICFACTOR25	CS Site-Specific Factor 7 - CS Site-Specific Factor 25
CSVERSIONDERIVED	CS Version Derived
CSVERSIONINPUTCURRENT	CS Version Input Current
CSVERSIONINPUTORIGINAL	CS Version Input Original
DATEDX	Date of Diagnosis
DATECONCLUSIVEDXFLAG	Date Conclusive DX Flag
DATEOFCONCLUSIVEDX	Date Conclusive DX
DATEOFDIAGNOSISFLAG	Date of Diagnosis Flag
DATEOFMULTIPLTUMORS	Date of Multiple Tumors
DATEOFMULTTUMORSFLAG	Date of Multiple Tumors Flag
DATESENTINELNBX	Date of Sentinel Lymph Node Biopsy
DATESENTLNBFXFLAG	Date of Sentinel Lymph Node Biopsy Flag
DERIVED_AJCC_FLAG	Derived AJCC Flag
DERIVED_AJCC_M	Derived AJCC-6 M
DERIVED_AJCC_M_DESC	Derived AJCC-6 M Descript
DERIVED_AJCC_N	Derived AJCC-6 N
DERIVED_AJCC_N_DESC	Derived AJCC-6 N Descript
DERIVED_AJCC_STG_GRP	Derived AJCC-6 Stage Grp
DERIVED_AJCC_T	Derived AJCC-6 T
DERIVED_AJCC_T_DESC	Derived AJCC-6 T Descript

California Cancer Registry Data Dictionary



DERIVED_SS1977	Derived SS1977
DERIVED_SS2000	Derived SS2000
DERIVEDAJCC7M	Derived AJCC-7 M
DERIVEDAJCC7MDESCRIPT	Derived AJCC-7 M Descript
DERIVEDAJCC7N	Derived AJCC-7 N
DERIVEDAJCC7NDESCRIPT	Derived AJCC-7 N Descript
DERIVEDAJCC7STAGEGRP	Derived AJCC-7 Stage Group
DERIVEDAJCC7T	Derived AJCC-7 T
DERIVEDAJCC7TDESCRIPT	Derived AJCC-7 T Descript
DERIVEDEOD18M	Derived EOD 2018 M
DERIVEDEOD18N	Derived EOD 2018 N
DERIVEDEOD18STGGP	Derived EOD 2018 Stage Group
DERIVEDEOD18T	Derived EOD 2018 T
DERIVEDSEERCLINSTGGRP	Derived SEER Clin Stg Grp
DERIVEDSEERCMBMSRC	Derived SEER Combined M Source
DERIVEDSEERCMBNSRC	Derived SEER Combined N Source
DERIVEDSEERCMBSTGGRP	Derived SEER Combined Stage Group
DERIVEDSEERCMBTSRC	Derived SEER Combined T Source
DERIVEDSEERCOMBINEDM	Derived SEER Combined M
DERIVEDSEERCOMBINEDN	Derived SEER Combined N
DERIVEDSEERCOMBINEDT	Derived SEER Combined T
DERIVEDSEERPATHSTGGRP	Derived SEER Path Stg Grp
DERIVEDSUMMARYSTAGE2018	Derived Summary Stage 2018
DIFFERN2	Grade
DIREXTTU	EOD--Extension
DRXTTU_P	EOD--Extension Prost Path
DXCONF	Diagnostic Confirmation
ENECLINHN	Extranodal Extension Head and Neck Clinical
ENECLINNOTHN	Extranodal Extension Clin (Non-Head and Neck)
ENEPATHHN	Extranodal Extension Head and Neck Pathological
ENEPATHNOTHN	Extranodal Extension Path (non-Head and Neck)
EODMETS	EOD Mets
EODPRIMARYTUMOR	EOD Primary Tumor
EODREGNODES	EOD Regional Nodes
ERPERCENTPOSORRNG	Estrogen Receptor Percent Positive or Range
ERSUMMARY	Estrogen Receptor Summary
ERTOTALALLRED	Estrogen Receptor Total Allred Score
ESOPHEPICENTER	Esophagus and EGJ Tumor Epicenter
FIGOSTAGE	FIGO Stage
GLEASONPATCLIN	Gleason Patterns Clinical
GLEASONPATPATH	Gleason Patterns Pathological

California Cancer Registry Data Dictionary



GLEASONSCORECLIN	Gleason Score Clinical
GLEASONSCOREPATH	Gleason Score Pathological
GLEASONTERTIARYPT	Gleason Tertiary Pattern
GRADECLIN	Grade Clinical
GRADEPATH	Grade Pathological
GRADEPATHSYSTEM	Grade Path System
GRADEPATHVALUE	Grade Path Value
GRADEPOST	Grade Post Therapy
HER2IHCSUMMARY	HER2 IHC Summary
HER2ISHDUALNUM	HER2 ISH Dual Probe Copy Number
HER2ISHDUALRATIO	HER2 ISH Dual Probe Ratio
HER2ISHSINGLENUM	HER2 ISH Single Probe Copy Number
HER2ISHSUMMARY	HER2 ISH Summary
HER2OVERALLSUMM	HER2 Overall Summary
HERITABLETRAIT	Heritable Trait
HIGHRISKCYTOGENET	High Risk Cytogenetics
HIGHRISKHISTFEAT	High Risk Histologic Features
HISTO_M2	Behavior (92-00) ICD-O-2
HISTO_M3	Behavior Code ICD-O-3
HISTO_T2	Histology (92-00) ICD-O-2
HISTO_T3	Histology Type ICD-O-3
ICCCWHO	SEER ICCR Recode/WHO 2008, Extended Class.
IPSIADRENALINVOLV	Ipsilateral Adrenal Gland Involvement
KI67	KI-67
KITGENEIHIC	KIT Gene Immunohistochemistry
LATERAL	Laterality
LNDISTANTMETHOD	LN Distant Assessment Method
LNDISTMEDIASSCALN	LN Distant, Mediastinal, Scalene
LNFEEMINGPARAAPELV	LN Status Femoral-Inguinal, Para-Aortic, Pelvic
LNHNLEVELSI_III	LN Head and Neck Levels I-III
LNHNLEVELSIV_V	LN Head and Neck Levels IV-V
LNHNLEVELSOTHER	LN Head and Neck Other
LNHNLEVELSVI_VII	LN Head and Neck Levels VI-VII
LNLATRALITY	LN Laterality
LNMETHODFEMING	LN Assessment Method Femoral-Inguinal
LNMETHODPARAAORT	LN Assessment Method Para-Aortic
LNMETHODPELVIC	LN Assessment Method Pelvic
LNPOSAXLEVELSI_II	LN Positive Axillary Level I-II
LNSIZE	LNSIZE
LNSUMTU	EOD--Lymph Node Involvement
LYMPHOCYTOSIS	Lymphocytosis

California Cancer Registry Data Dictionary



LYMPHVASCULARINVASION	Lymphovascular Invasion
MAJORVEININVOLV	Major Vein Involvement
MARKER1	Tum Markers 1
MARKER2	Tum Markers 2
MARKER3	Tum Markers 3
MARKERCA	Tum Markers CA 1
MCODE	EOD Recode of M Code for TNM
METSATDXBONE	Mets at DX-Bone
METSATDXBRAIN	Mets at DX-Brain
METSATDXDISTANTLN	Mets at DX-Distant LN
METSATDXLIVER	Mets at DX-Liver
METSATDXLUNG	Mets at DX-Lung
METSATDXOTHER	Mets at DX-Other
MULTIGENEMETHOD	Multigene Signature Method
MULTIGENERESULTS	Multigene Signature Results
MULTIPLICITYCOUNTER	Multiplicity Counter
MULTTUMRPTASONEPRIM	Multiple Tumor Reported As One Primary
NCODE	EOD Recode of N Code for TNM
NPCRDERIVEDCLINSTGGRP	NPCR Derived Clin Stg Grp
NPCRDERIVEDPATHSTGGRP	NPCR Derived Path Stg Grp
NUMCORESEXAM	Number of Cores Examined
NUMCORESPOS	Number of Cores Positive
PEDCODER	Pediatric Staged By
PEDSTAGE	Pediatric Stage
PEDSYS	Pediatric Staging System
PERITONEALCYTOL	Peritoneal Cytology
PLEURALEFFUSION	Pleural Effusion
PLEURALINV	Visceral and Parietal Pleural Invasion
PNODETU	Regional Nodes Positive
PROSTATEPATHEXT	Prostate Pathological Extension
PRPERCENTPOSORRNG	Progesterone Receptor Percent Positive or Range
PRSUMMARY	Progesterone Receptor Summary
PRTOTALALLRED	Progesterone Receptor Total Allred Score
PSAVALUE	PSA (Prostatic Specific Antigen) Lab Value
RXDATEDXSTGPROCFLAG	RX Date DX/Stg Proc Flag
RXDATESN	RX Date DX/Stg Proc
SARCOMATOID	Sarcomatoid Features
SCHEMADISC1	Schema Discriminator 1
SCHEMADISC2	Schema Discriminator 2
SCHEMADISC3	Schema Discriminator 3
SCHEMAID	Schema ID

California Cancer Registry Data Dictionary



SEERWHO	SEER Site Recode ICD-O-3/WHO 2008
SENTINELNODESEXAM	Sentinel Lymph Nodes Examined
SENTINELNODESPOS	Sentinel Lymph Nodes Positive
SEPNODULES	Separate Tumor Nodules
SEQNOCEN	Tumor Characteristics/Stage at Diagnosis
SITE_02	Primary Site
STAGE	Combined AJCC Variable
STAGE_SEER	Combined AJCC Variable with SEER Modifications
SUMMARYSTAGE2018	Summary Stage 2018
SUMSTAGE	Combined SEER Summary Stage
TCODE	EOD Recode of T Code for TNM
THICKNESS	Measured Thickness
THROMBOCYTOPENIA	Thrombocytopenia
TNM_CODER_CLINICAL	TNM Clin Staged By
TNM_CODER_PATH	TNM Path Staged By
TNM_M_CODE_CLINICAL	TNM Clin M
TNM_M_CODE_PATH	TNM Path M
TNM_N_CODE_CLINICAL	TNM Clin N
TNM_N_CODE_PATH	TNM Path N
TNM_STAGE_CLINICAL	TNM Clin Stage Group
TNM_STAGE_PATH	TNM Path Stage Group
TNM_T_CODE_CLINICAL	TNM Clin T
TNM_T_CODE_PATH	TNM Path T
TNMCLINDESCRIPTOR	TNM Clin Descriptor
TNMPATHDESCRIPTOR	TNM Path Descriptor
TSIZETU	EOD--Tumor Size
TUMORDEPOSITS	Tumor Deposits
TUMORGROWTHPAT	Tumor Growth Pattern
TUMORSIZE	Combined Tumor Size Variable
TUMORSIZECLINICAL	Tumor Size Clinical
TUMORSIZEPATHOLOGIC	Tumor Size Pathologic
TUMORSIZESUMMARY	Tumor Size Summary
XNODETU	Regional Nodes Examined
YEARDX	Year of Diagnosis



California Cancer Registry Research Data Dictionary

Variables, Definitions, and Allowable Values

UCDAVIS
INSTITUTE FOR POPULATION
HEALTH IMPROVEMENT

California Cancer Registry Data Dictionary

Variable Name: ACOS

Eureka Name: ACOS Approved

NAACCR Item: N/A

Category: Hospital and Physician

Level of Variable: Admission

Time Period Available: 1999 - 2017

Related Variables: CoC Accredited Flag (COCACCREDITEDFLAG)

Definition: Flag which indicates whether the reporting facility, with the earliest date of admission, has an ACOS-approved cancer program. Because of fluctuations in the ACOS status of hospitals, the quality of this variable is uncertain. Further information on the ACOS status of hospitals can be found at the American College of Surgeons website (www.facs.org). For cases diagnosed 2018 and forward, this information is captured in the field COCACCREDITEDFLAG.

Values:

- 1: Cancer program approved
- 2: Cancer program not approved
- Blank: Cases diagnosed or transmitted prior to 1999 or after 2017. Cases diagnosed or transmitted before 1999 or after 2017 that were not set to missing are considered invalid.

California Cancer Registry Data Dictionary

Variable Name: ADDRATDXCOUNTRY

Eureka Name: Addr at DX--Country

NAACCR Item: 102

Category: Patient Demographics

Level of Variable: Tumor

Time Period Available: 1988 – current year

Related Variables:

- Addr at DX--No & Street (DXADDR)
- Addr at DX--Supplemental (DXADDR_S)
- Addr at DX--City (DXCITY)
- Addr at DX--State (DXSTATE)
- Addr at DX--Postal Code (DXZIP)

Definition: Country code for the address of the patient's residence at the time the tumor was diagnosed. If the patient has multiple tumors, the country of residence may be different for each tumor.

Values: See Volume 1, Appendix C.1: [Volume I, Appendix C- Codes for Countries C.1 – Alphabetical and C.2 – Code Order](#)

California Cancer Registry Data Dictionary

Variable Name: ADDRCURRENTCOUNTRY

Eureka Name: Addr Current--Country

NAACCR Item: 1832

Category: Follow-Up

Level of Variable: Patient

Time Period Available: 1988 – current year

Related Variables:

- Address Current--No & Street (CONADDR)
- Addr Current--Supplemental (CONADDR_S)
- Addr Current--City (CONCITY)
- Addr Current--State (CONSTATE)
- Addr Current--Postal Code (CONZIP)

Definition: Country code for the address of patient's current usual residence. If the patient has multiple tumors, the current country of residence should be the same for all tumors.

Values: For complete list of allowable values and their definitions, see "Cancer Reporting in California, California Cancer Reporting System Standards, [Volume I, Appendix C- Codes for Countries C.1 – Alphabetical and C.2 – Code Order](#)

California Cancer Registry Data Dictionary

Variable Name: ADENOIDCYSTICBSLD

Eureka Name: Adenoid Cystic Basaloid Pattern

NAACCR Item: 3803

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 6 (CS_SITE_SPEC_F6)

Definition: Adenoid Cystic Basaloid Pattern, the presence of a basaloid pattern on pathological examination; is a prognostic factor for adenoid cystic carcinoma of the lacrimal gland. Valid for cases diagnosed January 1, 2018 and forward. For Lacrimal Gland tumors diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F6.

Values:

0.0-100.0:	0.0 to 100.0 percent basaloid pattern
XXX.5:	Basaloid pattern present, percentage not stated
XXX.8:	Not applicable: Information not collected for this case
XXX.9:	Not documented in medical record; Adenoid Cystic Basaloid Pattern not assessed or unknown if assessed
Blank:	Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: ADENOPATHY
Eureka Name: Adenopathy
NAACCR Item: 3804
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 – current year

Related Variables:

Definition: Adenopathy is defined as the presence of lymph nodes greater than 1.5 cm or physical examination (PE) and is part of the staging criteria for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Values:

- 0: Adenopathy not identified/not present; No lymph nodes >1.5 cm
- 1: Adenopathy present; Presence of lymph nodes >1.5 cm
- 9: Not documented in medical record; Adenopathy not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name:	AFPPOSTORCHRANGE
Eureka Name:	AFP Post-Orchiectomy Range
NAACCR Item:	3806
Category:	Prognostic Factors
Level of Variable:	Tumor
Time Period Available:	2018 – current year
Related Variables:	<ul style="list-style-type: none"> AFP Post-Orchiectomy Lab Value (AFPPOSTORCHVALUE) CS Site-Specific Factor 13 (CSSITESPECIFICFACTOR13)

Definition: AFP (Alpha Fetoprotein) Post-Orchiectomy Range identifies the range category of the lowest AFP value measured post-orchietomy. AFP is a serum tumor marker that is often elevated in patients with nonseminomatous germ cell tumors of the testis. The Post-Orchiectomy lab value is used to monitor response to therapy. Valid for cases diagnosed January 1, 2018 and forward. For testicular cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR13.

Values:	0:	Within normal limits
	1:	Above normal and less than 1,000 nanograms/milliliter (ng/mL)
	2:	1,000 -10,000 ng/mL
	3:	Greater than 10,000 ng/mL
	4:	Post-Orchiectomy alpha fetoprotein (AFP) stated to be elevated
	7:	Test ordered, results not in chart
	8:	Not applicable: Information not collected for this case
	9:	Not documented in medical record; No orchiectomy performed; AFP (Alpha Fetoprotein) Post-Orchiectomy Range not assessed or unknown if assessed
	Blank:	Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: AFPPOSTORCHVALUE
Eureka Name: AFP Post-Orchiectomy Lab Value
NAACCR Item: 3805
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 – current year

Related Variables:

- AFP Post-Orchiectomy Range (AFPPOSTORCHVALUE)
- CS Site-Specific Factor 12 (CSSITESPECIFICFACTOR12)

Definition: AFP (Alpha Fetoprotein) Post-Orchiectomy Lab Value refers to the lowest AFP value measured post-orchietomy. AFP is a serum tumor marker that is often elevated in patients with nonseminomatous germ cell tumors of the testis. The Post-Orchiectomy lab value is used to monitor response to therapy. Valid for cases diagnosed January 1, 2018 and forward. For testicular cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR12.

Values:

0.0:	0.0 nanograms/milliliter (ng/mL)
0.1-99999.9:	0.1–99,999.9 ng/mL
XXXXX.1:	100,000 ng/mL or greater
XXXXX.7:	Test ordered, results not in chart
XXXXX.8:	Not applicable: Information not collected for this case
XXXXX.9:	Not documented in medical record; No orchiectomy performed; AFP (Alpha Fetoprotein) Post-Orchiectomy Lab Value not assessed or unknown if assessed
Blank:	Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: AFPPREINTERP
Eureka Name: AFP Pretreatment Interpretation
NAACCR Item: 3809
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 – current year

Related Variables:

- AFP Pretreatment Lab Value (AFPPREVALUE)
- CS Site-Specific Factor 1 (CS_SITE_SPEC_F1)

Definition: AFP (Alpha Fetoprotein) Pretreatment Interpretation, anonspecific serum protein that generally is elevated in the setting of hepatocellular carcinoma (HCC), is a prognostic factor for liver cancer. Valid for cases diagnosed January 1, 2018 and forward. For liver cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F1.

Values:

- 0: Negative/normal; within normal limits
- 1: Positive/elevated
- 2: Borderline; undetermined if positive or negative
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; AFP Pretreatment Interpretation not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: AFPPREORCHRANGE

Eureka Name: AFP Pre-Orchiectomy Range

NAACCR Item: 3808

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables:

- AFP Pre-Orchiectomy Lab Value (AFPPREORCHVALUE)
- CS Site-Specific Factor 7 (CSSITESPECIFICFACTOR7)

Definition: AFP (Alpha Fetoprotein) Pre-Orchiectomy Range identifies the range category of the highest AFP value measured prior to treatment. AFP is a serum tumor marker that is often elevated in patients with nonseminomatous germ cell tumors of the testis. Valid for cases diagnosed January 1, 2018 and forward. For testicular cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR7.

Values:

- 0: Within normal limits
- 1: Above normal and less than 1,000 nanograms/milliliter (ng/mL)
- 2: 1,000 -10,000 ng/mL
- 3: Greater than 10,000 ng/mL
- 4: Pre-Orchiectomy alpha fetoprotein (AFP) stated to be elevated
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; AFP (Alpha Fetoprotein) Pre-Orchiectomy Range not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: AFPPREORCHVALUE

Eureka Name: AFP Pre-Orchiectomy Lab Value

NAACCR Item: 3807

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables:

- AFP Pre-Orchiectomy Range (AFPPREORCHVALUE)
- CS Site-Specific Factor 6 (CS_SITE_SPEC_F6)

Definition: AFP (Alpha Fetoprotein) Pre-Orchiectomy Lab Value refers to the AFP value measured prior to treatment. AFP is a tumor marker that is often elevated in patients with nonseminomatous germ cell tumors of the testis. Valid for cases diagnosed January 1, 2018 and forward. For testicular cancers diagnosed 2010 through 2017, this information was recorded in the field CS_SITE_SPEC_F6.

Values:

0.0:	0.0 nanograms/milliliter (ng/mL)
0.1-99999.9:	0.1–99,999.9 ng/mL
XXXXX.1:	100,000 ng/mL or greater
XXXXX.7:	Test ordered, results not in chart
XXXXX.8:	Not applicable: Information not collected for this case
XXXXX.9:	Not documented in medical record; AFP (Alpha Fetoprotein) Pre-Orchiectomy Lab Value not assessed or unknown if assessed
Blank:	Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: AFPPREVALUE

Eureka Name: AFP Pretreatment Lab Value

NAACCR Item: 3810

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables:

- AFP Pretreatment Interpretation (AFPPREINTERP)
- CS Site-Specific Factor 3 (CS_SITE_SPEC_F3)

Definition: AFP (Alpha Fetoprotein) Pretreatment Lab Value is a nonspecific serum protein that generally is elevated in the setting of hepatocellular carcinoma (HCC). This data item pertains to the pre-treatment lab value. Valid for cases diagnosed January 1, 2018 and forward. For liver cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F3.

Values:

0.0:	0.0 nanograms/milliliter (ng/ml); not detected
0.1-9999.9:	0.1-9999.9 ng/ml; (Exact value to nearest tenth of ng/ml)
XXXX.1:	10,000.0 ng/ml or greater
XXXX.7:	Test ordered, results not in chart
XXXX.8:	Not applicable: Information not collected for this case
XXXX.9:	Not documented in medical record; AFP (Alpha Fetoprotein) Pretreatment Lab Value not assessed or unknown if assessed
Blank:	Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: AGE
Eureka Name: Age at Diagnosis
NAACCR Item: 230
Category: Patient Demographics
Level of Variable: Tumor
Time Period Available: 1988 – current year
Related Variables:

- Date of Birth (DOB)
- Date of Diagnosis (DATEDX)

Definition: Age at Diagnosis is the system-generated age of the patient at diagnosis (in number of years) determined by calculating the difference between Date of Birth and Date of Diagnosis. Since Date of Birth is captured at the patient level and Date of Diagnosis is captured at the tumor level, different ages may be generated for each of a patient's tumors. If either date of birth or date of diagnosis is unknown, AGE will be unknown.

Values:

000:	Less than 1 year old; diagnosed in utero
001:	1 year old, but less than 2 years
002-120:	2 years old to 120 years old (show actual age in completed years)
999:	Unknown age at diagnosis

California Cancer Registry Data Dictionary

Variable Name:	AGECAT
Eureka Name:	Age-Group
NAACCR Item:	N/A
Category:	Patient Demographics
Level of Variable:	Tumor
Time Period Available:	1988 – current year
Related Variables:	Age at Diagnosis (AGE)
Definition:	Five-year age group derived from age at diagnosis (AGE).
Values:	<ul style="list-style-type: none"> 01: 0-4 years 02: 5-9 years 03: 10-14 years 04: 15-19 years 05: 20-24 years 06: 25-29 years 07: 30-34 years 08: 35-39 years 09: 40-44 years 10: 45-49 years 11: 50-54 years 12: 55-59 years 13: 60-64 years 14: 65-69 years 15: 70-74 years 16: 75-79 years 17: 80-84 years 18: 85-years and older 99: Unknown age

California Cancer Registry Data Dictionary

Variable Name: AJCCED
Eureka Name: TNM Edition Number
NAACCR Item: 1060
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Admission
Time Period Available: 1988 – current year

Related Variables:

Definition: Identifies the edition of the ***AJCC Cancer Staging Manual*** used to stage the case.
Value comes from the facility with the latest date of admission for this tumor.

Values:

- 00: Not staged (cases that have AJCC staging scheme and staging was not done)
- 01: 1st edition
- 02: 2nd edition (published 1983)
- 03: 3rd edition (published 1988)
- 04: 4th edition (published 1992), recommended for cases diagnosed 1993-1997
- 05: 5th edition (published 1997), recommended for cases diagnosed 1998-2002
- 06: 6th edition (published 2002), recommended for cases diagnosed 2003-2009
- 07: 7th edition (published 2009), recommended for use with cases diagnosed 2010-2017
- 08: 8th edition (published 2017), recommended for use with cases diagnosed 2018+
- 88: Not applicable (cases that do not have an AJCC staging scheme)
- 99: Unknown Edition

California Cancer Registry Data Dictionary

Variable Name: ALBUMINPRETXLEVL
Eureka Name: Serum Albumin Pretreatment Level
NAACCR Item: 3930
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 - current year

Related Variables:

Definition: Albumin is the most abundant protein in human blood plasma. Serum albumin pretreatment level is a prognostic factor for plasma cell myeloma.

Values:

- 0: Serum albumin <3.5 g/dL
- 1: Serum albumin =3.5 g/dL
- 7: Test ordered, results not in chart
- 9: Not documented in medical record; Serum Albumin Pretreatment Level not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: AMBIGUOUSTERMINOLOGY
Eureka Name: Ambiguous Terminology DX
NAACCR Item: 442
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2007 - 2012
Related Variables:

Definition: Identifies cases for which an ambiguous term is the most definitive word or phrase used to establish a cancer diagnosis. This field can be blank because the item is not required for all years of diagnosis.

Values: Refer to <http://seer.cancer.gov/tools/mphrules/index.html> for additional information.

- 0: Conclusive term
- 1: Ambiguous term only
- 2: Ambiguous term followed by conclusive term
- 9: Unknown term
- Blank: Date of Diagnosis before January 1, 2007 or after December 31, 2012

California Cancer Registry Data Dictionary

Variable Name: ANEMIA
Eureka Name: Anemia
NAACCR Item: 3811
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 – current year

Related Variables:

Definition: Anemia is defined by a deficiency of red blood cells or of hemoglobin in the blood. In staging of Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL), anemia is defined as Hgb less than 11.0 g/dL.

Values:

- 0: Anemia not present; Hgb \geq 11.0 g/dL
- 1: Anemia present; Hgb $<$ 11.0 g/dL
- 6: Lab value unknown, physician states patient is anemic
- 7: Test ordered, results not in chart
- 9: Not documented in medical record; Anemia not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name:	AYARECODE
Eureka Name:	N/A
NAACCR Item:	N/A
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	1988 – current year
Related Variables:	<ul style="list-style-type: none"> • Age at Diagnosis (AGE) • Behavior Code ICD-O-3 (HISTO_M3) • Histology Type ICD-O-3 (HISTO_T3) • Primary Site (SITE_02)
Definition:	SEER's classification scheme for tumors of adolescents and young adults (AYA) based on the classification scheme proposed by RD Barr and colleagues.* SEER's AYA site recode is based on ICD-O-3 and WHO's Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008). ¹ SEER's AYA site recode was developed to better define the major cancer sites that affect individuals between 15 and 39 years of age.
Notes:	*Barr RD, Holowaty EJ, Birch JM. Classification Scheme for Tumor diagnosed in adolescents and young adults. Cancer 2006;106(7):1425-30
Values:	Refer to SEER's website for value definitions and more detailed information regarding this coding scheme: http://seer.cancer.gov/ayarecode/aya-who2008.html

California Cancer Registry Data Dictionary

Variable Name: BASALDIAMETER
Eureka Name: Measured Basal Diameter
NAACCR Item: 3887
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year

Related Variables:

Definition: Measured Basal Diameter, the largest basal diameter of a uveal melanoma, is a prognostic indicator for this tumor.

Values:

- 0.0: No mass/tumor found
- 0.1-99.9: 0.1–99.9 millimeters (mm) (Exact measurement to nearest tenth of a mm)
- XX.0: 100 millimeters (mm) or greater
- XX.1: Described as "less than 3 mm"
- XX.2: Described as "at least" 3mm
- XX.3: Described as "at least" 6 mm
- XX.4: Described as "at least" 9 mm
- XX.5: Described as "at least" 12 mm
- XX.6: Described as "at least" 15 mm
- XX.8: Not applicable; Information not collected for this case
- XX.9: Not documented in medical record; Cannot be determined by pathologist; Measured Basal Diameter not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name:	BEHAVIOR
Eureka Name:	N/A
NAACCR Item:	N/A
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	1988 – current year
Related Variables:	<ul style="list-style-type: none"> • Behavior Code ICD-O-3 (HISTO_M3) • Histology Type ICD-O-3 (HISTO_T3) • Primary Site (SITE_02) • Year of Diagnosis (YEARDX)

Definition: This variable is SEER's behavior recode for analysis variable. It is created based on ICD-O-3 histology codes. HISTO-M3, whose values are based on the 5th digit of the ICD-O morphology code, designating the malignancy or behavior of the tumor. ICD-O-2 and ICD-O-3 histology and behavior codes are considered when creating BEHAVIOR.

Notes: The ICD-O-2 coding scheme was used for cases diagnosed prior to January 1, 2001; the ICD-O-3 coding scheme is used for cases diagnosed January 1, 2001 to the present. More information can be found under 'SEER behavior recode for analysis' at <http://seer.cancer.gov/behavrecode/>.

Values:	0: Benign in both ICD-O-2 and ICD-O-3
	1: Borderline malignancy in both ICD-O-2 and ICD-O-3
	2: In situ in both ICD-O-2 and ICD-O-3
	3: Malignant (invasive) in both ICD-O-2 and ICD-O-3
	4: Only malignant in ICD-O-3
	5: No longer reportable in ICD-O-3
	6: Only malignant for cases diagnosed 2010+

California Cancer Registry Data Dictionary

Variable Name: BELOW200
Eureka Name: N/A
NAACCR Item: N/A
Category: Socioeconomic Indicators
Level of Variable: Tumor

Time Period Available: 1988 – 2005

Related Variables:

- Census Block 90 (BLKGRP90)
- Census Block 2000 (BLKGRP00)
- Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: Percent of the population within the assigned Census block group living at or below 200% of the poverty line. This variable is obtained from the U.S. Census. Each CCR record is assigned a Census block group based on the patient's address at time of diagnosis. The block group is then used to append BELOW200 values from the 1990 Census for cases diagnosed 1988-1995 and from the 2000 Census for cases diagnosed 1996-2005. If a case received a randomly assigned block group, the BELOW200 value is that of the randomly assigned block group and RANDOM=1.

California Cancer Registry Data Dictionary

Variable Name: BELOW200CT

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 1988 – 2005

Related Variables:

- Percent of Population Living at or Below 200% of Poverty Line in Census Tract for Cases Diagnosed 2006 and Forward (BELOW200CTACS2011)
- Census Tract 1970/80/90 (CENSUS90)
- Census Tract 2000 (CENSUS00)
- Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: Percent of the population within the assigned Census tract that is living at or below 200% of the poverty line. This variable is obtained from the U.S. Census. Each CCR record is assigned a Census tract based on the patient's address at time of diagnosis. The Census tract is then used to append BELOW200CT values from the 1990 Census for cases diagnosed 1988-1995 and from the 2000 Census for cases diagnosed 1996-2005. If a case received a randomly assigned Census tract, the BELOW200CT value is that of the randomly assigned Census tract and RANDOM=1. For cases diagnosed 2006 and forward, use the variable BELOW200CTACS2011.

California Cancer Registry Data Dictionary

Variable Name: BELOW200CTACS2011

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 2006 – current year

Related Variables:

- Percent of Population Living at or Below 200% of Poverty Line in Census Tract for Cases Diagnosed 1988 through 2005 (BELOW200CT)
- Census Tract 2010 (CENSUSTRACT2010)
- Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: Percent of the population within the assigned Census tract that is living at or below 200% of the poverty line. This variable is obtained from the 2007-2011 American Community Survey (ACS) data. Each CCR record is assigned a Census tract based on the patient's address at time of diagnosis. The Census tract is then used to append BELOW200CTACS2011 values for cases diagnosed 2006 and forward. If a case received a randomly assigned Census tract, the BELOW200CTACS2011 value is that of the randomly assigned Census tract and RANDOM=1. For cases diagnosed prior to 2006, use the variable BELOW200CT.

California Cancer Registry Data Dictionary

Variable Name: BETA2MGPRETXLVL
Eureka Name: Serum Beta-2 Microglobulin Pretreatment Level
NAACCR Item: 3931
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 - current year

Related Variables:

Definition: Serum Beta-2 Microglobulin is a protein that is found on the surface of many cells and plentiful on the surface of white blood cells. Increased production or destruction of these cells causes Serum β 2 (beta-2) Microglobulin level to increase. Elevated Serum β 2 (beta-2) Microglobulin level is a prognostic factor for plasma cell myeloma.

Values:

- 0: β 2-microglobulin <3.5 mg/L
- 1: β 2-microglobulin =3.5 mg/L <5.5 mg/L
- 2: β 2-microglobulin =5.5 mg/L
- 7: Test ordered, results not in chart
- 9: Not documented in medical record
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: BEYONDCAPSULE
Eureka Name: Invasion Beyond Capsule
NAACCR Item: 3864
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year
Related Variables: CS Site-Specific Factor 1 (CS_SITE_SPEC_F1)

Definition: Invasion beyond capsule pertains to the pathologically confirmed invasion of the tumor beyond the fibrous capsule in which the kidney is enclosed. Valid for cases diagnosed January 1, 2018 and forward. For kidney cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F1.

Values:

- 0: Invasion beyond capsule not identified
- 1: Perinephric (beyond renal capsule) fat or tissue
- 2: Renal sinus
- 3: Gerota's fascia
- 4: Any combination of codes 1-3
- 5: Invasion beyond capsule, NOS
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Invasion beyond capsule not assessed or unknown if assessed; No surgical resection of primary site is performed

Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: BILIRUBINPREUNIT

Eureka Name: Bilirubin Pretreatment Unit of Measure

NAACCR Item: 3814

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: Bilirubin Pretreatment Total Lab Value (BILIRUBINPREVALUE)

Definition: Bilirubin Pretreatment Unit of Measure identifies the unit of measure for the bilirubin value measured prior to treatment. Bilirubin is commonly measured in units of Milligrams/deciliter (mg/dL) in the United States and Micromoles/liter (umol/L) in Canada and Europe.

Values:

- 1: Milligrams per deciliter (mg/dL)
- 2: Micromoles/liter (umol/L)
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Bilirubin unit of measure not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: BILIRUBINPREVALUE

Eureka Name: Bilirubin Pretreatment Total Lab Value

NAACCR Item: 3813

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: Bilirubin Pretreatment Unit of Measure (BILIRUBINPREUNIT)

Definition: Bilirubin Pretreatment Total Lab Value records the bilirubin value prior to treatment. Bilirubin level is an indicator of how effectively the liver excretes bile and is required to calculate the Model for End-Stage Liver Disease (MELD) score used to assign priority for liver transplant.

Values:

0.0:	0.0 milligram/deciliter (mg/dL); 0.0 micromole/liter (umol/L)
0.1-999.9:	0.1-999.9 milligram/deciliter (mg/dL); 0.1-999.9 micromole/liter (umol/L)
XXX.1:	1000 milligram/deciliter (mg/dL) or greater; 1000 micromole/liter (umol/L) or greater
XXX.7:	Test ordered, results not in chart
XXX.8:	Not applicable: Information not collected for this case
XXX.9	Not documented in medical record; Bilirubin Pretreatment Total Lab Value not assessed or unknown if assessed
Blank:	Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: BIRTHPLACECOUNTRY
Eureka Name: Birthplace--Country
NAACCR Item: 254
Category: Patient Demographics
Level of Variable: Patient
Time Period Available: 1988 – current year
Related Variables: Birthplace--State (BIRTHPLACESTATE)
Definition: Code for the country in which the patient was born. If the patient has multiple tumors, all records should contain the same code.
Values: For a list of allowable values, see “Cancer Reporting in California, California Cancer Reporting System Standards, [Volume I, Appendix C – Codes for Countries C.1 – Alphabetical and C.2 – Code Order](#)

California Cancer Registry Data Dictionary

Variable Name: BIRTHPLACESTATE
Eureka Name: Birthplace--State
NAACCR Item: 252
Category: Patient Demographics
Level of Variable: Patient
Time Period Available: 1988 – current year
Related Variables: Birthplace--Country (BIRTHPLACECOUNTRY)
Definition: USPS abbreviation for the state, commonwealth, U.S. possession; or Canada Post abbreviation for the Canadian province/territory in which the patient was born. If the patient has multiple tumors, the state of birth is the same for each tumor.
Values: See [Volume I, Appendix B](#) for all Postal Abbreviations for states/territories

California Cancer Registry Data Dictionary

Variable Name: BLKGRP00
Eureka Name: Census Block 2000
NAACCR Item: N/A
Category: Geographical Information
Level of Variable: Tumor
Time Period Available: 1995 – 2011

Related Variables:

- Census Block 90 (BLKGRP90)
- Census Block 2010 (CENSUSBLOCK2010)
- Census Block Group 2020 (CENBLOCKGRP2020)
- Census Tr Certainty 1970/80/90 (CENTRD90)
- Census Tr Certainty 2000 (CENTRD00)
- Census Tr Certainty 2010 (CENSUSTRCERTAINTY2010)
- Census Tract Certainty 2020 (CENTRACTCERT2020)

Definition: BLKGRP00 captures the value of both the 2000 Census block and the 2000 Census block group of the patient's address at time of diagnosis. A Census block is the smallest geographical unit used by the U.S. Census Bureau. A block group is a set of blocks sharing the same first digit of the four-digit block within a Census tract. The first digit of this variable identifies the 2000 Census block group. The last three digits of this variable, taken as whole, identifies the 2020 Census block.

Notes: Cases diagnosed 1995-2011 were geocoded to the 2000 U.S. Census and received 2000 block group and block assignments. When the 2010 U.S. Census data was released, cases diagnosed 2006-2018 were also geocoded to the 2010 U.S. Census and received 2010 block group and block assignments (see CENBLOCK2010).

Values:

0000-9999: Census block/group values as defined by the U.S. Census Bureau

Blank: Census block/group 2000 not coded

California Cancer Registry Data Dictionary

Variable Name:	BLKGRP90
Eureka Name:	Census Block 90
NAACCR Item:	N/A
Category:	Geographical Information
Level of Variable:	Tumor
Time Period Available:	1988 – 1999
Related Variables:	<ul style="list-style-type: none"> • Census Block 2000 (BLKGRP00) • Census Block 2010 (CENSUSBLOCK2010) • Census Block Group 2020 (CENBLOCKGRP2020) • Census Tr Certainty 1970/80/90 (CENTRD90) • Census Tr Certainty 2000 (CENTRD00) • Census Tr Certainty 2010 (CENSUSTRCERTAINTY2010) • Census Tr Certainty 2020 (CENTRACTCERT2020)
Definition:	Code indicating the Census block group of the patient's address at time of diagnosis based on the 1990 U.S. Census. Block groups are a set of blocks sharing the same first digit within a Census tract. A block group is a geographical unit between the size of a Census tract and a Census block. Each block group generally contains between 600 and 3,000 people.
Notes:	Cases diagnosed 1988-1999 were geocoded to the 1990 U.S. Census and received 1990 block group assignments. When the 2000 U.S. Census data was released, cases diagnosed 1995-2011 were also geocoded to the 2000 U.S. Census and received 2000 block group assignments (see BLKGRP00).
Values:	<p>0-9 Block group values as defined by the U.S. Census Bureau</p> <p>Blank: 1990 Census block group not coded</p>

California Cancer Registry Data Dictionary

Variable Name: BLUECOLR
Eureka Name: N/A
NAACCR Item: N/A
Category: Socioeconomic Indicators
Level of Variable: Tumor
Time Period Available: 1988 – 2005

Related Variables:

- Census Block 90 (BLKGRP90)
- Census Block 2000 (BLKGRP00)
- Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: Proportion of the population within the assigned Census block group, age 16 years and older, with a blue-collar job. This variable is obtained from the U.S. Census. Each CCR record is assigned a Census block group based on the patient's address at time of diagnosis. The block group is then used to append BLUECOLR values from the 1990 Census for cases diagnosed 1988-1995 and from the 2000 Census for cases diagnosed 1996-2005. If a case received a randomly assigned block group, the BLUECOLR value is that of the randomly assigned block group and RANDOM=1.

California Cancer Registry Data Dictionary

Variable Name: BLUECOLRCT
Eureka Name: N/A
NAACCR Item: N/A
Category: Socioeconomic Indicators
Level of Variable: Tumor
Time Period Available: 1988 – 2005
Related Variables: Proportion of Population with Blue Collar Job in Census Tract
 2006 and forward (BLUECOLRCTACS2011)

Definition: BLUECOLRCT indicates the proportion of persons aged 16 years and older within the assigned Census tract with a blue-collar job. This variable is obtained from the U.S. Census. Each CCR record is assigned a Census tract based on the patient's address at time of diagnosis. The Census tract is then used to append BLUECOLRCT values from the 1990 Census for cases diagnosed 1988-1995 and from the 2000 Census for cases diagnosed 1996-2005. If a case received a randomly assigned Census tract, the BLUECOLRCT value is that of the randomly assigned Census tract and RANDOM=1. For cases diagnosed 2006 and forward, use the variable BLUECOLRCTACS2011.

California Cancer Registry Data Dictionary

Variable Name: BLUECOLRCTACS2011

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 2006 - current year

Related Variables:

- Proportion of Population with Blue Collar Job in Census Tract 1988 through 2005 (BLUECOLRCT)
- Census Tract 2010 (CENSUSTRACT2010)
- Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: BLUECOLRCTACS2011 indicates the proportion of persons aged 16 years and older within the assigned Census tract with a blue-collar job. This variable is obtained from the 2007-2011 American Community Survey (ACS) data. Each CCR record is assigned a Census tract based on the patient's address at time of diagnosis. The Census tract is then used to append BLUECOLRCTACS2011 values for cases diagnosed 2006 and forward. If a case received a randomly assigned Census tract, the BLUECOLRCTACS2011 value is that of the randomly assigned Census tract and RANDOM=1. For cases diagnosed prior to 2006, use the variable BLUECOLRCT.

California Cancer Registry Data Dictionary

Variable Name: BONEINVASION
Eureka Name: Bone Invasion
NAACCR Item: 3815
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 – current year
Related Variables:

Definition: Bone invasion, the presence or absence of bone invasion based on imaging, is a prognostic factor for soft tissue sarcomas.

Values:

- 0: Bone invasion not present/not identified on imaging
- 1: Bone invasion present/identified on imaging
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Bone invasion not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: BRAINMOLMARKERS
Eureka Name: Brain Molecular Markers
NAACCR Item: 3816
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year

Related Variables:

Definition: Multiple brain molecular markers have become standard pathology components necessary for diagnosis. This data item captures clinically important brain cancer subtypes identified by molecular markers that are not distinguishable by ICD-O-3 codes.

Values:

- 01: Diffuse astrocytoma, IDH-mutant (9400/3)
- 02: Diffuse astrocytoma, IDH-wild type (9400/3)
- 03: Anaplastic astrocytoma, IDH-mutant (9401/3)
- 04: Anaplastic astrocytoma, IDH-wild type (9401/3)
- 05: Glioblastoma, IDH-wild type (9440/3)
- 06: Oligodendroglioma, IDH-mutant and 1 p/19q co-deleted (9450/3)
- 07: Anaplastic oligodendroglioma, IDH-mutant and 1 p/19q co-deleted (9451/3)
- 08: Medulloblastoma, SHH-activated and TP53-wildtype (9471/3)
- 09: Embryonal tumor with multilayered rosettes, C19MC-altered (9478/3)
- 85: Not applicable: Histology not 9400/3, 9401/3, 9440/3, 9450/3, 9451/3, 9471/3, 9478/3
- 86: Benign or borderline tumor
- 87: Test ordered, results not in chart
- 88: Not applicable: Information not collected for this case
- 99: Not documented in patient record; No microscopic confirmation; Brain molecular markers not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: BRESLOWTHICKNESS
Eureka Name: Breslow Tumor Thickness
NAACCR Item: 3817
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 – current year

Related Variables:

Definition: Breslow Tumor Thickness, the measurement of the thickness of a melanoma as defined by Dr. Alexander Breslow, is a prognostic factor for Melanoma of the Skin.

Values:

- 0.0: No mass/tumor found
- 0.1: Greater than 0.0 and less than or equal to 0.1
- 0.2-99.9: 0.2 - 99.9 millimeters
- XX.1: 100 millimeters or larger
- A0.1-A9.9: Stated as "at least" some measured value of 0.1 to 9.9
- AX.0: Stated as greater than 9.9 mm
- XX.8: Not applicable: Information not collected for this schema
- XX.9: Not documented in medical record; Microinvasion; microscopic focus or foci only and no depth given; Cannot be determined by pathologist; In situ melanoma; Breslow Tumor Thickness not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: BSYMPTOMS
Eureka Name: B Symptoms
NAACCR Item: 3812
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 – current year
Related Variables:

Definition: B symptoms refer to systemic symptoms of fever, night sweats, and weight loss which can be associated with both Hodgkin lymphoma and some non-Hodgkin lymphomas. The presence of B symptoms is a prognostic factor for some lymphomas.

Values:

- 0: No B symptoms (asymptomatic); Classified as "A" by physician when asymptomatic
- 1: Any B symptom(s); Night sweats (drenching); Unexplained fever (above 38 degrees C); Unexplained weight loss (generally greater than 10% of body weight in the six months before admission); B symptoms, NOS; Classified as "B" by physician when symptomatic
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; B symptoms not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: CA125PREINTERP
Eureka Name: CA-125 Pretreatment Interpretation
NAACCR Item: 3818
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 – current year

Related Variables:

Definition: Carbohydrate Antigen 125 (CA-125) is a tumor marker that is useful for following the response to therapy in patients with ovarian cancer, who may have elevated levels of this marker.

Values:

- 0: Negative/normal; within normal limits
- 1: Positive/elevated
- 2: Stated as borderline; undetermined whether positive or negative
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; CA-125 not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: CASEFIND
Eureka Name: Casefinding Source
NAACCR Item: 501
Category: Hospital and Physician
Level of Variable: Admission
Time Period Available: 1988 – current year

Related Variables:

Definition: Method used to first identify the case by the facility with the earliest date of admission (source of case finding).

Values: **Case finding identified in a cancer-reporting facility:**

- 10: Reporting Hospital, NOS
- 20: Pathology Department Review (surgical pathology reports, autopsies, or cytology reports)
- 21: Daily Discharge Review
- 22: Disease index review
- 23: Radiation therapy department/center
- 24: Laboratory reports (other than pathology reports, code 20)
- 25: Outpatient chemotherapy
- 26: Diagnostic imaging/radiology (other than radiation therapy, codes 23; includes nuclear medicine)
- 27: Tumor Board
- 28: Hospital rehabilitation service or clinic
- 29: Other hospital reporting source, including clinic, NOS or OPD, NOS

Case finding identified by source other than cancer-reporting facility:

- 30: Physician-initiated case
- 40: Consultation-only or pathology-only report (not abstracted by reporting hospital)
- 50: Private pathology lab report (non-hospital)
- 60: Nursing home-initiated case
- 70: Coroner's Office records review
- 75: Managed care organization (MCO) or insurance records
- 80: Death certificate follow-back
- 85: Out-of-state case sharing
- 90: Other non-reporting hospital source
- 95: Quality control review
- 99: Unknown

California Cancer Registry Data Dictionary

Variable Name: CASEFINDING_STATUS

Eureka Name: Casefinding Status

NAACCR Item: N/A

Category: Administrative

Level of Variable: Tumor

Time Period Available: 1988 - current year

Related Variables:

Definition: This field indicates whether an abstract/admission adequate for case finding purposes has been captured and related to a patient's tumor. If so, the case finding status is complete, but if not, that status is incomplete. The field was created when it became possible for preliminary patients and tumors to be created from a path report or other source document prior to the capture of an abstract/admission (case building). For case finding purposes, an adequate admission can be recognized automatically if a) it has a class of case code of 10-22, 34, or 36, b) it has a known year and month of diagnosis, and c) the admission's reporting facility is adequate given the selected follow-back source*. A data collection specialist may also determine that an admission is adequate and manually complete the case finding status for a tumor, regardless of the above criteria. Finally, admissions used to create new tumors and those linked to a tumor with no open case finding assignment queue tasks will be given a default case finding status of Complete.

*An admission has an adequate reporting facility given the path report's follow-back facility if at least one of the following conditions is true:

- The follow-back facility's reporting source number matches the reporting facility's reporting source number exactly
- The follow-back facility and reporting facility reporting source numbers match because of an entry in the Synonymous Hospital Numbers table
- The reporting facility's associated RSM reporting source is related to the same RSM affiliation as the follow-back facility and that affiliation's CaseFindingAdequacy checkbox is checked (1/true)
- The follow-back facility's associated RSM reporting source is a medical office (reporting source type) or its reporting source number is in the Generic Reporting Source Number Table.

Generic Reporting Source Number Table

Reporting Source Number	Name/Label
0000000001	CCR
0000000101	Region 1
0000000102	Region 2
0000000103	Region 3

California Cancer Registry Data Dictionary

0000000104	Region 4
0000000105	Region 5
0000000106	Region 6
0000000107	Region 7
0000000108	Region 8
0000000109	Region 9
0000000110	Region 10
0000000801	DC ONLY
0000000802	CORONER
0000000803	MD
0000000804	CONV. HOSPITAL
0000999990	HOSPICE
0000999991	HOME HEALTH
0000999992	SKILLED NURSING FACILITY
0000999993	STAFF PHYSICIAN
0000999994	UNSPEC NONCAL HOSP
0000999995	NON-HOSPITAL NOS
0000999996	PHYSICIAN ONLY
0000999997	UNSPEC BAY AREA HOSP
0000999998	UNSPEC CALIF HOSP
0000999998	UNSPEC CALIF HOSP
0000999999	UNKNOWN HOSP

Values:

Complete: An abstract/admission adequate for case finding purposes has been captured and related to a patient's tumor

Incomplete: There is not an abstract/admission adequate for case finding purposes related to a patient's tumor.

California Cancer Registry Data Dictionary

Variable Name: CDEATH
Eureka Name: Cause of Death
NAACCR Item: 1910
Category: Follow-Up
Level of Variable: Tumor
Time Period Available: 1988 – current year

Related Variables:

Definition Underlying cause of death on the death certificate. Deaths that occurred 1969-1978 are coded per ICD-A 8th Revision. Deaths that occurred 1979-1998 are coded per ICD-A 9th Revision. Deaths that occurred 1999 and forward are coded per ICD-10.

Notes: **Access to death data variables from the CCR for research purposes requires review by the Health and Human Services Agency Committee for the Protection of Human Subjects (CPHS), the Vital Statistics Advisory Committee (VSAC), and CCR. The Center for Health Statistics and Informatics (CHSI), CCR, and CPHS require requesters to submit their proposals for simultaneous review of research projects by CPHS and VSAC. Please allow sufficient time for review of your application. For more information, send inquiries to research@ccr.ca.gov.**

Values: In addition to ICD codes* as referenced above, the following values are valid:

0000: Patient not dead

7777: Death certificate not yet available

7797: Death certificate was available but cause of death not coded

*If the 4th digit is X, hyphen (-), or Blank, a 9 is substituted

California Cancer Registry Data Dictionary

Variable Name: CEAPREINTERP
Eureka Name: CEA Pretreatment Interpretation
NAACCR Item: 3819
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 – current year

Related Variables:

Definition: CEA (Carcinoembryonic Antigen) Pretreatment Interpretation refers to the interpretation of the CEA value prior to treatment. CEA is a glycoprotein that is produced by adenocarcinomas from all sites as well as many squamous cell carcinomas of the lung and other sites. CEA may be measured in blood, plasma, or serum. CEA is a prognostic marker for adenocarcinomas of the appendix, colon, and rectum and is used to monitor response to treatment.

Values:

- 0: CEA negative/normal; within normal limits
- 1: CEA positive/elevated
- 2: Borderline
- 3: Undetermined if positive or negative (normal values not available)
AND no MD interpretation
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; CEA (Carcinoembryonic Antigen)
Pretreatment Interpretation not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: CEAPREVALUE
Eureka Name: CEA Pretreatment Lab Value
NAACCR Item: 3820
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 – current year

Related Variables:

Definition: CEA (Carcinoembryonic Antigen) Pretreatment Lab Value records the CEA value prior to treatment. CEA is a nonspecific tumor marker that has prognostic significance for colon and rectum cancer.

Values:

0.0:	0.0 nanograms/milliliter (ng/ml) exactly
0.1-9999.9:	0.1-9999.9 ng/ml (Exact value to nearest tenth in ng/ml)
XXXX.1:	10,000 ng/ml or great tumor necrosis present, percent not stated
XXXX.7:	Test ordered, results not in chart
XXXX.8:	Not applicable: Information not collected for this case
XXXX.9:	Not documented in medical record; CEA (Carcinoembryonic Antigen) Pretreatment Lab Value not assessed or unknown if assessed
Blank:	Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: CENBLOCKGRP2020

Eureka Name: Census Block Group 2020

NAACCR Item: 361

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables:

- Census Block 90 (BLKGRP90)
- Census Block 2000 (BLKGRP00)
- Census Block 2010 (CENSUSBLOCK2010)
- Census Tr Certainty 1970/80/90 (CENTRD90)
- Census Tr Certainty 2000 (CENTRD00)
- Census Tr Certainty 2010 (CENSUSTRCERTAINTY2010)
- Census Tr Certainty 2020 (CENTRACTCERT2020)

Definition: Census Block Group 2020 captures the value of both the 2020 Census block and the 2020 Census block group of the patient's address at time of diagnosis. A census block is the smallest geographical unit used by the U.S. Census Bureau. A block group is a set of blocks sharing the same first digit of the four-digit block within a Census Tract. The first digit of this variable identifies the 2020 Census block group. The last three digits of this variable, taken as whole, identify the 2020 Census block group.

Values:

0000-9999: Census block group values as defined by the U.S. Census Bureau

Blank: Census block group 2020 not coded

California Cancer Registry Data Dictionary

Variable Name:	CENSUS00
Eureka Name:	Census Tract 2000
NAACCR Item:	130
Category:	Geographical Information
Level of Variable:	Tumor
Time Period Available:	1995 – 2011
Related Variables:	<ul style="list-style-type: none"> • Census Tract 90 (CENSUS90) • Census Tract 2010 (CENSUSTRACT2010) • Census Tract 2020 (CENTRACT2020) • Census Tr Certainty 1970/80/90 (CENTRD90) • Census Tr Certainty 2000 (CENTRD00) • Census Tr Certainty 2010 (CENSUSTRCERTAINTY2010) • Census Tr Certainty 2020 (CENTRACTCERT2020)
Definition:	Census tract of patient's address when this tumor was first diagnosed, using the boundaries defined by the U.S Census Bureau for the Year 2000 Census. This variable should be used in conjunction with the census certainty variable,
Notes:	CENTRD00, which indicates the accuracy of the census tract assignment. Cases diagnosed 1995-2011 were geocoded to the 2000 U.S. Census and received 2000 tract assignments. When the 2010 U.S. Census data was released, cases diagnosed 2006-2017 also received 2010 tract assignments (see CENSUSTRACT2010).
Values:	<p>Census tract codes have a 4-digit basic number and may have a 2-digit suffix. For example: Census tract 0145.05 is coded as 014505.</p> <p>000100-999992: Census tract codes</p> <p>999993: Unknown city and unknown zip, county and state known, street may be known or unknown</p> <p>999994: P.O. boxes for California residents only</p> <p>999996: Not yet submitted for tracting</p> <p>999997: Submitted for tracting once, unsuccessfully</p> <p>999998: California case – not machine tractable</p> <p>999999: Non-California resident or unknown residence</p>

California Cancer Registry Data Dictionary

Variable Name:	CENSUS90
Eureka Name:	Census Tract 1970/80/90
NAACCR Item:	110
Category:	Geographical Information
Level of Variable:	Tumor
Time Period Available:	1988 – 1999
Related Variables:	<ul style="list-style-type: none"> • Census Tract 2000 (CENSUS00) • Census Tract 2010 (CENSUSTRACT2010) • Census Tract 2020 (CENTRACT2020) • Census Tr Certainty 1970/80/90 (CENTRD90) • Census Tr Certainty 2000 (CENTRD00) • Census Tr Certainty 2010 (CENSUSTRCERTAINTY2010) • Census Tr Certainty 2020 (CENTRACTCERT2020)

Definition: Census tract of patient's address when this tumor was first diagnosed, using census tract boundaries used by the U.S. Census Bureau for the year 1990 Census. This variable should be used in conjunction with the census certainty variable, CENTRD90, which indicates the accuracy of the census tract assignment.

Notes: Cases diagnosed 1988-1999 were geocoded to the 1990 U.S. Census and received 1990 tract assignments. When the 2000 U.S. Census data was released, cases diagnosed 1995-2011 also received 2000 tract assignments (see CENSUS00).

Values:	000100-999992: Census tract codes
	999993: Unknown street address or unknown city, but state is California
	999994: P.O. boxes for California residents only
	999995: Neither manual nor machine tracting has been successful
	999996: Not yet submitted for tracting
	999997: Submitted for tracting once, unsuccessfully
	999998: California case – not machine tractable
	999999: Non-California resident or unknown residence

California Cancer Registry Data Dictionary

Variable Name: CENSUSBLOCK2010

Eureka Name: Census Block 2010

NAACCR Item: N/A

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: 2006 - 2018

Related Variables:

- Census Block 90 (BLKGRP90)
- Census Block 2000 (BLKGRP00)
- Census Block Group 2020 (CENBLOCKGRP2020)
- Census Tr Certainty 1970/80/90 (CENTRD90)
- Census Tr Certainty 2000 (CENTRD00)
- Census Tr Certainty 2010 (CENSUSTRCERTAINTY2010)
- Census Tr Certainty 2020 (CENTRACTCERT2020)

Definition: Census Block 2010 captures the value of both the 2010 Census block and the 2010 Census block group. A census block is the smallest geographical unit used by the U.S. Census Bureau. A block group is a set of blocks sharing the same first digit of the four-digit block within a Census tract. The first digit of this variable identifies the 2010 Census block group. The last three digits of this variable, taken as whole, identify the 2010 Census block.

Values:

0000-9999: Census block/group values as defined by the U.S. Census Bureau

Blank: Census block/group 2010 not coded

California Cancer Registry Data Dictionary

Variable Name: CENSUSCODSYS19708090

Eureka Name: Census Cod Sys 1970/80/90

NAACCR Item: 120

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: 1988 – 1999

Related Variables:

Definition: Identifies the set of U.S. Census Bureau Census tract definitions (boundaries) used to code the Census tract in Census Tract 1970/80/90 for a specific record.

Values:

- 0: Not tracted
- 1: 1970 Census Tract Definitions
- 2: 1980 Census Tract Definitions
- 3: 1990 Census Tract Definitions
- Blank: Census Tract 1970/80/90 not coded

California Cancer Registry Data Dictionary

Variable Name: CENSUSTRACT2010

Eureka Name: Census Tract 2010

NAACCR Item: 135

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: 2006 – 2018

Related Variables:

- Census Tract 1970/80/90 (CENSUS90)
- Census Tract 2000 (CENSUS00)
- Census Tract 2020 (CENTRACT2020)
- Census Tr Certainty 1970/80/90 (CENTRD90)
- Census Tr Certainty 2000 (CENTRD00)
- Census Tr Certainty 2010 (CENSUSTRCERTAINTY2010)
- Census Tr Certainty 2020 (CENTRACTCERT2020)

Definition: Census tract of patient's address when this tumor was first diagnosed, using 2010 Census tract boundaries used by the U.S. Census Bureau for the Year 2010 Census. This variable should be used in conjunction with the Census certainty variable, CENSUSTRCERTAINTY2010, which indicates the accuracy of the census tract assignment.

Notes: Census tract codes have a 4-digit basic number and may have a 2-digit suffix. For example: Census tract 0145-05 is coded as 014505.

Values:

000100-999992:	Census tract codes
999993:	Unknown city and unknown zip, county and state known, street may be known or unknown
999994:	P.O. boxes for California residents only
999996:	Not yet submitted for tracting
999997:	Submitted for tracting once, unsuccessfully
999998:	California case – not machine tractable
999999:	Non-California residence (includes unknown state)

California Cancer Registry Data Dictionary

Variable Name: CENSUSTRCERTAINTY2010

Eureka Name: Census Tr Certainty 2010

NAACCR Item: 367

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: 2006 – 2018

Related Variables: Census Tract 2010 (CENSUSTRACT2010)

Definition: The basis (certainty) of assignment of the 2010 Census tract, block group and latitude/longitude values. Values indicate whether the patient's address at the time of diagnosis was assigned (geocoded to) a Census tract based on a complete street match, a zip code only match, or whether the address was unable to be geocoded.

Values:

- 1: Census tract based on complete and valid street address of residence
- 2: Census tract based on residence zip + 4
- 3: Census tract based on residence zip + 2
- 4: Census tract based on residence zip code only
- 5: Census tract based on zip code of P.O. box
- 6: Census tract based on residence city where city has only one census tract, or based on residence zip code where zip code has only one census tract
- 9: Not assigned, geocoding attempted
- Blank: Not assigned, geocoding not attempted

California Cancer Registry Data Dictionary

Variable Name: CENTRACT2020
Eureka Name: Census Tract 2020
NAACCR Item: 125
Category: Geographical Information
Level of Variable: Tumor

Time Period Available: 2019 – current year

Related Variables:

- Census Tract 1970/80/90 (CENSUS90)
- Census Tract 2000 (CENSUS00)
- Census Tract 2010 (CENSUSTRACT2010)
- Census Tr Certainty 1970/80/90 (CENTRD90)
- Census Tr Certainty 2000 (CENTRD00)
- Census Tr Certainty 2010 (CENSUSTRCERTAINTY2010)
- Census Tr Certainty 2020 (CENTRACTCERT2020)

Definition: Census tract of patient's address when this tumor was first diagnosed, using census tract boundaries used by the U.S. Census Bureau for the Year 2020 Census. This variable should be used in conjunction with the census certainty variable, CENTRACTCERT2020, which indicates the accuracy of the census tract assignment.

Values:

000100-999992:	Census tract codes
999993:	Unknown city and unknown zip, county and state known, street may be known or unknown
999994:	P.O. boxes for California residents only
999996:	Not yet submitted for tracting
999997:	Submitted for tracting once, unsuccessfully
999998:	California case – not machine tractable
999999:	Not a California residence (includes unknown state)

California Cancer Registry Data Dictionary

Variable Name: CENTRACTCERT2020
Eureka Name: Census Tr Certainty 2020
NAACCR Item: 369
Category: Geographical Information
Level of Variable: Tumor
Time Period Available: 2019 – current year

Related Variables:

Definition: The basis (certainty) of assignment of the 2020 Census tract, block group and latitude/longitude values. Values indicate whether the patient's address at the time of diagnosis was assigned (geocoded to) a Census tract based on a complete street match, a zip code only match, or whether the address was unable to be geocoded.

Values:

- 1: Census tract based on complete and valid street address of residence
- 2: Census tract based on residence zip + 4
- 3: Census tract based on residence zip + 2
- 4: Census tract based on residence zip code only
- 5: Census tract based on zip code of P.O. box
- 6: Census tract based on residence city where city has only one census tract, or based on residence zip code where zip code has only one census tract
- 9: Not assigned, geocoding attempted
- Blank: Not assigned, geocoding not attempted

California Cancer Registry Data Dictionary

Variable Name: CENTRD00
Eureka Name: Census Tr Certainty 2000
NAACCR Item: 365
Category: Geographical Information
Level of Variable: Tumor
Time Period Available: 1995 – 2011
Related Variables: Census Tract 2000 (CENSUS00)

Definition: The basis (certainty) of assignment of the 2000 Census tract, block group and latitude/longitude values. Values indicate whether the patient's address at the time of diagnosis was assigned (geocoded to) a Census tract based on a complete street match, a zip code only match, or whether the address was unable to be geocoded.

Values:

- 1: Census tract based on complete and valid street address
- 2: Census tract based on residence zip + 4
- 3: Census tract based on residence zip + 2
- 4: Census tract based on residence zip code only
- 5: Census tract based on zip code of P.O. box
- 6: Census tract based on residence city where city has only one Census tract, or based on residence zip code where zip code has only one Census tract
- 9: Unable to assign Census tract based on available information
- Blank: Census tracting not yet attempted/not applicable

California Cancer Registry Data Dictionary

Variable Name: CENTRD90
Eureka Name: Census Tr Certainty 1970/80/90
NAACCR Item: 364
Category: Geographical Information
Level of Variable: Tumor
Time Period Available: 1988 - 1995

Related Variables:

Definition: The basis (certainty) of the assignment of the 1990 Census tract, block group, and latitude/longitude values. Values indicate whether the patient's address at the time of diagnosis was assigned a Census tract based on a complete street match, a zip code only match, or whether the address was unable to be geocoded.

Values:

- 1: Census tract based on complete and valid street address of residence
- 2: Census tract based on residence zip + 4
- 3: Census tract based on residence zip + 2
- 4: Census tract based on residence zip code only
- 5: Census tract based on zip code of P.O. box
- 6: Census tract based on residence city where city has only one Census tract, or based on residence zip code where zip code has only one Census tract
- 9: Not assigned, geocoding attempted
- Blank: Not assigned, geocoding not attempted

California Cancer Registry Data Dictionary

Variable Name: CHEMOSUM

Eureka Name: RX Summ--Chemo

NAACCR Item: 1390

Category: Treatment, Systemic

Level of Variable: Tumor

Time Period Available: 1988 – current year

Related Variables: RX Date Chemo (RXDATEC)

Definition: Identifies the type of chemotherapy given as first course of treatment at any facility. If chemotherapy not given, codes are provided that record the reason. RXDATEC records the date of initiation for chemotherapy.

Values:

- 00: None, diagnosed at autopsy
- 01: Chemotherapy, NOS
- 02: Single agent
- 03: Multiple agents
- 82: Contraindicated
- 85: Patient died prior to planned or recommended therapy
- 86: Recommended, not given
- 87: Refused
- 88: Recommended, unknown if given
- 99: Unknown or death certificate only case (DCO)

California Cancer Registry Data Dictionary

Variable Name: CHRLSON
Eureka Name: N/A
NAACCR Item: N/A
Category: Clinical, Other
Level of Variable: Tumor
Time Period Available: 1988 – current year

Related Variables:

Definition: The Charlson comorbidity score is a weighted index based on the presence of certain comorbid conditions twelve months prior through six months following this cancer diagnosis (as determined through ICD-9 and ICD-10 diagnosis codes), weighted by the severity of those conditions. The Charlson comorbidity score is based on the annual linkage of CCR data to the OSHPD Patient Discharge Data, Ambulatory Surgery Data, and Emergency Department Data. It is intended to be a measure of burden of serious comorbidity, not the number of comorbidities. The following conditions are included in this index: congestive heart failure, myocardial infarction (acute and old), peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatologic disease, peptic ulcer disease, mild liver disease, moderate/severe liver disease, diabetes, diabetes with chronic complications, hemi- or paraplegia, renal disease, and acquired immune deficiency syndrome.

Notes: For details please see: Lichtensztajn DY, Giddings BM, Morris CR, Parikh-Patel A, Kizer KW. Comorbidity index in central cancer registries: the value of hospital discharge data. Clinical Epidemiology. 2017; 9:601-609. doi:10.2147/CLEP.S146395.
<https://www.dovepress.com/comorbidity-index-in-central-cancer-registries-the-value-of-hospital-d-peer-reviewed-article-CLEP>

Values: 0-18: Weighted score. In general, a score of 0 may be interpreted as no significant comorbidity burden; scores of 3 or more are generally interpreted as a high comorbidity burden
 Blank: No relevant admissions in the OSHPD data for this tumor

California Cancer Registry Data Dictionary

Variable Name: CHROMOSOME19QLOH
Eureka Name: Chromosome 19q: Loss of Heterozygosity (LOH)
NAACCR Item: 3802
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 – current year

Related Variables:

Definition: Chromosome 19q: Loss of Heterozygosity (LOH) refers to the loss of genetic material normally found on the long arm of one of the patient's two copies of chromosome 19. Codeletion of Chromosome 1p and 19q is a diagnostic, prognostic and predictive marker for gliomas and is strongly associated with the oligodendroglioma phenotype.

Values:

- 0: Chromosome 19q deletion/LOH not identified/not present
- 1: Chromosome 19q deletion/LOH identified/present
- 6: Benign or borderline tumor
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in patient record; Cannot be determined by the pathologist; Chromosome 19q deletion/LOH not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: CHROMOSOME1PLOH
Eureka Name: Chromosome 1p: Loss of Heterozygosity (LOH)
NAACCR Item: 3801
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 – current year

Related Variables:

Definition: Chromosome 1p: Loss of Heterozygosity (LOH) refers to the loss of genetic material normally found on the short arm of one of the patient's two copies of chromosome 1. Codeletion of Chromosome 1p and 19q is a diagnostic, prognostic and predictive marker for gliomas and is strongly associated with the oligodendroglioma phenotype.

Values:

- 0: Chromosome 1p deletion/LOH not identified/not present
- 1: Chromosome 1p deletion/LOH identified/present
- 6: Benign or borderline tumor
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in patient record; Cannot be determined by the pathologist; Chromosome 1p deletion/LOH not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: CHROMOSOME3STATUS

Eureka Name: Chromosome 3 Status

NAACCR Item: 3821

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables:

Definition: Chromosome 3 Status refers to the partial or total loss of Chromosome 3, which is a prognostic factor for uveal melanoma.

Values:

- 0: No loss of chromosome 3
- 1: Partial loss of chromosome 3
- 2: Complete loss of chromosome 3
- 3: Loss of chromosome 3, NOS
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Chromosome 3 status not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: CHROMOSOME8QSTAT

Eureka Name: Chromosome 8q Status

NAACCR Item: 3822

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables:

Definition: Chromosome 8q Status refers to the partial or total loss of Chromosome 8q, which is a prognostic factor for uveal melanoma.

Values:

- 0: No gain in chromosome 8q
- 1: Gain in chromosome 8q
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Chromosome 8q status not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: CLASS
Eureka Name: Class of Case
NAACCR Item: 610
Category: Hospital and Physician
Level of Variable: Admission
Time Period Available: 1988 – current year

Related Variables:

Definition: Class of Case divides cases into two groups. Analytic cases (codes 00-22) are those that are required by CoC to be abstracted because of the program's primary responsibility in managing the cancer. Analytic cases are grouped according to the location of diagnosis and treatment. Treatment and outcome reports may be limited to analytic cases. Nonanalytic cases (codes 30-49 and 99) may be abstracted by the facility to meet central registry requirements or because of a request by the facility's cancer program. Nonanalytic cases are grouped according to the reason a patient who received care at the facility is nonanalytic, or the reason a patient who never received care at the facility may have been abstracted.

Class of Case reflects the facility's role in managing the cancer, whether the cancer is required to be reported by CoC, and whether the case was diagnosed after the program's Reference Date. The value in this field was taken from the facility with the earliest admission date for the tumor.

Values:

INITIAL DIAGNOSIS REPORTING FACILITY:

- 00*: Initial diagnosis at the reporting facility AND all treatment or a decision not to treat was done ELSEWHERE
- 10*: Initial diagnosis at the reporting facility or in a staff physician's office AND PART OR ALL of first course treatment or a decision not to treat was done at the reporting facility, NOS
- 11: Initial diagnosis in staff physician's office AND PART of first course treatment was done at the reporting facility
- 12: Initial diagnosis in staff physician's office AND ALL first course treatment or a decision not to treat was done at the reporting facility
- 13*: Initial diagnosis AND PART of first course treatment was done at the reporting facility
- 14*: Initial diagnosis at the reporting facility AND ALL first course treatment or a decision not to treat was done at the reporting facility

INITIAL DIAGNOSIS ELSEWHERE, FACILITY INVOLVED IN FIRST COURSE TREATMENT:

- 20*: Initial diagnosis elsewhere AND PART OR ALL of first course treatment was done at the reporting facility, NOS

California Cancer Registry Data Dictionary

- 21*: Initial diagnosis elsewhere AND PART of treatment was done at the reporting facility
- 22*: Initial diagnosis elsewhere AND ALL first course treatment was done at the reporting facility

PATIENT APPEARS IN PERSON AT REPORTING FACILITY; BOTH INITIAL DIAGNOSIS AND TREATMENT ELSEWHERE:

- 30*: Initial diagnosis and all first course treatment elsewhere AND reporting facility participated in DIAGNOSTIC WORKUP (for example, consult only, staging workup after initial diagnosis elsewhere)
- 31*: Initial diagnosis and all first course treatment elsewhere AND reporting facility provided IN-TRANSIT care
- 32*: Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease RECURRENCE OR PERSISTENCE
- 33*: Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease HISTORY ONLY
- 34: Type of case not required by CoC to be accessioned (for example, a benign colon tumor) AND initial diagnosis AND part or all of first course treatment by reporting facility
- 35: Case diagnosed before program's Reference Date AND initial diagnosis AND PART OR ALL of first course treatment by reporting facility
- 36: Type of case not required by CoC to be accessioned (for example, a benign colon tumor) AND initial diagnosis elsewhere AND part of all of first course treatment by reporting facility
- 37: Case diagnosed before program's Reference Date AND initial diagnosis elsewhere AND all or part of first course treatment by facility
- 38*: Initial diagnosis established by AUTOPSY at the reporting facility, cancer not suspected prior to Death

PATIENT DOES NOT APPEAR IN PERSON AT REPORTING FACILITY

- 40: Diagnosis AND all first course treatment given at the same staff physician's office
- 41: Diagnosis and all first course treatment given in two or more different staff physician offices
- 42: Non-staff physician or non-CoC approved clinic or other facility, not part of reporting facility, accessioned by reporting facility for diagnosis and/or treatment by that entity (for example, hospital abstracts cases from an independent radiation facility)
- 43*: PATHOLOGY or other lab specimens ONLY

California Cancer Registry Data Dictionary

49*: Death certificate only

UNKNOWN RELATIONSHIP TO REPORTING FACILITY

99*: Nonanalytic case of unknown relationship to facility (not for use by CoC accredited cancer programs for analytic cases.); UNKNOWN

*Indicates Class of Case codes appropriate for abstracting cases from non-hospital sources such as physician offices, ambulatory surgery centers, freestanding pathology laboratories, radiation therapy centers. When applied to these types of facilities, the non-hospital source is the reporting facility. The codes are applied the same way as if the case were reported from a hospital.

California Cancer Registry Data Dictionary

Variable Name: CNTYFIPS
Eureka Name: N/A
NAACCR Item: N/A
Category: Geographical Information
Level of Variable: Tumor
Time Period Available: 1988 – current year
Related Variables: County at DX Reported (COUNTY)
Definition: Federal Information Processing Standards (FIPS) County code.

Values:

1:	Alameda
3:	Alpine
5:	Amador
7:	Butte
9:	Calaveras
11:	Colusa
13:	Contra Costa
15:	Del Norte
17:	El Dorado
19:	Fresno
21:	Glenn
23:	Humboldt
25:	Imperial
27:	Inyo
29:	Kern
31:	Kings
33:	Lake
35:	Lassen
37:	Los Angeles
39:	Madera
41:	Marin
43:	Mariposa
45:	Mendocino
47:	Merced
49:	Modoc
51:	Mono
53:	Monterey
55:	Napa
57:	Nevada
59:	Orange
61:	Placer

California Cancer Registry Data Dictionary

63:	Plumas
65:	Riverside
67:	Sacramento
69:	San Benito
71:	San Bernardino
73:	San Diego
75:	San Francisco
77:	San Joaquin
79:	San Luis Obispo
81:	San Mateo
83:	Santa Barbara
85:	Santa Clara
87:	Santa Cruz
89:	Shasta
91:	Sierra
93:	Siskiyou
95:	Solano
97:	Sonoma
99:	Stanislaus
101:	Sutter
103:	Tehama
105:	Trinity
107:	Tulare
109:	Tuolumne
111:	Ventura
113:	Yolo
115:	Yuba

California Cancer Registry Data Dictionary

Variable Name: COC_FLAG
Eureka Name: N/A
NAACCR Item: N/A
Category: Hospital and Physician
Level of Variable: Tumor
Time Period Available: 1988 – current year

Related Variables:

Definition: COC_FLAG indicates whether a patient was seen at a California Commission on Cancer (CoC) accredited program for their cancer. The flag is created by reviewing all abstracts pertaining to a patient's cancer diagnosis. If an abstract was reported by a facility with a CoC accredited program and the facility indicated the patient's cancer was an analytic case (i.e. CLASS = 00 through 22) then COC_FLAG=1. Otherwise, COC_FLAG=0.

Notes: Unlike NCI_FLAG and NCCN_FLAG, COC_FLAG does not consider year of diagnosis because we do not have information on when hospitals received CoC accreditation. COC_FLAG differs from the variable ACOS in that COC_FLAG is a tumor-level variable which consolidates information from all abstracts reported for a cancer. ACOS only considers the earliest abstract reported for a cancer.

Values:

- 0: Patient was not seen at a California Commission on Cancer (CoC) accredited program for this cancer
- 1: Patient was seen at a California Commission on Cancer (CoC) accredited program for this cancer

California Cancer Registry Data Dictionary

Variable Name: COCACCREDTEDFLAG

Eureka Name: CoC Accredited Flag

NAACCR Item: 2152

Category: Hospital and Physician

Level of Variable: Admission

Time Period Available: 2018 – current year

Related Variables: ACOS Approved (ACOS)

Definition: CoC Accredited Flag indicates the abstract is being prepared as an analytic cancer case at a facility accredited by the Commission on Cancer (CoC). The flag may be assigned manually or can be defaulted by the registry's software. The value in this field comes from the facility with the earliest date of admission for this tumor. For cases diagnosed 1999 through 2017, see the variable ACOS.

Values:

- 0: Abstract prepared at a facility WITHOUT CoC accreditation of its cancer program
- 1: ANALYTIC abstract prepared at facility WITH CoC accreditation of its cancer program (Includes Class of Case codes 10-22)
- 2: NON-ANALYTIC abstract prepared at facility WITH CoC accreditation of its cancer program (Includes Class of Case codes 30-43 and 99, plus code 00 which CoC considers analytic but does not require to be staged)
- Blank: Not applicable; death certificate only

California Cancer Registry Data Dictionary

Variable Name: CODPROC
Eureka Name: Coding Proc
NAACCR Item: N/A
Category: Administrative
Level of Variable: Admission
Time Period Available: 1988 – current year

Related Variables:

Definition: Designates the set of rules used to code this case. The value in this field comes from the facility with the earliest date of admission for the patient/tumor.

Values:

- 03-09: Coded prior to May 1978 (Region 8 only)
- 10: Coded May 1978 - Dec. 1983 (Region 8 only)
- 11: Coded Jan. 1984 - Apr. 1988
- 12: Coded May 1988 and later
- 13: Coded June 1991 and later
- 14: Coded Jan. 1, 1992 and later
- 15: Coded during or after summer 1993
- 16: Coded beginning in 1996
- 17: Coded beginning in 1997
- 18: Coded beginning in 1998
- 19: Coded beginning in 2000
- 20: Coded beginning in 2001
- 21: Coded beginning in 2003
- 22: Coded beginning in 2004
- 23: Coded beginning in 2005
- 24: Coding rules implemented with 2006 data changes
- 25: Coding rules implemented with 2007 data changes
- 26: Coding rules implemented with 2008 data changes
- 27: Coding rules implemented with 2010 data changes
- 28: Coding rules implemented with 2011 data changes
- 29: Coding rules implemented with 2012 data changes
- 30: Coding rules implemented with 2013 data changes
- 31: Coding rules implemented with 2014 data changes
- 32: Coding rules implemented with 2015 data changes
- 33: Coding rules implemented with 2016 data changes
(No data changes for 2017 – code remained 33)
- 34: Coding rules implemented with 2018 data changes
- 99: Default value for blanks/non-numeric values

California Cancer Registry Data Dictionary

Variable Name: COLLEGE

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 1988 - 2005

Related Variables:

- Census Block 90 (BLKGRP90)
- Census Block 2000 (BLKGRP00)
- Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: Proportion of the population within the assigned Census block group, age 25 years and older with a college degree. This variable is obtained from the U.S. Census. Each CCR record is assigned a Census block group based on the patient's address at time of diagnosis. The block group is then used to append COLLEGE values from the 1990 Census for cases diagnosed 1988-1995 and from the 2000 Census for cases diagnosed 1996-2005. If a case received a randomly assigned block group, the COLLEGE value is that of the randomly assigned block group and RANDOM=1.

California Cancer Registry Data Dictionary

Variable Name: COLLEGECT

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 1988 - 2005

Related Variables:

- Census Tract 1970/80/90 (CENSUS90)
- Census Tract 2000 (CENSUS00)
- Proportion of Population with a College Degree in Census Tract 2006 and forward (COLLEGECTACS2011)
- Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: Proportion of the population within the assigned Census tract, age 25 years and older with a college degree. This variable is obtained from the U.S. Census. Each CCR record is assigned a Census tract based on the patient's address at time of diagnosis. The Census tract is then used to append COLLEGECT values from the 1990 Census for cases diagnosed 1988-1995 and from the 2000 Census for cases diagnosed 1996-2005. If a case received a randomly assigned Census tract, the COLLEGECT value is that of the randomly assigned Census tract and RANDOM=1. For cases diagnosed 2006 and forward, use the variable COLLEGECTACS2011.

California Cancer Registry Data Dictionary

Variable Name: COLLEGEACTACS2011

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 2006 - current year

Related Variables:

- Census Tract 2010 (CENSUSTRACT2010)
- Proportion of Population with a College Degree in Census Tract 1988 through 2005 (COLLEGEACT)
- Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: Proportion of the population within the assigned Census tract, age 25 years and older with a college degree. This variable is obtained from the 2007-2011 American Community Survey (ACS) data. Each CCR record is assigned a Census tract based on the patient's address at time of diagnosis. The Census tract is then used to append COLLEGEACTACS2011 values for cases diagnosed 2006 and forward. If a case received a randomly assigned Census tract, the COLLEGEACTACS2011 value is that of the randomly assigned Census tract and RANDOM=1. For cases diagnosed prior to 2006, use the variable COLLEGEACT.

California Cancer Registry Data Dictionary

Variable Name:	COMORBIDCOMPLICATION1, COMORBIDCOMPLICATION2 COMORBIDCOMPLICATION3, COMORBIDCOMPLICATION4 COMORBIDCOMPLICATION5, COMORBIDCOMPLICATION6, COMORBIDCOMPLICATION7, COMORBIDCOMPLICATION8, COMORBIDCOMPLICATION9, COMORBIDCOMPLICATION10
Eureka Name:	Comorbid/Complication 1, Comorbid/Complication 2, Comorbid/Complication 3, Comorbid/Complication 4, Comorbid/Complication 5, Comorbid/Complication 6, Comorbid/Complication 7, Comorbid/Complication 8, Comorbid/Complication 9, Comorbid/Complication 10
NAACCR Item:	3110, 3120, 3130, 3140, 3150, 3160, 3161, 3162, 3163, 3164, 3165
Category:	Clinical, Other
Level of Variable:	Tumor
Time Period Available:	2004 - 2015
Related Variables:	Secondary Diagnosis 1, Secondary Diagnosis 2, Secondary Diagnosis 3, Secondary Diagnosis 4, Secondary Diagnosis 5, Secondary Diagnosis 6, Secondary Diagnosis 7, Secondary Diagnosis 8, Secondary Diagnosis 9, Secondary Diagnosis 10
Definition:	Records the patient's pre-existing medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-9-CM codes. All are considered secondary diagnoses. Pre-existing medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Complications may be related to the quality of care.
Notes:	These data items are required by CCR "when available." However, CoC facilities are required to collect this information. As such, many cases in the CCR may have missing information. Only ICD-9-CM codes are allowed in these fields. ICD-10-CM codes are recorded in Secondary Diagnosis 1 through 10 fields. ICD-10-CM was implemented October 1, 2015.
Values:	ICD-9-CM Codes (decimal points omitted): 00100-13980 24000-99990 E8700-E8799 E9300-E9499 V0720-V0739 V1000-V1590 V2220- V2310 V2540 V4400-V4589 V5041-V5049 00000 No comorbid conditions or complications documented

California Cancer Registry Data Dictionary

Variable Name:	CONADDR
Eureka Name:	Address Current--No & Street
NAACCR Item:	2350
Category:	Follow-Up
Level of Variable:	Patient
Time Period Available:	1988 – current year
Related Variables:	<ul style="list-style-type: none"> • Addr Current--City (CONCITY) • Addr Current--Postal Code (CONZIP) • Addr Current--State (CONSTATE) • Addr Current--Supplemental (CONADDR_S)
Definition:	Current street address for either the patient or a contact person who can provide follow up information on the patient. CONADDR_S (NAACCR #2355) provides supplemental address information for the patient.
Values:	Any valid address: Any combination of alpha and numeric characters Unknown: Address not known

California Cancer Registry Data Dictionary

Variable Name:	CONADDR_S
Eureka Name:	Addr Current--Supplemental
NAACCR Item:	2355
Category:	Follow-Up
Level of Variable:	Patient
Time Period Available:	1988 – current year
Related Variables:	<ul style="list-style-type: none"> • Address Current--No & Street (CONADDR) • Addr Current--City (CONCITY) • Addr Current--Postal Code (CONZIP) • Addr Current--State (CONSTATE)
Definition:	Supplemental address for either the patient or a contact person who can provide follow up information on the patient; allows for the storage of extra address information, such as the name of a nursing home.
Values:	Any valid address: Any combination of alpha and numeric characters Unknown: Address not known

California Cancer Registry Data Dictionary

Variable Name:	CONCITY
Eureka Name:	Addr Current--City
NAACCR Item:	1810
Category:	Follow-Up
Level of Variable:	Patient
Time Period Available:	1988 – current year
Related Variables:	<ul style="list-style-type: none"> • Address Current--No & Street (CONADDR) • Addr Current--Postal Code (CONZIP) • Addr Current--State (CONSTATE) • Addr Current--Supplemental (CONADDR_S)
Definition:	City name of patient's current address or address where patient can be contacted.
Values:	<p>Any alpha</p> <p>Unknown: City of residence is not known</p>

California Cancer Registry Data Dictionary

Variable Name: CONSTATE

Eureka Name: Addr Current--State

NAACCR Item: 1820

Category: Follow-Up

Level of Variable: Patient

Time Period Available: 1988 - current year

Related Variables:

- Address Current--No & Street (CONADDR)
- Addr Current--City (CONCITY)
- Addr Current--Postal Code (CONZIP)
- Addr Current--Supplemental (CONADDR_S)

Definition: State of patient's current address or address where patient can be contacted.

Notes: For a list of allowable values, see "Cancer Reporting in California, California Cancer Reporting System Standards,

[Volume I, Appendix B – Postal Abbreviations for States and Territories of the United States](#)

Values:

AK-WY:	US States/Territories
AA-AP:	United States Military Personnel Serving Abroad
AB-YT:	Canadian Provinces/Territories
CD:	Canada, NOS
US:	Resident of United States, NOS
XX:	Not U.S., U.S. Territory, not Canada, and country is known
YY:	Not U.S., U.S. Territory, North American Islands, not Canada, and country is unknown
ZZ:	Residence is unknown

California Cancer Registry Data Dictionary

Variable Name:	CONZIP
Eureka Name:	Addr Current--Postal Code
NAACCR Item:	1830
Category:	Follow-Up
Level of Variable:	Patient
Time Period Available:	1988 – current year
Related Variables:	<ul style="list-style-type: none"> • Address Current--No & Street (CONADDR) • Addr Current--City (CONCITY) • Addr Current--State (CONSTATE) • Addr Current--Supplemental (CONADDR_S)
Definition:	Zip code of patient's current address or address where patient can be contacted.
Values:	<p>Nine-digit US ZIP code; 9's if US or Canadian resident, unknown zip; if first 5 <> 9's and last 4 unknown, then last 4 blank; 8's if unknown outside USA and Canada.</p> <p>If the code is known, regardless of the country that it is in, the postal code should be entered here.</p> <p>888888888: Resident of country other than the US (including its possessions, etc.) or Canada and postal code unknown.</p> <p>999999999: Resident of the US (including its possessions, etc.) or Canada and postal code unknown.</p>

California Cancer Registry Data Dictionary

Variable Name: COUNTY

Eureka Name: County at DX Reported

NAACCR Item: 90

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: 1988 – current year

Related Variables:

Definition: Code for the county of the patient's residence at the time the tumor was diagnosed. If the patient has multiple tumors, the county codes may be different for each tumor.

Values:

001-058:	California counties in alphabetical order. (See Volume I, Appendix H)
000:	California, county unknown or other USA state
100-725:	Non-USA (See Volume 1, Appendix C) (COUNTRY-CODES)
998:	Non-USA (other than Canada and Mexico), specific country code not yet assigned
999:	Unknown

California Cancer Registry Data Dictionary

Variable Name: COUNTYATDXGEOCODE1990
Eureka Name: County at DX Geocode1970/80/90
NAACCR Item: 94
Category: Geographical Information
Level of Variable: Tumor
Time Period Available: 1988 - 1999

Related Variables:

Definition: County of the patient's residence at the time the tumor was diagnosed. The value for county in this field is derived (geocoded) based on Census Boundary files from 1990 Decennial Census.

Values:

- 001-058: California counties in alphabetical order. ([See Volume I, Appendix H](#))
- 000: California, county unknown or other USA state
- 100-725: Non-USA ([See Volume 1, Appendix C](#)) (COUNTRY-CODES)
- 998: Non-USA (other than Canada and Mexico), specific country code not yet assigned
- 999: Unknown

California Cancer Registry Data Dictionary

Variable Name: COUNTYATDXGEOCODE2000

Eureka Name: County at DX Geocode2000

NAACCR Item: 95

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: 1995 - 2011

Related Variables:

Definition: County of the patient's residence at the time the tumor was diagnosed. The value for county in this field is derived (geocoded) based on Census Boundary files from 2000 Decennial Census.

Values:

- 001-058: California counties in alphabetical order. ([See Volume I, Appendix H](#))
- 000: California, county unknown or other USA state
- 100-725: Non-USA ([See Volume 1, Appendix C](#)) (COUNTRY-CODES)
- 998: Non-USA (other than Canada and Mexico), specific country code not yet assigned
- 999: Unknown

California Cancer Registry Data Dictionary

Variable Name: COUNTYATDXGEOCODE2010

Eureka Name: County at DX Geocode2010

NAACCR Item: 96

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: 2006 - current year

Related Variables:

Definition: County of the patient's residence at the time the tumor was diagnosed. The value for county in this field is derived (geocoded) based on Census Boundary files from 2010 Decennial Census.

Values:

- 001-058: California counties in alphabetical order. ([See Volume I, Appendix H](#))
- 000: California, county unknown or other USA state
- 100-725: Non-USA ([See Volume 1, Appendix C](#)) (COUNTRY-CODES)
- 998: Non-USA (other than Canada and Mexico), specific country code not yet assigned
- 999: Unknown

California Cancer Registry Data Dictionary

Variable Name: CREATININEPREUNIT
Eureka Name: Creatinine Pretreatment Unit of Measure
NAACCR Item: 3825
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 - current year

Related Variables:

Definition: Creatinine Pretreatment Unit of Measure identifies the unit of measure for the creatinine value measured in blood or serum prior to treatment. Creatinine is commonly measured in units of milligrams/deciliter (mg/dl) in the United States and micromoles/liter (umol/L) in Canada and Europe.

Values:

- 1: Milligrams/deciliter (mg/dl)
- 2: Micromoles/liter (umol/L)
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Creatinine unit of measure not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: CREATININEPREVALU
Eureka Name: Creatinine Pretreatment Lab Value
NAACCR Item: 3824
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 - current year

Related Variables:

Definition: Creatinine Pretreatment Lab Value, an indicator of kidney function is required to calculate the Model for End-Stage Liver Disease (MELD) score, which is used to assign priority for liver transplant.

Values:

- 0.0: 0.0 milligram/deciliter (mg/dl); 0.0 micromole/liter (umol/L)
- 0.1-99.9: 0.1-99.9 milligram/deciliter (mg/dl); 0.1-99.9 micromole/liter (umol/L)
(Exact value to nearest tenth of mg/dl or umol/L)
- XX.1: 100 mg/dl or greater; 100 umol/L or greater
- XX.7: Test ordered, results not in chart
- XX.8: Not applicable: Information not collected for this case
- XX.9: Not documented in medical record; Creatinine Pretreatment Lab Value
not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: CRMARGIN
Eureka Name: Circumferential Resection Margin (CRM)
NAACCR Item: 3823
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 – current year
Related Variables:

Definition: Circumferential or Radial Resection Margin, the distance in millimeters between the leading edge of the tumor and the surgically dissected margin as recorded on the pathology report is a prognostic indicator for colon and rectal cancer. This may also be referred to as the Radial Resection Margin or surgical clearance.

Values:

- 0.0: Circumferential resection margin (CRM) positive; Margin IS involved with tumor; Described as "less than 1 millimeter (mm)"
- 0.1-99.9: Distance of tumor from margin: 0.1- 99.9 millimeters (mm) (Exact size to nearest tenth of millimeter)
- XX.0: 100 mm or greater
- XX.1: Margins clear, distance from tumor not stated; Circumferential or radial resection margin negative, NOS; No residual tumor identified on specimen
- XX.2: Margins cannot be assessed
- XX.3: Described as "at least" 1 mm
- XX.4: Described as "at least" 2 mm
- XX.5: Described as "at least" 3 mm
- XX.6: Described as "greater than" 3 mm
- XX.7: No resection of primary site; Surgical procedure did not remove enough tissue to measure the circumferential or radial resection margin (Examples include: polypectomy only, endoscopic mucosal resection (EMR), excisional biopsy only, transanal disk excision)
- XX.8: Not applicable: Information not collected for this case
- XX.9: Not documented in medical record; Circumferential or radial resection margin not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name:	CS_EXT
Eureka Name:	CS Extension
NAACCR Item:	2810
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2004 – 2015
Related Variables:	<ul style="list-style-type: none"> • EOD--Extension (DIREXTTU) • TNM Path T (TNM_T_CODE_PATH) • TNM Clin T (TNM_T_CODE_CLINICAL) • EOD Primary Tumor (EODPRIMARYTUMOR) • Derived AJCC-6 T (DERIVED_AJCC_T) • Derived AJCC-6 T Descript (DERIVED_AJCC_T_DESC) • Derived AJCC-7 T (DERIVEDAJCC7T) • Derived AJCC-7 T Descript (DERIVEDAJCC7TDESCRIP)

Definition: This data item is part of the Collaborative Staging (CS) data item set. For cases diagnosed 2004 through 2015, this data item identifies contiguous growth (extension) of the primary tumor within the organ of origin or its direct extension into neighboring organs. Tumor extension at diagnosis is a prognostic indicator used by Collaborative Staging to derive some TNM-T codes and some SEER Summary Stage codes. It is based on and replaces the EOD extension variable (DIREXTTU) used to code cases diagnosed 1988 through 2003. For cases diagnosed 2016 and 2017, this information is recorded in the field TNM_T_CODE_PATH or TNM_T_CODE_CLINICAL. For cases diagnosed 2018 and forward, this information is recorded in the field EODPRIMARYTUMOR.

Notes: **For cases diagnosed prior to 2010**, this was a two-character field in CS version 1 which was converted to a three-character field in CS version 2. Most two-character codes were converted by adding a zero as the third character. For example, code 05 was usually converted to 050, 10 to 100, 11 to 110, etc. Special codes such as 88 and 99 were usually converted to 888 and 999, respectively. See the Collaborative Stage Data Collection System Manual and Coding Instructions (<http://cancerstaging.org/cstage>) for rules and site-specific codes and coding structures.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:	000-999: Site specific
	Blank: Year of Diagnosis is before 2004 or after 2015

California Cancer Registry Data Dictionary

Variable Name:	CS_LN
Eureka Name:	CS Lymph Nodes
NAACCR Item:	2830
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2004 – 2015
Related Variables:	<ul style="list-style-type: none"> • EOD--Lymph Node Involv (LNSUMTU) • TNM Path N (TNM_N_CODE_PATH) • TNM Clin N (TNM_N_CODE_CLINICAL) • EOD Regional Nodes (EODREGNODES) • Derived AJCC-6 N (DERIVED_AJCC_N) • Derived AJCC-6 N Descript (DERIVED_AJCC_N_DESC) • Derived AJCC-7 N (DERIVEDAJCC7N) • Derived AJCC-7 N Descript (DERIVEDAJCC7NDESCRPT)

Definition: Part of the Collaborative Staging (CS) data item set, this variable identifies the regional lymph nodes involved with the cancer at the time of diagnosis. The CS algorithm uses this data item to derive the TNM-N code value (DERIVED_AJCC_N, DERIVEDAJCC7N). CS_LN is based on and replaces EOD--Lymph Node Involv (LNSUMTU) used to code cases diagnosed 1988 through 2003. For cases diagnosed 2016 and 2017, this information is recorded in the field TNM_N_CODE_PATH or TNM_N_CODE_CLINICAL. For cases diagnosed 2018 and forward, this information is recorded in the field EODREGNODES.

Notes: **For cases diagnosed prior to 2010**, this was a two-character field in CS version 1 which was converted to a three-character field in CS version 2. Most two-character codes were converted by adding a zero as the third character. For example, code 05 was usually converted to 050, 10 to 100, 11 to 110, etc. Special codes such as 88 and 99 were usually converted to 888 and 999, respectively. See the Collaborative Stage Data Collection System Manual and Coding Instructions (<http://cancerstaging.org/cstage>) for rules and site-specific codes.

For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”

Values:	000-999: Site specific
	Blank: Year of Diagnosis is before 2004 or after 2015

California Cancer Registry Data Dictionary

Variable Name: CS_METS_DX

Eureka Name: CS Mets at DX

NAACCR Item: 2850

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2004 – 2015

Related Variables:

- EOD--Extension (DIREXTTU)
- TNM Path M (TNM_M_CODE_PATH)
- TNM Clin M (TNM_M_CODE_CLINICAL)
- EOD Mets (EODMETS)
- Derived AJCC-6 M (DERIVED_AJCC_M)
- Derived AJCC-6 M Descript (DERIVED_AJCC_M_DESC)
- Derived AJCC-7 M (DERIVEDAJCC7M)
- Derived AJCC-7 M Descript (DERIVEDAJCC7MDESCRIPT)

Definition: Part of the Collaborative Staging (CS) data item set, this variable identifies the extent/site(s) of metastatic involvement at the time of diagnosis. For many sites, the CS algorithm uses this data item to derive the TNM-M code value (DERIVED_AJCC_M, DERIVEDAJCC7M). CS_METS_DX is based on and replaces EOD--Extension (DIREXTTU) used to code cases diagnosed 1988 through 2003. For cases diagnosed 2016 and 2017, this information is recorded in the field TNM_M_CODE_PATH or TNM_M_CODE_CLINICAL. For cases diagnosed 2018 and forward, this information is recorded in the field EODMETS.

Notes: See the Collaborative Stage Data Collection System Manual and Coding Instructions (<http://cancerstaging.org/cstage>) for rules and site-specific codes and coding structures.

For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”

Values:

00-99: Site specific

Blank: Year of Diagnosis is before 2004 or after 2015

California Cancer Registry Data Dictionary

Variable Name: CS_METS_EVAL
Eureka Name: CS Mets Eval
NAACCR Item: 2860
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2004 – 2015
Related Variables: CS Mets at DX (CS_METS_DX)

Definition: This data item records how the code for CS Mets at DX (CS_METS_DX) was determined based on the diagnostic methods employed. This data item is used by Collaborative Staging to describe whether the staging basis for the TNM-M code is clinical or pathological and to record applicable prefix and suffix descriptors used with TNM staging. This data item was only reported to CCR by CoC accredited facilities for years of diagnosis 2004-2007. Beginning with cases diagnosed in 2008, all facilities were required to report this data item to CCR.

Notes: See the Collaborative Stage Data Collection System Manual and Coding Instructions (<http://cancerstaging.org/cstage>) for rules and site-specific codes and coding structures.

For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”

Values: 0, 1, 6, 8, 9: Site specific
 Blank: Year of Diagnosis is before 2004 or after 2015

California Cancer Registry Data Dictionary

Variable Name: CS_REG_LN_EVAL
Eureka Name: CS Lymph Nodes Eval
NAACCR Item: 2840
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2004 – 2015
Related Variables: CS Lymph Nodes (CS_LN)

Definition: Records how the code for CS Lymph Nodes (CS_LN) was determined, based on the diagnostic methods employed. This data item is used by Collaborative Staging to describe whether the staging basis for the TNM-N code is clinical or pathological and to record applicable prefix and suffix descriptors used with TNM staging. This data item was only reported to CCR by CoC accredited facilities for years of diagnosis 2004-2007. Beginning with cases diagnosed in 2008, all facilities were required to report this data item to CCR.

Notes: See the Collaborative Stage Data Collection System Manual and Coding Instructions (<http://cancerstaging.org/cstage>) for rules and site-specific codes and coding structures.

For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”

Values: 0-3, 5, 6, 8, 9: Site specific
 Blank: Year of Diagnosis is before 2004 or after 2015

California Cancer Registry Data Dictionary

Variable Name: CS_SITE_SPEC_F1, CS_SITE_SPEC_F2, CS_SITE_SPEC_F3, CS_SITE_SPEC_F4, CS_SITE_SPEC_F5, CS_SITE_SPEC_F6

Eureka Name: CS Site-Specific Factor 1, CS Site-Specific Factor 2, CS Site-Specific Factor 3, CS Site-Specific Factor 4, CS Site-Specific Factor 5, CS Site-Specific Factor 6

NAACCR Item: 2880, 2890, 2900, 2910, 2920, 2930

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2004 – 2017

Related Variables:

Definition: These data items are part of the Collaborative Stage (CS) Data Collection System, which is based on the **AJCC Cancer Staging Manual**, 6th and 7th editions. CS Site-Specific Factors are used to code additional site-specific information needed to derive TNM and/or SEER Summary Stage or to code prognostic factors that have an effect on stage or survival.

Notes: The information recorded in CS Site-Specific Factor 1 through 6 differs for each anatomic site. See the Collaborative Stage Data Collection System Manual and Coding Instructions (<http://cancerstaging.org/cstage>), for rules and site-specific codes and coding structures.

For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”

Values:

000-999:	Site specific
Blank:	Year of Diagnosis is before 2004, after 2017, or unknown

California Cancer Registry Data Dictionary

Variable Name: CS_TS_EXT_EVAL
Eureka Name: CS Tumor Size/Ext Eval
NAACCR Item: 2820
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2004 – 2015
Related Variables:

- CS Tumor Size (CS_TUM_SIZE)
- CS Extension (CS_EXT)

Definition: This data item records how the codes for CS Tumor Size (CS_TUM_SIZE) and CS Extension (CS_EXT) were determined based on the diagnostic methods employed. This item is used by Collaborative Staging to describe whether the staging basis for the TNM-T code is clinical or pathological and to record applicable prefix and suffix descriptors used with TNM staging. This data item was only reported to CCR by CoC accredited facilities for years of diagnosis 2004-2007. Beginning with cases diagnosed in 2008, all facilities were required to report this data item to CCR.

Notes: See the Collaborative Stage Data Collection System Manual and Coding Instructions (<http://cancerstaging.org/cstage>), for rules and site-specific codes and coding structures.

For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”

Values: 0-6, 8, 9: Site specific
 Blank: Year of Diagnosis is before 2004 or after 2015

California Cancer Registry Data Dictionary

Variable Name: CS_TUM_SIZE
Eureka Name: CS Tumor Size
NAACCR Item: 2800
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2004 – 2015
Related Variables:

- **Tumor Size (TUMORSIZE)**
- EOD--Tumor Size (TSIZETU)
- Tumor Size Summary (TUMORSIZESUMMARY)

Definition: This data item is part of the Collaborative Staging (CS) data item set. For most sites, CS_TUM_SIZE records the largest dimension or diameter of the primary tumor in millimeters. For many sites, the CS algorithm uses this data item to derive the TNM-T code value. CS_TUM_SIZE is based on and replaces EOD--Tumor Size (TSIZETU) used to code cases diagnosed 1988 through 2003. For cases diagnosed 2016 and forward, this information is recorded in the field TUMORSIZESUMMARY.

Notes: See the Collaborative Stage Data Collection System Manual and Coding Instructions (<http://cancerstaging.org/cstage>), for rules and site-specific codes and coding structures.

The variable **TUMORSIZE** is a summary variable that combines TSIZETU, CS_TUM_SIZE, and TUMORSIZESUMMARY to provide a single variable for tumor size across all years of diagnosis.

For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”

Values: 000-999: Site specific
 Blank: Year of Diagnosis is before 2004 or after 2015

California Cancer Registry Data Dictionary

Variable Name: CSMETSATDXBONE
Eureka Name: CS Mets at DX-Bone
NAACCR Item: 2851
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2010 – 2015
Related Variables:

- CS Mets at DX-Brain (CSMETSATDXBRAIN)
- CS Mets at DX-Liver (CSMETSATDXLIVER)
- CS Mets at DX-Lung (CSMETSATDXLUNG)
- CS Mets at DX (CS_METS_DX)

Definition: Identifies the presence of distant metastatic involvement of bone at time of diagnosis. The presence of metastatic bone disease at diagnosis is an independent prognostic indicator and is used by Collaborative Staging to derive TNM-M codes and SEER Summary Stage codes for some sites.

Notes: *For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”*

Values: 0, 1, 8, 9: Site specific (see the most current version of the Collaborative Stage Data Collection System [<https://cancerstaging.org/cstage/Pages/default.aspx>] for rules and site-specific codes and coding instructions).
 Blank: Year of Diagnosis is before 2010 or after 2015

California Cancer Registry Data Dictionary

Variable Name: CSMETSATDXBRAIN

Eureka Name: CS Mets at DX-Brain

NAACCR Item: 2852

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2010 – 2015

Related Variables:

- CS Mets at DX-Bone (CSMETSATDXBONE)
- CS Mets at DX-Liver (CSMETSATDXLIVER)
- CS Mets at DX-Lung (CSMETSATDXLUNG)
- CS Mets at DX (CS_METS_DX)

Definition: Identifies the presence of distant metastatic brain disease at time of diagnosis. The presence of metastatic brain disease is an independent prognostic indicator and is used by Collaborative Staging to derive TNM-M codes and SEER Summary Stage codes for some sites.

Notes: *For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”*

Values:

0, 1, 8, 9: Site specific (see the most current version of the Collaborative Stage Data Collection System [<https://cancerstaging.org/cstage/Pages/default.aspx>] for rules and site-specific codes and coding instructions).

Blank: Year of Diagnosis is before 2010 or after 2015

California Cancer Registry Data Dictionary

Variable Name: CSMETSATDXLIVER
Eureka Name: CS Mets at DX-Liver
NAACCR Item: 2853
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor

Time Period Available: 2010 – 2015

Related Variables:

- CS Mets at DX-Bone (CSMETSATDXBONE)
- CS Mets at DX-Brain (CSMETSATDXBRAIN)
- CS Mets at DX-Lung (CSMETSATDXLUNG)
- CS Mets at DX (CS_METS_DX)

Definition: Identifies the presence of distant metastatic involvement of the liver at time of diagnosis. The presence of metastatic liver disease is an independent prognostic indicator and is used by Collaborative Staging to derive TNM-M codes and SEER Summary Stage codes for some sites.

Notes: *For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”*

Values: 0, 1, 8, 9: Site specific (see the most current version of the Collaborative Stage Data Collection System [<https://cancerstaging.org/cstage/Pages/default.aspx>] for rules and site-specific codes and coding instructions).
 Blank: Year of Diagnosis is before 2010 or after 2015

California Cancer Registry Data Dictionary

Variable Name: CSMETSATDXLUNG
Eureka Name: CS Mets at DX-Lung
NAACCR Item: 2854
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2010 – 2015

Related Variables:

- CS Mets at DX-Bone (CSMETSATDXBONE)
- CS Mets at DX-Brain (CSMETSATDXBRAIN)
- CS Mets at DX-Liver (CSMETSATDXLIVER)
- CS Mets at DX (CS_METS_DX)

Definition: Identifies the presence of distant metastatic involvement of the lung at time of diagnosis. The presence of metastatic lung disease is an independent prognostic indicator and is used by Collaborative Staging to derive TNM-M codes and SEER Summary Stage codes for some sites.

Notes: *For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”*

Values:

0, 1, 8, 9: Site specific (see the most current version of the Collaborative Stage Data Collection System [<https://cancerstaging.org/cstage/Pages/default.aspx>] for rules and site-specific codes and coding instructions).

Blank: Year of Diagnosis is before 2010 or after 2015

California Cancer Registry Data Dictionary

Variable Name: CSSITESPECIFICFACTOR7, CSSITESPECIFICFACTOR8, CSSITESPECIFICFACTOR9, CSSITESPECIFICFACTOR10, CSSITESPECIFICFACTOR11, CSSITESPECIFICFACTOR12, CSSITESPECIFICFACTOR13, CSSITESPECIFICFACTOR14, CSSITESPECIFICFACTOR15, CSSITESPECIFICFACTOR16, CSSITESPECIFICFACTOR17, CSSITESPECIFICFACTOR18, CSSITESPECIFICFACTOR19, CSSITESPECIFICFACTOR20, CSSITESPECIFICFACTOR21, CSSITESPECIFICFACTOR22, CSSITESPECIFICFACTOR23, CSSITESPECIFICFACTOR24, CSSITESPECIFICFACTOR25

Eureka Name: CS Site-Specific Factor 7, CS Site-Specific Factor 8, CS Site-Specific Factor 9, CS Site-Specific Factor 10, CS Site-Specific Factor 11, CS Site-Specific Factor 12, CS Site-Specific Factor 13, CS Site-Specific Factor 14, CS Site-Specific Factor 15, CS Site-Specific Factor 16, CS Site-Specific Factor 17, CS Site-Specific Factor 18, CS Site-Specific Factor 19, CS Site-Specific Factor 20, CS Site-Specific Factor 21, CS Site-Specific Factor 22, CS Site-Specific Factor 23, CS Site-Specific Factor 24, CS Site-Specific Factor 25

NAACCR Item: 2861, 2862, 2863, 2864, 2865, 2866, 2867, 2868, 2869, 2870, 2871, 2872, 2873, 2874, 2875, 2876, 2877, 2878, 2879

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2010 – 2017

Related Variables:

Definition: These data items are part of the Collaborative Stage (CS) Data Collection System, which is based on the ***AJCC Cancer Staging Manual***, 6th and 7th editions. CS Site-Specific Factors 7 through 25 are used to code additional site-specific information needed to derive TNM and/or SEER Summary Stage or to code prognostic factors that impact stage or survival. Some site-specific information that was formerly recorded in "EOD--Tumor Size" (TSIZETU), such as Breslow's Thickness for melanoma and HIV/AIDS status for lymphoma, were recorded as CS Site-Specific Factors during this time period.

The information recorded in CS Site-Specific Factor 7 through 25 differs for each anatomic site. See the Collaborative Stage Data Collection System Manual and Coding Instructions (<http://cancerstaging.org/cstage>), for rules and site-specific codes and coding structures.

Notes: *For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."*

California Cancer Registry Data Dictionary

Values: 000-999: Site specific
Blank: Year of Diagnosis is before 2010, after 2017, or unknown

California Cancer Registry Data Dictionary

Variable Name: CSVERSIONDERIVED
Eureka Name: CS Version Derived
NAACCR Item: 2936
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2004 – 2017

Related Variables:

Definition: This item indicates the version number of CS used most recently to derive the CS output fields. This data item is recorded the first time the CS output fields are derived and should be updated each time the CS derived items are re-computed. The CS version number is returned as part of the output of the CS algorithm. The first two digits represent the major version number; the second two digits represent minor version changes; and, the last two digits represent even less significant changes, such as corrections of typographical errors that do not affect coding or derivation results (e.g., 010100).

Values: If not blank, the first four digits must be 0100, 0101, 0102, 0103, 0104 or 0205. As of 2014 data items changes, the first four digits must be 0205.

Blank: Date of diagnosis is before January 1, 2004 or after December 31, 2017

California Cancer Registry Data Dictionary

Variable Name: CSVERSIONINPUTCURRENT
Eureka Name: CS Version Input Current
NAACCR Item: 2937
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2010 – 2017

Related Variables:

Definition: This item indicates the number of the version after CS input fields have been updated or recoded. This data item is recorded the first time the CS input fields are entered and should be updated each time the CS input fields are modified. Valid for cases diagnosed 2010 and forward. For cases originally coded under CSv1, upon conversion from CSv1 to CSv2, CS Version Input Current will be set to 020000, a special version number to reflect its conversion status.

Notes: See the Collaborative Stage Data Collection System Manual and Coding Instructions (<http://www.cancerstaging.org/cstage>), for rules and site-specific codes and coding structures.

Values: Must be a six-digit number or blank. 000000-999999
 Digits 1 and 2: Major version number
 Digits 3 and 4: Minor version changes
 Digits 5 and 6: Less significant changes (such as typographical errors that do not affect coding or derivation of results)
 Blank: Date of Diagnosis is before January 1, 2010 or after December 31, 2017

California Cancer Registry Data Dictionary

Variable Name: CSVERSIONINPUTORIGINAL
Eureka Name: CS Version Input Original
NAACCR Item: 2935
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2004 – 2017

Related Variables:

Definition: Indicates the version used to initially code the CS fields. CS Version Original is a software-generated field and should be populated at the time the CS fields are first coded. The first two digits represent the major version number; the second two digits represent minor version changes; and, the last two digits represent even less significant changes, such as corrections of typographical errors that do not affect coding or derivation of results (e.g., 010100).

Values: Must be a six-digit number or blank. 000000-999999
 If not blank, the full six-digit number must be one of the following numbers:
 020550 or higher
 020440
 020302
 020200
 020100
 020001
 010401
 010400
 010300
 010200
 010100
 010005
 010004
 010003
 010002
 010000
 000937

California Cancer Registry Data Dictionary

Variable Name: DATEADM
Eureka Name: Date of 1st Contact
NAACCR Item: 580
Category: Hospital and Physician
Level of Variable: Admission
Time Period Available: 1988 - current year

Related Variables:

Definition: Date of the earliest admission, when the patient was first seen for evaluation and/or treatment of this tumor. This date is independent of whether the patient was an inpatient or an outpatient.

Values: Any valid date (YYYYMMDD)

California Cancer Registry Data Dictionary

Variable Name: DATECONCLUSIVEDXFLAG

Eureka Name: Date Conclusive DX Flag

NAACCR Item: 448

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2010 - current year

Related Variables:

- Date Conclusive DX (DATEOFCONCLUSIVEDX)
- Ambiguous Terminology DX (AMBIGUOUSTERMINOLOGY)

Definition: Flag to explain why no appropriate value is in the field Date Conclusive DX (DATEOFCONCLUSIVEDX).

Values:

10:	No information whatsoever can be inferred from this exceptional (non-date) value (e.g., unknown if the diagnosis was initially based on ambiguous terminology)
11:	No proper value is applicable in this context (e.g., not applicable, initial diagnosis made by unambiguous terminology (Code 0 in data item Ambiguous Terminology DX)
12:	A proper value is applicable but not known (e.g., the initial ambiguous diagnosis was followed by a conclusive term, but the date of the conclusive term is unknown)
15:	Information is not available at this time, but it is expected that it will be available later (e.g., accessioned based on ambiguous terminology only (Code 1 in data item Ambiguous Terminology DX).
Blank:	A valid date value is provided in item Date Conclusive DX, or the date was not expected to have been transmitted

California Cancer Registry Data Dictionary

Variable Name:	DATEDIS
Eureka Name:	Date of Inpt Disch
NAACCR Item:	600
Category:	Hospital and Physician
Level of Variable:	Admission
Time Period Available:	1997 - current year
Related Variables:	Date of Inpt Adm (DATEIADM)
Definition:	Date of the inpatient discharge from the reporting facility after the most definitive surgery. In the absence of surgery, it is the date of inpatient discharge for other therapy. In the absence of therapy, it is the date of inpatient discharge for diagnostic evaluation. This discharge date corresponds to the admission date described by Date of Inpatient Admission (DATEIADM). DATEDIS comes from the facility with the earliest date of admission for this tumor.
Notes:	Prior to 1997, date of discharge applied to both inpatient and outpatient admissions. After 1997, it refers to date of discharge for inpatients only; older cases were converted such that those with known outpatient admission had date of discharge set to zero.
Values:	Any valid date (YYYYMMDD)

California Cancer Registry Data Dictionary

Variable Name: DATEDX
Eureka Name: Date of Diagnosis
NAACCR Item: 390
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 1988 - current year

Related Variables:

Definition: Date when this tumor was first diagnosed. When variable TYPERP (Type of Reporting Source) = 6 (autopsy case) or TYPERP = 7 (DC only case), date of death is entered for date of diagnosis.

Values: A valid, complete date (YYYYMMDD)

California Cancer Registry Data Dictionary

Variable Name: DATEIADM

Eureka Name: Date of Inpt Adm

NAACCR Item: 590

Category: Hospital and Physician

Level of Variable: Admission

Time Period Available: 1988 - current year

Related Variables: Date of Inpt Disch (DATEDIS)

Definition: Date of the inpatient admission to the facility for the most definitive surgery. If no surgery, use the inpatient admission date for other cancer-directed therapy. If no cancer directed therapy, use date of inpatient admission for diagnostic work up. DATEIADM comes from the facility with the earliest date of admission for this tumor.

Values: A valid, complete date (YYYYMMDD)

California Cancer Registry Data Dictionary

Variable Name: DATEOFBIRTHFLAG

Eureka Name: Date of Birth Flag

NAACCR Item: 241

Category: Patient Demographics

Level of Variable: Tumor

Time Period Available: 2010 - current year

Related Variables: Date of Birth (DOB)

Definition: Flag to explain why no appropriate value is in the field Date of Birth (DOB).

Values: 12: A proper value is applicable but not known (e.g., Date of Birth (DOB) is unknown)

Blank: A valid date value is provided in item Date of Birth (DOB), or the date was not expected to be transmitted.

California Cancer Registry Data Dictionary

Variable Name:	DATEOFCONCLUSIVEDX
Eureka Name:	Date Conclusive DX
NAACCR Item:	443
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2006 - current year
Related Variables:	<ul style="list-style-type: none"> • Date Conclusive DX Flag (DATECONCLUSIVEDXFLAG) • Ambiguous Terminology DX (AMBIGUOUSTERMINOLOGY)
Definition:	Documents the date when a conclusive cancer diagnosis (definite statement of malignancy) is made following an initial diagnosis that was based on ambiguous terminology. The date of the conclusive diagnosis must be greater than two months following the initial (ambiguous terminology only) diagnosis.
Values:	A valid, complete date (YYYYMMDD)

California Cancer Registry Data Dictionary

Variable Name: DATEOFDIAGNOSISFLAG

Eureka Name: Date of Diagnosis Flag

NAACCR Item: 391

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2010 - current year

Related Variables:

- Date of Diagnosis (DATEDX)

Definition: Flag to explain why there is no appropriate value in the corresponding date field, Date of Diagnosis (DATEDX).

Values: 12: A proper value is applicable but not known (e.g., Date of Diagnosis is unknown)

Blank: A valid date value is provided in item Date of Diagnosis, or the date was not expected to be transmitted.

California Cancer Registry Data Dictionary

Variable Name: DATEOFINITIALRXFLAG

Eureka Name: Date Initial RX SEER Flag

NAACCR Item: 1261

Category: Treatment

Level of Variable: Tumor

Time Period Available: 2010 - current year

Related Variables: Date Initial RX SEER (RXDATE)

Definition: Flag explains why there is no appropriate value in the corresponding date field, Date Initial RX SEER (RXDATE).

Values:

- 10: No information whatsoever can be inferred from this exceptional value (e.g., unknown if therapy was administered)
- 11: No proper value is applicable in this context (e.g., therapy was not administered)
- 12: A proper value is applicable but not known (e.g., therapy was administered and date is unknown)
- Blank: A valid date value is provided in item RXDATE, or the date was not expected to have been transmitted

California Cancer Registry Data Dictionary

Variable Name: DATEOFINPTADMFLAG

Eureka Name: Date of Inpt Adm Flag

NAACCR Item: 591

Category: Hospital and Physician

Level of Variable: Admission

Time Period Available: 2010 - current year

Related Variables: Date of Inpatient Adm (DATEIADM)

Definition: Flag explains why there is no appropriate value in the corresponding date field, Date of Inpatient Adm (DATEIADM). Value comes from the facility with the earliest date of admission for this tumor.

Values:

- 10: No information whatsoever can be inferred from this exceptional value (e.g., unknown if patient was an inpatient)
- 11: No proper value is applicable in this context (e.g., patient was never an inpatient at the reporting facility)
- 12: A proper value is applicable but not known. This event occurred, but the date is unknown (e.g., the patient was an inpatient, but the date is unknown)
- Blank: A valid date value is provided in item Date of Inpatient Admission or the date was not expected to have been transmitted

California Cancer Registry Data Dictionary

Variable Name: DATEOFLASTCONTACTFLAG

Eureka Name: Date of Last Contact Flag

NAACCR Item: 1751

Category: Follow-Up

Level of Variable: Patient

Time Period Available: 2010 - current year

Related Variables: Date of Last Contact (FUDATE)

Definition: Flag explains why there is no appropriate value in the corresponding date field, Date of Last Contact (FUDATE).

Values: 12: A proper value is applicable but not known (e.g. Date of Last Contact is unknown)

Blank: A valid date value is provided in data item Date of Last Contact (FUDATE) or the date was not expected to have been transmitted

California Cancer Registry Data Dictionary

Variable Name: DATEOFMULTIPLETUMORS

Eureka Name: Date of Mult Tumors

NAACCR Item: 445

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2007 - current year

Related Variables: Date of Multiple Tumors Flag (DATEOFMULTTUMORSFLAG)

Definition: This data item is used to identify the month, day, and year the patient was diagnosed with multiple or subsequent reportable tumor(s) reported as a single primary using the SEER multiple tumor rules.

Values: A valid, complete date (YYYYMMDD)

California Cancer Registry Data Dictionary

Variable Name: DATEOFMULTTUMORSFLAG

Eureka Name: Date of Mult Tumors Flag

NAACCR Item: 439

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2010 - current year

Related Variables: Date of Mult Tumors (DATEOFMULTTUMORSFLAG)

Definition: Flag explains why there is no appropriate value in the corresponding date field, Date of Mult Tumors (DATEOFMULTIPLETUMORS).

Values:

- 11: No proper value is applicable in this context (e.g., information on multiple tumors not collected/not applicable for this site).
- 12: A proper value is applicable but not known. This event occurred, but the date is unknown (e.g. patient was diagnosed with multiple tumors and the date is unknown).
- 15: Information is not available at this time, but it is expected that it will be available later (e.g., single tumor).
- Blank: A valid date value is provided in item Date Mult Tumors or information not collected for this diagnosis date.

California Cancer Registry Data Dictionary

Variable Name: DATEREGLNDISS
Eureka Name: Date Regional Lymph Node Dissection
NAACCR Item: 682
Category: Treatment, Surgical
Level of Variable: Tumor
Time Period Available: 2018 - current year
Related Variables: Date Regional Lymph Node Dissection Flag (DATEREGLNDISSFLAG)
Definition: Records the date non-sentinel regional node dissection was performed.
Values: A valid, complete or partial date (YYYYMMDD). May be blank.

California Cancer Registry Data Dictionary

Variable Name:	DATEREGLNDISSFLAG
Eureka Name:	Date Regional Lymph Node Dissection Flag
NAACCR Item:	683
Category:	Treatment, Surgical
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	Date Regional Lymph Node Dissection (DATEREGLNDISS)
Definition:	Flag explains why there is no appropriate value in the corresponding data item, Date of Regional Lymph Node Dissection (DATEREGLNDISS).
Values:	<p>10: No information whatsoever can be inferred from this exceptional value (that is, unknown if any regional lymph node dissection was performed)</p> <p>11: No proper value is applicable in this context (for example, no regional lymph node dissection was performed; autopsy only cases)</p> <p>12: A proper value is applicable but not known. This event occurred, but the date is unknown (for example, regional lymph node dissection was performed but date is unknown)</p> <p>Blank: A valid date value is provided in item Date of Regional Lymph Node Dissection (DATEREGLNDISS). Case was diagnosed pre-2018.</p>

California Cancer Registry Data Dictionary

Variable Name: DATESENTINELNBX

Eureka Name: Date of Sentinel Lymph Node Biopsy

NAACCR Item: 832

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables: Date of Sentinel Lymph Node Biopsy Flag (DATESENTLNBXFLAG)

Definition: Records the date of the sentinel lymph node(s) biopsy procedure. ***This data item is required for breast and melanoma cases only.***

Values: A valid, complete or partial date in YYYYMMDD. May be blank.

California Cancer Registry Data Dictionary

Variable Name:	DATESENTLNBXFLAG
Eureka Name:	Date of Sentinel Lymph Node Biopsy Flag
NAACCR Item:	833
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	Date of Sentinel Lymph Node Biopsy (DATESENTINELLNBX)
Definition:	Flag explains why there is no appropriate value in the corresponding date field, Date of Sentinel Lymph Node Biopsy (DATESENTINELLNBX). <i>This data item is required for breast and melanoma cases only.</i>
Values	<p>10: No information whatsoever can be inferred from this exceptional value (that is, unknown if any sentinel lymph node biopsy was performed)</p> <p>11: No proper value is applicable in this context (for example, no sentinel lymph node biopsy performed; autopsy only cases)</p> <p>12: A proper value is applicable but not known. This event occurred, but the date is unknown (for example, sentinel lymph node biopsy performed but date is unknown)</p> <p>Blank: A valid date value is provided in item Date of Sentinel Lymph Node Biopsy (DATESENTINELLNBX). Case was diagnosed pre-2018.</p>

California Cancer Registry Data Dictionary

Variable Name: DATESTAT

Eureka Name: Date Cancer Status

NAACCR Item: N/A

Category: Follow-Up

Level of Variable: Tumor

Time Period Available: 1988 - 2017

Related Variables: Date of Last Cancer (tumor) Status

Definition: Date of last contact with the patient where there was specific information about the tumor being reported on. Valid for cases diagnosed 1988 through 2017. For cases diagnosed 2018 and forward, see Date of Last Cancer (tumor) Statue.

Values: Any valid date containing, at minimum, YYYY

California Cancer Registry Data Dictionary

Variable Name: DC_FATHERS_SURNAME

Eureka Name: DC Fathers Surname

NAACCR Item: N/A

Category: Follow-Up

Level of Variable: Patient

Time Period Available: 1988 – current year

Related Variables:

- DC Birth Place (DCBIRTHPL)
- DC State File Number (DCFILENO)
- DC Race (DCRACE)
- DC Spanish Origin (DCSPANISH)
- DC SSN (DCSSNO)
- Death File No State (DCSTATE)

Definition: Patient's father's surname as state on the death certificate.

Notes: Access to death data variables from the CCR for research purposes requires review by the Health and Human Services Agency Committee for the Protection of Human Subjects (CPHS), the Vital Statistics Advisory Committee (VSAC), and CCR. The Center for Health Statistics and Informatics (CHSI), CCR, and CPHS require requesters to submit their proposals for simultaneous review of research projects by CPHS and VSAC. Please allow sufficient time for review of your application. For more information, send inquiries to research@ccr.ca.gov.

California Cancer Registry Data Dictionary

Variable Name:	DCBIRTHPL
Eureka Name:	DC Birth Place
NAACCR Item:	N/A
Category:	Follow-Up
Level of Variable:	Patient
Time Period Available:	1988 – current year
Related Variables:	<ul style="list-style-type: none"> • DC State File Number (DCFILENO) • DC Race (DCRACE) • DC Spanish Origin (DCSPANISH) • DC SSN (DCSSNO) • Death File No State (DCSTATE) • DC Father's Surname (DC_FATHERS_SURNAME)

Definition: State or country of the patient's birth as stated on the death certificate.

Notes: Access to death data variables from the CCR for research purposes requires review by the Health and Human Services Agency Committee for the Protection of Human Subjects (CPHS), the Vital Statistics Advisory Committee (VSAC), and CCR. The Center for Health Statistics and Informatics (CHSI), CCR, and CPHS require requesters to submit their proposals for simultaneous review of research projects by CPHS and VSAC. Please allow sufficient time for review of your application. For more information, send inquiries to research@ccr.ca.gov.

California Cancer Registry Data Dictionary

Variable Name:	DCFILENO
Eureka Name:	DC State File Number
NAACCR Item:	N/A
Category:	Follow-Up
Level of Variable:	Patient
Time Period Available:	1988 – current year
Related Variables:	<ul style="list-style-type: none"> • DC Birth Place (DCBIRTHPL) • DC Race (DCRACE) • DC Spanish Origin (DCSPANISH) • DC SSN (DCSSNO) • Death File No State (DCSTATE) • DC Father's Surname (DC_FATHERS_SURNAME)
Definition:	Unique state file number assigned to the death certificate by the state specified in Death File No State (DCSTATE).
Notes:	Access to death data variables from the CCR for research purposes requires review by the Health and Human Services Agency Committee for the Protection of Human Subjects (CPHS), the Vital Statistics Advisory Committee (VSAC), and CCR. The Center for Health Statistics and Informatics (CHSI), CCR, and CPHS require requesters to submit their proposals for simultaneous review of research projects by CPHS and VSAC. Please allow sufficient time for review of your application. For more information, send inquiries to research@ccr.ca.gov.
Values:	<p>000000: Patient is not dead</p> <p>999999: Death certificate state file number is not known</p> <p>Any other number is the state file number.</p>

California Cancer Registry Data Dictionary

Variable Name:	DCRACE
Eureka Name:	DC Race
NAACCR Item:	N/A
Category:	Follow-Up
Level of Variable:	Patient
Time Period Available:	1988 – current year
Related Variables:	<ul style="list-style-type: none"> • DC Birth Place (DCBIRTHPL) • DC State File Number (DCFILENO) • DC Spanish Origin (DCSPANISH) • DC SSN (DCSSNO) • Death File No State (DCSTATE) • DC Father's Surname (DC_FATHERS_SURNAME)

Definition: Race/ethnicity of the patient as stated on the death certificate.

Notes: Access to death data variables from the CCR for research purposes requires review by the Health and Human Services Agency Committee for the Protection of Human Subjects (CPHS), the Vital Statistics Advisory Committee (VSAC), and CCR. The Center for Health Statistics and Informatics (CHSI), CCR, and CPHS require requesters to submit their proposals for simultaneous review of research projects by CPHS and VSAC. Please allow sufficient time for review of your application. For more information, send inquiries to research@ccr.ca.gov.

California Cancer Registry Data Dictionary

Variable Name: DCSPANISH
Eureka Name: DC Spanish Origin
NAACCR Item: N/A
Category: Follow-Up
Level of Variable: Patient

Time Period Available: 1988 – current year

Related Variables:

- DC Birth Place (DCBIRTHPL)
- DC State File Number (DCFILENO)
- DC Race (DCRACE)
- DC SSN (DCSSNO)
- Death File No State (DCSTATE)
- DC Father's Surname (DC_FATHERS_SURNAME)

Definition: This field is used to denote persons of Spanish origin as stated on the death certificate. Persons of Spanish origin may be of any race.

Notes: **Access to death data variables from the CCR for research purposes requires review by the Health and Human Services Agency Committee for the Protection of Human Subjects (CPHS), the Vital Statistics Advisory Committee (VSAC), and CCR. The Center for Health Statistics and Informatics (CHSI), CCR, and CPHS require requesters to submit their proposals for simultaneous review of research projects by CPHS and VSAC. Please allow sufficient time for review of your application. For more information, send inquiries to research@ccr.ca.gov.**

California Cancer Registry Data Dictionary

Variable Name: DCSSN_FLAG
Eureka Name: N/A
NAACCR Item: N/A
Category: Patient Demographics
Level of Variable: Tumor
Time Period Available: 1988 – current year
Related Variables: YR_SSNISSUED

Definition: Was the death certificate social security number used to derive the year of issue?

Values: 0: No, used Social Security Number in the registry
1: Yes, used Social Security Number from the death certificate

California Cancer Registry Data Dictionary

Variable Name:	DCSSNO
Eureka Name:	DC SSN
NAACCR Item:	N/A
Category:	Follow-Up
Level of Variable:	Patient
Time Period Available:	1988 – current year
Related Variables:	<ul style="list-style-type: none"> • DC Birth Place (DCBIRTHPL) • DC State File Number (DCFILENO) • DC Race (DCRACE) • DC Spanish Origin (DCSPANISH) • Death File No State (DCSTATE) • DC Father's Surname (DC_FATHERS_SURNAME)

Definition: Patient's social security number as stated on the death certificate.

Notes: Access to death data variables from the CCR for research purposes requires review by the Health and Human Services Agency Committee for the Protection of Human Subjects (CPHS), the Vital Statistics Advisory Committee (VSAC), and CCR. The Center for Health Statistics and Informatics (CHSI), CCR, and CPHS require requesters to submit their proposals for simultaneous review of research projects by CPHS and VSAC. Please allow sufficient time for review of your application. For more information, send inquiries to research@ccr.ca.gov.

California Cancer Registry Data Dictionary

Variable Name:	DCSTATE
Eureka Name:	Death File No State
NAACCR Item:	N/A
Category:	Follow-Up
Level of Variable:	Patient
Time Period Available:	1988 – current year
Related Variables:	<ul style="list-style-type: none"> • DC Birth Place (DCBIRTHPL) • DC State File Number (DCFILENO) • DC Race (DCRACE) • DC Spanish Origin (DCSPANISH) • DC SSN (DCSSNO) • DC Father's Surname (DC_FATHERS_SURNAME)

Definition: Postal code for the state that issued the death certificate.

Notes: Access to death data variables from the CCR for research purposes requires review by the Health and Human Services Agency Committee for the Protection of Human Subjects (CPHS), the Vital Statistics Advisory Committee (VSAC), and CCR. The Center for Health Statistics and Informatics (CHSI), CCR, and CPHS require requesters to submit their proposals for simultaneous review of research projects by CPHS and VSAC. Please allow sufficient time for review of your application. For more information, send inquiries to research@ccr.ca.gov.

California Cancer Registry Data Dictionary

Variable Name: DEN

Eureka Name: N/A

NAACCR Item: N/A

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: 1988 - 1995

Related Variables:

- Name of Medical Service Study Area (MSSANAME)
- Medical Service Study Area ID (MSSAID)

Definition: Density of the 1990 Medical Service Study Area (MSSA) as designated by the Office of Statewide Health Planning and Development (OSHPD). This variable is not a collected data item but comes from OSHPD.

Values:

- H: High population density MSSA
- L: Low population density MSSA
- 9: Unknown

California Cancer Registry Data Dictionary

Variable Name: DERIVED_AJCC_FLAG
Eureka Name: Derived AJCC Flag
NAACCR Item: 3030
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2004 - 2015

Related Variables:

Definition: A flag to indicate whether AJCC stage was coded directly or derived from Collaborative Stage (CS) or Extent of Disease (EOD) codes.

Notes: Detailed information on the Collaborative Stage Data Collection System can be found at: <http://www.cancerstaging.org/cstage/index.html>

Values:

- 1: AJCC 6th Edition derived from Collaborative Staging Manual and Coding Instructions, Version 1.0
- 2: AJCC 6th Edition derived from EOD (Prior to 2004)
- Blank: Not derived and Date of Diagnosis is before January 1, 2004 or after December 31, 2015

California Cancer Registry Data Dictionary

Variable Name: DERIVED_AJCC_M
Eureka Name: Derived AJCC-6 M
NAACCR Item: 2980
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2004 - 2015
Related Variables:

- CS Mets at DX (CS_METS_DX)
- Extent of Disease Derived M Code for TNM Staging (MCODE)

Definition: This data item belongs to the Collaborative Stage (CS) Data Collection System. This field contains the AJCC 6th edition "M" code derived from CS coded fields using the CS algorithm.

Notes: Detailed information on the Collaborative Staging Collection System can be found at: <http://www.cancerstaging.org/cstage/index.html>

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

00:	M0
10:	M1
11:	M1a
12:	M1b
13:	M1c
19:	M1, NOS
88:	Not applicable
99:	MX
Blank:	Date of Diagnosis is before January 1, 2004 or after December 31, 2015

California Cancer Registry Data Dictionary

Variable Name: DERIVED_AJCC_M_DESC
Eureka Name: Derived AJCC-6 M Descript
NAACCR Item: 2990
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2004 - 2015
Related Variables: Derived AJCC-6 M (DERIVED_AJCC_M)

Definition: This data item belongs to the Collaborative Stage (CS) Data Collection System.
 This field contains the AJCC 6th edition "M" code descriptor and is derived from CS coded fields using the CS algorithm.

Notes: Detailed information on the Collaborative Staging Data Collection System can be found at: <http://www.cancerstaging.org/cstage/index.html>

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

- c: Clinical stage
- p: Pathologic stage
- a: Autopsy stage
- y: Pathologic examination of metastatic tissue performed after presurgical systemic treatment and extension based on pathologic evidence
- N: No applicable (derived from Collaborative Stage fields)
- Blank: Date of Diagnosis is before January 1, 2004 or after December 31, 2015

California Cancer Registry Data Dictionary

Variable Name: DERIVED_AJCC_N
Eureka Name: Derived AJCC-6 N
NAACCR Item: 2960
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2004 - 2015
Related Variables:

- CS Lymph Nodes (CS_LN)
- Extent of Disease Derived N Code for TNM Staging (NCODE)

Definition: This data item belongs to the Collaborative Stage (CS) Data Collection System. This field contains the AJCC 6th edition "N" code and is derived from CS coded fields using the CS algorithm.

Notes: Detailed information on the Collaborative Staging Data Collection System can be found at:
<http://www.cancerstaging.org/cstage/index.html>

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

00:	N0
01:	N0(i-)
02:	N0(i+)
03:	N0(mol-)
04:	N0(mol+)
10:	N1
11:	N1a
12:	N1b
13:	N1c
18:	N1mi
19:	N1, NOS
20:	N2
21:	N2a
22:	N2b
23:	N2c
29:	N2, NOS
30:	N3
31:	N3a
32:	N3b
33:	N3c
39:	N3, NOS
88:	Not applicable
99:	NX
Blank:	Date of Diagnosis is before January 1, 2004 or after December 31, 2015

California Cancer Registry Data Dictionary

Variable Name: DERIVED_AJCC_N_DESC
Eureka Name: Derived AJCC-6 N Descript
NAACCR Item: 2970
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2004 - 2015
Related Variables: Derived AJCC-6 N (DERIVED_AJCC_N)

Definition: This data item belongs to the Collaborative Stage (CS) Data Collection System.
 This field contains the AJCC 6th edition "N" code descriptor and is derived from CS coded fields using the CS algorithm.

Notes: Detailed information on the Collaborative Staging Data Collection System can be found at: <http://www.cancerstaging.org/cstage/index.html>

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

- c: Clinical stage
- p: Pathologic stage
- a: Autopsy stage
- y: Lymph nodes removed for examination after presurgical systemic treatment or radiation and lymph node evaluation based on pathologic evidence
- N: Not applicable (derived from Collaborative Stage fields)
- Blank: Date of Diagnosis is before January 1, 2004 or after December 31, 2015

California Cancer Registry Data Dictionary

Variable Name: DERIVED_AJCC_STG_GRP
Eureka Name: Derived AJCC-6 Stage Grp
NAACCR Item: 3000
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor

Time Period Available: 2004 - 2015

Related Variables:

- Derived AJCC-6 T (DERIVED_AJCC_T)
- Derived AJCC-6 N (DERIVED_AJCC_N)
- Derived AJCC-6 M (DERIVED_AJCC_M)
- Derived AJCC-7 Stage Group (DERIVEDAJCC7STAGEGRP)

Definition: This data item belongs to the Collaborative Stage (CS) Data Collection System. This field contains the AJCC 6th edition "Stage Group" and is derived from CS coded fields using the CS algorithm.

Notes: Detailed information on the Collaborative Staging Data Collection System can be found at:
<http://www.cancerstaging.org/cstage/index.html>

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

00:	0
01:	0a
02:	0is
10:	I
11:	I, NOS
12:	IA
13:	IA1
14:	IA2
15:	IB
16:	IB1
17:	IB2
18:	IC
19:	IS
20:	IEA (lymphoma only)
21:	IEB (lymphoma only)
22:	IE (lymphoma only)
23:	ISA (lymphoma only)
24:	ISB (lymphoma only)
30:	II
31:	II, NOS
32:	IIA
33:	IIB

California Cancer Registry Data Dictionary

34:	IIC
35:	IIEA (lymphoma only)
36:	IIEB (lymphoma only)
37:	IIE (lymphoma only)
38:	IISA (lymphoma only)
39:	IISB (lymphoma only)
40:	IIS (lymphoma only)
41:	IIESA (lymphoma only)
42:	IIESB (lymphoma only)
43:	IIES (lymphoma only)
50:	III
51:	III, NOS
52:	IIIA
53:	IIIB
54:	IIIC
55:	IIIEA (lymphoma only)
56:	IIIEB (lymphoma only)
57:	IIIE (lymphoma only)
58:	IIISA (lymphoma only)
59:	IIISB (lymphoma only)
60:	IIIS (lymphoma only)
61:	IIIESA (lymphoma only)
62:	IIIESB (lymphoma only)
63:	IIIES (lymphoma only)
70:	IV
71:	IV, NOS
72:	IVA
73:	IVB
74:	IVC
88:	Not applicable
90:	Occult
99:	Unknown
Blank:	Date of Diagnosis is before January 1, 2004 or after December 31, 2015

California Cancer Registry Data Dictionary

Variable Name: DERIVED_AJCC_T
Eureka Name: Derived AJCC-6 T
NAACCR Item: 2940
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2004 - 2015
Related Variables:

- CS Tumor Size (CS_TUM_SIZE)
- CS Extension (CS_EXT)
- Extent of Disease Derived T Code for TNM Staging (TCODE)
- Derived AJCC-7 T (DERIVEDAJCC7T)

Definition: This data item belongs to the Collaborative Stage (CS) Data Collection System. This field contains the AJCC 6th edition "T" code and is derived from CS coded fields using the CS algorithm.

Notes: Detailed information on the Collaborative Staging Data Collection System can be found at:
<http://www.cancerstaging.org/cstage/index.html>

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

00:	T0
01:	Ta
05:	Tis
06:	Tispu (urethra only)
07:	Tispd (urethra only)
10:	T1
11:	T1mic
12:	T1a
13:	T1a1
14:	T1a2
15:	T1b
16:	T1b1
17:	T1b2
18:	T1c
19:	T1, NOS
20:	T2
21:	T2a
22:	T2b
23:	T2c
29:	T2, NOS
30:	T3
31:	T3a
32:	T3b
33:	T3c

California Cancer Registry Data Dictionary

39: T3, NOS

40: T4

41: T4a

42: T4b

43: T4c

44: T4d

49: T4, NOS

80: T1a, NOS

81: T1b, NOS

88: Not applicable

99: TX

Blank: Date of Diagnosis is before January 1, 2004 or after December 31, 2015

California Cancer Registry Data Dictionary

Variable Name: DERIVED_AJCC_T_DESC

Eureka Name: Derived AJCC-6 T Descript

NAACCR Item: 2950

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2004 - 2015

Related Variables:

- Derived AJCC-6 T (DERIVED_AJCC_T)
- Derived AJCC-7 T Descript (DERIVEDAJCC7TDESCRPT)

Definition: This data item belongs to the Collaborative Staging (CS) Data Collection System. This field contains the AJCC 6th edition "T" code descriptor component that is derived from CS coded fields using the CS algorithm.

Notes: Detailed information on the Collaborative Staging Data Collection System can be found at: <http://www.cancerstaging.org/cstage/index.html>

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

- c: Clinical stage
- p: Pathologic stage
- a: Autopsy stage
- y: Surgical resection performed AFTER pre-surgical systemic treatment or radiation; tumor size/extension based on pathologic evidence
- N: Not applicable (derived from Collaborative Stage fields)
- Blank: Date of Diagnosis is before January 1, 2004 or after December 31, 2015

California Cancer Registry Data Dictionary

Variable Name: DERIVED_SS1977

Eureka Name: Derived SS1977

NAACCR Item: 3010

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2004 - 2015

Related Variables: Derived SS2000 (DERIVED_SS2000)

Definition: SEER Summary Stage 1977 derived from the Collaborative Staging algorithm. Effective for cases diagnosed 2004 through 2015. Detailed information on the Collaborative Staging Data Collection System can be found at:

<http://www.cancerstaging.org/cstage/index.html>

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

0:	In situ
1:	Localized
2:	Regional, direct extension
3:	Regional, lymph nodes
4:	Regional, extension and nodes
5:	Regional, NOS
7:	Distant
8:	Not applicable
9:	Unknown/unstaged
Blank:	Date of diagnosis is before January 1, 2005 or after December 31, 2015

California Cancer Registry Data Dictionary

Variable Name: DERIVED_SS2000

Eureka Name: Derived SS2000

NAACCR Item: 3020

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2004 - 2015

Related Variables: Derived SS1977 (DERIVED_SS1977)

Definition: SEER Summary Stage 2000 derived from the Collaborative Staging algorithm. Effective for cases diagnosed 2004 through 2015. Detailed information on the Collaborative Staging Data Collection System can be found at:

<http://www.cancerstaging.org/cstage/index.html>

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

- 0: In situ
- 1: Localized
- 2: Regional, direct extension
- 3: Regional, lymph nodes
- 4: Regional, extension and nodes
- 5: Regional, NOS
- 7: Distant
- 8: Not applicable
- 9: Unknown/unstaged
- Blank: Date of diagnosis is before January 1, 2005 or after December 31, 2015

California Cancer Registry Data Dictionary

Variable Name: DERIVEDAJCC7M
Eureka Name: Derived AJCC-7 M
NAACCR Item: 3420
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2010 - 2015
Related Variables: Derived AJCC-6 M (DERIVED_AJCC_M)

Definition: This data item belongs to the Collaborative Stage (CS) Data Collection System. This field contains the AJCC 7th edition "M" code and is derived from CS coded fields using the CS algorithm.

Notes: Detailed information on the Collaborative Staging Data Collection System can be found at: <http://www.cancerstaging.org/cstage/index.html>. Refer to the **AJCC Cancer Staging Manual, 7th Edition** for the site-specific "M" code descriptions.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

000:	M0
010:	M0(i+)
100:	M1
110:	M1a
120:	M1b
130:	M1c
140:	M1d
150:	M1e
199:	M1, NOS
888:	NA
999:	MX
Blank:	Date of Diagnosis is before January 1, 2010 or after December 31, 2015

California Cancer Registry Data Dictionary

Variable Name: DERIVEDAJCC7MDESCRIPT
Eureka Name: Derived AJCC-7 M Descript
NAACCR Item: 3422
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2010 - 2015

Related Variables: Derived AJCC-6 M Descript (DERIVED_AJCC_M_DESC)

Definition: This data item belongs to the Collaborative Stage (CS) Data Collection System. This field contains the AJCC 7th edition "M" code descriptor and is derived from CS coded fields using the CS algorithm.

Notes: Detailed information on the Collaborative Staging Data Collection System can be found at: <http://www.cancerstaging.org/cstage/index.html>. Refer to the **AJCC Cancer Staging Manual, 7th Edition** for the site-specific "M" code descriptions.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

- c: Clinical stage
- p: Pathologic stage
- a: Autopsy stage
- y: Pathologic examination of metastatic tissue performed after presurgical systemic treatment and extension based on pathologic evidence
- N: Not applicable (derived from Collaborative Stage fields)
- Blank: Date of Diagnosis is before January 1, 2004 or after December 31, 2015

California Cancer Registry Data Dictionary

Variable Name: DERIVEDAJCC7N
Eureka Name: Derived AJCC-7 N
NAACCR Item: 3410
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2010 - 2015
Related Variables: Derived AJCC-6 N (DERIVED_AJCC_N)

Definition: This data item belongs to the Collaborative Stage (CS) Data Collection System. This field contains the AJCC 7th edition "N" code and is derived from CS coded fields using the CS algorithm.

Notes: Detailed information on the Collaborative Staging Data Collection System can be found at: <http://www.cancerstaging.org/cstage/index.html>. Refer to the **AJCC Cancer Staging Manual, 7th Edition** for the site-specific "N" code descriptions.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

000:	N0
010:	N0(i-)
020:	N0(i+)
030:	N0(mol-)
040:	N0(mol+)
100:	N1
110:	N1a
120:	N1b
130:	N1c
180:	N1mi
199:	N1, NOS
200:	N2
210:	N2a
220:	N2b
230:	N2c
299:	N2, NOS
300:	N3
310:	N3a
320:	N3b
330:	N3c
399:	N3, NOS
400:	N4
888:	Not applicable
999:	NX
Blank:	Date of Diagnosis is before January 1, 2010 or after December 31, 2015

California Cancer Registry Data Dictionary

Variable Name: DERIVEDAJCC7NDESCRIPT

Eureka Name: Derived AJCC-7 N Descript

NAACCR Item: 3412

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2010 - 2015

Related Variables:

- Derived AJCC-7 N (DERIVEDAJCC7N)
- Derived AJCC-6 N Descript (DERIVED_AJCC_N_DESC)

Definition: This data item belongs to the Collaborative Stage (CS) Data Collection System. This field contains the AJCC 7th edition "N" code descriptor and is derived from CS coded fields using the CS algorithm.

Detailed information on the Collaborative Staging Data Collection System can be found at: <http://www.cancerstaging.org/cstage/index.html>

Notes: *For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."*

Values:

- c: Clinical stage
- p: Pathologic stage
- a: Autopsy stage
- y: Lymph nodes removed for examination after presurgical systemic treatment or radiation and lymph node evaluation based on pathologic evidence
- N: Not applicable (derived from Collaborative Stage fields)
- Blank: Date of Diagnosis is before January 1, 2010 or after December 31, 2015

California Cancer Registry Data Dictionary

Variable Name: DERIVEDAJCC7STAGEGRP
Eureka Name: Derived AJCC-7 Stage Group
NAACCR Item: 3430
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor

Time Period Available: 2010 - 2015

Related Variables:

- Derived AJCC-7 M (DERIVEDAJCC7M)
- Derived AJCC-7 N (DERIVEDAJCC7N)
- Derived AJCC-7 T (DERIVEDAJCC7T)
- Derived AJCC-6 Stage Grp (DERIVED_AJCC_STG_GRP)

Definition: This data item belongs to the Collaborative Stage (CS) Data Collection System. This field contains the AJCC 7th edition "Stage Group" and is derived from CS coded fields using the CS algorithm.

Notes: Detailed information on the Collaborative Stage Data Collection System can be found at: <http://www.cancerstaging.org/cstage/index.html>. Refer to the **AJCC Cancer Staging Manual, 7th Edition** for site-specific stage group descriptions.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

000:	0
010:	0a
020:	0is
100:	I
110:	I, NOS
120:	IA
121:	IA, NOS
130:	IA1
140:	IA2
150:	IB
151:	IB, NOS
160:	IB1
170:	IB2
180:	IC
190:	IS
200:	IEB (lymphoma only)
210:	IEB (lymphoma only)
220:	IE (lymphoma only)
230:	ISA (lymphoma only)
240:	ISB (lymphoma only)
300:	II

California Cancer Registry Data Dictionary

310:	II, NOS
320:	IIA
321:	IIA, NOS
322:	IIA1
323:	IIA2
330:	IIB
340:	IIC
350:	IIEA (lymphoma only)
360:	IIEB (lymphoma only)
370:	IIE (lymphoma only)
380:	IISA (lymphoma only)
390:	IISB (lymphoma only)
400:	IIS (lymphoma only)
410:	IIESA (lymphoma only)
420:	IIESB (lymphoma only)
430:	IIIES (lymphoma only)
500:	III
510:	III, NOS
520:	IIIA
530:	IIIB
540:	IIIC
541:	IIIC1
542:	IIIC2
550:	IIIEA (lymphoma only)
560:	IIIEB (lymphoma only)
570:	IIIE (lymphoma only)
580:	IIISA (lymphoma only)
590:	IISB (lymphoma only)
600:	IIS (lymphoma only)
610:	IIIESA (lymphoma only)
620:	IIIESB (lymphoma only)
630:	IIIES (lymphoma only)
700:	IV
710:	IV, NOS
720:	IVA
721:	IVA1
722:	IVA2
730:	IVB
740:	IVC
888:	Not applicable
900:	Occult

California Cancer Registry Data Dictionary

999: Unknown

Blank: Date of Diagnosis is before January 1, 2010 or after December 31, 2015

California Cancer Registry Data Dictionary

Variable Name:	DERIVEDAJCC7T																																										
Eureka Name:	Derived AJCC-7 T																																										
NAACCR Item:	3400																																										
Category:	Tumor Characteristics/Stage at Diagnosis																																										
Level of Variable:	Tumor																																										
Time Period Available:	2010 - 2015																																										
Related Variables:	Derived AJCC-6 T (DERIVED_AJCC_T)																																										
Definition:	<p>This data item belongs to the Collaborative Stage (CS) Data Collection System. This field contains the AJCC 7th edition "T" code and is derived from CS coded fields using the CS algorithm.</p> <p>Detailed information on the Collaborative Stage Data Collection System can be found at: http://www.cancerstaging.org/cstage/index.html. Refer to the AJCC Cancer Staging Manual, 7th Edition for site-specific T-code descriptions.</p>																																										
Notes:	<i>For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."</i>																																										
Values:	<table> <tr><td>000:</td><td>T0</td></tr> <tr><td>010:</td><td>Ta</td></tr> <tr><td>050:</td><td>Tis</td></tr> <tr><td>060:</td><td>Tispu (urethra only)</td></tr> <tr><td>070:</td><td>Tispd (urethra only)</td></tr> <tr><td>100:</td><td>T1</td></tr> <tr><td>110:</td><td>T1mic</td></tr> <tr><td>120:</td><td>T1a</td></tr> <tr><td>130:</td><td>T1a1</td></tr> <tr><td>140:</td><td>T1a2</td></tr> <tr><td>155:</td><td>T1b</td></tr> <tr><td>160:</td><td>T1b1</td></tr> <tr><td>170:</td><td>T1b2</td></tr> <tr><td>180:</td><td>T1c</td></tr> <tr><td>181:</td><td>T1d</td></tr> <tr><td>199:</td><td>T1, NOS</td></tr> <tr><td>200:</td><td>T2</td></tr> <tr><td>210:</td><td>T2a</td></tr> <tr><td>211:</td><td>T2a1</td></tr> <tr><td>212:</td><td>T2a2</td></tr> <tr><td>213:</td><td>T2a, NOS</td></tr> </table>	000:	T0	010:	Ta	050:	Tis	060:	Tispu (urethra only)	070:	Tispd (urethra only)	100:	T1	110:	T1mic	120:	T1a	130:	T1a1	140:	T1a2	155:	T1b	160:	T1b1	170:	T1b2	180:	T1c	181:	T1d	199:	T1, NOS	200:	T2	210:	T2a	211:	T2a1	212:	T2a2	213:	T2a, NOS
000:	T0																																										
010:	Ta																																										
050:	Tis																																										
060:	Tispu (urethra only)																																										
070:	Tispd (urethra only)																																										
100:	T1																																										
110:	T1mic																																										
120:	T1a																																										
130:	T1a1																																										
140:	T1a2																																										
155:	T1b																																										
160:	T1b1																																										
170:	T1b2																																										
180:	T1c																																										
181:	T1d																																										
199:	T1, NOS																																										
200:	T2																																										
210:	T2a																																										
211:	T2a1																																										
212:	T2a2																																										
213:	T2a, NOS																																										

California Cancer Registry Data Dictionary

220: T2b
 230: T2c
 299: T2, NOS
 300: T3
 310: T3a
 320: T3b
 330: T3c
 340: T3d
 399: T3, NOS
 400: T4
 410: T4a
 420: T4b
 430: T4c
 440: T4d
 450: T4e
 499: T4, NOS
 800: T1a, NOS
 810: T1b, NOS
 888: Not applicable
 999: TX

Blank: Date of Diagnosis is before January 1, 2010 or after December 31, 2015

California Cancer Registry Data Dictionary

Variable Name: DERIVEDAJCC7TDESCRPT

Eureka Name: Derived AJCC-7 T Descript

NAACCR Item: 3402

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2010 – 2015

Related Variables:

- Derived AJCC-7 T (DERIVEDAJCC7T)
- Derived AJCC T Descript (DERIVED_AJCC_T_DESC)

Definition: This data item belongs to the Collaborative Stage (CS) Data Collection System. This field contains the AJCC 7th edition “T” code descriptor and is derived from CS coded fields using the CS algorithm.

Notes: Detailed information on the Collaborative Stage Data Collection System can be found at:
<http://www.cancerstaging.org/cstage/index.html>

For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”

Values:

- c: Clinical stage
- p: Pathologic stage
- a: Autopsy stage
- y: Surgical resection performed AFTER pre-surgical systemic treatment or radiation; tumor size/extension based on pathologic evidence.
- N: Not applicable
- Blank: Date of Diagnosis is before January 1, 2010 or after December 31, 2015

California Cancer Registry Data Dictionary

Variable Name: DERIVEDEOD18M
Eureka Name: Derived EOD 2018 M
NAACCR Item: 795
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 - current year

Related Variables:

- Derived EOD 2018 T (DERIVEDEOD18T)
- Derived EOD 2018 N (DERIVEDEOD18N)
- Derived EOD 2018 Stage Group (DERIVEDEOD18STGGP)
- Extent of Disease Derived M Code for TNM Staging (MCODE)
- Derived AJCC-6 M (DERIVED_AJCC_M)
- Derived AJCC-7 M (DERIVEDAJCC7M)
- TNM Clin M (TNM_M_CODE_CLINICAL)
- TNM Path M (TNM_M_CODE_PATH)
- Derived SEER Combined M (DERIVEDSEERCOMBINEDM)

Definition: Extent of Disease (EOD) derived "M" value for TNM staging which identifies the presence or absence of distant metastasis for the tumor. This variable is not a collected data item but derived according to the AJCC Cancer Staging Manual Eighth Edition using EOD staging data items. Valid for cases diagnosed January 1, 2018 and forward. For cases diagnosed 1988 through 2003, see MCODE (also derived from EOD staging data items according to the AJCC Cancer Staging Manual Third Edition for select cancer sites only). For cases diagnosed 2004 through 2015, this value is derived from collaborative stage data items according to the AJCC Cancer Staging Manual Sixth Edition and is recorded in the field DERIVED_AJCC_M. Additionally, for cases diagnosed 2010 through 2015, this value is derived from collaborative stage data items according to the AJCC Cancer Staging Manual Seventh Edition and is recorded in the field DERIVEDAJCC7M. For cases diagnosed 2016 and 2017, TNM values were directly coded by Certified Tumor Registrars and the AJCC Cancer Staging Manual Seventh Edition M value is recorded in the fields TNM_M_CODE_CLINICAL and TNM_M_CODE_PATH. Or, for the derived M value used to calculate DERIVEDSEERCMBSTGGRP, see DERIVEDSEERCOMBINEDM.

Notes: Refer to the ***AJCC Cancer Staging Manual, Eighth Edition*** for the site-specific M-code descriptions.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

- 88: Not applicable
- 90: Invalid/unable to derive value
- Blank: Date of Diagnosis is before January 1, 2018

California Cancer Registry Data Dictionary

Variable Name:	DERIVEDEOD18N
Eureka Name:	Derived EOD 2018 N
NAACCR Item:	815
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • Derived EOD 2018 T (DERIVEDEOD18T) • Derived EOD 2018 M (DERIVEDEOD18M) • Derived EOD 2018 Stage Group (DERIVEDEOD18STGGRP) • Extent of Disease Derived N Code for TNM Staging (NCODE) • Derived AJCC-6 N (DERIVED_AJCC_N) • Derived AJCC-7 N (DERIVEDAJCC7N) • TNM Clin N (TNM_N_CODE_CLINICAL) • TNM Path N (TNM_N_CODE_PATH) • Derived SEER Combined N (DERIVEDSEERCOMBINEDN)

Definition: Extent of Disease (EOD) derived “N” value for TNM staging which categorizes regional lymph node involvement. This variable is not a collected data item but derived according to the AJCC Cancer Staging Manual Eighth Edition using EOD staging data items. Valid for cases diagnosed January 1, 2018 and forward. For cases diagnosed 1988 through 2003, see NCODE (also derived from EOD staging data items according to the AJCC Cancer Staging Manual Third Edition for select cancer sites only). For cases diagnosed 2004 through 2015, this value is derived from collaborative stage data items according to the AJCC Cancer Staging Manual Sixth Edition and is recorded in the field DERIVED_AJCC_N. Additionally, for cases diagnosed 2010 through 2015, this value is derived from collaborative stage data items according to the AJCC Cancer Staging Manual Seventh Edition and is recorded in the field DERIVEDAJCC7N. For cases diagnosed 2016 and 2017, TNM values were directly coded by Certified Tumor Registrars and the AJCC Cancer Staging Manual Seventh Edition N value is recorded in the fields TNM_N_CODE_CLINICAL and TNM_N_CODE_PATH. Or, for the derived N value used to calculate DERIVEDSEERCMBSTGGRP, see DERIVEDSEERCOMBINEDN.

Notes: Refer to the ***AJCC Cancer Staging Manual, Eighth Edition*** for the site-specific N-code descriptions.

For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”

Values:	88:	Not applicable
	90:	Invalid/unable to derive value
	Blank:	Date of Diagnosis is before January 1, 2018

California Cancer Registry Data Dictionary

Variable Name: DERIVEDEOD18STGGP
Eureka Name: Derived EOD 2018 Stage Group
NAACCR Item: 818
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables:

- Extent of Disease Derived AJCC 3rd Edition Stage Group 1988 through 2003 (STAGE_AJCC)
- SEER Modified Extent of Disease Derived AJCC 3rd Edition Stage Group 1988 through 2003 (STAGE_AJCCSEERSTAGE)
- Derived AJCC-6 Stage Grp (DERIVED_AJCC_STG_GRP)
- Derived AJCC-7 Stage Group (DERIVEDAJCC7STAGEGRP)
- Derived SEER Cmb Stg Grp (DERIVEDSEERCMBSTGGRP)

Definition: Extent of Disease (EOD) derived AJCC stage group which identifies the anatomic extent of disease. This variable is not a collected data item but derived according to the AJCC Cancer Staging Manual Eighth Edition using EOD staging data items. Valid for cases diagnosed January 1, 2018 and forward. For cases diagnosed 1988 through 2003, this value is recorded in the field STAGE_AJCC or STAGE_AJCCSEER (also derived from EOD staging data items according to the AJCC Cancer Staging Manual Third Edition for select cancer sites only). For cases diagnosed 2004 through 2015, this value is derived from collaborative stage data items according to the AJCC Cancer Staging Manual Sixth Edition and is recorded in the field DERIVED_AJCC_STG_GRP. Additionally, for cases diagnosed 2010 through 2015, this value is derived from collaborative stage data items according to the AJCC Cancer Staging Manual Seventh Edition and is recorded in the field DERIVEDAJCC7STAGEGRP. For cases diagnosed 2016 and 2017, this value is recorded in the field DERIVEDSEERCMBSTGGRP and is derived from directly coded T, N, and M data fields according to the Union for International Cancer Control (UICC) TNM Classification of Malignant Tumours Seventh Edition. The rules of classification and staging in the UICC TNM Classification of Malignant Tumours Seventh Edition correspond to those appearing in the AJCC Cancer Staging Manual Seventh Edition.

Notes: Refer to the ***AJCC Cancer Staging Manual, Eighth Edition*** for the site-specific stage group descriptions.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

OC:	Occult
0:	0
0a:	0a
0is:	0is
1	I

California Cancer Registry Data Dictionary

1A:	IA
1A1:	IA1
1A2:	IA2
1A3:	IA3
1B:	IB
1B1:	IB1
1B2:	IB2
1C:	IC
1E:	IE
1S:	IS
2:	II
2 bulky:	II Bulky
2A:	IIA
2A1:	IIA1
2A2:	IIA2
2B:	IIB
2C:	IIC
2E:	IIE
3:	III
3A:	IIIA
3A1:	IIIA1
3A2:	IIIA2
3B:	IIIB
3C:	IIIC
3C1:	IIIC1
3C2:	IIIC2
3D:	IIID
4:	IV
4A:	IVA
4B:	IVB
4C:	IVC
88:	Not applicable
90:	Algorithm could not derive stage due to coding errors/conflicts
99:	Stage group for the combination of T, N, and M is not defined by AJCC
Blank:	Date of Diagnosis is before January 1, 2018

California Cancer Registry Data Dictionary

Variable Name:	DERIVEDEOD18T
Eureka Name:	Derived EOD 2018 T
NAACCR Item:	785
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> Derived EOD 2018 N (DERIVEDEOD18N) Derived EOD 2018 M (DERIVEDEOD18M) Derived EOD 2018 Stage Group (DERIVEDEOD18STGGP) Extent of Disease Derived T Code for TNM Staging (TCODE) Derived AJCC-6 T (DERIVED_AJCC_T) Derived AJCC-7 T (DERIVEDAJCC7T) TNM Clin T (TNM_T_CODE_CLINICAL) TNM Path T (TNM_T_CODE_PATH) Derived SEER Combined T (DERIVEDSEERCOMBINEDT)

Definition: Extent of Disease (EOD) derived “T” value for TNM staging which describes the size and/or extension of the primary tumor. This variable is not a collected data item but derived according to the AJCC Cancer Staging Manual Eighth Edition using EOD staging data items. Valid for cases diagnosed January 1, 2018 and forward. For cases diagnosed 1988 through 2003, see TCODE (also derived from EOD staging data items according to the AJCC Cancer Staging Manual Third Edition for select cancer sites only). For cases diagnosed 2004 through 2015, this value is derived from collaborative stage data items according to the AJCC Cancer Staging Manual Sixth Edition and is recorded in the field DERIVED_AJCC_T. Additionally, for cases diagnosed 2010 through 2015, this value is derived from collaborative stage data items according to the AJCC Cancer Staging Manual Seventh Edition and is recorded in the field DERIVEDAJCC7T. For cases diagnosed 2016 and 2017, TNM values were directly coded by Certified Tumor Registrars and the AJCC Cancer Staging Manual Seventh Edition T value is recorded in the fields TNM_T_CODE_CLINICAL and TNM_T_CODE_PATH. Or, for the derived T value used to calculate DERIVEDSEERCMBSTGGRP, see DERIVEDSEERCOMBINEDT.

Notes: Refer to the ***AJCC Cancer Staging Manual, Eighth Edition*** for the site-specific T-code descriptions.

For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”

Values:	88:	Not applicable
	90:	Invalid/unable to derive value
	Blank:	Date of Diagnosis is before January 1, 2018

California Cancer Registry Data Dictionary

Variable Name: DERIVEDSEERCLINSTGGRP
Eureka Name: Derived SEER Clin Stg Grp
NAACCR Item: 3610
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2016 - 2017
Related Variables:

- TNM Clin T (TNM_T_CODE_CLINICAL)
- TNM Clin N (TNM_N_CODE_CLINICAL)
- TNM Clin M (TNM_M_CODE_CLINICAL)

Definition: The SEER program's derived clinical stage group based on the Union for International Cancer Control (UICC) TNM Classification of Malignant Tumours Seventh Edition. The rules of classification and staging in the UICC TNM Classification of Malignant Tumours Seventh Edition correspond to those appearing in the AJCC Cancer Staging Manual Seventh Edition. Clinical stage identifies the anatomic extent of disease based on the T, N, and M information known prior to the start of any therapy.

Notes: Refer to the ***AJCC Cancer Staging Manual, Seventh Edition*** for the site-specific stage group descriptions.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

0:	Stage 0
0A:	Stage 0A
0IS:	Stage 0is
1:	Stage I
1A:	Stage IA
1A1:	Stage IA1
1A2:	Stage IA2
1B:	Stage IB
1B1:	Stage IB1
1B2:	Stage IB2
1C:	Stage IC
1S:	Stage IS
2:	Stage II
2A:	Stage IIA
2A1:	Stage IIA1
2A2:	Stage IIA2
2B:	Stage IIB
2C:	Stage IIC
3:	Stage III
3A:	Stage IIIA

California Cancer Registry Data Dictionary

3B:	Stage IIIB
3C:	Stage IIIC
3C1:	Stage IIIC1
3C2:	Stage IIIC2
4:	Stage IV
4A:	Stage IVA
4A1:	Stage IVA1
4A2:	Stage IVA2
4B:	Stage IVB
4C:	Stage IVC
OC:	Occult
88:	Not applicable
90:	Algorithm could not derive stage due to coding errors/conflicts
99:	Unknown
Blank:	Algorithm has not run

California Cancer Registry Data Dictionary

Variable Name: DERIVEDSEERCMBMSRC

Eureka Name: Derived SEER Cmb M Src

NAACCR Item: 3626

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2016 – 2017

Related Variables: Derived SEER Combined M (DERIVEDSEERCOMBINEDM)

Definition: Indicates the source information selected for the calculation of Derived SEER Combined M (DERIVEDSEERCOMBINEDM). A computer algorithm derives the Combined M category based on the respective clinical and pathologic M components plus any additional information as needed. Based on the algorithm, the computer chooses to use just the clinical component, just the pathologic component, or in a few rare instances to combine information from both the clinical and pathologic components to determine the Derived SEER Combined M category based on the Union for International Cancer Control (UICC) TNM Classification of Malignant Tumours Seventh Edition. The UICC is used by SEER as the framework for assigning TNM and stage group. The rules of classification and staging in the UICC TNM Classification of Malignant Tumours Seventh Edition correspond to those appearing in the AJCC Cancer Staging Manual Seventh Edition.

Notes: *For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”*

Values:

- 1: Clinical
- 2: Pathologic
- 3: Clinical and pathologic
- 9: Unknown

California Cancer Registry Data Dictionary

Variable Name: DERIVEDSEERCMBNSRC

Eureka Name: Derived SEER Cmb N Src

NAACCR Item: 3624

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2016 – 2017

Related Variables: Derived SEER Combined N (DERIVEDSEERCOMBINEDN)

Definition: Indicates the source information selected for the calculation of Derived SEER Combined N (DERIVEDSEERCOMBINEDN). A computer algorithm derives the Combined N category based on the respective clinical and pathologic N components plus any additional information as needed. Based on the algorithm, the computer chooses to use just the clinical component, just the pathologic component, or in a few rare instances to combine information from both the clinical and pathologic components to determine the Derived SEER Combined N category based on the Union for International Cancer Control (UICC) TNM Classification of Malignant Tumours Seventh Edition. The UICC is used by SEER as the framework for assigning TNM and stage group. The rules of classification and staging in the UICC TNM Classification of Malignant Tumours Seventh Edition correspond to those appearing in the AJCC Cancer Staging Manual Seventh Edition.

Notes: *For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”*

Values:

- 1: Clinical
- 2: Pathologic
- 3: Clinical and pathologic
- 9: Unknown

California Cancer Registry Data Dictionary

Variable Name: DERIVEDSEERCMBSTGGRP
Eureka Name: Derived SEER Cmb Stg Grp
NAACCR Item: 3614
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2016 - 2017

Related Variables:

- Derived SEER Combined T (DERIVEDSEERCOMBINEDT)
- Derived SEER Combined N (DERIVEDSEERCOMBINEDN)
- Derived SEER Combined M (DERIVEDSEERCOMBINEDM)
- Derived SEER Cmb T Src (DERIVEDSEERCMBTSRC)
- Derived SEER Cmb N Src (DERIVEDSEERCMBNSRC)
- Derived SEER Cmb M Src (DERIVEDSEERCMBMSRC)

Definition: This data item stores the results of the SEER program's algorithm for calculating a combined stage group to describe the anatomic extent of disease using the clinical and pathologic T, N, M information of the tumor and additional information as needed. SEER's combined stage group is based on the Union for International Cancer Control (UICC) TNM Classification of Malignant Tumours Seventh Edition. The rules of classification and staging in the UICC TNM Classification of Malignant Tumours Seventh Edition correspond to those appearing in the AJCC Cancer Staging Manual Seventh Edition.

Notes: Refer to the ***AJCC Cancer Staging Manual, Seventh Edition*** for site-specific stage group descriptions.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

0:	Stage 0
0A:	Stage 0A
0IS:	Stage 0is
1:	Stage I
1A:	Stage IA
1A1:	Stage IA1
1A2:	Stage IA2
1B:	Stage IB
1B1:	Stage IB1
1B2:	Stage IB2
1C:	Stage IC
1S:	Stage IS
2:	Stage II
2A:	Stage IIA
2A1:	Stage IIA1
2A2:	Stage IIA2
2B:	Stage IIB

California Cancer Registry Data Dictionary

2C:	Stage IIC
3:	Stage III
3A:	Stage IIIA
3B:	Stage IIIB
3C:	Stage IIIC
3C1:	Stage IIIC1
3C2:	Stage IIIC2
4:	Stage IV
4A:	Stage IVA
4A1:	Stage IVA1
4A2:	Stage IVA2
4B:	Stage IVB
4C:	Stage IVC
OC:	Occult
88:	Not applicable
90:	Algorithm could not derive stage due to coding errors/conflicts
99:	Unknown
Blank:	Algorithm has not been run

California Cancer Registry Data Dictionary

Variable Name: DERIVEDSEERCMBTSRC

Eureka Name: Derived SEER Cmb T Src

NAACCR Item: 3622

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2016 – 2017

Related Variables: Derived SEER Combined T (DERIVEDSEERCOMBINEDT)

Definition: Indicates the source information selected for the calculation of Derived SEER Combined T (DERIVEDSEERCOMBINEDT). A computer algorithm derives the Combined T category based on the respective clinical and pathologic T components plus any additional information as needed. Based on the algorithm, the computer chooses to use just the clinical component, just the pathologic component, or in a few rare instances to combine information from both the clinical and pathologic components to determine the Derived SEER Combined T category based on the Union for International Cancer Control (UICC) TNM Classification of Malignant Tumours Seventh Edition. The UICC is used by SEER as the framework for assigning TNM and stage group. The rules of classification and staging in the UICC TNM Classification of Malignant Tumours Seventh Edition correspond to those appearing in the AJCC Cancer Staging Manual Seventh Edition.

Notes: *For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”*

Values:

- 1: Clinical
- 2: Pathologic
- 3: Clinical and pathologic
- 9: Unknown

California Cancer Registry Data Dictionary

Variable Name: DERIVEDSEERCOMBINEDM
Eureka Name: Derived SEER Combined M
NAACCR Item: 3620
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2016 – 2017

Related Variables:

- Derived SEER Cmb M Src (DERIVEDSEERCMBMSRC)
- Derived SEER Combined T (DERIVEDSEERCOMBINEDT)
- Derived SEER Combined N (DERIVEDSEERCOMBINEDN)
- Derived SEER Cmb Stg Grp (DERIVEDSEERCMBSTGGRP)

Definition: This data item stores the source information selected by the SEER program's algorithm to derive the "M" category for TNM staging. The values listed below will have a leading "c" or "p" depending on whether the clinical or pathologic M value was selected by the algorithm. The "M" category identifies the presence or absence of distant metastasis of the tumor. The combined M value is used in conjunction with the combined T and combined N values to derive a combined stage group based on the Union for International Cancer Control (UICC) TNM Classification of Malignant Tumours 7th Ed. SEER uses the UICC TNM Classification as the framework for assigning TNM and stage group. The rules of classification and staging in the UICC TNM Classification of Malignant Tumours 7th Ed. correspond to those appearing in the AJCC Cancer Staging Manual 7th Ed.

Notes: Refer to the ***AJCC Cancer Staging Manual, Seventh Edition*** for the site-specific M-code descriptions.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

0:	M0
0I+:	M0(i+)
1:	M1
1A:	M1a
1B:	M1b
1C:	M1c
1D:	M1d
1E:	M1e
88:	Not applicable
Blank:	Not derived

California Cancer Registry Data Dictionary

Variable Name: DERIVEDSEERCOMBINEDN
Eureka Name: Derived SEER Combined N
NAACCR Item: 3618
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2016 – 2017

Related Variables:

- Derived SEER Cmb N Src (DERIVEDSEERCMBNSRC)
- Derived SEER Combined T (DERIVEDSEERCOMBINEDT)
- Derived SEER Combined M (DERIVEDSEERCOMBINEDM)
- Derived SEER Cmb Stg Grp (DERIVEDSEERCMBSTGGRP)

Definition: This data item stores the source information selected by the SEER program's algorithm to derive the "N" category for TNM staging. The values listed below will have a leading "c" or "p" depending on whether the clinical or pathologic N value was selected by the algorithm. The "N" category describes regional lymph node involvement of the tumor. The combined N value is used in conjunction with the combined T and combined M values to derive a combined stage group based on the Union for International Cancer Control (UICC) TNM Classification of Malignant Tumours 7th Ed. SEER uses the UICC TNM Classification as the framework for assigning TNM and stage group. The rules of classification and staging in the UICC TNM Classification of Malignant Tumours 7th Ed. correspond to those appearing in the AJCC Cancer Staging Manual 7th Ed.

Notes: Refer to the ***AJCC Cancer Staging Manual, Seventh Edition*** for the site-specific N-code descriptions.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

X:	NX
0:	N0
0I-:	N0i-
0I+:	N0i+
0M-:	N0m-
0M+:	N0m+
1MI:	N1mi
0A:	N0a
0B:	N0b
1:	N1
1a:	N1a
1B:	N1b
1C:	N1c
2:	N2
2A:	N2a
2B:	N2b

California Cancer Registry Data Dictionary

2C:	N2c
3:	N3
3A:	N3a
3B:	N3b
3C:	N3c
4:	N4
88:	Not applicable
Blank:	Not derived

California Cancer Registry Data Dictionary

Variable Name:	DERIVEDSEERCOMBINEDT
Eureka Name:	Derived SEER Combined T
NAACCR Item:	3616
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2016 – 2017
Related Variables:	<ul style="list-style-type: none"> Derived SEER Cmb T Src (DERIVEDSEERCMBTSRC) Derived SEER Combined N (DERIVEDSEERCOMBINEDN) Derived SEER Combined M (DERIVEDSEERCOMBINEDM) Derived SEER Cmb Stg Grp (DERIVEDSEERCMBSTGGRP)

Definition: This data item stores the source information selected by the SEER program's algorithm to derive the "T" category for TNM staging. The values listed below will have a leading "c" or "p" depending on whether the clinical or pathologic T value was selected by the algorithm. The "T" category describes the size and/or extension of the primary tumor. The combined T value is used in conjunction with the combined N and combined M values to derive a combined stage group based on the Union for International Cancer Control (UICC) TNM Classification of Malignant Tumours 7th Ed. SEER uses the UICC TNM Classification as the framework for assigning TNM and stage group. The rules of classification and staging in the UICC TNM Classification of Malignant Tumours 7th Ed. correspond to those appearing in the AJCC Cancer Staging Manual 7th Edition.

Notes: Refer to the ***AJCC Cancer Staging Manual, Seventh Edition*** for the site-specific T-code descriptions. *For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."*

Values:	X	TX
	0:	T0
	A:	Ta
	IS:	Tis
	ISPU:	Tispu
	ISPD:	Tispd
	1MI	T1mi, T1mic
	1:	T1
	1A:	T1a
	1A1:	T1a1
	1A2:	T1a2
	1B:	T1b
	1B1:	T1b1
	1B2:	T1b2
	1C:	T1c
	1D:	T1d

California Cancer Registry Data Dictionary

2:	T2
2A:	T2a
2A1:	T2a1
2A2:	T2a2
2B:	T2b
2C:	T2c
2D:	T2d
3:	T3
3A:	T3a
3B:	T3b
3C:	T3c
3D:	T3d
4:	T4
4A:	T4a
4B:	T4b
4C:	T4c
4D:	T4d
4E:	T4e
88:	Not applicable
Blank:	Not derived

California Cancer Registry Data Dictionary

Variable Name: DERIVEDSEERPATHSTGGRP
Eureka Name: Derived SEER Path Stg Grp
NAACCR Item: 3605
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2016 – 2017
Related Variables:

- TNM Path T (TNM_T_CODE_PATH)
- TNM Path N (TNM_N_CODE_PATH)
- TNM Path M (TNM_M_CODE_PATH)

Definition: The SEER program's derived pathologic stage group based on the Union for International Cancer Control (UICC) TNM Classification of Malignant Tumours Seventh Edition. The rules of classification and staging in the UICC TNM Classification of Malignant Tumours Seventh Edition correspond to those appearing in the AJCC Cancer Staging Manual Seventh Edition. Pathologic stage identifies the anatomic extent of disease based on the T, N, and M information known following the completion of surgical therapy.

Notes: Refer to the ***AJCC Cancer Staging Manual, Seventh Edition*** for the site-specific stage group descriptions.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

0:	Stage 0
0A:	Stage 0A
0IS:	Stage 0is
1:	Stage I
1A:	Stage IA
1A1:	Stage IA1
1A2:	Stage IA2
1B:	Stage IB
1B1:	Stage IB1
1B2:	Stage IB2
1C:	Stage IC
1S:	Stage IS
2:	Stage II
2A:	Stage IIA
2A1:	Stage IIA1
2A2:	Stage IIA2
2B:	Stage IIB
2C:	Stage IIC
3:	Stage III

California Cancer Registry Data Dictionary

3A:	Stage IIIA
3B:	Stage IIIB
3C:	Stage IIIC
3C1:	Stage IIIC1
3C2:	Stage IIIC2
4:	Stage IV
4A:	Stage IVA
4A1:	Stage IVA1
4A2:	Stage IVA2
4B:	Stage IVB
4C:	Stage IVC
OC:	Occult
88:	Not applicable
90:	Algorithm could not derive stage due to coding errors/conflicts
99:	Unknown
Blank:	Algorithm has not been run

California Cancer Registry Data Dictionary

Variable Name:	DERIVEDSUMMARYSTAGE2018
Eureka Name:	Derived Summary Stage 2018
NAACCR Item:	762
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 – current year
Related Variables:	<ul style="list-style-type: none"> • EOD Primary Tumor (EODPRIMARYTUMOR) • EOD Regional Nodes (EODREGNODES) • EOD Mets (EODMETS)

Definition: Derived summary stage at time of diagnosis. This data item is derived using the Extent of Disease (EOD) data collection system including EOD Primary Tumor (EODPRIMARYTUMOR), EOD Regional Nodes (EODREGNODES), EOD Mets (EODMETS) and additional information as needed. Effective for cases diagnosed January 1, 2018 and forward. For cases diagnosed 1988 through 1993, see SUMSTAGE77. For cases diagnosed 1994 through 2000, see SEERSUMMARYSTAGE1977. For cases diagnosed 2001 through 2003, see SEERSUMMARYSTAGE2000. For cases diagnosed 2004 through 2015, see DERIVED_SS2000.

Notes: *For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”*

Values:	0:	In situ
	1:	Localized
	2:	Regional, direct extension only
	3:	Regional, regional lymph nodes only
	4:	Regional, direct extension and regional lymph nodes
	7:	Distant
	8:	Benign, borderline
	9:	Unknown if extension or metastasis (unstaged, unknown, or unspecified); death certificate only

California Cancer Registry Data Dictionary

Variable Name: DIFFERN2
Eureka Name: Grade
NAACCR Item: 440
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 1988 - 2017
Related Variables:

- Grade Clinical (GRADECLIN)
- Grade Pathological (GRADEPATH)
- Grade Post Therapy (GRADEPOST)

Definition: Sixth digit of ICD-O-3; designates the grade or differentiation of the tumor. For lymphomas and leukemia, this field also is used to indicate T-, B-, Null-, or NK-cell origin. Code 8 was adopted for use with lymphomas for cases diagnosed 1995 and later. For cases diagnosed 2018 and forward see, GRADECLIN, GRADEPATH, AND GRADEPOST.

Values:

- 1: Grade I or (well) differentiated
- 2: Grade II or moderately (well) differentiated
- 3: Grade III or poorly differentiated
- 4: Grade IV or undifferentiated/anaplastic
- 5: T-cell
- 6: B-cell
- 7: Null cell
- 8: NK (Natural killer cell)
- 9: Grade and differentiation not stated
- Blank: Case diagnosed 2018 and forward

California Cancer Registry Data Dictionary

Variable Name:	DIREXTTU
Eureka Name:	EOD--Extension
NAACCR Item:	790
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	1988 - 2003
Related Variables:	<ul style="list-style-type: none"> • CS Extension (CS_EXT) • EOD Primary Tumor (EODPRIMARYTUMOR)

Definition Two-digit extension code that represents the growth of the primary tumor within the organ of origin, its extension into neighboring organs, or its metastasis to distant structures. It is a hierarchical code in which the most extensive disease is coded. For cases diagnosed 2004 through 2017 this information is recorded in the field CS_EXT. For cases diagnosed January 1, 2018 and forward, this information is recorded in the field EODPRIMARYTUMOR.

Notes: See [SEER Extent of Disease, 1988: Codes and Coding Instructions, Third Edition](#) for site-specific codes and coding rules.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values: Site specific: 00, 01, 03, 05, 06, 10, 11, 12, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 40, 41, 42, 43, 44, 45, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 60, 61, 62, 63, 64, 65, 66, 67, 68, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 85, 87

90: Unknown for prostate

99: Unknown

Blank: Case not abstracted; or for cases diagnosed after January 1, 2004

California Cancer Registry Data Dictionary

Variable Name: DOB
Eureka Name: Date of Birth
NAACCR Item: 240
Category: Patient Demographics
Level of Variable: Patient
Time Period Available: 1988 - current year
Related Variables:
Definition: Date of birth of the patient
Values: A valid, complete date in YYYYMMDD

California Cancer Registry Data Dictionary

Variable Name: DRATTEND

Eureka Name: Physician--Managing

NAACCR Item: 2460

Category: Hospital and Physician

Level of Variable: Admission

Time Period Available: 1988 - current year

Related Variables:

- Physician--Follow-Up (DRFOLLOW)
- Physician 3 (DRRADONC)
- Physician 4 (DRMEDONC)
- Physician Other 1 (DROTHER1)
- Physician Other 2 (DROTHER2)
- Physician--Primary Surg (DRSURG)
- Physician--Referring (DRREF)

Definition: California license number of the attending (managing) physician as reported by the facility with the earliest date of admission.

Values: Individual California license numbers may be searched for at the Medical Board of California (<https://www.mbc.ca.gov/>).

Out-of-state physicians' license numbers begin with the letter X.

99999999: Unknown

California Cancer Registry Data Dictionary

Variable Name: DRFOLLOW

Eureka Name: Physician--Follow-Up

NAACCR Item: 2470

Category: Hospital and Physician

Level of Variable: Admission

Time Period Available: 1988 - current year

Related Variables:

- Physician--Managing (DRATTEND)
- Physician 3 (DRRADONC)
- Physician 4 (DRMEDONC)
- Physician Other 1 (DROTHER1)
- Physician Other 2 (DROTHER2)
- Physician--Primary Surg (DRSURG)
- Physician--Referring (DRREF)

Definition: California license number of the physician who will be seeing the patient after discharge from the hospital and who could be contacted for follow-up information. Value taken from the facility with the earliest date of admission.

Values: Individual California license numbers may be searched for at the Medical Board of California (<https://www.mbc.ca.gov/>).
Out-of-state physicians' license numbers begin with the letter X.
99999999: Unknown

California Cancer Registry Data Dictionary

Variable Name: DRMEDONC

Eureka Name: Physician 4

NAACCR Item: 2500

Category: Hospital and Physician

Level of Variable: Admission

Time Period Available: 1988 - current year

Related Variables:

- Physician--Managing (DRATTEND)
- Physician--Follow-Up (DRFOLLOW)
- Physician 3 (DRRADONC)
- Physician Other 1 (DROTHER1)
- Physician Other 2 (DROTHER2)
- Physician--Primary Surg (DRSURG)
- Physician--Referring (DRREF)

Definition: California license number of the medical oncologist. Value taken from the facility with the earliest date of admission.

Values: Individual California license numbers may be searched for at the Medical Board of California (<https://www.mbc.ca.gov/>).
 Out-of-state physicians' license numbers begin with the letter X.
 00000000: No chemotherapy or chemotherapy consult performed
 99999999: Unknown

California Cancer Registry Data Dictionary

Variable Name: DROTHER1
Eureka Name: Physician Other 1
NAACCR Item: N/A
Category: Hospital and Physician
Level of Variable: Admission

Time Period Available: 1988 - current year

Related Variables:

- Physician--Managing (DRATTEND)
- Physician--Follow-Up (DRFOLLOW)
- Physician 3 (DRRADONC)
- Physician 4 (DRMEDONC)
- Physician Other 2 (DROTHER2)
- Physician--Primary Surg (DRSURG)
- Physician--Referring (DRREF)

Definition: California license number of a physician other than the attending and following physicians. Value taken from the facility with the earliest date of admission.

Values: Individual California license numbers may be searched for at the Medical Board of California (<https://www.mbc.ca.gov/>).
 Out-of-state physicians' license numbers begin with the letter X.
 00000000: No other consult was performed
 99999999: Unknown

California Cancer Registry Data Dictionary

Variable Name: DROTHER2
Eureka Name: Physician Other 2
NAACCR Item: N/A
Category: Hospital and Physician
Level of Variable: Admission
Time Period Available: 1988 - current year

Related Variables:

- Physician--Managing (DRATTEND)
- Physician--Follow-Up (DRFOLLOW)
- Physician 3 (DRRADONC)
- Physician 4 (DRMEDONC)
- Physician Other 1 (DROTHER1)
- Physician--Primary Surg (DRSURG)
- Physician--Referring (DRREF)

Definition: California license number of a physician other than the attending and following physicians. Value taken from the facility with the earliest date of admission.

Values: Individual California license numbers may be searched for at the Medical Board of California (<https://www.mbc.ca.gov/>).
 Out-of-state physicians' license numbers begin with the letter X.
 00000000: No other consult was performed
 99999999: Unknown

California Cancer Registry Data Dictionary

Variable Name: DRRADONC
Eureka Name: Physician 3
NAACCR Item: 2490
Category: Hospital and Physician
Level of Variable: Admission
Time Period Available: 1988 - current year

Related Variables:

- Physician--Managing (DRATTEND)
- Physician--Follow-Up (DRFOLLOW)
- Physician 4 (DRMEDONC)
- Physician Other 1 (DROTHER1)
- Physician Other 2 (DROTHER2)
- Physician--Primary Surg (DRSURG)
- Physician--Referring (DRREF)

Definition: California license number of the radiation oncologist. Value taken from the facility with the earliest date of admission.

Values: Individual California license numbers may be searched for at the Medical Board of California (<https://www.mbc.ca.gov/>).
 Out-of-state physicians' license numbers begin with the letter X.
 00000000: No radiation therapy or radiation therapy consult performed
 99999999: Unknown

California Cancer Registry Data Dictionary

Variable Name:	DRREF
Eureka Name:	Physician--Referring
NAACCR Item:	N/A
Category:	Hospital and Physician
Level of Variable:	Admission
Time Period Available:	1988 - current year
Related Variables:	<ul style="list-style-type: none"> • Physician--Managing (DRATTEND) • Physician--Follow-Up (DRFOLLOW) • Physician 3 (DRRADONC) • Physician 4 (DRMEDONC) • Physician Other 1 (DROTHER1) • Physician Other 2 (DROTHER2) • Physician--Primary Surg (DRSURG)
Definition:	California license number of the referring physician. Value taken from the facility with the earliest date of admission.
Values:	<p>Individual California license numbers may be searched for at the Medical Board of California (https://www.mbc.ca.gov/).</p> <p>Out-of-state physicians' license numbers begin with the letter X.</p> <p>00000000: No referral</p> <p>99999999: Unknown</p>

California Cancer Registry Data Dictionary

Variable Name:	DRSURG
Eureka Name:	Physician--Primary Surg
NAACCR Item:	2480
Category: Level of Variable:	Hospital and Physician Admission
Time Period Available:	1988 - current year
Related Variables:	<ul style="list-style-type: none"> • Physician--Managing (DRATTEND) • Physician--Follow-Up (DRFOLLOW) • Physician 3 (DRRADONC) • Physician 4 (DRMEDONC) • Physician Other 1 (DROTHER1) • Physician Other 2 (DROTHER2) • Physician--Referring (DRREF)
Definition:	California license number of the surgeon. Value taken from the facility with the earliest date of admission.
Values:	<p>Individual California license numbers may be searched for at the Medical Board of California (https://www.mbc.ca.gov/).</p> <p>Out-of-state physicians' license numbers begin with the letter X.</p> <p>00000000: No surgery or surgical consult performed</p> <p>88888888: Non-surgeon performed the procedure</p> <p>99999999: Unknown</p>

California Cancer Registry Data Dictionary

Variable Name: DRXTTU_P
Eureka Name: EOD--Extension Prost Path
NAACCR Item: 800
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 1995 - 2003
Related Variables:

- CS Site-Specific Factor 3 (CS_SITE_SPEC_F3)
- Prostate Pathological Extension (PROSTATEPATHEXT)

Definition: Two-digit Extent of Disease (EOD) code for prostate cancers only (and used only after prostatectomy within 4 months of diagnoses) to code the extension of the tumor. This field is only coded for cases diagnosed prior to January 1, 2004. For cases diagnosed 2004 through 2017, values are recorded in the field CS_SITE_SPEC_F3 (prostate cancers). For cases diagnosed January 1, 2018 and forward, values are recorded in the field PROSTATEPATHEXT.

Notes: For definitions, see EOD coding manual:
<http://seer.cancer.gov/tools/codingmanuals/historical.html>

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values: 00: In situ: Noninvasive; intraepithelial

No extension beyond prostate

- 20: Involvement of one lobe, NOS (B) (pT2a)
- 23: More than one lobe involved (B) (pT2b)
- 30: Localized, NOS; confined to prostate, NOS; Intracapsular involvement only; Stage B, NOS, (pT2, NOS)
- 31: Into prostatic apex/arising in prostatic apex, NOS
- 33: Arising in prostatic apex
- 34: Extending into prostatic apex
- 32: Invasion into (but not beyond) prostatic capsule (C1)

Extension beyond prostate

- 40: No extracapsular extension but margins involved
- 41: Extension to periprostatic tissue (C1): Extracapsular extension (beyond prostatic capsule), NOS; Through capsule, NOS
- 42: Unilateral extracapsular extension (pT3a)
- 43: Bilateral extracapsular extension (pT3a)

California Cancer Registry Data Dictionary

- 45: Extension to seminal vesicle(s) (C2) (pT3b)
- 48: Extracapsular extension and margins involved
- 50: Extension to or fixation to adjacent structures other than seminal vesicles (pT4):
Rectovesical (Denonvillier's) fascia; Bladder, NOS; Ureter(s); Fixation, NOS;
Extension to/fixation to bladder neck; Rectum; external sphincter; Levator muscles;
Skeletal muscle, NOS
- 60: Extension to or fixation to: Pelvic wall or pelvic bone
- 70: FURTHER extension to bone, soft tissue or other organs (D2)
- 85: Metastasis (D2); D, not further specified
- 90: UNKNOWN if extension or metastasis
- 98: Prostatectomy was done within first course of treatment, but there was disease progression
- 99: No prostatectomy done within first course of treatment
- Blank: Not abstracted, non-prostate case, prostate lymphoma, or cases diagnosed after January 1, 2004

California Cancer Registry Data Dictionary

Variable Name: DTDEFSURG

Eureka Name: RX Date Mst Defn Surg

NAACCR Item: 3170

Category: Treatment, Surgical

Level of Variable: Tumor

Time Period Available: 2003 – current year

Related Variables: Rx Summ--Surg Prim Site (SURGPRIM)

Definition: Records the date of SURGPRIM, the most definitive surgical resection of the primary site performed as the first course of treatment. Different from SURGDATE, which is the date the earliest surgical procedure was performed. Collected directly for cases diagnosed 2003 and forward. For cases diagnosed 1998 through 2002, date taken from three historical surgery fields which are no longer required. Dates before 1997 and 1998 are mostly unknown.

Values: Any valid date: YYYYMMDD format

All 9's: Death certificate only case or definitive surgery performed but the date is unknown

All 0's: No surgery or unknown if ever treated

California Cancer Registry Data Dictionary

Variable Name: DTSYSTEMIC
Eureka Name: RX Date Systemic
NAACCR Item: 3230
Category: Treatment, Systemic
Level of Variable: Tumor
Time Period Available: 2003 – current year

Related Variables:

Definition: Records the date of initiation of systemic therapy that is part of the first course of treatment. Systemic therapy is considered to be chemotherapy agents, hormonal agents, biological response modifiers, bone marrow transplants, stem cell harvests, and surgical and/or radiation endocrine therapy.

Values: Any valid date: YYYYMMDD format
 All 0's: No treatment or unknown if treated
 All 9's: Death certificate only case or definitive surgery performed, but the date is unknown

California Cancer Registry Data Dictionary

Variable Name:	DTTRANSP
Eureka Name:	RX Date Transp Endo
NAACCR Item:	N/A
Category:	Treatment, Systemic
Level of Variable:	Tumor
Time Period Available:	2003 – current year
Related Variables:	RX Summ--Transplnt/Endocr (TRANSSUM)
Definition:	Date that TRANSSUM, the transplant/endocrine procedure, was performed. If multiple records exist, consolidation for item involves comparing codes and selecting most extensive procedure. Required for cases diagnosed 2003 and forward.
Notes:	“Unknown” dates include cases where treatment was not given
Values:	Any valid date: YYYYMMDD format

California Cancer Registry Data Dictionary

Variable Name: DX_STG_SUM

Eureka Name: RX SUMM--DX/STG PROC

NAACCR Item: 1350

Category: Treatment, Surgical

Level of Variable: Tumor

Time Period Available: 1988 – current year

Related Variables:

- RX Date DX/STG Proc (RXDATESN)
- RX Date DX/STG Proc Flag (RXDATEDXSTGPROCFLAG)

Definition: Identifies the surgical procedure(s) performed in an effort to diagnose and/or stage disease.

Values:

00	No surgical diagnostic or staging procedure was performed
01	A biopsy (incisional, needle, or aspiration) was done to a site other than the primary site; No exploratory procedure was done
02	A biopsy (incisional, needle, or aspiration) was done of the primary site
03	A surgical exploratory only; The patient was not biopsied or treated
04	A surgical procedure with a bypass was performed, but no biopsy was done
05	An exploratory procedure was performed, and a biopsy of either the primary site or another site was done
06	A bypass procedure was performed, and a biopsy of either the primary site or another site was done
07	A procedure was done, but the type of procedure is unknown
09	No information about whether a diagnostic or staging procedure was performed

California Cancer Registry Data Dictionary

Variable Name:	DXADDR
Eureka Name:	Addr at DX--No & Street
NAACCR Item:	2330
Category:	Patient Demographics
Level of Variable:	Tumor
Time Period Available:	1988 – current year
Related Variables:	<ul style="list-style-type: none"> • Addr at DX--Supplemental (DXADDR_S) • Addr at DX--City (DXCITY) • Addr at DX--State (DXSTATE) • Addr at DX--Postal Code (DXZIP) • Address Current--No & Street (CONADDR)
Definition:	House number and street name of patient's residence at the time of diagnosis. CONADDR provides the house number and street name of the patient's current address or address where the patient can be contacted.
Values:	Item may not be blank.

California Cancer Registry Data Dictionary

Variable Name: DXADDR_S

Eureka Name: Addr at DX--Supplemental

NAACCR Item: 2335

Category: Patient Demographics

Level of Variable: Tumor

Time Period Available: 1988 – current year

Related Variables:

- Addr at DX--No & Street (DXADDR)
- Addr at DX--City (DXCITY)
- Addr at DX--State (DXSTATE)
- Addr at DX--Postal Code (DXZIP)
- Addr at DX--Supplemental (CONADDR_S)

Definition: This data item allows the storage of additional address information, such as the name of a place or facility (i.e., a nursing home, or name of an apartment complex) where the patient resided at time of diagnosis. CONADDR_S provides additional address information of the patient's current address or address where the patient can be contacted.

California Cancer Registry Data Dictionary

Variable Name:	DXCITY
Eureka Name:	Addr at DX--City
NAACCR Item:	70
Category:	Patient Demographics
Level of Variable:	Tumor
Time Period Available:	1988 – current year
Related Variables:	<ul style="list-style-type: none"> • Addr at DX--No & Street (DXADDR) • Addr at DX--Supplemental (DXADDR_S) • Addr at DX--State (DXSTATE) • Addr at DX--Postal Code (DXZIP) • Addr Current--City (CONCITY)
Definition:	City name of patient's residence at the time of diagnosis. CONCITY provides the city name of patient's current address or address where patient can be contacted.
Values:	Any alpha. UNKNOWN if city of residence is unknown.

California Cancer Registry Data Dictionary

Variable Name: DXCONF
Eureka Name: Diagnostic Confirmation
NAACCR Item: 490
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 1988 – current year

Related Variables:

Definition: Indicates whether at any time during the patient's medical history there was microscopic confirmation of this cancer.

Notes: Code 3 (used only for hematopoietic and lymphoid neoplasms 9590/3-9992/3) was adopted for use effective with 2010 diagnoses.

Values:

- 1: Positive histology
- 2: Positive cytology
- 3: Positive histology PLUS - positive immunophenotyping AND/OR positive genetic studies (used only for hematopoietic and lymphoid neoplasms 95903-99923)
- 4: Positive microscopic confirmation, method not specified (used only for hematopoietic and lymphoid neoplasms M-9590/3 - 9992/3)
- 5: Positive lab test or marker study
- 6: Direct visualization without microscopic confirmation
- 7: Radiography and/or other imaging techniques without microscopic confirmation
- 8: Clinical diagnosis only (other than 5,6, or 7)
- 9: Unknown whether microscopically confirmed; death certificate only

California Cancer Registry Data Dictionary

Variable Name:	DXSTATE
Eureka Name:	Addr at DX--State
NAACCR Item:	80
Category:	Patient Demographics
Level of Variable:	Tumor
Time Period Available:	1988 – current year
Related Variables:	<ul style="list-style-type: none"> • Addr at DX--No & Street (DXADDR) • Addr at DX--Supplemental (DXADDR_S) • Addr at DX--City (DXCITY) • Addr at DX--Postal Code (DXZIP) • Addr Current--State (CONSTATE)
Definition:	State or Canadian province of patient's residence at the time of diagnosis. CONSTATE provides the state or Canadian province of patient's current address or address where the patient can be contacted.
Notes:	<p>For a list of postal abbreviations for states and territories, as well as Canadian provinces, see "Cancer Reporting in California, California Cancer Reporting System Standards,</p> <p>Volume I, Appendix B – Postal Abbreviations for States and Territories of the United States</p>
Values:	<p>AK-WY: Postal abbreviation for states and territories</p> <p>AA-AP United States military personnel serving abroad</p> <p>AB-YT: Canadian provinces</p> <p>CD: Resident of Canada, Not Otherwise Specified (province/territory unknown)</p> <p>US: Resident of United States, Not Otherwise Specified (state/commonwealth/territory/possession unknown)</p> <p>XX: Resident of country other than the US (including its territories, commonwealths, or possessions) or Canada, and country is known.</p> <p>YY: Resident of country other than the US (including its territories, commonwealths, or possessions) or Canada, and country is unknown.</p> <p>ZZ: Residence unknown</p>

California Cancer Registry Data Dictionary

Variable Name:	DXSTATEGEO708090
Eureka Name:	State at DX Geocode 1970/80/90
NAACCR Item:	81
Category:	Geographical Information
Level of Variable:	Tumor
Time Period Available:	1995 – 1999
Related Variables:	<ul style="list-style-type: none"> • State at DX Geocode 2000 (DXSTATEGEO2000) • State at DX Geocode 2010 (DXSTATEGEO2010) • State at DX Geocode 2020 (DXSTATEGEO2020)
Definition:	Code for the state of the patient's residence at the time of diagnosis. This data item is derived (geocoded) based on Census boundary files from the 1990 decennial Census.
Values:	<p>01-95: Valid FIPS code</p> <p>Blank: Residence unknown, geocoding not performed, geocoding unsuccessful, residence outside US (including its territories, commonwealths, or possessions) residence US, Not Otherwise Specified</p>

California Cancer Registry Data Dictionary

Variable Name: DXSTATEGEO2000

Eureka Name: State at DX Geocode 2000

NAACCR Item: 82

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: 1995 – 2011

Related Variables:

- State at DX Geocode 1970/80/90 (DXSTATEGEO708090)
- State at DX Geocode 2010 (DXSTATEGEO2010)
- State at DX Geocode 2020 (DXSTATEGEO2020)

Definition: Code for the state of the patient's residence at the time of diagnosis. This data item is derived (geocoded) based on Census boundary files from the 2000 decennial Census.

Values:

01-95: Valid FIPS code

Blank: Residence unknown, geocoding not performed, geocoding unsuccessful, residence outside US (including its territories, commonwealths, or possessions) residence US, Not Otherwise Specified

California Cancer Registry Data Dictionary

Variable Name: DXSTATEGEO2010

Eureka Name: State at DX Geocode 2010

NAACCR Item: 83

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: 2006 – current year

Related Variables:

- State at DX Geocode 1970/80/90 (DXSTATEGEO708090)
- State at DX Geocode 2000 (DXSTATE2000)
- State at DX Geocode 2020 (DXSTATE2020)

Definition: Code for the state of the patient's residence at the time of diagnosis. This data item is derived (geocoded) based on Census boundary files from 2010 decennial Census.

Values:

01-95: Valid FIPS code

Blank: Residence unknown, geocoding not performed, geocoding unsuccessful, residence outside US (including its territories, commonwealths, or possessions) residence US, Not Otherwise Specified

California Cancer Registry Data Dictionary

Variable Name: DXSTATEGEO2020

Eureka Name: State at DX Geocode 2020

NAACCR Item: 84

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: Currently not available

Related Variables:

- State at DX Geocode 1970/80/90 (DXSTATEGEO708090)
- State at DX Geocode 2000 (DXSTATEGEO2000)
- State at DX Geocode 2010 (DXSTATEGEO2010)

Definition: Code for the state of the patient's residence at the time of diagnosis. This data item is derived (geocoded) based on Census boundary files from 2020 decennial Census.

Values:

01-95: Valid FIPS code

Blank: Residence unknown, geocoding not performed, geocoding unsuccessful, residence outside US (including its territories, commonwealths, or possessions) residence US, Not Otherwise Specified

California Cancer Registry Data Dictionary

Variable Name:	DXZIP
Eureka Name:	Addr at DX--Postal Code
NAACCR Item:	100
Category:	Patient Demographics
Level of Variable:	Tumor
Time Period Available:	1988 – current year
Related Variables:	<ul style="list-style-type: none"> • Addr at DX--No & Street (DXADDR) • Addr at DX--Supplemental (DXADDR_S) • Addr at DX--City (DXCITY) • Addr at DX--State (DXSTATE) • Addr Current--Postal Code (CONZIP)
Definition:	<p>Zip code of patient's residence at time of diagnosis; may be entered for any country. CONZIP provides the zip code of patient's current address or address where the patient can be contacted.</p>
Notes:	If the code is known, regardless of the country that it is in, the postal code should be entered here. Alpha characters allowed.
Values:	<p>Any combination of alpha and numeric characters is allowed.</p> <p>888888888: Resident of country other than the US (including its possessions, etc.) or Canada and postal code unknown</p> <p>999999999: Resident of the US (including its possessions, etc.) or Canada and postal code unknown</p>

California Cancer Registry Data Dictionary

Variable Name: EDINDEX

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 1988 – 2005

Related Variables:

- Census Block 90 (BLKGRP90)
- Census Block 2000 (BLKGRP00)
- Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: Represents the average years of schooling in a Census block group. Calculated as a weighted sum of the distribution of years of schooling among persons age 25 years and older within the assigned Census block group. *Each CCR record is assigned a Census block group based on the patient's address at time of diagnosis. The block group is then used to append EDINDEX values calculated using 1990 Census data for cases diagnosed 1988-1995 and using 2000 Census data for cases diagnosed 1996-2005. If a case received a randomly assigned block group, the EDINDEX value is that of the randomly assigned block group and RANDOM=1.

Notes: *For more information on the creation of this variable see: Liu L, Deapen D, Bernstein L. Socioeconomic status and cancers of the female breast and reproductive organs: a comparison across racial/ethnic populations in Los Angeles County, California (United States). *Cancer Causes Control*, 1998;9:369-380

Values: 9.00-16.00

California Cancer Registry Data Dictionary

Variable Name: EDINDEXACS2011

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 2006 – current year

Related Variables:

- Census Tract 2010 (CENSUSTRACT2010)
- Average Years of Schooling of Persons in Census Tract 1988 through 2005 (EDINDEXCT)
- Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: Represents the average years of schooling in a Census tract. Calculated as a weighted sum of the distribution of years of schooling among persons age 25 years and older within the assigned Census tract. *Each CCR record is assigned a Census tract based on the patient's address at time of diagnosis. This tract is then used to append EDINDEXACS2011 values calculated using 2007-2011 American Community Survey data for cases diagnosed 2006 and forward. If a case received a randomly assigned Census tract, the EDINDEXACS2011 value is that of the randomly assigned tract and RANDOM=1. For cases diagnosed 1988 to 2005, use the variable EDINDEXCT.

Notes: *For more information on the creation of this variable see: Liu L, Deapen D, Bernstein L. Socioeconomic status and cancers of the female breast and reproductive organs: a comparison across racial/ethnic populations in Los Angeles County, California (United States). *Cancer Causes Control*, 1998;9:369-380

Values: 9.00 - 16.00

California Cancer Registry Data Dictionary

Variable Name: EDINDEXACS2011MOE
Eureka Name: N/A
NAACCR Item: N/A
Category: Socioeconomic Indicators
Level of Variable: Tumor
Time Period Available: 2006 – current year
Related Variables: Average Years of Schooling of Persons in Census Tract 2006 and forward (EDINDEXACS2011)
Definition: Margin of error associated with EDINDEXACS2011
Values: 0.3846696784 – 297.64466556

California Cancer Registry Data Dictionary

Variable Name: EDINDEXCT

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 1988 – 2005

Related Variables:

- Census Tract 1970/80/90 (CENSUS90)
- Census Tract 2000 (CENSUS00)
- Average Years of Schooling of Persons in Census Tract 2006 and forward (EDINDEXACS2011)
- Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: Represents the average years of schooling in a Census tract. Calculated as a weighted sum of the distribution of years of schooling among persons age 25 years and older within the assigned Census tract. *Each CCR record is assigned a Census tract based on the patient's address at time of diagnosis. This tract is then used to append EDINDEXCT values calculated using 1990 Census data for cases diagnosed 1988 to 1995 and 2000 Census data for cases diagnosed 1996 to 2005. If a case received a randomly assigned Census tract, the EDINDEXCT value is that of the randomly assigned tract and RANDOM=1. For cases diagnosed 2006 and forward, use the variable EDINDEXCTACS2011.

Notes: *For more information on the creation of this variable see: Liu L, Deapen D, Bernstein L. Socioeconomic status and cancers of the female breast and reproductive organs: a comparison across racial/ethnic populations in Los Angeles County, California (United States). *Cancer Causes Control*, 1998;9:369-380

Values: 9.00-16.00

California Cancer Registry Data Dictionary

Variable Name: ENECLINHN

Eureka Name: Extranodal Extension Head and Neck Clinical

NAACCR Item: 3831

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 8 (CSSITESPECIFICFACTOR8)

Definition: Extranodal extension (ENE) is defined as "the extension of a nodal metastasis through the lymph node capsule into adjacent tissue" and is a prognostic factor for most head and neck tumors. This data item pertains to clinical staging extension. Valid for cases diagnosed January 1, 2018 and forward. For head and neck cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR8.

Values:

- 0: Regional lymph nodes involved, ENE not present/not identified during diagnostic workup
- 1: Regional lymph nodes involved, ENE present/identified during diagnostic workup, based on physical exam WITH or WITHOUT imaging
- 2: Regional lymph nodes involved, ENE present/identified during diagnostic workup, based on microscopic confirmation
- 7: No lymph node involvement during diagnostic workup (cN0)
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; ENE not assessed during diagnostic workup, or unknown if assessed; Clinical assessment of lymph nodes not done, or unknown if done
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: ENECLINNOTHN

Eureka Name: Extranodal Extension Clin (Non-Head and Neck)

NAACCR Item: 3830

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 17 (CSSITESPECIFICFACTOR17)

Definition: Extranodal Extension (ENE) Clinical is defined as "the extension of a nodal metastasis through the lymph node capsule into adjacent tissue" during the diagnostic workup. This data item defines clinical ENE for sites other than Head and Neck. Valid for cases diagnosed January 1, 2018 and forward. For penile cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR17.

Values:

- 0: Regional lymph nodes involved, ENE not present/not identified during diagnostic workup
- 1: Regional lymph nodes involved, ENE present/identified during diagnostic workup, based on physical exam and/or imaging
- 2: Regional lymph nodes involved, ENE present/identified during diagnostic workup, based on microscopic confirmation
- 7: No lymph node involvement during diagnostic workup (cN0)
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Clinical ENE not assessed or unknown if assessed during diagnostic workup; Clinical assessment of lymph nodes not done, or unknown if done
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name:	ENEPATHHN
Eureka Name:	Extranodal Extension Head and Neck Pathological
NAACCR Item:	3832
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 – current year
Related Variables:	CS Site-Specific Factor 9 (CSSITESPECIFICFACTOR9)

Definition: Extranodal extension (ENE) is defined as "the extension of a nodal metastasis through the lymph node capsule into adjacent tissue" and is a prognostic factor for most head and neck tumors. This data item pertains to pathological staging extension. Valid for cases diagnosed January 1, 2018 and forward. For head and neck cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR9.

Values:	0.0:	Lymph nodes positive for cancer but ENE not identified or negative
	0.1-9.9:	ENE 0.1 to 9.9 mm
	X.1:	ENE 10 mm or greater
	X.2:	ENE microscopic, size unknown; Stated as ENE (mi)
	X.3:	ENE major, size unknown; Stated as ENE (ma)
	X.4:	ENE present, microscopic or major unknown, size unknown
	X.7:	Surgically resected regional lymph nodes negative for cancer (pN0)
	X.8:	Not applicable: Information not collected for this case
	X.9:	Not documented in medical record; No surgical resection of regional lymph nodes; ENE not assessed pathologically, or unknown if assessed; Pathological assessment of lymph nodes not done, or unknown if done
	Blank:	Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: ENEPATHNOTHN

Eureka Name: Extranodal Extension Path (non-Head and Neck)

NAACCR Item: 3833

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 17 (CSSITESPECIFICFACTOR17)

Definition: Extranodal Extension Pathological is defined as "the extension of a nodal metastasis through the lymph node capsule into adjacent tissue" identified as part of the surgical resection. This data item defines pathological ENE for sites other than Head and Neck. Valid for cases diagnosed January 1, 2018 and forward. For penile cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR17.

Values:

- 0: Regional lymph nodes involved, ENE not present/not identified from surgical resection
- 1: Regional lymph nodes involved, ENE present/identified from surgical resection
- 7: No lymph node involvement from surgical resection (pN0)
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; No surgical resection of regional lymph nodes; Cannot be determined; Pathological assessment of lymph nodes not done, or unknown if done Extranodal Extension Pathological not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: EODMETS
Eureka Name: EOD Mets
NAACCR Item: 776
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year
Related Variables:

- Derived EOD 2018 M (DERIVEEOD18M)
- EOD Primary Tumor (EODPRIMARYTUMOR)
- EOD Regional Nodes (EODREGNODES)

Definition: EOD Mets is part of the EOD 2018 data collection system and is used to classify the distant site(s) of metastatic involvement at time of diagnosis. Valid for cases diagnosed January 1, 2018 and forward.

Notes: See the most current version of EOD (<https://staging.seer.cancer.gov/>) for rules and site-specific codes and coding structures.

For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”

Values:

00:	None; No distant metastasis; Unknown if distant metastasis; 05, 10, 20, 30, 40, 50, 60, 70: Definitions are site-specific (aka schema-specific)
88:	Not applicable: Information not collected for this schema; Use for these sites only: HemeRetic, III Defined Other (includes unknown primary site), Kaposi Sarcoma, Lymphoma, Lymphoma-CLL/SLL, Myeloma Plasma Cell Disorder
99:	Death certificate only (DCO)
Blank:	Date of Diagnosis pre-2018

California Cancer Registry Data Dictionary

Variable Name: EODPRIMARYTUMOR
Eureka Name: EOD Primary Tumor
NAACCR Item: 772
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year
Related Variables:

- Derived EOD 2018 T (DERIVEEOD18N)
- EOD Mets (EODMETS)
- EOD Regional Nodes (EODREGNODES)

Definition: EOD Primary Tumor is part of the EOD 2018 data collection system and is used to classify contiguous growth (extension) of the primary tumor within the organ of origin or its direct extension into neighboring organs. Effective for cases diagnosed January 1, 2018 and forward.

Notes: See the most current version of EOD (<https://staging.seer.cancer.gov/>) for rules and site-specific codes and coding structures.

For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”

Values:

- 000: In situ, intraepithelial, noninvasive; 050, 070, 100, 110, 120, 125, 130, 150, 170, 175, 200, 210, 220, 225, 275, 300, 325, 350, 370, 375, 400, 425, 450, 475, 500, 525, 550, 600, 650, 675, 700, 720, 750, 980: Definitions are site-specific (aka schema-specific)
- 800: No evidence of primary tumor
- 888: Not applicable: Information not collected for this schema
- 999: Unknown; primary tumor not stated; Primary tumor cannot be assessed; Not documented in patient record; Death certificate only (DCO)
- Blank: Date of Diagnosis pre-2018

California Cancer Registry Data Dictionary

Variable Name: EODREGNODES
Eureka Name: EOD Regional Nodes
NAACCR Item: 774
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year
Related Variables:

- Derived EOD 2018 N (DERIVEEOD18N)
- EOD Mets (EODMETS)
- EOD Primary Tumor (EODPRIMARYTUMOR)

Definition: EOD Regional Nodes is part of the EOD 2018 data collection system and is used to classify the regional lymph nodes involved with cancer at the time of diagnosis. Valid for cases diagnosed January 1, 2018 and forward.

Notes: See the most current version of EOD (<https://staging.seer.cancer.gov/>) for rules and site-specific codes and coding structures.

For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”

Values:

000:	None; 030, 050, 070, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750: Definitions are site-specific (aka schema-specific)
800:	Regional lymph node(s), NOS Lymph node(s), NOS
888:	Not applicable: CNS, hematopoietic
999:	Unknown
Blank:	Date of Diagnosis pre-2018

California Cancer Registry Data Dictionary

Variable Name:	ERPERCENTPOSORRNG
Eureka Name:	Estrogen Receptor Percent Positive or Range
NAACCR Item:	3826
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 – current year
Related Variables:	<ul style="list-style-type: none"> • Estrogen Receptor Summary (ERSUMMARY) • Estrogen Receptor Total Allred Score (ERTOTALALLRED)
Definition:	Estrogen Receptor, Percent Positive Range is the percent of cells staining estrogen receptor positive by IHC.
Values:	<p>000: ER negative, or stated as less than 1%</p> <p>001-100: 1-100 percent</p> <p>R10: Stated as 1-10%</p> <p>R20: Stated as 11-20%</p> <p>R30: Stated as 21-30%</p> <p>R40: Stated as 31-40%</p> <p>R50: Stated as 41-50%</p> <p>R60: Stated as 51-60%</p> <p>R70: Stated as 61-70%</p> <p>R80: Stated as 71-80%</p> <p>R90: Stated as 81-90%</p> <p>R99: Stated as 91-100%</p> <p>XX8: Not applicable: Information not collected for this case</p> <p>XX9: Not documented in medical record; Estrogen Receptor, Percent Positive Range not assessed or unknown if assessed</p> <p>Blank: Date of Diagnosis pre-2018; Non-required Schema ID</p>

California Cancer Registry Data Dictionary

Variable Name:	ERSUMMARY
Eureka Name:	Estrogen Receptor Summary
NAACCR Item:	3827
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 – current year
Related Variables:	<ul style="list-style-type: none"> • Estrogen Receptor Percent Positive or Range (ERPERCENTPOSORRNG) • Estrogen Receptor Total Allred Score (ERTOTALALLRED) • Tum Markers 1 (MARKER1) • CS Site-Specific Factor 1 (CS_SITE_SPEC_F1)
Definition:	ER (Estrogen Receptor) Summary is a summary of results of the estrogen receptor (ER) assay. Valid for breast cancers diagnosed January 1, 2018 and forward. For breast cancers diagnosed 1988 through 2003, this information was recorded in the field MARKER1 and for breast cancers diagnosed 2004 through 2017 this information was recorded in the field CS_SITE_SPEC_F1.
Values:	<p>0: ER negative</p> <p>1: ER positive</p> <p>7: Test ordered, results not in chart</p> <p>9: Not documented in medical record; Cannot be determined (indeterminate); ER (Estrogen Receptor) Summary status not assessed or unknown if assessed</p> <p>Blank: Date of Diagnosis pre-2018; Non-required Schema ID</p>

California Cancer Registry Data Dictionary

Variable Name: ERTOTALALLRED
Eureka Name: Estrogen Receptor Total Allred Score
NAACCR Item: 3828
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables:

- Estrogen Receptor Percent Positive or Range (ERPERCENTPOSORRNG)
- Estrogen Receptor Summary (ERSUMMARY)

Definition: Estrogen Receptor, Total Allred Score is based on the percentage of cells that stain positive by IHC for estrogen receptor (ER) and the intensity of that staining.

Values:

- 00: Total ER Allred score of 0
- 01: Total ER Allred score of 1
- 02: Total ER Allred score of 2
- 03: Total ER Allred score of 3
- 04: Total ER Allred score of 4
- 05: Total ER Allred score of 5
- 06: Total ER Allred score of 6
- 07: Total ER Allred score of 7
- 08: Total ER Allred score of 8
- X8: Not applicable: Information not collected for this case
- X9: Not documented in medical record; Estrogen Receptor, Total Allred Score not assessed, or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: ESOPHEPICENTER
Eureka Name: Esophagus and EGJ Tumor Epicenter
NAACCR Item: 3829
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year

Related Variables:

Definition: For squamous cell (including adenosquamous) tumors of the esophagus and esophagogastric junction (EGJ), refers to the position of the epicenter of the tumor in the esophagus. Valid for cases diagnosed January 1, 2018 and forward.

Values:

- 0: Upper (Cervical/Proximal esophagus to lower border of azygos vein)
- 1: Middle (Lower border of azygos vein to lower border of inferior pulmonary vein)
- 2: Lower (Lower border of inferior pulmonary vein to stomach, including gastroesophageal junction)
- 9: Esophagus, NOS; Specific location of epicenter not documented in medical record; Specific location of epicenter not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: EXTRAVASCMATRIX

Eureka Name: Extravascular Matrix Patterns

NAACCR Item: 3834

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables:

- CS Site-Specific Factor 11 (CSSITESPECIFICFACTOR11)
- CS Site-Specific Factor 12 (CSSITESPECIFICFACTOR12)

Definition: Extravascular Matrix Patterns, the presence of loops and networks in extracellular matrix patterns is a prognostic factor for uveal melanoma. Valid for cases diagnosed January 1, 2018 and forward. For uveal melanomas diagnosed 2010 through 2017, this information was recorded in the fields CSSITESPECIFICFACTOR11 and CSSITESPECIFICFACTOR12.

Values:

- 0: Extravascular matrix pattern not present/not identified
- 1: Extravascular matrix pattern present/identified
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Extravascular Matrix Pattern not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: FIBROSISSCORE

Eureka Name: Fibrosis Score

NAACCR Item: 3835

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 2 (CS_SITE_SPEC_F2)

Definition: Fibrosis Score, the degree of fibrosis of the liver based on pathological examination, is a prognostic factor for liver cancer. Valid for cases diagnosed January 1, 2018 and forward. For liver cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F2.

Values:

- 0: Ishak fibrosis score 0-4; No to moderate fibrosis; METAVIR score F0-F3; Batt-Ludwig score 0-3
- 1: Ishak fibrosis score 5-6; Advanced/severe fibrosis; METAVIR score F4; Batt-Ludwig score 4; Developing cirrhosis; Incomplete cirrhosis; Transition to cirrhosis; Cirrhosis, probable or definite; Cirrhosis, NOS
- 7: Clinical statement of advanced/severe fibrosis or cirrhosis, AND Not histologically confirmed or unknown if histologically confirmed
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Stated in medical record that patient does not have advanced cirrhosis/advanced fibrosis, not histologically confirmed or unknown if histologically confirmed; Fibrosis score stated but cannot be assigned to codes 0 or 1; Fibrosis score stated but scoring system not recorded; Fibrosis Score not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name:	FIGOSTAGE
Eureka Name:	FIGO Stage
NAACCR Item:	3836
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 – current year
Related Variables:	<ul style="list-style-type: none"> CS Site-Specific Factor 1 (Vagina, Cervix, Corpus, Fallopian Tube, and Peritoneum Female Genital) (CS_SITE_SPEC_F1) CS Site-Specific Factor 2 (Ovary and Placenta) (CS_SITE_SPEC_F2) CS Site-Specific Factor 10 (Vulva) (CSSITESPECIFICFACTOR10)

Definition: Federation Internationale de Gynecologie et d'Obstetrique (FIGO) is a staging system for female reproductive cancers.

Values:	01:	FIGO Stage I
	02:	FIGO Stage IA
	03:	FIGO Stage IA1
	04:	FIGO Stage IA2
	05:	FIGO Stage IB
	06:	FIGO Stage IB1
	07:	FIGO Stage IB2
	08:	FIGO Stage IC
	09:	FIGO Stage IC1
	10:	FIGO Stage IC2
	11:	FIGO Stage IC3
	20:	FIGO Stage II
	21:	FIGO Stage IIA
	22:	FIGO Stage IIA1
	23:	FIGO Stage IIA2
	24:	FIGO Stage IIB
	30:	FIGO Stage III
	31:	FIGO Stage IIIA
	32:	FIGO Stage IIIA1
	33:	FIGO Stage IIIAi
	34:	FIGO Stage IIIAii
	35:	FIGO Stage IIIA2
	36:	FIGO Stage IIIB
	37:	FIGO Stage IIIC
	38:	FIGO Stage IIIC1
	39:	FIGO Stage IIIC2
	40:	FIGO Stage IV
	41:	FIGO Stage IVA

California Cancer Registry Data Dictionary

- 42: FIGO Stage IVB
- 97: Not applicable: Carcinoma in situ (intraepithelial, noninvasive, preinvasive)
- 98: Not applicable: Information not collected for this case
- 99: Not documented in medical record; FIGO stage unknown, not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: FNAME

Eureka Name: Name--First

NAACCR Item: 2240

Category: Administrative

Level of Variable: Patient

Time Period Available: 1988 – current year

Related Variables:

- Name--Last (LNAME)
- Name--Middle (MIDLNAME)
- Name--Maiden (MAIDNAME)

Definition: Patient's first name.

Values: Alpha only.
NFN: No first name

California Cancer Registry Data Dictionary

Variable Name: FOLLOWUPCONTACTCOUNTRY

Eureka Name: Follow-Up Contact--Country

NAACCR Item: 1847

Category: Follow-Up

Level of Variable: Patient

Time Period Available: 1988 – current year

Related Variables:

Definition: Country code for the address of follow-up contact's current usual residence. The follow-up contact referenced is someone other than the patient.

Values: See: [Volume I, Appendix C.1](#)

California Cancer Registry Data Dictionary

Variable Name:	FUDATE
Eureka Name:	Date of Last Contact
NAACCR Item:	1750
Category:	Follow-Up
Level of Variable:	Patient
Time Period Available:	1988 – current year
Related Variables:	<ul style="list-style-type: none"> • Date of Last Contact Flag (DATEOFLASTCONTACTFLAG) • Vital Status (VITSTAT)
Definition:	Date of last known information about this patient, or date of death if patient is deceased.
Values:	Any valid or partial date (YYYYMMDD format). Month and/or day can be missing.

California Cancer Registry Data Dictionary

Variable Name: FUTYPPAT
Eureka Name: Follow-Up Last Type Patient
NAACCR Item: N/A
Category: Follow-Up
Level of Variable: Patient
Time Period Available: 1988 – current year

Related Variables:

Definition: Source of last follow-up information, whether that follow-up was specifically looking for patient or tumor information.

Values:

HOSPITAL:

- 00: Admission Being Reported
- 01: Re-admission to Reporting Hospital
- 02: Follow-up Report from Physician
- 03: Follow-up Report from Patient
- 04: Follow-up Report from Relative
- 05: Obituary
- 06: Follow-up Report from Social Security Administration or Medicare
- 07: Follow-up Report from Hospice
- 08: Follow-up Report from Other Hospital
- 09: Other Source
- 11: Telephone call to any source
- 12: Special Studies
- 13: Equifax
- 14: ARS (AIDS Registry System)
- 15: Computer Match with Discharge Data
- 16: SSDI Match

REGIONAL REGISTRY:

- 20: Letter to Physician
- 21: Computer match with Department of Motor Vehicles
- 22: Computer match with Medicare or Medicaid file
- 23: Computer match with HMO file
- 24: Computer match with voter registration file
- 25: National Death Index
- 26: Computer match with State Death Tape
- 27: Social Security, Death Master file
- 29: Computer match, Other or NOS
- 30: Other Source
- 31: Telephone call to any source
- 32: Special Studies
- 33: Equifax

California Cancer Registry Data Dictionary

- 34: ARS (AIDS Registry System)
- 35: Computer Match with Discharge Data
- 36: Obituary
- 37: Computer-Match using Address Service
- 38: TRW Credit
- 39: Regional Registry Follow-up Listing

CENTRAL REGISTRY:

- 40: Letter to a Physician
- 41: Telephone call to any source
- 48: Research Study Follow-up
- 49: Birth StatMaster Linkage
- 50: CMS (Center for Medicare & Medicaid Services)
- 51: Department of Motor Vehicles
- 52: CMS-SEER
- 53: HMO file
- 54: CalVoter Registration
- 55: National Death Index
- 56: State Death Tape-Death Clearance (StatMaster)
- 57: Medi-Cal Eligibility
- 59: Social Security - Deaths
- 60: Other Source
- 61: Social Security - SSN
- 62: Special Studies
- 63: Master Files
- 64: Accurint
- 65: Hospital Discharge Data - OSHPD
- 66: National Change of Address (NCOA)
- 67: Social Security Administration - Epidemiological Vital Status
- 68: Property Tax Linkage
- 69: State Death Tape - Death Clearance (Incremental)
- 70: Death Clearance LA County

HOSPITAL SUPPLEMENTAL:

- 73: Computer match with HMO file
- 76: Computer match with State Death Tape

REGIONAL REGISTRY (Additional Codes):

- 80: Social Security Administration - Epidemiological Vital Status
- 81: Property Tax Linkage
- 82: Probe360
- 83: SSDI Internet

California Cancer Registry Data Dictionary

84: E-Path

85: Path Labs

86: Patient

87: Relative

UNKNOWN SOURCE:

99: Source Unknown

California Cancer Registry Data Dictionary

Variable Name: FUTYPTUM
Eureka Name: Follow-Up Last Type Tumor
NAACCR Item: N/A
Category: Follow-Up
Level of Variable: Tumor
Time Period Available: 1988 – current year

Related Variables:

Definition: Source of last tumor follow-up information which gave a specific tumor status.

Values:

HOSPITAL:

- 00: Admission Being Reported
- 01: Re-admission to Reporting Hospital
- 02: Follow-up Report from Physician
- 03: Follow-up Report from Patient
- 04: Follow-up Report from Relative
- 05: Obituary
- 07: Follow-up Report from Hospice
- 08: Follow-up Report from Other Hospital
- 09: Other Source
- 11: Telephone call to any source
- 12: Special Studies
- 13: Equifax
- 14: ARS (AIDS Registry System)
- 15: Computer Match with Discharge Data

REGIONAL REGISTRY:

- 20: Letter to Physician
- 22: Medicare or Medicaid file
- 23: HMO file
- 25: National Death Index
- 26: State Death Tape
- 29: Computer match, Other or NOS
- 30: Other Source
- 31: Telephone call to any source
- 32: Special Studies
- 34: ARS (AIDS Registry System)
- 35: Discharge Data
- 36: Obituary

CENTRAL REGISTRY:

- 40: Letter to a Physician
- 41: Telephone call to any source
- 50: CMS (Center for Medicare & Medicaid Services)

California Cancer Registry Data Dictionary

- 52: Medicare or Medicaid File
- 53: HMO file
- 55: National Death Index
- 56: State Death Tape
- 59: Computer match, Other or NOS
- 60: Other Source

HOSPITAL SUPPLEMENTAL:

- 73: Computer match with HMO file
- 76: Computer match with State Death Tape

REGIONAL REGISTRY (Additional Codes):

- 85: Path Labs

UNKNOWN SOURCE:

- 99: Source Unknown

California Cancer Registry Data Dictionary

Variable Name: FUYEAR
Eureka Name: N/A
NAACCR Item: N/A
Category: Follow-Up
Level of Variable: Patient
Time Period Available: 1988 – current year
Related Variables: Date of Last Contact (FUDATE)
Definition: Year of last follow-up or death.

California Cancer Registry Data Dictionary

Variable Name:	GESTPROGNOSTINDEX
Eureka Name:	Gestational Trophoblastic Prognostic Scoring Index
NAACCR Item:	3837
Category:	Prognostic Factors
Level of Variable:	Tumor
Time Period Available:	2018 – current year
Related Variables:	CS Site-Specific Factor 1 (for placenta only) (CS_SITE_SPEC_F1)
Definition:	Gestational Trophoblastic Prognostic Scoring Index, a score based on the FIGO-modified World Health Organization (WHO) Prognostic Scoring Index, is used to stratify women with gestational trophoblastic neoplasia in addition to the anatomical stage group. The risk score is appended to the anatomic stage. Effective for cases diagnosed January 1, 2018 and forward. For cases diagnosed 2004-2017, see CS_SITE_SPEC_F1.
Values:	<p>00-25: Risk factor score</p> <p>X9: Not documented in medical record; Prognostic scoring index not assessed or unknown if assessed</p> <p>Blank: Date of Diagnosis pre-2018; Non-required Schema ID</p>

California Cancer Registry Data Dictionary

Variable Name: GISCOORDINATEQUALITY

Eureka Name: GIS Coordinate Quality

NAACCR Item: 366

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: 2012 – current year

Related Variables:

- Latitude (LATITUDE)
- Longitude (LONGITUDE)

Definition: Code indicating the basis of assignment of latitude and longitude coordinates for an individual record from an address. This data item is helpful in identifying cases that were assigned coordinates based on incomplete information, post office boxes, or rural routes. Most of the time, this information is provided by geocoding software. Alternatively, a central registry staff member manually assigns the code. Codes are hierarchical, with lower numbers having priority.

Values:

- 00: Coordinates derived from local government-maintained address points, which are based on property parcel locations, not interpolation over a street segment's address range
- 01: Coordinates assigned by Global Positioning System (GPS)
- 02: Coordinates are match of house number and street, and based on property parcel location
- 03: Coordinates are match of house number and street, interpolated over the matching street segment's address range
- 04: Coordinates are street intersections
- 05: Coordinates are at mid-point of street segment (missing or invalid building number)
- 06: Coordinates are address ZIP code+4 centroid
- 07: Coordinates are address ZIP code+2 centroid.
- 08: Coordinates were obtained manually by looking up a location on a paper or electronic map
- 09: Coordinates are address 5-digit ZIP code centroid
- 10: Coordinates are point ZIP code of Post Office Box or Rural Route
- 11: Coordinates are centroid of address city (when address ZIP code is unknown or invalid, and there are multiple ZIP codes for the city)
- 12: Coordinates are centroid of county
- 98: Latitude and longitude are assigned, but coordinate quality is unknown
- 99: Latitude and longitude are not assigned, but geocoding was attempted; unable to assign coordinates based on available information
- Blank: GIS Coordinate Quality not coded

California Cancer Registry Data Dictionary

Variable Name: GLEASONPATCLIN

Eureka Name: Gleason Patterns Clinical

NAACCR Item: 3838

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 7 (CSSITESPECIFICFACTOR7)

Definition: Prostate cancers are graded using Gleason score or pattern. This data item represents the Gleason primary and secondary patterns from needle core biopsy or transurethral resection of the prostate (TURP). Valid for cases diagnosed January 1, 2018 and forward. For prostate cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR7.

Values:

- 11: Primary pattern 1, secondary pattern 1
- 12: Primary pattern 1, secondary pattern 2
- 13: Primary pattern 1, secondary pattern 3
- 14: Primary pattern 1, secondary pattern 4
- 15: Primary pattern 1, secondary pattern 5
- 19: Primary pattern 1, secondary pattern unknown
- 21: Primary pattern 2, secondary pattern 1
- 22: Primary pattern 2, secondary pattern 2
- 23: Primary pattern 2, secondary pattern 3
- 24: Primary pattern 2, secondary pattern 4
- 25: Primary pattern 2, secondary pattern 5
- 29: Primary pattern 2, secondary pattern unknown
- 31: Primary pattern 3, secondary pattern 1
- 32: Primary pattern 3, secondary pattern 2
- 33: Primary pattern 3, secondary pattern 3
- 34: Primary pattern 3, secondary pattern 4
- 35: Primary pattern 3, secondary pattern 5
- 39: Primary pattern 3, secondary pattern unknown
- 41: Primary pattern 4, secondary pattern 1
- 42: Primary pattern 4, secondary pattern 2
- 43: Primary pattern 4, secondary pattern 3
- 44: Primary pattern 4, secondary pattern 4
- 45: Primary pattern 4, secondary pattern 5
- 49: Primary pattern 4, secondary pattern unknown
- 51: Primary pattern 5, secondary pattern 1
- 52: Primary pattern 5, secondary pattern 2
- 53: Primary pattern 5, secondary pattern 3
- 54: Primary pattern 5, secondary pattern 4

California Cancer Registry Data Dictionary

- 55: Primary pattern 5, secondary pattern 5
- 59: Primary pattern 5, secondary pattern unknown
- X6: Primary pattern unknown, secondary pattern unknown
- X7: No needle core biopsy/TURP performed
- X8: Not applicable: Information not collected for this case
- X9: Not documented in medical record; Gleason Patterns Clinical not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: GLEASONPATPATH

Eureka Name: Gleason Patterns Pathological

NAACCR Item: 3839

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 9 (CSSITESPECIFICFACTOR9)

Definition: Prostate cancers are graded using Gleason score or pattern. This data item represents the Gleason primary and secondary patterns from prostatectomy or autopsy. Valid for cases diagnosed January 1, 2018 and forward. For prostate cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR9.

Values:

- 11: Primary pattern 1, secondary pattern 1
- 12: Primary pattern 1, secondary pattern 2
- 13: Primary pattern 1, secondary pattern 3
- 14: Primary pattern 1, secondary pattern 4
- 15: Primary pattern 1, secondary pattern 5
- 19: Primary pattern 1, secondary pattern unknown
- 21: Primary pattern 2, secondary pattern 1
- 22: Primary pattern 2, secondary pattern 2
- 23: Primary pattern 2, secondary pattern 3
- 24: Primary pattern 2, secondary pattern 4
- 25: Primary pattern 2, secondary pattern 5
- 29: Primary pattern 2, secondary pattern unknown
- 31: Primary pattern 3, secondary pattern 1
- 32: Primary pattern 3, secondary pattern 2
- 33: Primary pattern 3, secondary pattern 3
- 34: Primary pattern 3, secondary pattern 4
- 35: Primary pattern 3, secondary pattern 5
- 39: Primary pattern 3, secondary pattern unknown
- 41: Primary pattern 4, secondary pattern 1
- 42: Primary pattern 4, secondary pattern 2
- 43: Primary pattern 4, secondary pattern 3
- 44: Primary pattern 4, secondary pattern 4
- 45: Primary pattern 4, secondary pattern 5
- 49: Primary pattern 4, secondary pattern unknown
- 51: Primary pattern 5, secondary pattern 1
- 52: Primary pattern 5, secondary pattern 2
- 53: Primary pattern 5, secondary pattern 3
- 54: Primary pattern 5, secondary pattern 4
- 55: Primary pattern 5, secondary pattern 5

California Cancer Registry Data Dictionary

- 59: Primary pattern 5, secondary pattern unknown
- X6: Primary pattern unknown, secondary pattern unknown
- X7: No prostatectomy/autopsy performed
- X8: Not applicable: Information not collected for this case
- X9: Not documented in medical record; Gleason Patterns Pathological not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: GLEASONSCORECLIN

Eureka Name: Gleason Score Clinical

NAACCR Item: 3840

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 8 (CSSITESPECIFICFACTOR8)

Definition: This data item records the Gleason score based on adding the values for primary and secondary patterns in Needle Core Biopsy or transurethral resection of the prostate (TURP). Valid for cases diagnosed January 1, 2018 and forward. For prostate cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR8.

Values:

- 02: Gleason score 2
- 03: Gleason score 3
- 04: Gleason score 4
- 05: Gleason score 5
- 06: Gleason score 6
- 07: Gleason score 7
- 08: Gleason score 8
- 09: Gleason score 9
- 10: Gleason score 10
- X7: No needle core biopsy/TURP performed
- X8: Not applicable: Information not collected for this case
- X9: Not documented in medical record; Gleason Score Clinical not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: GLEASONSCOREPATH
Eureka Name: Gleason Score Pathological
NAACCR Item: 3841
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year
Related Variables: CS Site-Specific Factor 10 (CSSITESPECIFICFACTOR10)

Definition: This data item records the Gleason score based on adding the values for primary and secondary patterns from prostatectomy or autopsy. Valid for cases diagnosed January 1, 2018 and forward. For prostate cancers diagnosed 2010 through 2017, see CSSITESPECIFICFACTOR10.

Values:

- 02: Gleason score 2
- 03: Gleason score 3
- 04: Gleason score 4
- 05: Gleason score 5
- 06: Gleason score 6
- 07: Gleason score 7
- 08: Gleason score 8
- 09: Gleason score 9
- 10: Gleason score 10
- X7: No prostatectomy done
- X8: Not applicable: Information not collected for this case
- X9: Not documented in medical record; Gleason Score Pathological not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name:	GLEASONTERTIARYPT
Eureka Name:	Gleason Tertiary Pattern
NAACCR Item:	3842
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 – current year
Related Variables:	CS Site-Specific Factor 11 (CSSITESPECIFICFACTOR11)
Definition:	Prostate cancers are graded using Gleason score or pattern. This data item represents the tertiary pattern value from prostatectomy or autopsy. Effective for cases diagnosed January 1, 2018 and forward. For cases diagnosed 2010 through 2017, see CSSITESPECIFICFACTOR11.
Values:	<p>10: Tertiary pattern 1</p> <p>20: Tertiary pattern 2</p> <p>30: Tertiary pattern 3</p> <p>40: Tertiary pattern 4</p> <p>50: Tertiary pattern 5</p> <p>X7: No prostatectomy/autopsy performed</p> <p>X8: Not applicable: Information not collected for this case</p> <p>X9: Not documented in medical record; Gleason Tertiary Pattern not assessed or unknown if assessed</p> <p>Blank: Date of Diagnosis pre-2018; Non-required Schema ID</p>

California Cancer Registry Data Dictionary

Variable Name:	GRADECLIN
Eureka Name:	Grade Clinical
NAACCR Item:	3843
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 – current year
Related Variables:	<ul style="list-style-type: none"> • Grade Pathological (GRADEPATH) • Grade Post Therapy (GRADEPOST) • Grade (DIFFERN2) • CS Site-Specific Factor 7 (for breast) (CSSITESPECIFICFACTOR7) • CS Site-Specific Factor 8 (for prostate) (CSSITESPECIFICFACTOR8) • CS Site-Specific Factor 10 (for prostate) (CSSITESPECIFICFACTOR10)
Definition:	<p>This data item records the grade of a solid primary tumor before any treatment (surgical resection or initiation of any treatment including neoadjuvant). Grade is a measure of the aggressiveness of the tumor. Grade and cell type are important prognostic indicators for many cancers. For some sites, grade is required to assign the clinical stage group.</p>
Notes:	<p>For cases diagnosed January 1, 2018, and later, this data item, along with Grade Pathological (GRADEPATH, NAACCR #3844) and Grade Post-Neoadjuvant (GRADEPOST, NAACCR #3845), replaces grade (DIFFERN2, NAACCR #440) as well as Collaborative Stage Site Specific Factors for cancers with alternative grading systems (e.g., breast [Bloom-Richardson, CSSITESPCIFICFACTOR7] and prostate [Gleason, CSSITESPECIFICFACTOR8 and CSSITESPECIFICFACTOR10]). For cases diagnosed 1988-2017, see DIFFERN2.</p>
Values:	<p>A, B, C, D, E, H, L, Refer to the most recent version of the SSDI Manual M, S, 1, 2, 3, 4, 5: for site-specific values and definitions.</p> <p>8: Not applicable</p> <p>9: Grade cannot be assessed; Unknown</p>

California Cancer Registry Data Dictionary

Variable Name:	GRADEPATH
Eureka Name:	Grade Pathological
NAACCR Item:	3844
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 – current year
Related Variables:	<ul style="list-style-type: none"> • Grade (DIFFERN2) • Grade Clinical (GRADECLIN) • Grade Post Therapy (GRADEPOST)

Definition: This data item records the grade of a solid primary tumor that has been resected and for which no neoadjuvant therapy was administered. The highest grade from any microscopic specimen of the primary site whether from the clinical workup or the surgical resection is recorded. Grade is a measure of the aggressiveness of the tumor. Grade and cell type are important prognostic indicators for many cancers. For some sites, grade is required to assign the pathological stage group.

Notes: For cases diagnosed January 1, 2018, and later, this data item, along with Grade Clinical (GRADECLIN, NAACCR #3843) and Grade Post-Neoadjuvant (GRADEPOST, NAACCR #3845), replaces grade (DIFFERN2, NAACCR #440) as well as Collaborative Stage Site Specific Factors for cancers with alternative grading systems (e.g., breast [Bloom-Richardson, CSSITESPECIFICFACTOR7] and prostate [Gleason, CSSITESPECIFICFACTOR8 and CSSITESPECIFICFACTOR10]). For cases diagnosed 1988-2017, see DIFFERN2.

Values:

A, B, C, D, E, H, L,	Refer to the most recent version of the SSDI Manual
M, S, 1, 2, 3, 4, 5:	for site-specific values and definitions.
8:	Not applicable
9:	Grade cannot be assessed; Unknown

California Cancer Registry Data Dictionary

Variable Name: GRADEPATHSYSTEM

Eureka Name: Grade Path System

NAACCR Item: 449

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2010 – current year

Related Variables: Grade Path Value (GRADEPATHVALUE)

Definition: Indicates whether a two, three, or four grade system is used. This is the grade system stated in the path report. This item is used in conjunction with Grade Path Value (GRADEPATHVALUE, NAACCR #441).

Values:

- 2: Two-Grade System
- 3: Three-Grade System
- 4: Four-Grade System
- Blank: Not a two, three, or four grade system; unknown; case diagnosed prior to January 1, 2010.

California Cancer Registry Data Dictionary

Variable Name: GRADEPATHVALUE

Eureka Name: Grade Path Value

NAACCR Item: 441

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2010 – current year

Related Variables: Grade Path System (GRADEPATHSYSTEM)

Definition: Describes the actual grade according to the grading system in Grade Path System (GRADEPATHSYSTEM, NAACCR #449). It does not replace grade (DIFFERN2, NAACCR #440).

Values:

- 1: Recorded as Grade I or 1
- 2: Recorded as Grade II or 2
- 3: Recorded as Grade III or 3
- 4: Recorded as Grade IV or 4
- Blank: No 2, 3, or 4 system grade available; unknown; case diagnosed prior to January 1, 2010.

California Cancer Registry Data Dictionary

Variable Name:	GRADEPOST
Eureka Name:	Grade Post Therapy
NAACCR Item:	3845
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 – current year
Related Variables:	<ul style="list-style-type: none"> • Grade (DIFFERN2) • Grade Clinical (GRADECLIN) • Grade Pathological (GRADEPATH)

Definition: This data item records the highest grade documented from the surgical treatment resection specimen of the primary site following neoadjuvant therapy. Grade is a measure of the aggressiveness of the tumor. Grade and cell type are important prognostic indicators for many cancers. For some sites, grade is required to assign post-neoadjuvant stage group. For cases diagnosed January 1, 2018, and later, this data item, along with Grade Clinical (GRADECLIN, NAACCR #3843) and Grade Pathological (GRADEPATH, NAACCR #3844) replaces grade (DIFFERN2, NAACCR #440) as well as Collaborative Stage Site Specific Factors for cancers with alternative grading systems (e.g., breast [Bloom-Richardson, CSSITESPCIFICFACTOR7] and prostate [Gleason, CSSITESPECIFICFACTOR8 and CSSITESPECIFICFACTOR10]).

Values:	A, B, C, D, E, H, L,	Refer to the most recent version of the SSDI Manual
	M, S, 1, 2, 3, 4, 5:	for site-specific values and definitions.
	8:	Not applicable
	9:	Grade cannot be assessed; Unknown

California Cancer Registry Data Dictionary

Variable Name:	HCGPOSTORCHRANGE
Eureka Name:	hCG Post-Orchiectomy Range
NAACCR Item:	3847
Category:	Prognostic Factors
Level of Variable:	Tumor
Time Period Available:	2018 – current year
Related Variables:	<ul style="list-style-type: none"> • hCG Post-Orchiectomy Lab Value (HCGPOSTORCHVALUE) • hCG Pre-Orchiectomy Lab Value (HCGPREORCHVALUE) • hCG Pre-Orchiectomy Range (HCGPREORCHRANGE) • CS Site-Specific Factor 15 (CSSITESPECIFICFACTOR15)

Definition: Human Chorionic Gonadotropin (hCG) Post-orchietomy Range identifies the range category of the lowest hCG value measured post-orchietomy. hCG is a serum tumor marker that is often elevated in patients with nonseminomatous germ cell tumors of the testis. The Post-Orchietomy lab value is used to monitor response to therapy. Valid for cases diagnosed January 1, 2018 and forward. For testicular cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR15.

Values:	0:	Within normal limits
	1:	Above normal and less than 5,000 milli-International Units/milliliter (mIU/mL)
	2:	5,000-50,000 mIU/mL
	3:	Greater than 50,000 mIU/mL
	4:	Post-orchietomy human chorionic gonadotropin (hCG) stated to be elevated
	7:	Test ordered, results not in chart
	8:	Not applicable: Information not collected for this case
	9:	Not documented in medical record; No orchietomy performed; hCG (Human Chorionic Gonadotropin) Post-Orchietomy Range not assessed or unknown if assessed
	Blank:	Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: HCGPOSTORCHVALUE
Eureka Name: hCG Post-Orchiectomy Lab Value
NAACCR Item: 3846
Category: Prognostic Factors
Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables:

- hCG Post-Orchiectomy Range (HCGPOSTORCHVALUE)
- hCG Pre-Orchiectomy Lab Value (HCGPREORCHVALUE)
- hCG Pre-Orchiectomy Range (HCGPREORCHVALUE)
- CS Site-Specific Factor 14 (CSSITESPECIFICFACTOR14)

Definition: Human Chorionic Gonadotropin (hCG) Post-orchietomy Lab Value refers to the lowest hCG value measured post-orchietomy. hCG is a serum tumor marker that is often elevated in patients with nonseminomatous germ cell tumors of the testis. The Post-Orchiectomy lab value is used to monitor response to therapy. Valid for cases diagnosed January 1, 2018 and forward. For testicular cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR14.

Values:

00:	0.0 milli-International Units/milliliter (mIU/mL)
0.1-99999.9:	0.1-99,999.9 mIU/mL
XXXXX.1:	100,000 mIU/mL or greater
XXXXX.7:	Test ordered, results not in chart
XXXXX.8:	Not applicable: Information not collected for this case
XXXXX.9:	Not documented in medical record; No orchiectomy performed; hCG (Human Chorionic Gonadotropin) Post-Orchiectomy Lab Value not assessed or unknown if assessed
Blank:	Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: HCGPREORCHRANGE

Eureka Name: hCG Pre-Orchiectomy Range

NAACCR Item: 3849

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables:

- hCG Post-Orchiectomy Lab Value (HCGPOSTORCHVALUE)
- hCG Post-Orchiectomy Range (HCGPOSTORCHRANGE)
- hCG Pre-Orchiectomy Lab Value (HCGPREORCHVALUE)
- CS Site-Specific Factor 9 (CSSITESPECIFICFACTOR9)

Definition: Human Chorionic Gonadotropin (hCG) Pre-orchiectomy Range identifies the range category of the highest hCG value measured prior to treatment. hCG is a serum tumor marker that is often elevated in patients with nonseminomatous germ cell tumors of the testis. Valid for cases diagnosed January 1, 2018 and forward. For testicular cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR9.

Values:

- 0: Within normal limits
- 1: Above normal and less than 5,000 milli-International Units/milliliter (mIU/mL)
- 2: 5,000-50,000 mIU/mL
- 3: Greater than 50,000 mIU/mL
- 4: Pre-orchiectomy human chorionic gonadotropin (hCG) stated to be elevated
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; hCG Pre-Orchiectomy Range not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name:	HCGPREORCHVALUE														
Eureka Name:	hCG Pre-Orchiectomy Lab Value														
NAACCR Item:	3848														
Category:	Prognostic Factors														
Level of Variable:	Tumor														
Time Period Available:	2018 – current year														
Related Variables:	<ul style="list-style-type: none"> • hCG Post-Orchiectomy Lab Value (HCGPOSTORCHVALUE) • hCG Post-Orchiectomy Range (HCGPOSTORCHVALUE) • hCG Pre-Orchiectomy Range (HCGPREORCHVALUE) • CS Site-Specific Factor 8 (CSSITESPECIFICFACTOR8) 														
Definition:	<p>Human Chorionic Gonadotropin (hCG) Pre-orchietomy Lab Value refers to the hCG value measured prior to treatment. hCG is a serum tumor marker that is often elevated in patients with nonseminomatous germ cell tumors of the testis. Valid for cases diagnosed January 1, 2018 and forward. For testicular cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR8.</p>														
Values:	<table> <tr> <td>0.0:</td><td>0.0 milli-International Units/milliliter (mIU/mL)</td></tr> <tr> <td>0.1-99999.9:</td><td>0.1-99,999.9 mIU/mL</td></tr> <tr> <td>XXXXX.1:</td><td>100,000 mIU/mL or greater</td></tr> <tr> <td>XXXXX.7:</td><td>Test ordered, results not in chart</td></tr> <tr> <td>XXXXX.8:</td><td>Not applicable: Information not collected for this case</td></tr> <tr> <td>XXXXX.9:</td><td>Not documented in medical record; hCG (Human Chorionic Gonadotropin) Pre-Orchiectomy Lab Value not assessed or unknown if assessed</td></tr> <tr> <td>Blank:</td><td>Date of Diagnosis pre-2018; Non-required Schema ID</td></tr> </table>	0.0:	0.0 milli-International Units/milliliter (mIU/mL)	0.1-99999.9:	0.1-99,999.9 mIU/mL	XXXXX.1:	100,000 mIU/mL or greater	XXXXX.7:	Test ordered, results not in chart	XXXXX.8:	Not applicable: Information not collected for this case	XXXXX.9:	Not documented in medical record; hCG (Human Chorionic Gonadotropin) Pre-Orchiectomy Lab Value not assessed or unknown if assessed	Blank:	Date of Diagnosis pre-2018; Non-required Schema ID
0.0:	0.0 milli-International Units/milliliter (mIU/mL)														
0.1-99999.9:	0.1-99,999.9 mIU/mL														
XXXXX.1:	100,000 mIU/mL or greater														
XXXXX.7:	Test ordered, results not in chart														
XXXXX.8:	Not applicable: Information not collected for this case														
XXXXX.9:	Not documented in medical record; hCG (Human Chorionic Gonadotropin) Pre-Orchiectomy Lab Value not assessed or unknown if assessed														
Blank:	Date of Diagnosis pre-2018; Non-required Schema ID														

California Cancer Registry Data Dictionary

Variable Name: HEIGHT
Eureka Name: Height
NAACCR Item: 9960
Category: Clinical, Other
Level of Variable: Tumor
Time Period Available: 2011 – current year

Related Variables:

Definition: The height of the patient on or near the time of diagnosis.

Values: 00-97: Height in inches
98: Height of 98 inches or greater
99: Unknown height

California Cancer Registry Data Dictionary

Variable Name: HER2IHCSUMMARY

Eureka Name: HER2 IHC Summary

NAACCR Item: 3850

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables:

- CS Site-Specific Factor 8 (for breast) (CSSITESPECIFICFACTOR8)
- CS Site-Specific Factor 9 (for breast) (CSSITESPECIFICFACTOR9)

Definition: HER2 IHC Summary is the summary score for HER2 testing by IHC. Valid for cases diagnosed January 1, 2018 and forward. For breast cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR8 and CSSITESPECIFICFACTOR9.

Values:

- 0: Negative (Score 0)
- 1: Negative (Score 1+)
- 2: Equivocal (Score 2+); Stated as equivocal
- 3: Positive (Score 3+); Stated as positive
- 4: Stated as negative, but score not stated
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Cannot be determined (indeterminate); HER2 IHC Summary not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name:	HER2ISHDUALNUM
Eureka Name:	HER2 ISH Dual Probe Copy Number
NAACCR Item:	3851
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 – current year
Related Variables:	HER2 ISH Dual Probe Ratio (HER2ISHDUALRATIO)
Definition:	HER2 in situ hybridization (ISH) Dual Probe Copy Number is the HER2 copy number based on a dual probe test.
Values:	<p>0.0-99.9: Reported HER2 copy number of 0.0-99.9</p> <p>XX.1: Reported HER2 copy number of 100 or greater</p> <p>XX.7: Test ordered, results not in chart</p> <p>XX.8: Not applicable: Information not collected for this case</p> <p>XX.9: Not documented in medical record; Cannot be determined (indeterminate); HER2 ISH Dual Probe Copy Number not assessed or unknown if assessed</p> <p>Blank: Date of Diagnosis pre-2018; Non-required Schema ID</p>

California Cancer Registry Data Dictionary

Variable Name:	HER2ISHDUALRATIO
Eureka Name:	HER2 ISH Dual Probe Ratio
NAACCR Item:	3852
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 – current year
Related Variables:	HER2 ISH Dual Probe Copy Number (HER2ISHDUALNUM)
Definition:	HER2 in situ hybridization (ISH) Dual Probe Ratio is the summary score for HER2 testing using a dual probe. The test will report results for both HER2 and CEP17, the latter used as a control. The HER2/CEP17 ratio is reported.
Values:	<p>0.0-99.9: Ratio of 0.0-99.9</p> <p>XX.2: Less than 2.0</p> <p>XX.3: Greater than or equal to 2.0</p> <p>XX.7: Test ordered, results not in chart</p> <p>XX.8: Not applicable: Information not collected for this case</p> <p>XX.9: Not documented in medical record; Cannot be determined (indeterminate); HER2 ISH Dual Probe Ratio not assessed or unknown if assessed</p> <p>Blank: Date of Diagnosis pre-2018; Non-required Schema ID</p>

California Cancer Registry Data Dictionary

Variable Name: HER2ISHSINGLENUM
Eureka Name: HER2 ISH Single Probe Copy Number
NAACCR Item: 3853
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year

Related Variables:

Definition: HER2 in situ hybridization (ISH) Single Probe Copy Number is the HER2 copy number based on a single probe test.

Values:

- 0.0-99.9: Reported HER2 copy number of 0.0-99.9
- XX.1: Reported HER2 copy number of 100 or greater
- XX.7: Test ordered, results not in chart
- XX.8: Not applicable: Information not collected for this case
- XX.9: Not documented in medical record; Cannot be determined (indeterminate);
HER2 ISH Single Probe Copy Number not assessed or unknown if
assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: HER2ISHSUMMARY
Eureka Name: HER2 ISH Summary
NAACCR Item: 3854
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year

Related Variables:

Definition: HER2 in situ hybridization (ISH) Summary is the summary score for results of testing for ERBB2 gene copy number by any ISH method. An immunohistochemistry (IHC) test identifies the protein expressed by the gene (ERBB2), and an ISH test identifies the number of copies of the gene (ERBB2) itself.

Values:

- 0: Negative (not amplified)
- 2: Equivocal
- 3: Positive (amplified)
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Cannot be determined (indeterminate);
HER2 ISH Summary status not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: HER2OVERALLSUMM

Eureka Name: HER2 Overall Summary

NAACCR Item: 3855

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 15 (CSSITESPECIFICFACTOR15)

Definition: HER2 Overall Summary is a summary of results from HER2 testing. Valid for breast cancers diagnosed January 1, 2018 and forward. For breast cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR15.

Values:

- 0: HER2 negative; equivocal
- 1: HER2 positive
- 7: Test ordered, results not in chart
- 9: Not documented in medical record; Cannot be determined (indeterminate);
HER2 Overall Summary status not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: HERITABLETRAIT
Eureka Name: Heritable Trait
NAACCR Item: 3856
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year

Related Variables:

Definition: Heritable trait pertains to evidence that a tumor is associated with a heritable mutation. In retinoblastoma, the heritable trait is a germline mutation in the RB1 gene, which is associated with bilateral disease, family history of retinoblastoma, presence of concomitant CNS midline embryonic tumor (commonly in pineal region), or retinoblastoma with an intracranial primitive neuroectodermal tumor (i.e., trilateral retinoblastoma). Children with any of these features may be assigned the H1 status without molecular testing. High quality molecular testing for RB1 mutation is required to determine the presence or absence of RB1 mutation for children without clinical features of a heritable mutation.

Values:

- 0: H0: Normal RB1 alleles; No clinical evidence of mutation
- 1: H1: RB1 gene mutation OR clinical evidence of mutation
- 7: Test ordered, results not in chart
- 9: Not documented in medical record; Test not done, or unknown if done;
Insufficient evidence of a constitutional RB1 gene mutation
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: HIGHRISKCYTOGENET
Eureka Name: High Risk Cytogenetics
NAACCR Item: 3857
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year

Related Variables:

Definition: High Risk Cytogenetics is defined as one or more of t(4;14), t(14;16), or del 17p identified from FISH test results and is part of the staging criteria for plasma cell myeloma.

Values:

- 0: High-risk cytogenetics not identified/not present
- 1: High-risk cytogenetics present
- 7: Test ordered, results not in chart
- 9: Not documented in medical record; High Risk Cytogenetics not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: HIGHRISKHISTFEAT
Eureka Name: High Risk Histologic Features
NAACCR Item: 3858
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year
Related Variables: CS Site-Specific Factor 12 (CSSITESPECIFICFACTOR12)

Definition: High Risk Histologic Features are defined in AJCC 8 Chapter 15 to include the terms "poor differentiation, desmoplasia, sarcomatoid differentiation, undifferentiated." High risk histologic features are a prognostic factor for cutaneous squamous cell carcinomas of the head and neck. Valid for cases diagnosed January 1, 2018 and forward. For skin cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR12.

Values:

- 0: No high-risk histologic features
- 1: Desmoplasia
- 2: Poor differentiation (grade 3)
- 3: Sarcomatoid differentiation
- 4: Undifferentiated (grade 4)
- 5: Multiple high-risk histologic features
- 6: Histologic features, NOS (type of high-risk histologic feature not specified)
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; High risk histologic features not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: HISPSURN

Eureka Name: N/A

NAACCR Item: N/A

Category: Patient Demographics

Level of Variable: Patient

Time Period Available: 1988 – current year

Related Variables: Name--Last (LNAME)

Definition: Variable indicates whether the patient's last name is on the 1980 Spanish Surname List provided by the United States Census Bureau.

Notes: For additional information, please see the Appendix "Variables Pertaining to Race/Ethnicity in the CCR".

Values:

- 0: No
- 1: Yes

California Cancer Registry Data Dictionary

Variable Name:	HISTO_M2
Eureka Name:	Behavior (92-00) ICD-O-2
NAACCR Item:	430
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	1988 – 2000
Related Variables:	<ul style="list-style-type: none"> • Behavior Code ICD-O-3 (HISTO_M3) • Behavior Recode for Analysis (SEER) (BEHAVIOR)
Definition:	Fifth digit of the ICD-O-2 morphology code which indicates the malignancy or behavior of this tumor. This data item was required by all standard-setting organizations for tumors diagnosed from January 1, 1992, through December 31, 2000, and recommended for tumors diagnosed before 1992.
Notes:	Behavior (92-00) ICD-O-2 = 1 no longer allowed.
Values:	2: In situ 3: Malignant (invasive) Blank: ICDO-3 case, diagnosed 2001 or later

California Cancer Registry Data Dictionary

Variable Name:	HISTO_M3
Eureka Name:	Behavior Code ICD-O-3
NAACCR Item:	523
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	1988 – current year
Related Variables:	<ul style="list-style-type: none"> • Behavior (92-00) ICD-O-2 (HISTO_M2) • Behavior Recode for Analysis (SEER) (BEHAVIOR)
Definition:	Fifth digit of the ICD-O-3 morphology code which indicates the malignancy or behavior of this tumor. Coded directly for cases diagnosed January 1, 2001 and forward. Cases diagnosed prior to 2001 were converted to ICD-O-3 codes.
Values:	0: Benign 1: Uncertain/Borderline 2: In situ 3: Malignant

California Cancer Registry Data Dictionary

Variable Name: HISTO_T2
Eureka Name: Histology (92-00) ICD-O-2
NAACCR Item: 420
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 1988 – 2000
Related Variables: Behavior Code ICD-O-3 (HISTO_M3)

Definition: The first four digits of the ICD-O-2 morphology code, indicates the histology/cell type of this tumor.

Values: 8000-9989: Entire range is not used (Refer to ICD-O-2 manual for value definitions. See [California Cancer Reporting Standards: Volume III, Appendix 9A](#) for valid values)
 Blank: ICD-O-3 case diagnosed 2001 or later

California Cancer Registry Data Dictionary

Variable Name:	HISTO_T3
Eureka Name:	Histology Type ICD-O-3
NAACCR Item:	522
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	1988 – current year
Related Variables:	Histology (92-00) ICD-O-2 (HISTO_T2)
Definition:	The first four digits of the ICD-O-3 morphology code, indicates the histology/cell type of this tumor. Coded directly for cases diagnosed January 1, 2001 and forward. Cases coded prior to 2001 were converted to ICDO-3.
Values:	8000-9992: Entire range is not used (Refer to ICD-O-3 manual for value definitions. See California Cancer Reporting Standards: Volume III, Appendix 9B for valid values)

California Cancer Registry Data Dictionary

Variable Name: HIVSTATUS

Eureka Name: HIV Status

NAACCR Item: 3859

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 1 (CS_SITE_SPEC_F1)

Definition: HIV status refers to infection with the Human Immunodeficiency Virus which causes Acquired Immune Deficiency Syndrome (AIDS). AIDS is associated with increased risk of developing some lymphomas. Valid for cases diagnosed January 1, 2018 and forward. For cases of lymphoma and Kaposi Sarcoma diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F1.

Values:

- 0: Not associated with Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS); HIV negative
- 1: Associated with HIV/AIDS; HIV positive
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; HIV Status not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: HMNGSURN
Eureka Name: N/A
NAACCR Item: N/A
Category: Patient Demographics
Level of Variable: Patient
Time Period Available: 1988 – current year
Related Variables: Name--Last (LNAME)

Definition: This variable indicates whether the patient's last name is on a Hmong surname list.

Notes: For additional information, please see the Appendix "Variables Pertaining to Race/Ethnicity in the CCR".

Values: 0: No
 1: Yes

California Cancer Registry Data Dictionary

Variable Name: HORMSUM
Eureka Name: RX Summ--Hormone
NAACCR Item: 1400
Category: Treatment, Systemic
Level of Variable: Tumor
Time Period Available: 1988 – current year
Related Variables: RX Date Hormone (RXDATEH)

Definition: Records whether systemic hormonal agents were given as first course of treatment at any facility, or the reason why they were not given. Hormone therapy consists of a group of drugs that may affect the long-term control of a cancer's growth. It is not usually used as a curative measure. RXDATEH provides the date hormone therapy started.

Values:

- 00: None, hormone therapy was not part of the planned first course of therapy.
- 01: Hormones therapy administered as first course therapy.
- 82: Hormone therapy was not recommended/administered because it was contraindicated due to patient risk factors (i.e., comorbid conditions, advanced age).
- 85: Hormone therapy was not administered because the patient died prior to planned or recommended therapy.
- 86: Hormone therapy was not administered. It was recommended by the patient's physician but was not administered as part of first-course therapy. No reason was stated in the patient record.
- 87: Hormone therapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in the patient record.
- 88: Hormone therapy was recommended, but it is unknown if it was administered.
- 99: It is unknown whether a hormonal agent(s) was recommended or administered because it is not stated in the patient record. Death certificate-only cases.

California Cancer Registry Data Dictionary

Variable Name:	HOSPNO
Eureka Name:	Reporting Facility
NAACCR Item:	540
Category:	Hospital and Physician
Level of Variable:	Admission
Time Period Available:	1988 – current year
Related Variables:	Date of 1 st Contact (DATEADM)
Definition:	Unique ten-digit number assigned by CCR to the hospital or other facility reporting this case that was the first to see the patient for evaluation and/or treatment of this tumor. The first hospital/facility to see the patient for this tumor is that with the earliest date of first contact (DATEADM). In the research file, DATEADM and HOSPNO come from the same abstract.
Values:	For hospital code numbers, see CA Hosp Codes at https://www.ccrca.org/submit-data/cancer-registrars-hospitals-and-facilities/reporting-for-hospitals-and-facilities/

California Cancer Registry Data Dictionary

Variable Name:	ICCCWHO
Eureka Name:	N/A
NAACCR Item:	N/A
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	1988 – current year
Related Variables:	<ul style="list-style-type: none"> • Age at Diagnosis (AGE) • Behavior Code ICD-O-3 (HISTO_M3) • Histologic Type ICD-O-3 (HISTO_T3) • Primary Site (SITE_02)
Definition:	For patients diagnosed with cancer aged 19 years or younger, this variable is a site/histology recode based on the International Classification of Childhood Cancer, third edition (ICCC-3) which is based on ICD-O-3 and updated for Hematopoietic codes based on "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008)." The values in this field are those of the extended classification as defined by SEER.
Notes:	This variable is not a collected data item but derived from tumor location (SITE_02), histology according to ICD-O-3 (HISTO_T3), and behavior according to ICD-O-3 (HISTO_M3).
Values:	For allowable values and definitions, see https://seer.cancer.gov/iccc/iccc-who2008.html

California Cancer Registry Data Dictionary

Variable Name: ICDREVISIONNUMBER
Eureka Name: ICD Revision Number
NAACCR Item: 1920
Category: Follow-Up
Level of Variable: Tumor
Time Period Available: 1988 – current year
Related Variables: Cause of Death (CDEATH)
Definition: Indicates the coding scheme used to code cause of death.
Values: 0: Patient alive at last follow-up
 1: ICD-10 (1999+ deaths)
 7: ICD-7
 8: ICDA-8
 9: ICD-9

California Cancer Registry Data Dictionary

Variable Name: IHSLINK
Eureka Name: IHS Link
NAACCR Item: 192
Category: Patient Demographics
Level of Variable: Patient
Time Period Available: 1988 – current year

Related Variables:

Definition: IHSLINK captures the results of the CCR database linkage with the Indian Health Service (IHS) patient registration database. This field indicates whether the CCR patient matched to the Indian Health Services file. The CCR linkage with IHS occurs annually in November.

Notes: For additional information, please see the Appendix "Variables Pertaining to Race/Ethnicity in the CCR".

Values:

- 0: Record sent for linkage, no IHS match
- 1: Record sent for linkage, IHS match
- Blank: Record not sent for linkage or linkage result pending

California Cancer Registry Data Dictionary

Variable Name: IMMUNESUPP
Eureka Name: Profound Immune Suppression
NAACCR Item: 3918
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 - current year

Related Variables:

Definition: Profound Immune Suppression, suppressed immune status that may be associated with HIV/AIDs, solid organ transplant, chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple conditions or other conditions, increases the risk of developing Merkel Cell Carcinoma and is an adverse prognostic factor.

Values:

- 0: No immune suppression condition(s) identified/not present
- 1: Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS)
- 2: Solid organ transplant recipient
- 3: Chronic lymphocytic leukemia
- 4: Non-Hodgkin lymphoma
- 5: Multiple immune suppression conditions
- 6: Profound immune suppression present
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Profound immune suppression not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: IMMUSUM
Eureka Name: RX Summ--BRM
NAACCR Item: 1410
Category: Treatment, Systemic
Level of Variable: Tumor
Time Period Available: 1988 – current year
Related Variables: RX Date BRM (RXDATEI)

Definition: Records whether immunotherapeutic (biologic response modifiers) agents were administered as first-course treatment at all facilities or the reason they were not given. Immunotherapy consists of biological or chemical agents that alter the immune system or change the host's response to tumor cells. RXDATEI records the date of initiation for immunotherapy (a.k.a. biological response modifier) that is part of the first course of treatment.

Values:

- 00: None, diagnosed at autopsy
- 01: Immunotherapy given
- 82: Immunotherapy contraindicated
- 85: Patient died
- 86: Recommended, not given
- 87: Refused
- 88: Recommended, unknown if given
- 99: Unknown, death certificate only (DCO)

California Cancer Registry Data Dictionary

Variable Name:	INDUS80
Eureka Name:	Industry 80
NAACCR Item:	N/A
Category:	Patient Demographics
Level of Variable:	Tumor
Time Period Available:	1988 – 2003
Related Variables:	<ul style="list-style-type: none"> • Occupation 80 (OCCUP80) • Industry Associated with Patient's Longest-Held Occupation (INDUSTRY_CODE) • Patient's Longest-Held Occupation (OCCUPATION_CODE)
Definition:	Identifies the type of industry or business associated with the patient's longest-held occupation at time of diagnosis. Coding reflects that used by the Census Bureau in 1980. Historically, this field was inconsistently coded. Use the field INSUSTRY_CODE instead.
Notes:	For additional information, please see the Appendix "Industry & Occupation Variables in the CCR". For coding scheme, please refer to Appendix 14B in "California Cancer Reporting System Standards, Volume III" located at: https://www.ccrca.org/submit-data/cancer-registrars-hospitals-and-facilities/reporting-by-cancer-registrars/#volumes-anchor
Values:	010-971 with trailing 0; Entire range is not used 9900: Not reported 9999: Code not yet assigned

California Cancer Registry Data Dictionary

Variable Name:	INDUS90
Eureka Name:	Industry 90
NAACCR Item:	N/A
Category:	Patient Demographics
Level of Variable:	Tumor
Time Period Available:	1988 – 2002
Related Variables:	<ul style="list-style-type: none"> • Occupation 90 (OCCUP90) • Industry Associated with Patient's Longest-Held Occupation (INDUSTRY_CODE) • Patient's Longest-Held Occupation (OCCUPATION_CODE)
Definition:	Identifies the type of industry or business associated with the patient's longest-held occupation at time of diagnosis. Coding reflects that used by the Census Bureau in 1990. Historically, this field was inconsistently coded. Use the field INSUSTRY_CODE instead.
Notes:	For additional information, please see the Appendix "Industry & Occupation Variables in the CCR". For coding scheme, please refer to Appendix 14B in "California Cancer Reporting System Standards, Volume III" located at: https://www.ccrca.org/submit-data/cancer-registrars-hospitals-and-facilities/reporting-by-cancer-registrars/#volumes-anchor
Values:	010-971 with trailing 0; Entire range is not used 9900: Not reported 9999: Code not yet assigned

California Cancer Registry Data Dictionary

Variable Name: INDUSTRY_CODE

Eureka Name: N/A

NAACCR Item: N/A

Category: Patient Demographics

Level of Variable: Tumor

Time Period Available: 1988 – current year

Related Variables: Patient's Longest-Held Occupation (OCCUPATION_CODE)

Definition: Code for the type of industry or business associated with the patient's longest-held occupation at the time of diagnosis. The code is assigned by applying a NIOSH look-up table to text string obtained from the medical record. Coding reflects that used by the Census Bureau in 1990.

Notes: For additional information, please see the Appendix "Industry & Occupation Variables in the CCR". For coding scheme, please refer to **Appendix 14B** in "California Cancer Reporting System Standards, Volume III" located at: <https://www.ccrca.org/submit-data/cancer-registrars-hospitals-and-facilities/reporting-by-cancer-registrars/#volumes-anchor>

Values: 010-971 (entire range is not used)
990, 999: Not Reported/Unknown

California Cancer Registry Data Dictionary

Variable Name:	INRPROTIME																
Eureka Name:	International Normalized Ratio Prothrombin Time																
NAACCR Item:	3860																
Category:	Prognostic Factors																
Level of Variable:	Tumor																
Time Period Available:	2018 – current year																
Related Variables:	CS Site-Specific Factor 8 (CSSITESPECIFICFACTOR8)																
Definition:	International Normalized Ratio for Prothrombin Time (INR), an indicator of the liver's ability to make clotting factors, is required to calculate the Model for End-Stage Liver Disease (MELD) score, which is used to assign priority for liver transplant. Valid for cases diagnosed January 1, 2018 and forward. For liver cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR8.																
Values:	<table> <tr> <td>0.0:</td><td>0.0</td></tr> <tr> <td>0.1:</td><td>0.1 or less</td></tr> <tr> <td>0.2-9.9:</td><td>0.2 - 9.9 (exact ratio to the nearest tenth)</td></tr> <tr> <td>X.1:</td><td>10 or greater</td></tr> <tr> <td>X.7:</td><td>Test ordered, results not in chart</td></tr> <tr> <td>X.8:</td><td>Not applicable: Information not collected for this case</td></tr> <tr> <td>X.9:</td><td>Not documented in medical record; INR (International Normalized Ratio for Prothrombin Time) not assessed or unknown if assessed</td></tr> <tr> <td>Blank:</td><td>Date of Diagnosis pre-2018; Non-required Schema ID</td></tr> </table>	0.0:	0.0	0.1:	0.1 or less	0.2-9.9:	0.2 - 9.9 (exact ratio to the nearest tenth)	X.1:	10 or greater	X.7:	Test ordered, results not in chart	X.8:	Not applicable: Information not collected for this case	X.9:	Not documented in medical record; INR (International Normalized Ratio for Prothrombin Time) not assessed or unknown if assessed	Blank:	Date of Diagnosis pre-2018; Non-required Schema ID
0.0:	0.0																
0.1:	0.1 or less																
0.2-9.9:	0.2 - 9.9 (exact ratio to the nearest tenth)																
X.1:	10 or greater																
X.7:	Test ordered, results not in chart																
X.8:	Not applicable: Information not collected for this case																
X.9:	Not documented in medical record; INR (International Normalized Ratio for Prothrombin Time) not assessed or unknown if assessed																
Blank:	Date of Diagnosis pre-2018; Non-required Schema ID																

California Cancer Registry Data Dictionary

Variable Name: IPSIADRENALINVOLV
Eureka Name: Ipsilateral Adrenal Gland Involvement
NAACCR Item: 3861
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year
Related Variables: CS Site-Specific Factor 3 (CS_SITE_SPEC_F3)

Definition: Ipsilateral adrenal gland involvement pertains to direct extension of the tumor into the ipsilateral adrenal gland (continuous) or ipsilateral adrenal gland involvement by a separate nodule (noncontiguous). Valid for cases diagnosed January 1, 2018 and forward. For kidney cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F3.

Values:

- 0: Ipsilateral adrenal gland involvement not present/not identified
- 1: Adrenal gland involvement by direct involvement (contiguous involvement)
- 2: Adrenal gland involvement by separate nodule (noncontiguous involvement)
- 3: Combination of code 1-2
- 4: Ipsilateral adrenal gland involvement, unknown if direct involvement or separate nodule
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Ipsilateral adrenal gland not resected; Ipsilateral adrenal gland involvement not assessed or unknown if assessed; No surgical resection of primary site is performed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: JAK2

Eureka Name: JAK2

NAACCR Item: 3862

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 1 (CS_SITE_SPEC_F1)

Definition: Janus Kinase 2 (JAK2, JAK 2) is a gene mutation that increases susceptibility to several myeloproliferative neoplasms (MPNs). Testing for the JAK2 mutation is done on whole blood. Nearly all people with polycythemia vera, and about half of those with primary myelofibrosis and essential thrombocythemia, have the mutation. JAK2 analysis continues to increase in use for hematopoietic neoplasms. Valid for cases diagnosed January 1, 2018 and forward. For hematopoietic/reticuloendothelial cancers diagnosed 2004 through 2017, see CS_SITE_SPEC_F1.

Values:

- 0: JAK2 result stated as negative
- 1: JAK2 positive for mutation V617F WITH or WITHOUT other mutations
- 2: JAK2 positive for exon 12 mutation
- 3: JAK2 positive for other specified mutation
- 4: JAK2 positive for more than one mutation other than V617F
- 5: JAK2 positive NOS; Specific mutation(s) not stated
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; JAK2 not assessed or unknown if assessed

Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: KI67
Eureka Name: KI-67
NAACCR Item: 3863
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year

Related Variables:

Definition: KI-67 (MIB-1) is a marker of cell proliferation. A high value indicates a tumor that is proliferating more rapidly.

Values:

- 0.0-100.0: 0.0 to 100.0 percent positive: enter percent positive
- XXX.7: Test ordered, results not in chart
- XXX.8: Not applicable: Information not collected for this case
- XXX.9: Not documented in medical record; KI-67 (MIB-1) not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: KITGENEIHC
Eureka Name: KIT Gene Immunohistochemistry
NAACCR Item: 3865
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year

Related Variables:

Definition: KIT Gene Immunohistochemistry (IHC) is the expression of the KIT gene in tumor tissue specimens based on immunohistochemical (IHC) stains. A positive test is a diagnostic and predictive marker for GIST tumors. Valid for cases diagnosed January 1, 2018 and forward. For earlier years of diagnosis, this data item was collected for GIST schemas under the Collaborative Stage Data Collection System in several different site-specific factors. Please consult the Collaborative Stage Data Collection system website for additional information:

<https://cancerstaging.org/cstage/schema/Pages/version0205.aspx>

Values:

- 0: KIT negative/normal; within normal limits
- 1: KIT positive
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Cannot be determined by pathologist; KIT not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: KRAS
Eureka Name: KRAS
NAACCR Item: 3866
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 – current year
Related Variables: CS Site-Specific Factor 9 (for colon and rectum) (CSSITESPECIFICFACTOR9)

Definition: KRAS is an important signaling intermediate in the growth receptor pathway which controls cell proliferation and survival. KRAS is a protein with production controlled by the K-ras gene. When the K-ras gene is activated through mutation during colorectal carcinogenesis, production of KRAS continuously stimulates cell proliferation and prevents cell deaths. Activating mutations in KRAS are an adverse prognostic factor for colorectal carcinoma and predict a poor response to monoclonal anti-EGFR antibody therapy in advanced colorectal carcinoma. Effective for cases diagnosed January 1, 2018 and forward. For cases diagnosed 2010 through 2017, see CSSITESPECIFICFACTOR9 (for colon and rectum).

Values:

- 0: Normal (wild type); Negative for mutations
- 1: Abnormal (mutated) in codon(s) 12, 13 and/or 61
- 2: Abnormal (mutated) in codon 146 only
- 3: Abnormal (mutated), but not in codon(s) 12, 13, 61, or 146
- 4: Abnormal (mutated), NOS, codon(s) not specified
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; KRAS not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: LATERAL

Eureka Name: Laterality

NAACCR Item: 410

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 1988 – current year

Related Variables:

Definition: For specific primary sites, the side of the body in which the tumor originated.

Notes: For a complete list of paired sites, see Volume I V.2.1 Laterality – Paired Sites:
<https://www.ccrca.org/submit-data/cancer-registrars-hospitals-and-facilities/reporting-for-hospitals-and-facilities/>

Values:

- 0: Not a paired site
- 1: Right
- 2: Left
- 3: Unilateral, Not Otherwise Specified
- 4: Bilateral involvement at time of diagnosis, lateral origin unknown for a single primary; or both ovaries involved simultaneously, single histology; bilateral retinoblastomas; bilateral Wilms tumors
- 5: Paired site: midline tumor
- 9: Paired site, but no information concerning laterality

California Cancer Registry Data Dictionary

Variable Name: LATITUDE

Eureka Name: Latitude

NAACCR Item: 2352

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: 1996 – current year

Related Variables: Longitude (LONGITUDE)

Definition: The distance, north or south of the equator, measured in degrees along a meridian as provided by the geocoding vendor for the patient's address at time of diagnosis. Paired with longitude, this represents the point location of the individual's residence on the earth's surface.

Values: Any numeric or decimal value
Blank: Not tracted

California Cancer Registry Data Dictionary

Variable Name: LDHPOSTORCHRANGE
Eureka Name: LDH Post-Orchiectomy Range

NAACCR Item: 3867

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 16 (CSSITESPECIFICFACTOR16)

Definition: LDH (Lactate Dehydrogenase) Post-Orchiectomy Range identifies the range category of the lowest LDH value measured post-orchietomy. LDH is a nonspecific marker for testicular cancer that is elevated in some germ cell tumors. The Post-Orchiectomy lab value is used to monitor response to therapy. Valid for cases diagnosed January 1, 2018 and forward. For testicular cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR16.

Values:

- 0: Within normal limits
- 1: Less than 1.5 x N (Less than 1.5 times the upper limit of normal for LDH)
- 2: 1.5 to 10 x N (Between 1.5 and 10 times the upper limit of normal for LDH)
- 3: Greater than 10 x N (Greater than 10 times the upper limit of normal for LDH)
- 4: Post-Orchiectomy lactate dehydrogenase (LDH) range stated to be elevated
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; No orchiectomy performed; LDH (Lactate Dehydrogenase) Post-Orchiectomy Range not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: LDHPREORCHRANGE

Eureka Name: LDH Pre-Orchiectomy Range

NAACCR Item: 3868

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 10 (CSSITESPECIFICFACTOR10)

Definition: Lactate Dehydrogenase (LDH) Range identifies the range category of the highest LDH value measured prior to treatment. LDH is a nonspecific marker for testicular cancer that is elevated in some germ cell tumors. This data item refers to the Pre-Orchiectomy range. Valid for cases diagnosed January 1, 2018 and forward. For testicular cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR10.

Values:

- 0: Within normal limits
- 1: Less than 1.5 x N (Less than 1.5 times the upper limit of normal for LDH)
- 2: 1.5 to 10 x N (Between 1.5 and 10 times the upper limit of normal for LDH)
- 3: Greater than 10 x N (Greater than 10 times the upper limit of normal for LDH)
- 4: Pre-Orchiectomy lactate dehydrogenase (LDH) range stated to be elevated
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; LDH (Lactate Dehydrogenase)
Pre-Orchiectomy Range not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: LDHPRETXLEVEL

Eureka Name: LDH Pretreatment Level

NAACCR Item: 3869

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 4 (CS_SITE_SPEC_F4)

Definition: LDH (Lactate Dehydrogenase) is an enzyme involved in conversion of sugars to energy and present in most cells in the body. Elevated pretreatment LDH is an adverse prognostic factor for plasma cell myeloma and melanoma of the skin. Valid for cases diagnosed January 1, 2018 and forward. For melanomas diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F4.

Values:

- 0: Normal LDH level; Low, below normal
- 1: Above normal LDH level; High
- 7: Test ordered, results not in chart
- 9: Not documented in medical record; LDH (Lactate Dehydrogenase) Pretreatment Level not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: LDHPRETVALUE

Eureka Name: LDH Pretreatment Lab Value

NAACCR Item: 3932

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 5 (CS_SITE_SPEC_F5)

Definition: LDH (Lactate Dehydrogenase) Pretreatment Lab Value, measured in serum, is a predictor of treatment response, progression-free survival and overall survival for patients with Stage IV melanoma of the skin. Valid for cases diagnosed January 1, 2018 and forward. For melanomas diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F5.

Values:

0.0:	0.0 (U/L)
0.1-99999.9:	0.1-99,999.9 U/L
XXXXX.1:	100,000 U/L or greater
XXXXX.7:	Test ordered, results not in chart
XXXXX.8	Not applicable: Information not collected for this case
XXXXX.9:	Not documented in medical record; LDH (Lactate Dehydrogenase) Pretreatment Lab Value not assessed or unknown if assessed
Blank:	Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: LDHUPPERNORMAL

Eureka Name: LDH Upper Limits of Normal

NAACCR Item: 3870

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 6 (CS_SITE_SPEC_F6)

Definition: LDH (Lactate Dehydrogenase), an enzyme involved in converting sugars to energy in the body, is elevated in some malignancies. LDH level is a prognostic factor for patients with Stage IV melanoma. This data Item refers to the Upper Limit of Normal in the laboratory test used to interpret the Serum LDH result. Valid for cases diagnosed January 1, 2018 and forward. For melanomas diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F6.

Values:

- 001-999: Exact upper limit of normal
- XX8: Not applicable: Information not collected for this case
- XX9: Not documented in medical record; LDH Upper Limit not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: LN_ITCS

Eureka Name: LN Isolated Tumor Cells (ITC)

NAACCR Item: 3880

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 18 (CSSITESPECIFICFACTOR18)

Definition: Lymph Nodes Isolated Tumor Cells (ITC), records the presence of isolated tumor cells (ITC) in regional lymph node(s). ITCs may be detected by hematoxylin and eosin or by immunohistochemical staining. ITCs present in regional lymph nodes is a potential prognostic factor for Merkel Cell Carcinoma. Valid for cases diagnosed January 1, 2018 and forward. For Merkel Cell Carcinomas diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR18.

Values:

- 0: Regional lymph nodes negative for ITCs
- 1: Regional lymph nodes positive for ITCs (Tumor cell clusters not greater than 0.2 millimeter (mm))
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; ITCs not assessed, or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: LNAME

Eureka Name: Name--Last

NAACCR Item: 2230

Category: Administrative

Level of Variable: Patient

Time Period Available: 1988 – current year

Related Variables:

- NAME--First (FNAME)
- NAME--Middle (MIDLNAME)
- NAME--Maiden (MAIDNAME)

Definition: Patient's last name.

Values: Alpha only

NLN: No last name

UNKNOWN: Unknown last name

California Cancer Registry Data Dictionary

Variable Name: LNDISTANTMETHOD

Eureka Name: LN Distant Assessment Method

NAACCR Item: 3874

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 7 (CSSITESPECIFICFACTOR7)

Definition: This data item describes the method used to assess involvement of distant (mediastinal, scalene) nodes associated with certain female genital cancers. Valid for cases diagnosed January 1, 2018 and forward. For vaginal cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR7.

Values:

- 0: Radiography, imaging; Ultrasound (US), computed tomography scan (CT), magnetic resonance imaging (MRI), positron emission tomography scan (PET)); Physical exam only
- 1: Incisional biopsy; fine needle aspiration (FNA)
- 2: Lymphadenectomy; Excisional biopsy or resection with microscopic confirmation
- 7: Distant lymph node(s) assessed, unknown assessment method
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Distant lymph nodes not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name:	LNDISTMEDIASSCALN
Eureka Name:	LN Distant, Mediastinal, Scalene
NAACCR Item:	3875
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 – current year
Related Variables:	CS Site-Specific Factor 6 (CS_SITE_SPEC_F6)
Definition:	This data item describes the status of distant (mediastinal, scalene) nodes associated with certain female genital cancers. Valid for cases diagnosed January 1, 2018 and forward. For vaginal cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F6.
Values:	<ul style="list-style-type: none"> 0: Negative mediastinal and scalene lymph nodes 1: Positive mediastinal lymph nodes 2: Positive scalene lymph nodes 3: Positive mediastinal and scalene lymph nodes 8: Not applicable: Information not collected for this case 9: Not documented in medical record; Mediastinal and scalene lymph nodes not assessed or unknown if assessed Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: LNFEMINGPARAAPELV
Eureka Name: LN Status Femoral-Inguinal, Para-Aortic, Pelvic
NAACCR Item: 3884
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year
Related Variables:

- CS Site-Specific Factor 2 (CS_SITE_SPEC_F2)
- CS Site-Specific Factor 4 (CS_SITE_SPEC_F4)

Definition: This data item describes the status of femoral-inguinal, para-aortic and pelvic lymph nodes associated with certain female genital cancers. Valid for cases diagnosed January 1, 2018 and forward. For vaginal cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F2 and CS_SITE_SPEC_F4.

Values:

- 0: Negative femoral-inguinal, para-aortic and pelvic lymph nodes
- 1: Positive femoral-inguinal lymph nodes
- 2: Positive para-aortic lymph nodes
- 3: Positive pelvic lymph nodes
- 4: Positive femoral-inguinal and para-aortic lymph nodes
- 5: Positive femoral-inguinal and pelvic lymph nodes
- 6: Positive para-aortic and pelvic lymph nodes
- 7: Positive para-aortic, pelvic, and femoral-inguinal lymph nodes
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Femoral-Inguinal, Para-aortic and Pelvic lymph node assessed, or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: LNHLEVELSI_III
Eureka Name: LN Head and Neck Levels I-III
NAACCR Item: 3876
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year
Related Variables: CS Site-Specific Factor 3 (CS_SITE_SPEC_F3)

Definition: Lymph Nodes for Head and Neck, Levels I-III records the involvement of Levels I-III lymph nodes. Valid for cases diagnosed January 1, 2018 and forward. For head and neck cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F3.

Values:

- 0: No involvement in Levels I, II, or III lymph nodes
- 1: Level I lymph node(s) involved
- 2: Level II lymph node(s) involved
- 3: Level III lymph node(s) involved
- 4: Levels I and II lymph nodes involved
- 5: Levels I and III lymph nodes involved
- 6: Levels II and III lymph nodes involved
- 7: Levels I, II and III lymph nodes involved
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Positive nodes, but level of positive node(s) unknown; Lymph node levels I-III not assessed, or unknown if assessed

Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: LNHLEVELSIV_V
Eureka Name: LN Head and Neck Levels IV-V
NAACCR Item: 3877
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year
Related Variables: CS Site-Specific Factor 4 (CS_SITE_SPEC_F4)

Definition: Lymph Nodes for Head and Neck, Levels IV-V records the involvement of Levels IV-V lymph nodes. Valid for cases diagnosed January 1, 2018 and forward. For head and neck cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F4.

Values:

- 0: No involvement in Levels IV or V lymph nodes
- 1: Level IV lymph node(s) involved
- 2: Level V lymph node(s) involved
- 3: Level IV and V lymph node(s) involved
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Positive nodes, but level of positive node(s) unknown; Lymph node levels IV-V not assessed, or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: LNHLEVELSOTHER
Eureka Name: LN Head and Neck Other
NAACCR Item: 3879
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year
Related Variables: CS Site-Specific Factor 6 (CS_SITE_SPEC_F6)

Definition: Lymph Nodes for Head and Neck, Other records the involvement of lymph nodes other than Levels I-III, IV-V, and VI-VII. Valid for cases diagnosed January 1, 2018 and forward. For head and neck cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F6.

Values:

- 0: No involvement in other head and neck lymph node regions
- 1: Buccinator (facial) lymph node(s) involved
- 2: Parapharyngeal lymph node(s) involved
- 3: Periparotid and intraparotid lymph node(s) involved
- 4: Preauricular lymph node(s) involved
- 5: Retropharyngeal lymph node(s) involved
- 6: Suboccipital/retroauricular lymph node(s) involved
- 7: Any combination of codes 1-6
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Positive nodes, but level of positive node(s) unknown; Other Head and Neck lymph nodes assessed, or unknown if assessed

Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: LNHNLEVELSVI_VII
Eureka Name: LN Head and Neck Levels VI-VII
NAACCR Item: 3878
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year
Related Variables: CS Site-Specific Factor 5 (CS_SITE_SPEC_F5)

Definition: Lymph Nodes for Head and Neck, Levels VI-VII records the involvement of Levels VI-VII lymph nodes. Valid for cases diagnosed January 1, 2018 and forward. For head and neck cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F5.

Values:

- 0: No involvement in Levels VI or VII lymph nodes
- 1: Level VI lymph node(s) involved
- 2: Level VII lymph node(s) involved
- 3: Level VI and VII lymph node(s) involved
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Positive nodes, but level of positive node(s) unknown; Lymph node levels VI-VII not assessed, or unknown if assessed

Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: LNLATERALITY

Eureka Name: LN Laterality

NAACCR Item: 3881

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 11 (CSSITESPECIFICFACTOR11)

Definition: This data item describes whether positive regional lymph nodes are unilateral or bilateral. Valid for cases diagnosed January 1, 2018 and forward. For cancers of the vulva diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR11.

Values:

- 0: No regional lymph node involvement
- 1: Unilateral - all positive regional nodes with same laterality OR only one regional node positive
- 2: Bilateral - positive bilateral regional lymph nodes
- 3: Laterality unknown - positive regional lymph nodes with unknown laterality
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Lymph node laterality not assessed, or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: LNMETHODFEMING

Eureka Name: LN Assessment Method Femoral-Inguinal

NAACCR Item: 3871

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 15 (CSSITESPECIFICFACTOR15)

Definition: This data item describes the method used to assess involvement of femoral-inguinal lymph nodes associated with certain female genital cancers. Valid for cases diagnosed January 1, 2018 and forward. For cancers of the vulva diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR15.

Values:

- 0: Radiography, imaging (Ultrasound (US), computed tomography scan (CT), magnetic resonance imaging (MRI), positron emission tomography scan (PET)); Physical exam only
- 1: Incisional biopsy; fine needle aspiration (FNA)
- 2: Lymphadenectomy; Excisional biopsy or resection with microscopic confirmation
- 7: Regional lymph node(s) assessed, unknown assessment method
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Regional lymph nodes not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: LNMETHODPARAAORT
Eureka Name: LN Assessment Method Para-Aortic
NAACCR Item: 3872
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year
Related Variables: CS Site-Specific Factor 5 (CS_SITE_SPEC_F5)

Definition: This data item describes the method used to assess involvement of para-aortic lymph nodes associated with certain female genital cancers. Valid for cases diagnosed January 1, 2018 and forward. For vaginal cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F5.

Values:

- 0: Radiography, imaging (Ultrasound (US), computed tomography scan (CT), magnetic resonance imaging (MRI), positron emission tomography scan (PET)); Physical exam only
- 1: Incisional biopsy; fine needle aspiration (FNA)
- 2: Lymphadenectomy; Excisional biopsy or resection with microscopic confirmation
- 7: Regional lymph node(s) assessed, unknown assessment method
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Regional lymph nodes not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: LNMETHODPELVIC
Eureka Name: LN Assessment Method Pelvic
NAACCR Item: 3873
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year
Related Variables: CS Site-Specific Factor 3 (CS_SITE_SPEC_F3)

Definition: This data item describes the method used to assess involvement of pelvic lymph nodes associated with certain female genital cancers. Valid for cases diagnosed January 1, 2018 and forward. For vaginal cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F3.

Values:

- 0: Ultrasound (US), computed tomography scan (CT), magnetic resonance imaging (MRI), positron emission tomography scan (PET)); Physical exam only
- 1: Incisional biopsy; fine needle aspiration (FNA)
- 2: Lymphadenectomy; Excisional biopsy or resection with microscopic confirmation
- 7: Regional lymph node(s) assessed, unknown assessment method
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Regional lymph nodes not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name:	LNPOSAXLEVELSI_II
Eureka Name:	LN Positive Axillary Level I-II
NAACCR Item:	3882
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 – current year
Related Variables:	CS Site-Specific Factor 3 (CS_SITE_SPEC_F3)
Definition:	This data item pertains to the number of positive ipsilateral level I and II axillary lymph nodes and intramammary lymph nodes based on pathological information. Valid for cases diagnosed January 1, 2018 and forward. For breast cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F3.
Values:	<p>00: All ipsilateral axillary nodes examined negative</p> <p>01-99: 1 - 99 nodes positive (Exact number of nodes positive)</p> <p>X1: 100 or more nodes positive</p> <p>X5: Positive nodes, number unspecified</p> <p>X6: Positive aspiration or needle core biopsy of lymph node(s)</p> <p>X8: Not applicable: Information not collected for this case</p> <p>X9: Not documented in medical record; Level I-II axillary nodes not assessed, or unknown if assessed</p> <p>Blank: Date of Diagnosis pre-2018; Non-required Schema ID</p>

California Cancer Registry Data Dictionary

Variable Name: LNSIZE
Eureka Name: LN Size
NAACCR Item: 3883
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year
Related Variables: CS Site-Specific Factor 1 (CS_SITE_SPEC_F1)

Definition: Records the diameter of the involved regional lymph node with the largest diameter of any involved regional lymph node(s). Pathological measurement takes precedence over a clinical measurement for the same node. Valid for cases diagnosed January 1, 2018 and forward. For head and neck cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F1.

Values:

- 0.0: No involved regional nodes
- 0.1-99.9: 0.1–99.9 millimeters (mm) (Exact size of lymph node to nearest tenth of a mm)
- XX.1: 100 millimeters (mm) or greater
- XX.2: Microscopic focus or foci only and no size of focus given
- XX.3: Described as "less than 1 centimeter (cm)"
- XX.4: Described as "at least" 2 cm
- XX.5: Described as "at least" 3 cm
- XX.6: Described as "at least" 4 cm
- XX.7: Described as greater than 5 cm
- XX.8: Not applicable: Information not collected for this case
- XX.9: Not documented in medical record; Regional lymph node(s) involved, size not stated Lymph Nodes Size not assessed, or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: LNSUMTU
Eureka Name: EOD--Lymph Node Involv
NAACCR Item: 810
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 1988 – 2003
Related Variables:

- CS Lymph Nodes (CS_LN)
- EOD Regional Nodes (EODREGNODES)

Definition: Extent of disease (EOD) variable that specifies furthest lymph node involvement. Valid for cases diagnosed 1988 through 2003. For cases diagnosed 2004 through 2017, values are recorded in CS_LN. For cases diagnosed 2018 and forward, values are recorded in EODREGNODES.

For more information on stage at diagnosis in the CCR, see the Appendix, “CCR Stage at Diagnosis.”

Values:

- 0: No nodes involved
- 1-8: Definition varies by cancer site (see SEER Extent of Disease – 1988 Codes and Coding Instructions, Third Edition available at <https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf>)
- 9: Unknown whether nodes involved
- Blank: Not abstracted; or for cases diagnosed after January 1, 2004

California Cancer Registry Data Dictionary

Variable Name: LONGITUDE

Eureka Name: Longitude

NAACCR Item: 2354

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: 1996 – current year

Related Variables: Latitude (LATITUDE)

Definition: The distance, east or west of the Prime Meridian at Greenwich, England, measured in degrees along a meridian as provided by the geocoding vendor for the patient's address at time of diagnosis. Paired with latitude, longitude represents the point location of the individual's residence on the earth's surface.

Values: Any numeric or decimal; may be preceded by a negative sign (-)
Blank: Not tracted

California Cancer Registry Data Dictionary

Variable Name: LYMPHOCYTOSIS
Eureka Name: Lymphocytosis
NAACCR Item: 3885
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 – current year

Related Variables:

Definition: Lymphocytosis is defined by an excess of lymphocytes in the blood. In staging of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), lymphocytosis is defined as an absolute lymphocyte count (ALC) greater than 5,000 cells/ μ L.

Values:

- 0: Lymphocytosis not present; Absolute lymphocyte count = 5,000 cells/ μ L
- 1: Lymphocytosis present; Absolute lymphocyte count > 5,000 cells/ μ L
- 6: Lab value unknown, physician states lymphocytosis is present
- 7: Test ordered, results not in chart
- 9: Not documented in medical record; Lymphocytosis not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: LYMPHVASCULARINVASION
Eureka Name: Lymphovascular Invasion
NAACCR Item: 1182
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2010 – current year

Related Variables:

Definition: Lymphovascular invasion (LVI) indicates the presence or absence of tumor cells in lymphatic channels (not lymph nodes) or blood vessels within the primary tumor as noted microscopically by the pathologist. LVI includes lymphatic invasion, vascular invasion, and lymphovascular invasion. Presence or absence of cancer cells in the lymphatic ducts or blood vessels is useful for prognosis.

Values:

- 0: Lymphovascular Invasion stated as not present
- 1: Lymphovascular Invasion present/identified
- 2: Lymphatic and small vessel invasion only (L)
- 3: Venous (large vessel) invasion only (V)
- 4: BOTH lymphatic and small vessel AND venous (large vessel) invasion
- 8: Not applicable
- 9: Unknown/indeterminate/not mentioned in path report
- Blank: Date of Diagnosis prior to 2010

California Cancer Registry Data Dictionary

Variable Name: MAIDNAME

Eureka Name: Name--Maiden

NAACCR Item: 2390

Category: Administrative

Level of Variable: Patient

Time Period Available: 1988 – current year

Related Variables:

- Name--First (FNAME)
- Name--Middle (MIDLNAME)
- Name--Last (LNAME)

Definition: This is the maiden name (unmarried name) of the patient when the patient has a different Last Name (LNAME).

Values: Alpha or hyphen only

California Cancer Registry Data Dictionary

Variable Name: MAIDSURN
Eureka Name: N/A
NAACCR Item: N/A
Category: Patient Demographics
Level of Variable: Patient
Time Period Available: 1988 – current year
Related Variables: Name--Maiden (MAIDNAME)

Definition: This variable indicates whether a female patient's maiden name (MAIDNAME) is on the 1980 Spanish Surname List provided by the United States Census Bureau.

Notes: For additional information, please see the Appendix "Variables Pertaining to Race/Ethnicity in the CCR".

Values:
 0: No, the patient's maiden name is not on the 1980 Spanish Surname List
 1: Yes, the patient's maiden name is on the 1980 Spanish Surname List

California Cancer Registry Data Dictionary

Variable Name: MAJORVEININVOLV

Eureka Name: Major Vein Involvement

NAACCR Item: 3886

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2018 – current year

Related Variables: CS Site-Specific Factor 2 (CS_SITE_SPEC_F2)

Definition: Major vein involvement pertains to the invasion of the kidney tumor into major veins. Valid for cases diagnosed January 1, 2018 and forward. For kidney cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F2.

Values:

- 0: Major vein involvement not present/not identified
- 1: Renal vein or its segmental branches
- 2: Inferior vena cava (IVC)
- 3: Major vein invasion, Not Otherwise Specified
- 4: Any combination of codes 1-3
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Vein involvement not assessed or unknown if assessed; No surgical resection of primary site is performed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name:	MARKER1
Eureka Name:	Tum Markers 1
NAACCR Item:	1150
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	See definition
Related Variables:	<ul style="list-style-type: none"> • AFP Post-Orchiectomy Lab Value (AFPPOSTORCHVALUE) • AFP Post-Orchiectomy Range (AFPPOSTORCHRANGE) • AFP Pre-Orchiectomy Lab Value (AFPPREORCHVALUE) • AFP Pre-Orchiectomy Range (AFPPREORCHRANGE) • CA-125 Pretreatment Interpretation (CA125PREINTERP) • CEA Pretreatment Interpretation (CEAPREINTERP) • CS Site-Specific Factor 1 (CS_SITE_SPEC_F1) • Estrogen Receptor Summary (ERSUMMARY)

Definition: Field to record estrogen receptor (ER) status for breast cancers diagnosed 1990 through 2003, acid phosphatase value for prostate cancers diagnosed 1998 through 2003, alpha fetoprotein (AFP) value for testicular cancers diagnosed 1998 through 2003, carcinoembryonic antigen (CEA) value for colon and rectum cancers diagnosed 2000 through 2003, and carbohydrate antigen (CA-125) value for ovarian cancers diagnosed 2000 through 2003. It was not required to record CEA or CA-125 for this data item.

For breast cancers diagnosed 2004 through 2017, ER status is recorded in the field CS_SITE_SPEC_F1. For breast cancers diagnosed 2018 and forward, ER status is recorded in the field ERSUMMARY.

For testicular cancers diagnosed 2004 through 2009, AFP value is recorded in the field CS_SITE_SPEC_F1. AFP was not collected for testicular cancers diagnosed 2010 through 2017. For testicular cancers diagnosed 2018 and forward, AFP pre-orchiectomy and post-orchiectomy AFP lab value/range are recorded in the fields AFPPREORCHVALUE, AFPPREORCHRANGE, AFPPOSTORCHVALUE, and AFPPOSTORCHRANGE.

For colon and rectum cancers diagnosed 2004 through 2017, CEA results are recorded in the field CS_SITE_SPEC_F1. For colon and rectum cancers diagnosed 2018 and forward, CEA results are recorded in the field CEAPREINTERP.

For ovarian cancers diagnosed 2004 through 2017, CA-125 results are recorded in the field CS_SITE_SPEC_F1. For ovarian cancers diagnosed 2018 and forward, CA-125 results are recorded in the field CA125PREINTERP.

California Cancer Registry Data Dictionary

Notes: Although there may be values in MARKER1 for other cancer sites, these values are considered invalid. Hospitals were allowed to use this data item to collect tumor markers for other cancer sites, but CCR has no way of knowing what tumor marker each hospital was collecting.

Values:

- 0: Test not done (includes cases diagnosed at autopsy)
- 1: Test done, results positive/elevated
- 2: Test done, results negative/normal
- 3: Test done, results borderline or undetermined whether positive or negative
- 4: Range 1 (<1,000 ng/ml)
- 5: Range 2 (1,000-10,000 ng/ml)
- 6: Range 3 (>10,000 ng/ml)
- 8: Test ordered, results not in chart
- 9: Unknown if test done or ordered/no information OR not applicable (site for which MARKER1 is not collected)

Codes 0, 1, 2, 3, 8, and 9 pertain to breast, prostate, colorectal, and ovarian cancers.

Codes 0, 2, 4, 5, 6, 8, and 9 pertain to testicular cancer.

California Cancer Registry Data Dictionary

Variable Name:	MARKER2
Eureka Name:	Tum Markers 2
NAACCR Item:	1160
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	See definition
Related Variables:	<ul style="list-style-type: none"> • CS Site-Specific Factor 1 (CS_SITE_SPEC_F1) • CS Site-Specific Factor 2 (CS_SITE_SPEC_F2) • hCG Post-Orchiectomy Range (HCGPOSTORCHRANGE) • hCG Post-Orchiectomy Lab Value (HCGPOSTORCHVALUE) • hCG Pre-Orchiectomy Range (HCGPREORCHRANGE) • hCG Pre-Orchiectomy Lab Value (HCGPREORCHVALUE) • Progesterone Receptor Summary (PRSUMMARY) • PSA (Prostatic Specific Antigen) Lab Value (PSALABVALUE)
Definition:	<p>Field to record progesterone receptor (PR) status for breast cancers diagnosed 1990 through 2003, prostate specific antigen (PSA) value for prostate cancers diagnosed 1998 through 2003, and human chorionic gonadotropin (hCG) value for testicular cancers diagnosed 1998 through 2003.</p> <p>For breast cancers diagnosed 2004 through 2017, PR status is recorded in the field CS_SITE_SPEC_F2. For breast cancers diagnosed 2018 and forward, PR Status is recorded in the field PRSUMMARY.</p> <p>For prostate cancers diagnosed 2004 through 2017, PSA value is recorded in the field CS_SITE_SPEC_F1. For prostate cancers diagnosed 2018 and forward, PSA value is recorded in the field PSAVALUE.</p> <p>For testicular cancers diagnosed 2004 through 2009, hCG value is recorded in the field CS_SITE_SPEC_F2. HCG was not collected for testicular cancers diagnosed 2010 through 2017. For testicular cancers diagnosed 2018 and forward, pre-orchietomy and post-orchietomy hCG value/range are recorded in the fields HCGPREORCHVALUE, HCGPREORCHRANGE, HCGPOSTORCHVALUE, and HCGPOSTORCHRANGE.</p>
Notes:	<p>Although there may be values in MARKER2 for other cancer sites, these values are considered invalid. Hospitals were allowed to use this data item to collect tumor markers for other cancer sites, but CCR has no way of knowing what tumor marker each hospital was collecting.</p>
Values:	<p>0: Test not done (includes cases diagnosed at autopsy)</p> <p>1: Test done, results positive/elevated</p>

California Cancer Registry Data Dictionary

- 2: Test done, results negative/normal
- 3: Test done, results borderline or undetermined whether positive or negative
- 4: Range 1 <5,000 mIU/ml
- 5: Range 2 5,000-50,000 mIU/ml
- 6: Range 3 >50,000 mIU/ml
- 8: Test ordered, results not in chart
- 9: Unknown if test done or ordered/no information (includes death certificate only cases) OR not applicable (site for which MARKER2 is not collected)

For testicular cancer, the valid codes are 0, 2, 4-6, 8, 9

California Cancer Registry Data Dictionary

Variable Name:	MARKER3
Eureka Name:	Tum Markers 3
NAACCR Item:	1170
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	1998 - 2003
Related Variables:	<ul style="list-style-type: none"> • CS Site-Specific Factor 3 (CS_SITE_SPEC_F3) • LDH Post-Orchiectomy Range (LDHPOSTORCHRange) • LDH Pre-Orchiectomy Range (LDHPREORCHRange)

Definition: This field records Lactate Dehydrogenase (LDH) level for testicular cancers diagnosed 1998 through 2003. For testicular cancers diagnosed 2004 through 2009, LDH values were recorded in the field CS_SITE_SPEC_F3. LDH was not collected for testicular cancers diagnosed 2010 through 2017. For testicular cancers diagnosed 2018 and forward, pre-orchiectomy and post-orchiectomy LDH range are recorded in the fields LDHPREORCHRange and LDHPOSTORCHRange.

Values:	0: Test not done (includes cases diagnosed at autopsy)
	1: Test done, results positive/elevated
	2: Test done, results negative/normal
	3: Test done, results borderline or undetermined whether positive or negative
	4: Range 1 <1.5 *N
	5: Range 2 1.5-10 *N
	6: Range 3 >10 *N
	8: Test ordered, results not in chart
	9: Unknown if test done or ordered; No information (includes death certificate only cases)

*Where N indicates the upper limit of normal for LDH.

California Cancer Registry Data Dictionary

Variable Name: MARKERCA
Eureka Name: Tum Markers CA 1
NAACCR Item: N/A
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 1999 - 2009
Related Variables:

- CS Site-Specific Factor 15 (CSSITESPECIFICFACTOR15)
- HER2 Overall Summary (HER2OVERALLSUMM)

Definition: This field records Her2/neu (also known as c-erbB2 or ERBB2) status for breast cancers diagnosed 1999 through 2009. For breast cancers diagnosed 2010 through 2017, Her2/neu summary information is captured in the field CSSITESPECIFICFACTOR15. For breast cancers diagnosed 2018 and forward, Her2/neu information is captured in the field HER2OVERALLSUMM.

Notes: It's important to note that tumors are not always entered into the registry the same year they are diagnosed. As such, you should evaluate the information in all three fields -- MARKERCA, CSSITESPECIFICFACTOR15, and HER2OVERALLSUM -- to ascertain the best Her2/neu data for the tumor. Cases diagnosed before 1999 that are not coded to unknown are considered invalid. Although this has been a required data item since 1999, a large proportion of breast cancer cases were left as the default value of unknown even if HER2 information was available. A manuscript regarding this issue has been published: Bauer K, Brown M, Creech C, Schlag N, Caggiano V. Data quality assessment of HER2 tumor marker status in the Sacramento Region of the California Cancer Registry. Journal of Registry Management. Spring 2007; 34(1)4-7.

Values:

- 0: Not done
- 1: Positive
- 2: Negative
- 3: Borderline
- 8: Ordered, results not in chart
- 9: Unknown

California Cancer Registry Data Dictionary

Variable Name: MARSTAT
Eureka Name: Marital Status at DX
NAACCR Item: 150
Category: Patient Demographics
Level of Variable: Tumor
Time Period Available: 1988 - current year

Related Variables:

Definition: Marital status when the patient was first diagnosed with this tumor.

Values:

- 1: Single, never married
- 2: Married
- 3: Separated
- 4: Divorced
- 5: Widowed
- 6: Unmarried or Domestic Partner (same sex or opposite sex, registered or unregistered other than common law marriage)
- 9: Unknown

California Cancer Registry Data Dictionary

Variable Name:	MCODE
Eureka Name:	N/A
NAACCR Item:	N/A
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	1988 - 2003
Related Variables:	<ul style="list-style-type: none"> • EOD--Lymph Node Involv (LNSUMTU) • EOD--Extension (DIREXTTU) • Extent of Disease Derived T Code for TNM Staging (TCODE) • Extent of Disease Derived N Code for TNM Staging (NCODE) • Extent of Disease Derived AJCC 3rd Edition Stage Group 1988 through 2003 (STAGE_AJCC) • SEER Modified Extent of Disease Derived AJCC 3rd Edition Stage Group 1988 through 2003 (STAGE_AJCCSEER) • AJCC Stage of Cancer (STAGE) • SEER-Modified AJCC Stage of Cancer (STAGE_SEER) • Derived AJCC-6 M (DERIVED_AJCC_M) • Derived AJCC-7 M (DERIVEDAJCC7M) • TNM Clin M (TNM_M_CODE_CLINICAL) • TNM Path M (TNM_M_CODE_PATH) • Derived SEER Combined M (DERIVEDSEERCOMBINEDM) • Derived EOD 2018 M (DERIVEDEOD18M)

Definition: Extent of Disease (EOD) derived "M" value for TNM staging which identifies the presence or absence of distant metastasis for the tumor. This variable is not a collected data item but derived according to the AJCC third edition using the EOD staging data items for lymph node involvement (LNSUMTU) and extension (DIREXTTU). For cases diagnosed 2004 through 2015, this value is derived from collaborative stage data items according to the AJCC sixth edition and is recorded in the field DERIVED_AJCC_M. Additionally, for cases diagnosed 2010 through 2015, this value is derived from collaborative stage data items according to the AJCC seventh edition and is recorded in the field DERIVEDAJCC7M. For cases diagnosed 2016 and 2017, TNM values were directly coded by Certified Tumor Registrars and the AJCC seventh edition M value is recorded in the fields TNM_M_CODE_CLINICAL and TNM_M_CODE_PATH. Or, for the M value used to calculate DERIVEDSEERCMBSTGGRP, see DERIVEDSEERCOMBINEDM. For cases diagnosed 2018 and forward, this value was once again derived from EOD staging data items according to the AJCC eighth edition and is recorded in the field, DERIVEDEOD18M.

California Cancer Registry Data Dictionary

Notes: MCODE only has values for the following sites: breast, cervix, colon, lung, ovarian, rectum, vagina and vulva.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values: M0, M1, MX
Values are site-specific; see SEER Program: Comparative Staging Guide For Cancer (https://seer.cancer.gov/archive/manuals/historic/comp_stage1.1.pdf).

California Cancer Registry Data Dictionary

Variable Name:	MDINC
Eureka Name:	N/A
NAACCR Item:	N/A
Category:	Socioeconomic Indicators
Level of Variable:	Tumor
Time Period Available:	1988 - 2005
Related Variables:	<ul style="list-style-type: none"> • Median Household Income in Census Tract 1988 through 2005 (MDINCCT) • Median Household Income in Census Tract 2006 and forward (MDINCCTACS2011) • Census Block 90 (BLKGRP90) • Census Block 2000 (BLKGRP00) • Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: MDINC indicates the median household income within the assigned Census block group and is obtained from the U.S. Census. Each CCR record is assigned a Census block group based on the patient's address at time of diagnosis. The Census block group is then used to append MDINC values from the 1990 Census for cases diagnosed 1988 through 1995 and from the 2000 Census for cases diagnosed 1996 through 2005. If a case received a randomly assigned Census block group, the MDINC value is that of the randomly assigned Census block group and the variable RANDOM=1.

Beginning in 2010, the U.S. Census stopped collecting socioeconomic information on the long questionnaire. As such, the CCR began using the American Community Survey (ACS) Data to obtain this information. Due to the much smaller sample size of the ACS, socioeconomic measures were no longer reliable at the block-group level and CCR began using tract-level measures instead. For consistency in evaluating socioeconomic measures over time, use MDINCCT for cases diagnosed 1988 through 2005 and MDINCCTACS2011 for cases diagnosed 2006 and forward.

California Cancer Registry Data Dictionary

Variable Name: MDINCCT

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 1988 - 2005

Related Variables:

- Census Tract 1970/80/90 (CENSUS90)
- Census Tract 2000 (CENSUS00)
- Census Tract/Block Group Randomly Assigned (RANDOM)
- Median Household Income in Census Tract 2006 and forward (MDINCCTACS2011)

Definition: MDINCCT indicates the median household income within the assigned Census tract and is obtained from the U.S. Census. Each CCR record is assigned a Census tract based on the patient's address at time of diagnosis. The Census tract is then used to append MDINCCT values from the 1990 Census for cases diagnosed 1988 through 1995 and from the 2000 Census for cases diagnosed 1996 through 2005. If a case received a randomly assigned Census tract, the MDINC value is that of the randomly assigned Census tract and the variable RANDOM=1.

Beginning in 2010, the U.S. Census stopped collecting socioeconomic information on the long questionnaire. As such, the CCR began using the American Community Survey (ACS) Data to obtain this information. Due to the much smaller sample size of the ACS, socioeconomic measures were no longer reliable at the block-group level and CCR began using tract-level measures instead. For consistency in evaluating socioeconomic measures over time, use MDINCCT for cases diagnosed 1988 through 2005 and MDINCTCTACS2011 for cases diagnosed 2006 and forward.

California Cancer Registry Data Dictionary

Variable Name: MDINCCTACS2011

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 2006 - current year

Related Variables:

- Census Tract 2010 (CENSUSTRACT2010)
- Census Tract/Block Group Randomly Assigned (RANDOM)
- Median Household Income in Census Tract 1988 through 2005 (MDINCCT)

Definition: MDINCCTACS2011 indicates the median household income within the assigned Census tract and is obtained from the 2007-2011 American Community Survey (ACS) data. Each CCR record is assigned a Census tract based on the patient's address at time of diagnosis. The Census tract is then used to append MDINCCTACS2011 values for cases diagnosed 2006 and forward. If a case received a randomly assigned Census tract, the MDINCCTACS2011 value is that of the randomly assigned Census tract and the variable RANDOM=1.

Beginning in 2010, the U.S. Census stopped collecting socioeconomic information on the long questionnaire. As such, the CCR began using the American Community Survey (ACS) Data to obtain this information. Due to the much smaller sample size of the ACS, socioeconomic measures were no longer reliable at the block-group level and CCR began using tract-level measures instead. For consistency in evaluating socioeconomic measures over time, use MDINCCT for cases diagnosed 1988 through 2005 and MDINCCTACS2011 for cases diagnosed 2006 and forward.

California Cancer Registry Data Dictionary

Variable Name: MEDICAREBENEFID
Eureka Name: Medicare Beneficiary Identifier
NAACCR Item: 2315
Category: Administrative
Level of Variable: Tumor
Time Period Available: 2018 - current year

Related Variables:

Definition: Congress passed the Medicare Access and CHIP Reauthorization Act to remove Social Security Number (SSN) from Medicare ID cards and replace the existing Medicare Health Insurance Claim Numbers with a Medicare Beneficiary Identifier (MBI). The MBI will be a randomly generated identifier that will not include SSN or any personal identifiable information. The MBI is a step to minimize the risk of identity theft for Medicare beneficiaries and reduce opportunities for fraud. In early 2018, CMS plans to issue new Medicare cards with an MBI. A Health Insurance Claim Number will still be assigned to each Medicare beneficiary and will still be used for internal data exchanges between CMS and the states, but the new MBI must be used in all interactions with the beneficiary, the provider community and all external partners. The collection of the MBI should not change how registries currently collect SSN.

Notes: The Medicare Beneficiary Identifier (MBI) is randomly generated and has 11 characters, consisting of numbers and letters, entered without dashes. The MBI format: <https://www.cms.gov/Medicare/New-Medicare-Card/Understanding-the-MBI-with-Format.pdf>

California Cancer Registry Data Dictionary

Variable Name: MEDREC1
Eureka Name: Medical Record Number-CCR
NAACCR Item: N/A
Category: Administrative
Level of Variable: Admission
Time Period Available: 1988 - current year

Related Variables:

Definition: Medical record number assigned to the patient/admission by the reporting hospital.
The value in this field is taken from the facility with the latest date of admission for this tumor.

California Cancer Registry Data Dictionary

Variable Name:	MEDRENT
Eureka Name:	N/A
NAACCR Item:	N/A
Category:	Socioeconomic Indicators
Level of Variable:	Tumor
Time Period Available:	1988 - 2005
Related Variables:	<ul style="list-style-type: none"> • Median Rent in Census Tract 1988 through 2005 (MEDRENTCT) • Median Rent in Census Tract 2006 and forward (MEDRENTCTACS2011) • Census Block 90 (BLKGRP90) • Census Block 2000 (BLKGRP00) • Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: MEDRENT is the median gross rent of renter occupied houses within the assigned census block group and is obtained from the U.S. Census. Each CCR record is assigned a Census block group based on the patient's address at time of diagnosis. The Census block group is then used to append MEDRENT values from the 1990 Census for cases diagnosed 1988 through 1995 and from the 2000 Census for cases diagnosed 1996 through 2005. If a case received a randomly assigned Census block group, the MEDRENT value is that of the randomly assigned Census block group and the variable RANDOM=1.

Beginning in 2010, the U.S. Census stopped collecting socioeconomic information on the long questionnaire. As such, the CCR began using the American Community Survey (ACS) Data to obtain this information. Due to the much smaller sample size of the ACS, socioeconomic measures were no longer reliable at the block-group level and CCR began using tract-level measures instead. For consistency in evaluating socioeconomic measures over time, use MEDRENTCT for cases diagnosed 1988 through 2005 and MEDRENTCTACS2011 for cases diagnosed 2006 and forward.

California Cancer Registry Data Dictionary

Variable Name:	MEDRENTCT
Eureka Name:	N/A
NAACCR Item:	N/A
Category:	Socioeconomic Indicators
Level of Variable:	Tumor
Time Period Available:	1988 - 2005
Related Variables:	<ul style="list-style-type: none"> • Census Tract 1970/80/90 (CENSUS90) • Census Tract 2000 (CENSUS00) • Census Tract/Block Group Randomly Assigned (RANDOM) • Median Rent in Census Tract 2006 and forward (MEDRENTCTACS2011)

Definition: MEDRENTCT indicates the median gross rent of renter occupied houses within the assigned Census tract and is obtained from the U.S. Census. Each CCR record is assigned a Census tract based on the patient's address at time of diagnosis. The Census tract is then used to append MEDRENTCT values from the 1990 Census for cases diagnosed 1988 through 1995 and from the 2000 Census for cases diagnosed 1996 through 2005. If a case received a randomly assigned Census tract, the MEDRENTCT value is that of the randomly assigned Census tract and the variable RANDOM=1.

Beginning in 2010, the U.S. Census stopped collecting socioeconomic information on the long questionnaire. As such, the CCR began using the American Community Survey (ACS) Data to obtain this information. Due to the much smaller sample size of the ACS, socioeconomic measures were no longer reliable at the block-group level and CCR began using tract-level measures instead. For consistency in evaluating socioeconomic measures over time, use MEDRENTCT for cases diagnosed 1988 through 2005 and MEDRENTCTACS2011 for cases diagnosed 2006 and forward.

California Cancer Registry Data Dictionary

Variable Name: MEDRENTCTACS2011

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 2006 - current year

Related Variables:

- Census Tract 2010 (CENSUSTRACT2010)
- Census Tract/Block Group Randomly Assigned (RANDOM)
- Median Rent in Census Tract 1988 through 2005 (MEDRENTCT)

Definition: MEDRENTCTACS2011 indicates the median gross rent of renter occupied houses within the assigned Census tract and is obtained from the 2007-2011 American Community Survey (ACS) data. Each CCR record is assigned a Census tract based on the patient's address at time of diagnosis. The Census tract is then used to append EDRENTCTACS2011 values for cases diagnosed 2006 and forward. If a case received a randomly assigned Census tract, the MEDRENTCTACS2011 value is that of the randomly assigned Census tract and the variable RANDOM=1.

Beginning in 2010, the U.S. Census stopped collecting socioeconomic information on the long questionnaire. As such, the CCR began using the American Community Survey (ACS) Data to obtain this information. Due to the much smaller sample size of the ACS, socioeconomic measures were no longer reliable at the block-group level and CCR began using tract-level measures instead. For consistency in evaluating socioeconomic measures over time, use MEDRENTCT for cases diagnosed 1988 through 2005 and MEDRENTCTACS2011 for cases diagnosed 2006 and forward.

California Cancer Registry Data Dictionary

Variable Name:	MEDVALUE
Eureka Name:	N/A
NAACCR Item:	N/A
Category:	Socioeconomic Indicators
Level of Variable:	Tumor
Time Period Available:	1988 - 2005
Related Variables:	<ul style="list-style-type: none"> • Median Value of Homes in Census Tract 1988 through 2005 (MEDVALUECT) • Median Value of Homes in Census Tract 2006 and forward (MEDVALUECTACS2011) • Census Block 90 (BLKGRP90) • Census Block 2000 (BLKGRP00) • Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: MEDVALUE indicates the median value of owner-occupied houses within the assigned census block group and is obtained from the U.S. Census. Each CCR record is assigned a Census block group based on the patient's address at time of diagnosis. The Census block group is then used to append MEDVALUE information from the 1990 Census for cases diagnosed 1988 through 1995 and from the 2000 Census for cases diagnosed 1996 through 2005. If a case received a randomly assigned Census block group, the MEDVALUE information is that of the randomly assigned Census block group and the variable RANDOM=1.

Beginning in 2010, the U.S. Census stopped collecting socioeconomic information on the long questionnaire. As such, the CCR began using the American Community Survey (ACS) Data to obtain this information. Due to the much smaller sample size of the ACS, socioeconomic measures were no longer reliable at the block-group level and CCR began using tract-level measures instead. For consistency in evaluating socioeconomic measures over time, use MEDVALUECT for cases diagnosed 1988 through 2005 and MEDVALUECTACS2011 for cases diagnosed 2006 and forward.

California Cancer Registry Data Dictionary

Variable Name: MEDVALUECT

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 1988 - 2005

Related Variables:

- Census Tract 1970/80/90 (CENSUS90)
- Census Tract 2000 (CENSUS00)
- Census Tract/Block Group Randomly Assigned (RANDOM)
- Median Rent in Census Tract 2006 and forward (MEDRENTCTACS2011)

Definition: MEDVALUECT indicates the median value of owner-occupied houses within the assigned Census tract and is obtained from the U.S. Census. Each CCR record is assigned a Census tract based on the patient's address at time of diagnosis. The Census tract is then used to append MEDVALUECT information from the 1990 Census for cases diagnosed 1988 through 1995 and from the 2000 Census for cases diagnosed 1996 through 2005. If a case received a randomly assigned Census tract, the MEDVALUECT information is that of the randomly assigned Census tract and the variable RANDOM=1.

Beginning in 2010, the U.S. Census stopped collecting socioeconomic information on the long questionnaire. As such, the CCR began using the American Community Survey (ACS) Data to obtain this information. Due to the much smaller sample size of the ACS, socioeconomic measures were no longer reliable at the block-group level and CCR began using tract-level measures instead. For consistency in evaluating socioeconomic measures over time, use MEDVALUECT for cases diagnosed 1988 through 2005 and MEDVALUECTACS2011 for cases diagnosed 2006 and forward.

California Cancer Registry Data Dictionary

Variable Name: MEDVALUECTACS2011

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 2006 - current year

Related Variables:

- Census Tract 2010 (CENSUSTRACT2010)
- Census Tract/Block Group Randomly Assigned (RANDOM)
- Median Value of Homes in Census Tract 1988 through 2005 (MEDVALUECT)

Definition: MEDVALUECTACS2011 indicates the median value of owner-occupied houses within the assigned Census tract and is obtained from the 2007-2011 American Community Survey (ACS) data. Each CCR record is assigned a Census tract based on the patient's address at time of diagnosis. The Census tract is then used to append MEDVALUECTACS2011 information from the 1990 Census for cases diagnosed 1988 through 1995 and from the 2000 Census for cases diagnosed 1996 through 2005. If a case received a randomly assigned Census tract, the MEDVALUECTACS2011 information is that of the randomly assigned Census tract and the variable RANDOM=1.

Beginning in 2010, the U.S. Census stopped collecting socioeconomic information on the long questionnaire. As such, the CCR began using the American Community Survey (ACS) Data to obtain this information. Due to the much smaller sample size of the ACS, socioeconomic measures were no longer reliable at the block-group level and CCR began using tract-level measures instead. For consistency in evaluating socioeconomic measures over time, use MEDVALUECT for cases diagnosed 1988 through 2005 and MEDVALUECTACS2011 for cases diagnosed 2006 and forward.

California Cancer Registry Data Dictionary

Variable Name: METHYLATIONO6MGMT
Eureka Name: Methylation of O6-Methylguanine-Methyltransferase
NAACCR Item: 3889
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 - current year
Related Variables: CS Site-Specific Factor 4 (CS_SITE_SPEC_F4)

Definition: O6-Methylguanine-Methyltransferase (MGMT) is an enzyme in cells that repairs DNA. Methylation of the MGMT gene reduces production of MGMT enzyme and the ability of tumor cells to repair damage caused by chemotherapy. Methylation of MGMT is a prognostic and predictive factor for high grade gliomas. Valid for cases diagnosed January 1, 2018 and forward. For brain cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F4.

Values:

- 0: MGMT methylation absent/not present, unmethylated MGMT
- 1: MGMT methylation present, low level; Hypomethylated; Partial methylated
- 2: MGMT methylation present, high level; Hypermethylated
- 3: MGMT Methylation present, level unspecified
- 6: Benign or borderline tumor
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in patient record; Cannot be determined by the pathologist; MGMT not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: METSATDXBONE

Eureka Name: Mets at DX-Bone

NAACCR Item: 1112

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2016 - current year

Related Variables:

- Mets at DX-Brain (METSATDXBRAIN)
- Mets at DX-Distant LN (METSATDXDISTANTLN)
- Mets at DX-Liver (METSATDXLIVER)
- Mets at DX-Lung (METATDXLUNG)
- Mets at DX-Other (METSATDXOTHER)
- CS Mets at DX-Bone (CSMETSATDXBONE)

Definition: This field identifies whether bone is an involved metastatic site. Information on site of metastatic disease at diagnosis has prognostic implications for survival among patients with initial late stage disease. Valid for cases diagnosed January 1, 2016 and forward. For cases diagnosed 2010 through 2015, see CSMETSATDXBONE.

Values:

- 0: None; no bone metastases
- 1: Yes; distant bone metastases
- 8: Not applicable
- 9: Unknown whether bone is an involved metastatic site. Not documented in patient record.

California Cancer Registry Data Dictionary

Variable Name: METSATDXBRAIN

Eureka Name: Mets at DX-Brain

NAACCR Item: 1113

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2016 - current year

Related Variables:

- Mets at DX-Bone (METSATDXBONE)
- Mets at DX-Distant LN (METSATDXDISTANTLN)
- Mets at DX-Liver (METSATDXLIVER)
- Mets at DX-Lung (METATDXLUNG)
- Mets at DX-Other (METSATDXOTHER)
- CS Mets at DX-Brain (CSMETSATBRAIN)

Definition: This field identifies whether brain is an involved metastatic site. Information on site of metastatic disease at diagnosis has prognostic implications for survival among patients with initial late stage disease. Valid for cases diagnosed January 1, 2016 and forward. For cases diagnosed 2010 through 2015, see CSMETSATDXBRAIN.

Values:

- 0: None; no brain metastases
- 1: Yes; distant brain metastases
- 8: Not applicable
- 9: Unknown whether brain is an involved metastatic site. Not documented in patient record.

California Cancer Registry Data Dictionary

Variable Name:	METSATDXDISTANTLN
Eureka Name:	Mets at DX-Distant LN
NAACCR Item:	1114
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2016 - current year
Related Variables:	<ul style="list-style-type: none"> • Mets at DX-Bone (METSATDXBONE) • Mets at DX-Brain (METSATBRAIN) • Mets at DX-Liver (METSATDXLIVER) • Mets at DX-Lung (METSATDXLUNG) • Mets at DX-Other (METSATDXOTHER)

Definition: This field identifies whether distant lymph node(s) are an involved metastatic site. Information on site of metastatic disease at diagnosis has prognostic implications for survival among patients with initial late stage disease.

Values:

- 0: None; no lymph node metastases
- 1: Yes; distant lymph node metastases
- 8: Not applicable
- 9: Unknown whether distant lymph node(s) are an involved metastatic site.
Not documented in patient record.

California Cancer Registry Data Dictionary

Variable Name: METSATDXLIVER

Eureka Name: Mets at DX-Liver

NAACCR Item: 1115

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2016 - current year

Related Variables:

- Mets at DX-Bone (METSATDXBONE)
- Mets at DX-Brain (METSATBRAIN)
- Mets at DX-Distant LN (METSATDXDISTANTLN)
- Mets at DX-Lung (METATDXLUNG)
- Mets at DX-Other (METSATDXOTHER)
- CS Mets at DX-Liver (CSMETSATDXLIVER)

Definition: This field identifies whether liver is an involved metastatic site. Information on site of metastatic disease at diagnosis has prognostic implications for survival among patients with initial late stage disease. Valid for cases diagnosed January 1, 2016 and forward. For cases diagnosed 2010 through 2015, see CSMETSATDXLIVER.

Values:

- 0: None; no liver metastases
- 1: Yes; distant liver metastases
- 8: Not applicable
- 9: Unknown whether liver is an involved metastatic site. Not documented in patient record.

California Cancer Registry Data Dictionary

Variable Name: METSATDXLUNG

Eureka Name: Mets at DX-Lung

NAACCR Item: 1116

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2016 - current year

Related Variables:

- Mets at DX-Bone (METSATDXBONE)
- Mets at DX-Brain (METSATBRAIN)
- Mets at DX-Distant LN (METSATDXDISTANTLN)
- Mets at DX-Liver (METATDXLIVER)
- Mets at DX-Other (METSATDXOTHER)
- CS Mets at DX-Lung (CSMETSATDXLUNG)

Definition: This field identifies whether lung is an involved metastatic site. Information on site of metastatic disease at diagnosis has prognostic implications for survival among patients with initial late stage disease. Valid for cases diagnosed January 1, 2016 and forward. For cases diagnosed 2010 through 2015, see CSMETSATDXLUNG.

Values:

- 0: None; no lung metastases
- 1: Yes; distant lung metastases
- 8: Not applicable
- 9: Unknown whether lung is an involved metastatic site. Not documented in patient record.

California Cancer Registry Data Dictionary

Variable Name: METSATDXOTHER

Eureka Name: Mets at DX-Other

NAACCR Item: 1117

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2016 - current year

Related Variables:

- Mets at DX-Bone (METSATDXBONE)
- Mets at DX-Brain (METSATDXBRAIN)
- Mets at DX-Distant LN (METSATDXDISTANTLN)
- Mets at DX-Liver (METSATDXLIVER)
- Mets at DX-Lung (METSATDXLUNG)

Definition: Identifies whether other metastatic involvement, other than bone, brain, liver, lung or distant lymph nodes exists. Some examples include but are not limited to the adrenal gland, bone marrow, pleura, peritoneum and skin. Information on site of metastatic disease at diagnosis has prognostic implications for survival among patients with initial late stage disease.

Values:

- 0: None; no other metastases
- 1: Yes; distant metastases in known site(s) other than bone, brain, liver, lung, or distant lymph nodes
- 8: Not applicable
- 9: Unknown whether any other metastatic site involved. Not documented in patient record.

California Cancer Registry Data Dictionary

Variable Name: MICROVASCEDENSITY

Eureka Name: Microvascular Density

NAACCR Item: 3891

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables: CS Site-Specific Factor 13 (CSSITESPECIFICFACTOR13)

Definition: Microvascular Density (MVD), a quantitative measure of tumor vascularity, is a prognostic factor for uveal melanoma. Valid for cases diagnosed January 1, 2018 and forward. For uveal melanomas diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR13.

Values:

- 00: No vessels involved
- 01-99: 01-99 vessels per 0.3 square millimeter (mm²)
- X1: Greater than or equal to 100 vessels per 0.3 square millimeter (mm²)
- X2: Lowest quartile for laboratory
- X3: Second quartile for laboratory
- X4: Third quartile for laboratory
- X5: Highest quartile for laboratory
- X7: Test ordered, results not in chart
- X8: Not applicable: Information not collected for this case
- X9: Not documented in medical record; Microvascular Density (MVD) not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: MIDLNAME
Eureka Name: Name--Middle
NAACCR Item: 2250
Category: Administrative
Level of Variable: Patient
Time Period Available: 1988 - current year
Related Variables:

- Name--Last (LNAME)
- Name--First (FNAME)
- Name--Maiden (MAIDNAME)

Definition: The patient's middle name.
Values: Must be alpha; may be blank

California Cancer Registry Data Dictionary

Variable Name: MITOTICCOUNTUEA
Eureka Name: Mitotic Count Uveal Melanoma
NAACCR Item: 3892
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 - current year
Related Variables: CS Site-Specific Factor 9 (CSSITESPECIFICFACTOR9)

Definition: Mitotic Count Uveal Melanoma, the number of mitoses per 40 high-power fields (HPF) based on pathological evaluation, is a prognostic factor for uveal melanoma. Valid for cases diagnosed January 1, 2018 and forward. For uveal melanomas diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR9.

Values:

0.0:	0 mitoses per 40 high-power fields (HPF); Mitoses absent, no mitoses present, no mitotic activity
0.1-99.9:	0.1-99.9 mitosis per 40 HPF
XX.1:	100 or more mitoses per 40 HPF
XX.2:	Stated as low mitotic count or rate with no specific number
XX.3:	Stated as high mitotic count or rate with no specific number
XX.4:	Mitotic count described with denominator other than 40 HPF
XX.7:	Test ordered, results not in chart
XX.8:	Not applicable: Information not collected for this case
XX.9:	Not documented in medical record; Mitotic Count Uveal Melanoma not assessed or unknown if assessed
Blank:	Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: MITOTICRATEMELANO

Eureka Name: Mitotic Rate Melanoma

NAACCR Item: 3893

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables: CS Site-Specific Factor 7 (CSSITESPECIFICFACTOR7)

Definition: Mitotic Rate Melanoma, the number of mitoses per square millimeter based on pathological evaluation is a prognostic factor for melanoma of the skin. Valid for cases diagnosed January 1, 2018 and forward. For melanomas of the skin diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR7.

Values:

- 00: 0 mitoses per square millimeter (mm); Mitoses absent; No mitoses present
- 01-99: 1 - 99 mitoses/square mm (Exact measurement in mitoses/square mm)
- X1: 100 mitoses/square mm or more
- X2: Stated as "less than 1 mitosis/square mm"; Stated as "nonmitogenic"
- X3: Stated as "at least 1 mitosis/square mm"; Stated as "mitogenic"
- X4: Mitotic rate described with denominator other than square millimeter (mm)
- X7: Test ordered, results not in chart
- X8: Not applicable: Information not collected for this case
- X9: Not documented in medical record; Mitotic Rate Melanoma not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: MSI
Eureka Name: Microsatellite Instability (MSI)
NAACCR Item: 3890
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 - current year
Related Variables: CS Site-Specific Factor 7 (CSSITESPECIFICFACTOR7)

Definition: Microsatellite Instability (MSI) is a form of genetic instability manifested by changes in the length of repeated single- to six-nucleotide sequences (known as DNA microsatellite sequences). High MSI, found in about 15% of colorectal carcinomas, is an adverse prognostic factor for colorectal carcinomas and predicts poor response to 5-FU chemotherapy (although the addition of oxaliplatin in FOLFOX regimens negates the adverse effects). High MSI is a hallmark of hereditary nonpolyposis colorectal carcinoma, also known as Lynch syndrome. Valid for cases diagnosed January 1, 2018 and forward. For colon and rectum cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR7.

Values:

- 0: Microsatellite instability (MSI) stable; microsatellite stable (MSS); negative, NOS, AND/OR Mismatch repair (MMR) intact, no loss of nuclear expression of MMR proteins
- 1: MSI unstable low (MSI-L)
- 2: MSI unstable high (MSI-H) AND/OR MMR-D (loss of nuclear expression of one or more MMR proteins, MMR protein deficient)
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; MSI-indeterminate; Microsatellite instability not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: MSSAID

Eureka Name: N/A

NAACCR Item: N/A

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: 1988 - current year

Related Variables:

- Name of Medical Service Study Area (MSSANAME)
- Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: This field contains a Medical Service Study Area (MSSA) identification number. MSSAs are aggregations of census tracts that make up 'rational service areas' for primary health care and are used to identify medically underserved areas. The California Office of Statewide Health Planning and Development (OSHPD) defines the boundaries of MSSAs. MSSAs are assigned to CCR cases based on the census tract value of the patient's address at time of diagnoses.

Notes: Cases with a year of diagnosis of:

- 1988 through 1995 receive MSSAIDs based on the 1990 U.S. Census boundaries;
- 1996 through 2005 receive MSSAIDs based on the 2000 U.S. Census boundaries;
- 2006 and forward receive MSSAIDs based on the 2010 U.S. Census boundaries.

Cases that received a randomly assigned census tract/block group (RANDOM=1) received MSSAID's based on the randomly assigned census tract/block group values.

California Cancer Registry Data Dictionary

Variable Name: MSSANAME

Eureka Name: N/A

NAACCR Item: N/A

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: 1988 - current year

Related Variables:

- Medical Service Study Area Identification Number (MSSAID)
- Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: This field contains the name of the Medical Service Study Area (MSSA) and describes the local communities composing each MSSA. MSSAs are aggregations of census tracts that make up 'rational service areas' for primary health care and are used to identify medically underserved areas. The California Office of Statewide Health Planning and Development (OSHPD) defines the boundaries of MSSAs. MSSAs are assigned to CCR cases based on the census tract value of the patient's address at time of diagnoses.

Notes: Cases with a year of diagnosis of:

- 1988 through 1995 receive MSSANAME based on the 1990 U.S. Census boundaries;
- 1996 through 2005 receive MSSANAME based on the 2000 U.S. Census boundaries;
- 2006 and forward receive MSSANAME based on the 2010 U.S. Census boundaries.

Cases that received a randomly assigned census tract/block group (RANDOM=1) receive MSSANAME based on the randomly assigned census tract/block group values.

California Cancer Registry Data Dictionary

Variable Name:	MULTIGENEMETHOD
Eureka Name:	Multigene Signature Method
NAACCR Item:	3894
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • Multigene Signature Results (MULTIGENERESULTS) • CS Site-Specific Factor 22 (CSSITESPECIFICFACTOR22)

Definition: Multigene signatures or classifiers are assays of a panel of genes from a tumor specimen, intended to provide a quantitative assessment of the likelihood of response to chemotherapy and to evaluate prognosis or the likelihood of future metastasis. This data item identifies the multigene signature method used. Oncotype Dx is coded elsewhere. Valid for cases diagnosed January 1, 2018 and forward. For breast cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR22.

Values:	1: Mammaprint
	2: PAM50 (Prosigna)
	3: Breast Cancer Index
	4: EndoPredict
	5: Test performed, type of test unknown
	6: Multiple tests, any tests in codes 1-4
	7: Test ordered, results not in chart
	8: Not applicable: Information not collected for this case
	9: Not documented in medical record; Multigene Signature Method not assessed or unknown if assessed
	Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name:	MULTIGENERESULTS
Eureka Name:	Multigene Signature Results
NAACCR Item:	3895
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • Multigene Signature Method (MULTIGENEMETHOD) • CS Site-Specific Factor 23 (CSSITESPECIFICFACTOR23)

Definition: Multigene signatures or classifiers are assays of a panel of genes from a tumor specimen, intended to provide a quantitative assessment of the likelihood of response to chemotherapy and to evaluate prognosis or the likelihood of future metastasis. This data item identifies the multigene signature result. Oncotype Dx is coded elsewhere. Valid for cases diagnosed January 1, 2018 and forward. For breast cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR23.

Values:	00-99: Enter actual recurrence score; Note: Depending on the test, the range of values may be different
	X1: Score 100
	X2: Low risk
	X3: Moderate (intermediate) risk
	X4: High risk
	X7: Test ordered, results not in chart
	X8: Not applicable: Information not collected for this case
	X9: Not documented in medical record; Multigene Signature Results not assessed or unknown if assessed
	Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: MULTIPLICITYCOUNTER
Eureka Name: Multiplicity Counter
NAACCR Item: 446
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2007 - 2012

Related Variables:

Definition: This data item is used to count the number of individual reportable tumors (multiplicity) that are present at the time of diagnosis or the number of reportable tumors that occur within one year of the original diagnosis reported as a single primary using the SEER multiple primary rules.

Values:

- 00: No primary tumor identified
- 01: One tumor only
- 02: Two tumors present; bilateral ovaries involved with cystic carcinoma
- 03: Three tumors present
- 04-87: Respective number of tumors present
- 88: Information on multiple tumors not collected/not applicable for this site
- 89: Multicentric, multifocal, number unknown
- 99: Unknown if multiple tumors; not documented
- Blank: Information not collected for this diagnosis date - Year of Diagnosis is prior to 2007 or 2013 and later.

California Cancer Registry Data Dictionary

Variable Name: MULTTUMRPTASONEPRIM
Eureka Name: Mult Tum Rpt As One Prim
NAACCR Item: 444
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2007 - 2012

Related Variables:

Definition: Identifies cases with multiple tumors that are abstracted and reported as a single primary using the SEER multiple primary rules. Multiple tumors may individually exhibit in situ, invasive, or any combination of in situ and invasive behaviors. Multiple intracranial and central nervous system tumors may individually exhibit benign, borderline, malignant, or any combination of these behaviors. Multiple tumors found in the same organ or in a single primary site may occur at the time of initial diagnosis or within one year of the initial diagnosis.

Values:

- 00: Single tumor
- 10: At least two benign tumors in same organ/primary site (Intracranial and CNS sites only)
- 11: At least two borderline tumors in the same organ/primary site (Intracranial and CNS sites only)
- 12: Benign and borderline tumors in the same organ/primary site (Intracranial and CNS sites only)
- 20: At least two in situ tumors in the same organ/primary site
- 30: One or more in situ and one or more invasive tumors in the same organ/primary site
- 31: One or more in situ/invasive adenocarcinoma in a polyp and one or more de novo (previously called frank) adenocarcinoma in one segment of colon
- 32: Familial polyposis with one or more in situ/invasive carcinoma
- 40: At least two invasive tumors in the same organ (Includes one or more invasive tumors with histology "NOS" and one or more separate invasive tumors with a more specific histology)
- 80: Multiple tumors present in the same organ/primary site, unknown if *in situ* or invasive
- 88: Information on multiple tumors not collected/not applicable for this site
- 99: Unknown
- Blank: Information not collected for this diagnosis date - Year of Diagnosis is prior to 2007 or 2013 and later.

California Cancer Registry Data Dictionary

Variable Name:	NAPIIA
Eureka Name:	Race--NAPIIA (Derived API)
NAACCR Item:	193
Category:	Patient Demographics
Level of Variable:	Patient
Time Period Available:	1988 - current year
Related Variables:	<ul style="list-style-type: none"> • Race 1 (RACE1) • Race 2 (RACE2) • Race 3 (RACE3) • Race 4 (RACE4) • Race 5 (RACE5) • Birthplace—Country (BIRTHPLACECOUNTRY) • Name--Last (LNAME) • Name--First (FNAME) • Name--Maiden (MAIDNAME)

Definition: NAPIIA stands for NAACCR Asian and Pacific Islander Identification Algorithm. NAPIIA attempts to recode a patient's race to a more specific Asian or Pacific Islander race category if they have a code of 96 (Asian, Not Otherwise Specified) or 97 (Pacific Islander, Not Otherwise Specified) in any of the race fields (RACE1, RACE2, RACE3, RACE4, or RACE5). The algorithm uses birthplace and name fields (first, last, and maiden names).

Notes: For additional information, please see the Appendix "Variables Pertaining to Race/Ethnicity in the CCR".

Values:	01:	White
	02:	Black
	03:	American Indian, Aleutian, or Eskimo (includes all indigenous populations of the Western hemisphere)
	04:	Chinese
	05:	Japanese
	06:	Filipino
	07:	Hawaiian
	08:	Korean
	10:	Vietnamese
	11:	Laotian
	12:	Hmong
	13:	Kampuchean (Cambodian)
	14:	Thai
	15:	Asian Indian or Pakistani, NOS
	16:	Asian Indian
	17:	Pakistani
	20:	Micronesian, NOS

California Cancer Registry Data Dictionary

21:	Chamorro/Chamoru
22:	Guamanian, NOS
25:	Polynesian, NOS
26:	Tahitian
27:	Samoan
28:	Tongan
30:	Melanesian, NOS
31:	Fiji Islander
32:	New Guinean
96:	Other Asian, including Asian, NOS and Oriental, NOS
97:	Pacific Islander, NOS
98:	Other
99:	Unknown
Blank:	Algorithm has not been run

California Cancer Registry Data Dictionary

Variable Name: NCCN_FLAG
Eureka Name: N/A
NAACCR Item: N/A
Category: Hospital and Physician
Level of Variable: Tumor
Time Period Available: 1988 - current year

Related Variables:

Definition: NCCN_FLAG indicates whether or not a patient was seen at a California National Comprehensive Cancer Network (NCCN) Member Institution for their cancer. The flag is created by reviewing all abstracts pertaining to a patient's cancer diagnosis. If an abstract was reported by a California NCCN Member Institution, and the reporting facility indicated the patient's cancer was an analytic case (i.e. CLASS = 00 through 22), and the cancer was diagnosed when the facility had NCCN designation then NCCN_FLAG=1. Otherwise, NCCN_FLAG=0.

Values:

- 0: Patient was not seen at a California National Comprehensive Cancer Network (NCCN) Member Institution for this cancer
- 1: Patient was seen at a California National Comprehensive Cancer Network (NCCN) Member Institution for this cancer

California Cancer Registry Data Dictionary

Variable Name: NCCNIPI
Eureka Name: NCCN International Prognostic Index (IPI)
NAACCR Item: 3896
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 - current year

Related Variables:

Definition: The NCCN International Prognostic Index (IPI) (previously only "IPI") is used to define risk groups for specific lymphomas using a 0-5 score range, based on age, stage, number of extranodal sites of involvement, patient's performance status and pretreatment LDH level.

Values:

- 00-08: 0-8 points
- X1: Stated as low risk (0-1 point)
- X2: Stated as low intermediate risk (2-3 points)
- X3: Stated as intermediate risk (4-5 points)
- X4: Stated as high risk (6-8 points)
- X8: Not applicable: Information not collected for this case
- X9: Not documented in medical record; NCCN International Prognostic Index (IPI) not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: NCI_FLAG
Eureka Name: N/A
NAACCR Item: N/A
Category: Hospital and Physician
Level of Variable: Tumor
Time Period Available: 1988 - current year

Related Variables:

Definition: NCI_FLAG indicates whether or not a patient was seen at a California NCI-designated cancer center for their cancer. The flag is created by reviewing all abstracts pertaining to a patient's cancer diagnosis. If an abstract was reported by a California NCI-designated cancer center, and the reporting facility indicated the patient's cancer was an analytic case (i.e. CLASS = 00 through 22), and the cancer was diagnosed when the facility had NCI designation then NCI_FLAG=1. Otherwise, NCI_FLAG=0.

Values:

- 0: Patient was not seen at a California NCI-designated cancer center for this cancer
- 1: Patient was seen at a California NCI-designated cancer center for this cancer

California Cancer Registry Data Dictionary

Variable Name:	NCODE
Eureka Name:	N/A
NAACCR Item:	N/A
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	1988 - 2003
Related Variables:	<ul style="list-style-type: none"> • EOD--Lymph Node Involv (LNSUMTU) • Extent of Disease Derived T Code for TNM Staging (TCODE) • Extent of Disease Derived M Code for TNM Staging (MCODE) • AJCC Stage of Cancer (STAGE) • SEER-Modified AJCC Stage of Cancer (STAGE_SEER) • Derived AJCC-6 N (DERIVED_AJCC_N) • Derived AJCC-7 N (DERIVEDAJCC7N) • TNM Clin N (TNM_N_CODE_CLINICAL) • TNM Path N (TNM_N_CODE_PATH) • Derived SEER Combined N (DERIVEDSEERCOMBINEDN) • Derived EOD 2018 N (DERIVEDEOD18N)

Definition: Extent of Disease (EOD) derived "N" value for TNM staging which identifies the presence or absence of cancer in regional lymph nodes. This variable is not a collected data item but derived according to the AJCC third edition using the EOD staging data item for lymph node involvement (LNSUMTU). For cases diagnosed 2004 through 2015, this value is derived from collaborative stage data items according to the AJCC sixth edition and is recorded in the field DERIVED_AJCC_N. Additionally, for cases diagnosed 2010 through 2015, this value is derived from collaborative stage data items according to the AJCC seventh edition and is recorded in the field DERIVEDAJCC7N. For cases diagnosed 2016 and 2017, TNM values were directly coded by Certified Tumor Registrars and the AJCC seventh edition N value is recorded in the fields TNM_N_CODE_CLINICAL and TNM_N_CODE_PATH. Or, for the N value used to calculate DERIVEDSEERCMBSTGGRP, see DERIVEDSEERCOMBINEDN. For cases diagnosed 2018 and forward, this value was once again derived from EOD staging data items according to the AJCC eighth edition and is recorded in the field, DERIVEDEOD18N.

California Cancer Registry Data Dictionary

Notes: NCODE only has values for the following sites: breast, cervix, colon, lung, ovarian, rectum, vagina and vulva.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values: N0, N1, N1a, N1b, N1x, N2, N3, NX, NXr, NXu
Values are site-specific; see SEER Program: Comparative Staging Guide For Cancer (https://seer.cancer.gov/archive/manuals/historic/comp_stage1.1.pdf).

California Cancer Registry Data Dictionary

Variable Name:	NHIA
Eureka Name:	NHIA Derived Hisp Origin
NAACCR Item:	191
Category:	Patient Demographics
Level of Variable:	Patient
Time Period Available:	1988 - current year
Related Variables:	<ul style="list-style-type: none"> • Race 1 (RACE1) • Sex (SEX) • Spanish/Hispanic Origin (SPANISH) • IHS Link (IHSLINK) • Birthplace—Country (BIRTHPLACECOUNTRY) • Name--Last (LNAME) • Name--Maiden (MAIDNAME)

Definition: The NAACCR Hispanic Identification Algorithm (NHIA) uses a combination of variables to directly or indirectly classify cases as Hispanic for analytical purposes.

Notes: For additional information, please see the Appendix "Variables Pertaining to Race/Ethnicity in the CCR".

Values:	0: Non-Hispanic
	1: Mexican, by birthplace or other specific identifier
	2: Puerto Rican, by birthplace or other specific identifier
	3: Cuban, by birthplace or other specific identifier
	4: South or Central American (except Brazil), by birthplace or other specific identifier
	5: Other specified Spanish/Hispanic origin (includes European; excludes Dominican Republic), by birthplace or other specific identifier
	6: Spanish, NOS; Hispanic, NOS; Latino, NOS
	7: NHIA surname match only
	8: Dominican Republic
	Blank: Algorithm has not been run

California Cancer Registry Data Dictionary

Variable Name: NNODES
Eureka Name: RX Reg LN Examined
NAACCR Item: 1296
Category: Treatment, Surgical
Level of Variable: Tumor
Time Period Available: 1988 - 2002
Related Variables: Rx Summ--Scope Reg LN Sur (SCOPE)

Definition: Number of regional lymph nodes identified in the pathology report during surgical procedure. This variable is only valid for cases diagnosed prior to January 1, 2003. Information in NNODES from 1988 through 2003 was incorporated into the variable SCOPE. NNODES was required for cases diagnosed from 1998 through 2002 (values for cases diagnosed prior to 1998 were coded if information was available).

Notes: The American College of Surgeons is responsible for establishing data items, codes, and definitions for the surgical treatment of cancer. Whenever possible, surgery codes for cases diagnosed prior to any changes introduced by the College are converted to reflect current coding rules. However, in some cases the information available may not allow for an accurate conversion. Please keep these changes in mind when evaluating time trends in cancer treatment.

Values:

- 00: No regional nodes examined
- 01: One regional node examined
- 02-89: Actual number of regional nodes examined; two up to 89
- 90: Ninety or more regional nodes examined
- 95: No regional lymph node(s) removed but aspiration of regional lymph node(s) was performed
- 96: Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97: Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98: Regional lymph nodes surgically removed, but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99: Unknown; not stated; death certificate only (DCO)
- Blank: Date of Diagnosis is on or after January 1, 2003

California Cancer Registry Data Dictionary

Variable Name: NOCONTAC
Eureka Name: Patient No Contact
NAACCR Item: N/A
Category: Administrative
Level of Variable: Patient
Time Period Available: 1988 - current year

Related Variables:

Definition: A flag to indicate that the patient does not want to be contacted for research purposes, ever.

Values:

- 0: No flag
- 1: Hospital first notified
- 2: Region first notified
- 3: CCR first notified
- 4: Out of state case, not for research
- 5: VA Case

California Cancer Registry Data Dictionary

Variable Name: NOEDUC

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 1988-2005

Related Variables:

- Census Block 90 (BLKGRP90)
- Census Block 2000 (BLKGRP00)
- Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: Proportion of the population aged 25 years and older within the assigned Census block group without a high school diploma. This variable is obtained from the U.S. Census. Each CCR record is assigned a Census block group based on the patient's address at time of diagnosis. The block group is then used to append NOEDUC values from the 1990 Census for cases diagnosed 1988-1995 and from the 2000 Census for cases diagnosed 1996-2005. If a case received a randomly assigned block group, the NOEDUC value is that of the randomly assigned block group and RANDOM=1.

California Cancer Registry Data Dictionary

Variable Name: NOEDUCCT

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 1988 - 2005

Related Variables:

- Proportion of Population 25+ Years Old in Census Tract without a High School Diploma for Cases Diagnosed 2006 and Forward (NOEDUCCTACS2011)
- Census Tract 1970/80/90 (CENSUS90)
- Census Tract 2000 (CENSUS00)
- Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: Proportion of the population aged 25 years and older within the assigned Census tract without a high school diploma. This variable is obtained from the U.S. Census. Each CCR record is assigned a Census tract based on the patient's address at time of diagnosis. The Census tract is then used to append NOEDUCCT values from the 1990 Census for cases diagnosed 1988-1995 and from the 2000 Census for cases diagnosed 1996-2005. If a case received a randomly assigned Census tract, the NOEDUCCT value is that of the randomly assigned Census tract and RANDOM=1. For cases diagnosed 2006 and forward, use the variable NOEDUCCTACS2011.

California Cancer Registry Data Dictionary

Variable Name: NOEDUCCTACS2011

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 2006 – current year

Related Variables:

- Proportion of Population 25+ Years Old in Census Tract without a High School Diploma for Cases Diagnosed 1988-2005 (NOEDUCCT)
- Census Tract 2010 (CENSUSTRACT2010)
- Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: Proportion of the population aged 25 years and older within the assigned Census tract without a high school diploma. This variable is obtained from the 2007-2011 American Community Survey (ACS) data. Each CCR record is assigned a Census tract based on the patient's address at time of diagnosis. The Census tract is then used to append NOEDUCCTACS2011 values for cases diagnosed 2006 and forward. If a case received a randomly assigned Census tract, the NOEDUCCTACS2011 value is that of the randomly assigned Census tract and RANDOM=1. For cases diagnosed prior to 2006, use the variable NOEDUCCT.

California Cancer Registry Data Dictionary

Variable Name: NOJOB

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 1988 - 2005

Related Variables:

- Census Block 90 (BLKGRP90)
- Census Block 2000 (BLKGRP00)
- Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: Proportion of those aged 16 years or older within the assigned Census block group that are in the labor force but are unemployed. This variable is obtained from the U.S. Census. Each CCR record is assigned a Census block group based on the patient's address at time of diagnosis. The block group is then used to append NOJOB values from the 1990 Census for cases diagnosed 1988-1995 and from the 2000 Census for cases diagnosed 1996-2005. If a case received a randomly assigned block group, the NOJOB value is that of the randomly assigned block group and RANDOM=1.

California Cancer Registry Data Dictionary

Variable Name: NOJOBCT

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 1988 - 2005

Related Variables:

- Proportion of Population 16+ Years Old in Census Tract in Labor Force but Unemployed for Cases Diagnosed 2006 and Forward (NOJOBCTACS2011)
- Census Tract 1970/80/90 (CENSUS90)
- Census Tract 2000 (CENSUS00)
- Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: Proportion of those aged 16 years or older within the assigned Census tract that are in the labor force but are unemployed. This variable is obtained from the U.S. Census. Each CCR record is assigned a Census tract based on the patient's address at time of diagnosis. The Census tract is then used to append NOJOBCT values from the 1990 Census for cases diagnosed 1988-1995 and from the 2000 Census for cases diagnosed 1996-2005. If a case received a randomly assigned Census tract, the NOJOBCT value is that of the randomly assigned Census tract and RANDOM=1.

California Cancer Registry Data Dictionary

Variable Name: NOJOBCTACS2011

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 2006 – current year

Related Variables:

- Proportion of Population 16+ Years Old in Census Tract in Labor Force but Unemployed for Cases Diagnosed 1988-2005 (NOJOBCT)
- Census Tract 2010 (CENSUSTRACT2010)
- Census Tract/Block Group Randomly Assigned (RANDOM)

Definition: Proportion of those aged 16 years or older within the assigned Census tract that are in the labor force but are unemployed. This variable is obtained from the 2007-2011 American Community Survey (ACS) data. Each CCR record is assigned a Census tract based on the patient's address at time of diagnosis. The Census tract is then used to append NOJOBCTACS2011 values for cases diagnosed 2006 and forward. If a case received a randomly assigned Census tract, the NOJOBCTACS2011 value is that of the randomly assigned Census tract and RANDOM=1. For cases diagnosed prior to 2006, use the variable NOJOBCT.

California Cancer Registry Data Dictionary

Variable Name: NONRURAL

Eureka Name: N/A

NAACCR Item: N/A

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: 1988 - 1995

Related Variables:

- Medical Service Study Area Identification Number (MSSAID)
- Name of Medical Service Study Area (MSSANAME)

Definition: The rural/urban indicator for the 1990 Medical Service Study Area (MSSA) as defined by the Office of Statewide Health Planning and Development (OSHPD). Values are based on the 1990 U.S. Census.

Values:

- 0: Rural
- 1: Urban
- 9: Unknown

California Cancer Registry Data Dictionary

Variable Name: NORAD

Eureka Name: Reason for No Radiation

NAACCR Item: 1430

Category: Treatment, Radiation

Level of Variable: Tumor

Time Period Available: 1988 - current year

Related Variables: RX Summ--Radiation (RADSUM)

Definition: Reason why the first course of treatment did not include radiation.

Values:

- 0: Radiation performed
- 1: Not part of planned first-course treatment; Diagnosed at autopsy
- 2: Contraindicated due to other conditions or other patient risk factors
- 5: Patient died prior to planned or recommended treatment
- 6: Recommended but not performed; No reason documented
- 7: Recommended but refused by patient, family member, or guardian; Refusal is documented
- 8: Recommended, unknown if given
- 9: Unknown if radiation recommended or given; Death Certificate Only (DCO)

California Cancer Registry Data Dictionary

Variable Name: NOSURG

Eureka Name: Reason for No Surgery

NAACCR Item: 1340

Category: Treatment, Surgical

Level of Variable: Tumor

Time Period Available: 1988 - current year

Related Variables: RX Summ--Surg Prim Site (SURGPRIM)

Definition: Reason why the first course of treatment did not include definitive surgery. Reason for No Surgery only applies to surgery of the primary site.

Values:

- 0: Surgery was performed
- 1: None
- 2: Contraindicated due to patient risk factors
- 5: Patient died prior to surgery
- 6: Recommended, not given
- 7: Refused
- 8: Recommended, unknown if performed
- 9: Unknown, diagnosed at autopsy or death certificate only (DCO)

California Cancer Registry Data Dictionary

Variable Name: NPCRDERIVEDCLINSTGGRP
Eureka Name: NPCR Derived Clin Stg Grp
NAACCR Item: 3650
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2016 - 2017

Related Variables:

Definition: This item stores the results of NPCR's derived algorithmic calculation of clinical stage group based on AJCC T, N, and M and relevant biomarkers and prognostic factors. At this time, the algorithm derives AJCC 7th edition stage group; however, updates to future AJCC editions are anticipated.

Notes: Values are site-specific; Refer to the ***AJCC Cancer Staging Manual, 7th Edition.***
For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

- 0: Stage 0
- 0A: Stage 0A
- 0IS: Stage 0is
- 1: Stage I
- 1A: Stage IA
- 1A1: Stage IA1
- 1A2: Stage IA2
- 1B: Stage IB
- 1B1: Stage IB1
- 1B2: Stage IB2
- 1C: Stage IC
- 1S: Stage IS
- 2: Stage II
- 2A: Stage IIA
- 2A1: Stage IIA1
- 2A2: Stage IIA2
- 2B: Stage IIB
- 2C: Stage IIC
- 3: Stage III
- 3A: Stage IIIA
- 3B: Stage IIIB
- 3C: Stage IIIC
- 3C1: Stage IIIC1
- 3C2: Stage IIIC2
- 4: Stage IV
- 4A: Stage IVA
- 4A1: Stage IVA1
- 4A2: Stage IVA2
- 4B: Stage IVB
- 4C: Stage IVC
- OC: Occult
- 88: Not Applicable
- 99: Unknown

California Cancer Registry Data Dictionary

Variable Name: NPCRDERIVEDPATHSTGGRP
Eureka Name: NPCR Derived Path Stg Grp
NAACCR Item: 3655
Category: Level of Variable: Tumor Characteristics/Stage at Diagnosis
Time Period Available: 2016 - 2017

Related Variables:

Definition: This item stores the results of NPCR's derived algorithmic calculation of pathological stage group based on AJCC T, N, and M and relevant biomarkers and prognostic factors. At this time, the algorithm derives AJCC 7th edition stage group; however, updates to future AJCC editions are anticipated.

Notes: Values are site-specific; Refer to the ***AJCC Cancer Staging Manual, 7th Edition.***
For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

- 0: Stage 0
- 0A: Stage 0A
- 0IS: Stage 0is
- 1: Stage I
- 1A: Stage IA
- 1A1: Stage IA1
- 1A2: Stage IA2
- 1B: Stage IB
- 1B1: Stage IB1
- 1B2: Stage IB2
- 1C: Stage IC
- 1S: Stage IS
- 2: Stage II
- 2A: Stage IIA
- 2A1: Stage IIA1
- 2A2: Stage IIA2
- 2B: Stage IIB
- 2C: Stage IIC
- 3: Stage III
- 3A: Stage IIIA
- 3B: Stage IIIB
- 3C: Stage IIIC
- 3C1: Stage IIIC1
- 3C2: Stage IIIC2
- 4: Stage IV
- 4A: Stage IVA
- 4A1: Stage IVA1
- 4A2: Stage IVA2
- 4B: Stage IVB
- 4C: Stage IVC
- OC: Occult
- 88: Not Applicable
- 99: Unknown

California Cancer Registry Data Dictionary

Variable Name:	NUMCORESEXAM
Eureka Name:	Number of Cores Examined
NAACCR Item:	3897
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	Number of Cores Positive (NUMCoresPOS)
Definition:	This data item represents the number of cores examined as documented in the pathology report from needle biopsy of the prostate gland.
Values:	<p>01-99: 1-99 cores examined (Exact number of cores examined)</p> <p>X1: 100 or more cores examined</p> <p>X6: Biopsy cores examined, number unknown</p> <p>X7: No needle core biopsy performed</p> <p>X8: Not applicable: Information not collected for this case</p> <p>X9: Not documented in medical record; Number of cores examined not assessed or unknown if assessed</p> <p>Blank: Date of Diagnosis pre-2018; Non-required Schema ID</p>

California Cancer Registry Data Dictionary

Variable Name:	NUMCORESPOS
Eureka Name:	Number of Cores Positive
NAACCR Item:	3898
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	Number of Cores Examined (NUMCORESEXAM)
Definition:	This data item represents the number of positive cores documented in the pathology report from needle biopsy of the prostate gland.
Values:	<p>00: All examined cores negative</p> <p>01-99: 1-99 cores positive (Exact number of cores positive)</p> <p>X1: 100 or more cores positive</p> <p>X6: Biopsy cores positive, number unknown</p> <p>X7: No needle core biopsy performed</p> <p>X8: Not applicable: Information not collected for this case</p> <p>X9: Not documented in medical record; Number of cores positive not assessed or unknown if assessed</p> <p>Blank: Date of Diagnosis pre-2018; Non-required Schema ID</p>

California Cancer Registry Data Dictionary

Variable Name:	NUMNODESEXAMPARAA
Eureka Name:	Number of Examined Para-Aortic Nodes
NAACCR Item:	3899
Category:	Treatment, Surgical
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • Number of Positive Para-Aortic Nodes (NUMNODESPOSPARAA) • CS Site-Specific Factor 6 (CS_SITE_SPEC_F6)
Definition:	Number of examined para-aortic nodes is the number of nodes examined based on para-aortic nodal dissection. Valid for cases diagnosed January 1, 2018 and forward. For tumors of the corpus diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F6.
Values:	<p>00: No para-aortic nodes examined</p> <p>01-99: 1-99 para-aortic nodes examined (Exact number of para-aortic lymph nodes examined)</p> <p>X1: 100 or more para-aortic lymph nodes examined</p> <p>X2: Para-aortic nodes examined, number unknown</p> <p>X6: No para-aortic lymph nodes removed, but aspiration or core biopsy of para-aortic node(s) only</p> <p>X8: Not applicable: Information not collected for this case</p> <p>X9: Not documented in medical record; Cannot be determined, indeterminate if positive para-aortic nodes present; Para-aortic lymph nodes not assessed or unknown if assessed</p> <p>Blank: Date of Diagnosis pre-2018; Non-required Schema ID</p>

California Cancer Registry Data Dictionary

Variable Name: NUMNODESEXAMPELV

Eureka Name: Number of Examined Pelvic Nodes

NAACCR Item: 3900

Category: Treatment, Surgical

Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables:

- Number of Positive Pelvic Nodes (NUMNODESPOSPELV)
- CS Site-Specific Factor 4 (CS_SITE_SPEC_F4)

Definition: Number of examined pelvic nodes is the number of nodes examined based on pelvic nodal dissection. Valid for cases diagnosed January 1, 2018 and forward. For tumors of the corpus diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F4.

Values:

00:	No pelvic lymph nodes examined
01-99:	1-99 pelvic lymph nodes examined (Exact number of pelvic lymph nodes examined)
X1:	100 or more pelvic nodes examined
X2:	Positive pelvic nodes examined, number unknown
X6:	No pelvic lymph nodes removed, but aspiration or core biopsy of pelvic node(s) only
X8:	Not applicable: Information not collected for this case
X9:	Not documented in medical record; Cannot be determined, indeterminate if positive pelvic nodes present; Pelvic lymph nodes not assessed or unknown if assessed
Blank:	Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: NUMNODESPOSPARAA
Eureka Name: Number of Positive Para-Aortic Nodes
NAACCR Item: 3901
Category: Treatment, Surgical
Level of Variable: Tumor
Time Period Available: 2018 - current year
Related Variables:

- Number of Examined Para-Aortic Nodes (NUMNODESEXAMPARAA)
- CS Site-Specific Factor 5 (CS_SITE_SPEC_F5)

Definition: Number of Positive Para-Aortic Nodes is the number of positive nodes based on para-aortic nodal dissection. Valid for cases diagnosed January 1, 2018 and forward. For tumors of the corpus diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F5.

Values:

00:	All para-aortic lymph nodes examined negative
01-99:	1-99 para-aortic lymph nodes positive (Exact number of nodes positive)
X1:	100 or more para-aortic nodes positive
X2:	Positive para-aortic nodes identified, number unknown
X6:	Positive aspiration or core biopsy of para-aortic lymph node(s)
X8:	Not applicable: Information not collected for this case
X9:	Not documented in medical record; Cannot be determined, indeterminate if positive para-aortic nodes present; Para-aortic lymph nodes not assessed or unknown if assessed
Blank:	Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: NUMNODESPOSPELV

Eureka Name: Number of Positive Pelvic Nodes

NAACCR Item: 3902

Category: Treatment, Surgical

Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables:

- Number of Examined Pelvic Nodes (NUMNODESEXAMPELV)
- CS Site-Specific Factor 3 (CS_SITE_SPEC_F3)

Definition: Number of Positive Pelvic Nodes is the number of positive nodes based on pelvic nodal dissection. Valid for cases diagnosed January 1, 2018 and forward. For tumors of the corpus diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F3.

Values:

00:	All pelvic nodes examined negative
01-99:	1-99 pelvic nodes positive (Exact number of nodes positive)
X1:	100 or more pelvic nodes positive
X2:	Positive pelvic nodes identified, number unknown
X6:	Positive aspiration or core biopsy of pelvic lymph node(s)
X8:	Not applicable: Information not collected for this case
X9:	Not documented in medical record; Cannot be determined, indeterminate if positive pelvic nodes present; Pelvic lymph nodes not assessed or unknown if assessed
Blank:	Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: NUMPHASESRTTOVOL
Eureka Name: Number of Phases of Rad Treatment to This Volume
NAACCR Item: 1532
Category: Treatment, Radiation
Level of Variable: Tumor
Time Period Available: 2018 - current year

Related Variables:

Definition: Identifies the total number of phases of radiation therapy administered to the patient during the first course of treatment. A “phase” consists of one or more consecutive treatments delivered to the same anatomic volume with no change in the treatment technique. Although the majority of courses of radiation therapy are completed in one or two phases (historically, the “regional” and “boost” treatments) there are occasions in which three or more phases are used, most typically with head and neck malignancies.

Values:

- 00: No radiation treatment
- 01: 1 phase
- 02: 2 phases
- 03: 3 phases
- 04: 4 or more phases
- 99: Unknown number of phases; Unknown if radiation therapy administered

California Cancer Registry Data Dictionary

Variable Name:	OCCUP80
Eureka Name:	Occupation 80
NAACCR Item:	N/A
Category:	Patient Demographics
Level of Variable:	Tumor
Time Period Available:	1988 - 2003
Related Variables:	<ul style="list-style-type: none"> • Industry 80 (INDUS80) • Patient's Longest-Held Occupation (OCCUPATION_CODE) • Industry Associated with Patient's Longest-Held Occupation (INDUSTRY_CODE)
Definition:	The code for the patient's longest-held occupation at the time of diagnosis. The coding scheme is that used by the Census Bureau in 1980. Historically, this field was inconsistently coded. Use the field OCCUPATION_CODE instead.
Notes:	For additional information, please see the Appendix "Industry & Occupation Variables in the CCR". For coding scheme, please refer to Appendix 14A in "California Cancer Reporting System Standards, Volume III" located at: https://www.ccrca.org/submit-data/cancer-registrars-hospitals-and-facilities/reporting-by-cancer-registrars/
Values:	003-917 with trailing 0 (entire range is not used) 9990: Not reported 9999: Code not yet assigned

California Cancer Registry Data Dictionary

Variable Name:	OCCUP90
Eureka Name:	Occupation 90
NAACCR Item:	N/A
Category:	Patient Demographics
Level of Variable:	Tumor
Time Period Available:	1988 - 2002
Related Variables:	<ul style="list-style-type: none"> • Industry 90 (INDUS90) • Patient's Longest-Held Occupation (OCCUPATION_CODE) • Industry Associated with Patient's Longest-Held Occupation (INDUSTRY_CODE)
Definition:	The code for the patient's longest-held occupation at the time of diagnosis. The coding scheme is that used by the Census Bureau in 1990. Historically, this field was inconsistently coded. Use the field OCCUPATION_CODE instead.
Notes:	For additional information, please see the Appendix "Industry & Occupation Variables in the CCR". For coding scheme, please refer to Appendix 14A in "California Cancer Reporting System Standards, Volume III" located at: https://www.ccrca.org/submit-data/cancer-registrars-hospitals-and-facilities/reporting-by-cancer-registrars/
Values:	003-917 with trailing 0 (entire range is not used) 9990: Not reported 9999: Code not yet assigned

California Cancer Registry Data Dictionary

Variable Name: OCCUPATION_CODE

Eureka Name: N/A

NAACCR Item: N/A

Category: Patient Demographics

Level of Variable: Tumor

Time Period Available: 1988 - current year

Related Variables: Industry Associated with Patient's Longest-Held Occupation (INDUSTRY_CODE)

Definition: Code for the patient's longest-held occupation at the time of diagnosis. The code is assigned by applying a NIOSH look-up table to text string obtained from the medical record.

Notes: For additional information, please see the Appendix "Industry & Occupation Variables in the CCR". For coding scheme, please refer to **Appendix 14A** in "California Cancer Reporting System Standards, Volume III" located at: <https://www.ccrca.org/submit-data/cancer-registrars-hospitals-and-facilities/reporting-by-cancer-registrars/>

Values: 003-917 (entire range is not used)
990, 999: Not Reported/Unknown

California Cancer Registry Data Dictionary

Variable Name:	ONCOTYPERISKDCIS
Eureka Name:	Oncotype DX Risk Level-DCIS
NAACCR Item:	3905
Category:	Prognostic Factors
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	Oncotype DX Recurrence Score-DCIS (ONCOTYPESCOREDCIS)
Definition:	Oncotype Dx Risk Level-DCIS stratifies Oncotype DX Recurrence Score-DCIS (ONCOTYPESCOREDCIS) into low, intermediate, and high risk of local recurrence.
Values:	<ul style="list-style-type: none"> 0: Low risk (recurrence score 0-38) 1: Intermediate risk (recurrence score 39-54) 2: High risk (recurrence score greater than or equal to 55) 6: Not applicable: invasive case 7: Test ordered, results not in chart 8: Not applicable: Information not collected for this case 9: Not documented in medical record; Oncotype DX Risk level-DCIS not assessed or unknown if assessed Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name:	ONCOTYPERISKINVAS
Eureka Name:	Oncotype DX Risk Level-Invasive
NAACCR Item:	3906
Category:	Prognostic Factors
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	Oncotype DX Recurrence Score-Invasive (ONCOTYPESCOREINVAS)
Definition:	Oncotype Dx Risk Level-Invasive stratifies Oncotype DX Recurrence Score-Invasive (ONCOTYPESCOREINVAS) into low, intermediate, and high risk of distant recurrence.
Values:	<ul style="list-style-type: none"> 0: Low risk (recurrence score 0-17) 1: Intermediate risk (recurrence score 18-30) 2: High risk (recurrence score greater than or equal to 31) 6: Not applicable: DCIS case 7: Test ordered, results not in chart 8: Not applicable: Information not collected for this case 9: Not documented in medical record; Oncotype DX Risk Level-Invasive not assessed or unknown if assessed Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name:	ONCOTYPESCOREDCIS
Eureka Name:	Oncotype DX Recurrence Score-DCIS
NAACCR Item:	3903
Category:	Prognostic Factors
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	ONCOTYPE DX RISK LEVEL-DCIS (ONCOTYPERISKDCIS)
Definition:	Oncotype Dx Recurrence Score-DCIS is a numeric score of a genomic test to predict the risk of local recurrence of breast cancer based on the assessment of 21 genes.
Values:	<p>0-100: Actual recurrence score between 0 and 100</p> <p>XX6: Not applicable: invasive case</p> <p>XX7: Test ordered, results not in chart</p> <p>XX8: Not applicable: Information not collected for this case</p> <p>XX9: Not documented in medical record; Oncotype Dx Recurrence Score-DCIS not assessed or unknown if assessed</p> <p>Blank: Date of Diagnosis pre-2018; Non-required Schema ID</p>

California Cancer Registry Data Dictionary

Variable Name:	ONCOTYPESCOREINV
Eureka Name:	Oncotype DX Recurrence Score-Invasive
NAACCR Item:	3904
Category:	Prognostic Factors
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	ONCOTYPE DX RISK LEVEL-INVASIVE (ONCOTYPERISKINV)
Definition:	Oncotype Dx Recurrence Score-Invasive is a numeric score of a genomic test to predict the likelihood of distant recurrence of invasive breast cancer based on the assessment of 21 genes.
Values:	<p>0-100: Actual recurrence score between 0 and 100</p> <p>XX4: Stated as less than 11</p> <p>XX5: Stated as equal to or greater than 11</p> <p>XX6: Not applicable: in situ case</p> <p>XX7: Test ordered, results not in chart</p> <p>XX9: Not documented in medical record; Oncotype Dx Recurrence Score-Invasive not assessed or unknown if assessed</p> <p>Blank: Date of Diagnosis pre-2018; Non-required Schema ID</p>

California Cancer Registry Data Dictionary

Variable Name: ORGANOMEGALY

Eureka Name: Organomegaly

NAACCR Item: 3907

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables:

Definition: Organomegaly is defined as presence of enlarged liver and/or spleen on physical examination and is part of the staging criteria for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Values:

- 0: Organomegaly of liver and/or spleen not present
- 1: Organomegaly of liver and/or spleen present
- 9: Not documented in medical record; Organomegaly not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: OTHSUM

Eureka Name: RX Summ--Other

NAACCR Item: 1420

Category: Treatment

Level of Variable: Tumor

Time Period Available: 1988 - current year

Related Variables: RX Date Other (RXDATEO)

Definition: Indicates whether the first course of treatment included other types of therapy that cannot be defined as surgery, radiation, or systemic therapy. RX Date Other (RXDATEO) provides the date that the other type of therapy started.

Values:

- 0: None
- 1: Other
- 2: Other Experimental
- 3: Other Double-blind study
- 6: Other Unproven
- 7: Refused
- 8: Recommended
- 9: Unknown; unknown if administered

California Cancer Registry Data Dictionary

Variable Name: PATIENT_ID

Eureka Name: Patient ID Number

NAACCR Item: 20

Category: Administrative

Level of Variable: Patient

Time Period Available: 1988 - current year

Related Variables:

Definition: Unique number automatically assigned by the CCR (Eureka system) to identify each patient.

Values: 1-99999999

California Cancer Registry Data Dictionary

Variable Name: PAYER
Eureka Name: Primary Payer at DX
NAACCR Item: 630
Category: Administrative
Level of Variable: Admission
Time Period Available: 1988 - current year
Related Variables: Pay Source 2 (PAYER2)

Definition: Primary payer/insurance carrier at the time of initial diagnosis and/or treatment.
Value taken from the facility with the latest date of admission.

Notes: Codes 28-HMO and 29-PPO are California specific codes that are converted to code 20-Managed Care for submission to standard setting agencies. This was effective with 2004 cases.

Code 89-County Funded, NOS is a California specific code that is converted to code 31-Medicaid for submission to standard setting agencies. This was effective with 2006 cases.

Values:

- 01: Not insured
- 02: Not insured, self-pay
- 10: Insurance, NOS
- 20: Private Insurance - Managed Care, HMO, or PPO
- 21: Private Insurance - Fee-for-Service
- 28: HMO
- 29: PPO
- 31: Medicaid
- 35: Medicaid - Administered through Managed Care Plan
- 60: Medicare without supplement; Medicare, NOS
- 61: Medicare with supplement, NOS
- 62: Medicare - Administered through a Managed Care Plan
- 63: Medicare with private supplement
- 64: Medicare with Medicaid eligibility
- 65: TRICARE
- 66: Military
- 67: Veterans Affairs
- 68: Indian/Public Health Service
- 89: County funded, NOS
- 99: Unknown
- Blank: Blank allowed when Date of Diagnosis < 1996

California Cancer Registry Data Dictionary

Variable Name: PAYER2

Eureka Name: Pay Source 2

NAACCR Item: N/A

Category: Administrative

Level of Variable: Admission

Time Period Available: 1988 - current year

Related Variables: Primary Payer at DX (PAYER)

Definition: Secondary source of payment at the time of initial diagnosis and/or treatment. Value taken from the facility with the latest date of admission.

Notes: Codes 28-HMO and 29-PPO are California specific codes that are converted to code 20-Managed Care for submission to standard setting agencies. This was effective with 2004 cases.

Code 89-County Funded, NOS is a California specific code that is converted to code 31-Medicaid for submission to standard setting agencies. This was effective with 2006 cases.

Values:

- 01: Not insured
- 02: Not insured, self-pay
- 10: Insurance, NOS
- 20: Private Insurance - Managed Care, HMO, or PPO
- 21: Private Insurance - Fee-for-Service
- 28: HMO
- 29: PPO
- 31: Medicaid
- 35: Medicaid - Administered through Managed Care Plan
- 60: Medicare without supplement; Medicare, NOS
- 61: Medicare with supplement, NOS
- 62: Medicare - Administered through a Managed Care Plan
- 63: Medicare with private supplement
- 64: Medicare with Medicaid eligibility
- 65: TRICARE
- 66: Military
- 67: Veterans Affairs
- 68: Indian/Public Health Service
- 89: County funded, NOS
- 99: Unknown
- Blank: Blank allowed when Date of Diagnosis < 1996

California Cancer Registry Data Dictionary

Variable Name: PEDCODER
Eureka Name: Pediatric Staged By
NAACCR Item: 1140
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Admission
Time Period Available: 1996 - current year

Related Variables:

Definition: Identifies the person who documented the pediatric staging. Pediatric staging applies to patients younger than 20 years of age. Value taken from the facility with the latest date of admission.

Values: For Pediatric cases:

- 0: Not staged
- 1: Managing physician
- 2: Pathologist
- 3: Other physician
- 4: Any combination of 1, 2 and 3
- 5: Registrar
- 6: Any combination of 5 with 1, 2 or 3
- 7: Other
- 8: Staged, individual not specified
- 9: Unknown

California Cancer Registry Data Dictionary

Variable Name:	PEDSTAGE
Eureka Name:	Pediatric Stage
NAACCR Item:	1120
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Admission
Time Period Available:	1996 - current year
Related Variables:	<ul style="list-style-type: none"> • Pediatric Staged By (PEDCODER) • Pediatric Staging System (PEDSYS)

Definition: The pediatric stage as specified in the pediatric staging system selected (so values vary based on the staging system used). See the data item Pediatric Staging System (PEDSYS) which identifies the type of pediatric staging system used. Value taken from the facility with the latest date of admission. Pediatric staging applies to patients younger than 20 years of age.

Notes: See the historical **ROADS 1998** manual for additional information regarding this data item. The **ROADS 1998** manual can be found at: <https://www.facs.org/-/media/files/quality-programs/cancer/coc/roads/roads1998.ashx>

Values:	1: Stage I
	1A: Stage IA (rhabdomyosarcomas and related sarcomas only)
	1B: Stage IB (rhabdomyosarcomas and related sarcomas only)
	2: Stage II
	2A: Stage IIA (rhabdomyosarcomas and related sarcomas only)
	2B: Stage IIB (rhabdomyosarcomas and related sarcomas only)
	2C: Stage IIC (rhabdomyosarcomas and related sarcomas only)
	3: Stage III
	3A: Stage IIIA (liver, rhabdomyosarcomas and related sarcomas, Wilms' tumor only)
	3B: Stage IIIB (liver, rhabdomyosarcomas and related sarcomas, Wilms' tumor only)
	3C: Stage IIIC (Wilms' tumor only)
	3D: Stage IIID (Wilms' tumor only)
	3E: Stage IIIE (Wilms' tumor only)
	4: Stage IV
	4A: Stage IVA (bone only)
	4B: Stage IVB (bone only)
	4S: Stage IVS (neuroblastoma only)
	5: Stage V (Wilms' tumor, retinoblastoma only)
	A: Stage A (neuroblastoma only)
	B: Stage B (neuroblastoma only)
	C: Stage C (neuroblastoma only)
	D: Stage D (neuroblastoma only)
	DS: Stage DS (neuroblastoma only)
	88: Not applicable (not a pediatric cases)
	99: Unstaged, Unknown (for pediatric cases only)
	Blank: For case not abstracted or not a pediatric case prior to 1996

California Cancer Registry Data Dictionary

Variable Name:	PEDSYS
Eureka Name:	Pediatric Staging System
NAACCR Item:	1130
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Admission
Time Period Available:	1996 - current year
Related Variables:	<ul style="list-style-type: none"> • Pediatric Staged By (PEDCODER) • Pediatric Stage (PEDSTAGE)

Definition: Identifies the type of staging system used for the pediatric staging. Pediatric staging applies to patients younger than 20 years of age. Value taken from the facility with the latest date of admission.

Values:	00: None (used when pediatric case is unstaged)
	01: American Joint Committee on Cancer (AJCC)
	02: Ann Arbor
	03: Children's Cancer Group (CCG)
	04: Evans
	05: General Summary
	06: Intergroup Ewings
	07: Intergroup Hepatoblastoma
	08: Intergroup Rhabdomyosarcoma
	09: International System
	10: Murphy
	11: National Cancer Institute (Pediatric oncology)
	12: National Wilms' Tumor Study
	13: Pediatric Oncology Group (POG)
	14: Reese-Ellsworth
	15: SEER Extent of Disease
	16: Children's Oncology Group (COG)
	88: Not applicable (used for non-pediatric cases)
	97: Other
	99: Unknown (used when pediatric case is staged but staging system is unknown)

California Cancer Registry Data Dictionary

Variable Name: PERCNTNECROSPOST

Eureka Name: Percent Necrosis Post Neoadjuvant

NAACCR Item: 3908

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables: CS Site-Specific Factor 3 (CS_SITE_SPEC_F3)

Definition: Percent Necrosis Post Neoadjuvant is a prognostic factor for bone sarcomas. Valid for cases diagnosed January 1, 2018 and forward. For bone tumors diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F3.

Values:

- 0.0: Tumor necrosis not identified/not present
- 0.1-100.0: 0.1–100.0 percent tumor necrosis (Percentage of tumor necrosis to nearest tenth of a percent)
- XXX.2: Tumor necrosis present, percent not stated
- XXX.8: Not applicable: Information not collected for this case
- XXX.9: Not documented in medical record; No histologic examination of primary site; No neoadjuvant therapy; No surgical resection of primary site performed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: PERINEURALINV

Eureka Name: Perineural Invasion

NAACCR Item: 3909

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables:

- CS Site-Specific Factor 4 (CS_SITE_SPEC_F4)
- CS Site-Specific Factor 8 (CSSITESPECIFICFACTOR8)

Definition: Perineural Invasion, within or adjacent to the primary tumor, is a negative prognostic factor for cutaneous squamous cell carcinomas of the head and neck and carcinomas of the colon and rectum, eyelid and lacrimal gland. Valid for cases diagnosed January 1, 2018 and forward. For colon and rectum cancers diagnosed 2004 through 2017, this information was recorded in the field CSSITESPECIFFACTOR8. For lacrimal gland tumors diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F4.

Values:

- 0: Perineural invasion not identified/not present
- 1: Perineural invasion identified/present
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Pathology report does not mention perineural invasion; Cannot be determined by the pathologist; Perineural invasion not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: PERIPHBLOODINV

Eureka Name: Peripheral Blood Involvement

NAACCR Item: 3910

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables: CS Site-Specific Factor 1 (CS_SITE_SPEC_F1)

Definition: Peripheral blood involvement, summarized in "B category", refers to the percentage of peripheral blood lymphocytes that are atypical (Sezary) cells and whether they are "Clone negative" or "Clone positive". Peripheral blood involvement is a prognostic factor for staging Mycosis Fungoides and Sezary Syndrome. Valid for cases diagnosed January 1, 2018 and forward. For Mycosis Fungoides diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F1.

Values:

- 0: Absence of significant blood involvement; 5% or less of peripheral blood lymphocytes are atypical (Sezary) cells; Clone unknown; Stated as B0
- 1: Absence of significant blood involvement; 5% or less of peripheral blood lymphocytes are atypical (Sezary) cells; Clone negative; Stated as B0a
- 2: Absence of significant blood involvement; 5% or less of peripheral blood lymphocytes are atypical (Sezary) cells; Clone positive; Stated as B0b
- 3: Low blood tumor burden; More than 5% of peripheral blood lymphocytes are atypical (Sezary) cells but does not meet the criteria of B2; Clone unknown; Stated as B1
- 4: Low blood tumor burden; More than 5% of peripheral blood lymphocytes are atypical (Sezary) cells but does not meet the criteria of B2; Clone negative; Stated as B1a
- 5: Low blood tumor burden; More than 5% of peripheral blood lymphocytes are atypical (Sezary) cells but does not meet the criteria of B2; Clone positive; Stated as B1b
- 6: High blood tumor burden; Greater than or equal to 1000 Sezary cells per microliter (uL); Clone positive; Stated as B2
- 7: Test ordered, results not in chart
- 9: Not documented in medical record; Peripheral Blood Involvement not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: PERITONEALCYTOL

Eureka Name: Peritoneal Cytology

NAACCR Item: 3911

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables: CS Site-Specific Factor 2 (CS_SITE_SPEC_F2)

Definition: Peritoneal cytology pertains to the results of cytologic examination for malignant cells performed on fluid that is obtained from the peritoneal cavity. Valid for cases diagnosed January 1, 2018 and forward. For corpus cancers diagnosed 2004 through 2017, this data was recorded in the field CS_SITE_SPEC_F2.

Values:

- 0: Peritoneal cytology/washing negative for malignancy
- 1: Peritoneal cytology/washing atypical and/or suspicious
- 2: Peritoneal cytology/washing malignant (positive for malignancy)
- 3: Unsatisfactory/non-diagnostic
- 7: Test ordered, results not in chart
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Peritoneal cytology not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: PHASEIBEAMTECH

Eureka Name: Phase I Radiation External Beam Planning Tech

NAACCR Item: 1502

Category: Treatment, Radiation

Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables:

- Phase I Dose Per Fraction (PHASEIDOSEFRACT)
- Phase I Number of Fractions (PHASEINUMFRACT)
- Phase I Radiation Primary Treatment Volume (PHASEIPRIMTXVOL)
- Phase I Radiation to Draining Lymph Nodes (PHASEIRTTOLN)
- Phase I Radiation Treatment Modality (PHASEIRTMODALITY)
- Phase I Total Dose (PHASEITOTALDOSE)

Definition: Identifies the external beam radiation planning technique used to administer the first phase of radiation treatment during the first course of treatment.

Values:

- 00: No radiation treatment
- 01: External beam, NOS
- 02: Low energy x-ray/photon therapy
- 03: 2-D therapy
- 04: Conformal or 3-D conformal therapy
- 05: Intensity modulated therapy
- 06: Stereotactic radiotherapy or radiosurgery, NOS
- 07: Stereotactic radiotherapy or radiosurgery, robotic
- 08: Stereotactic radiotherapy or radiosurgery, Gamma Knife®
- 09: CT-guided online adaptive therapy
- 10: MR-guided online adaptive therapy
- 88: Not Applicable
- 98: Other, NOS
- 99: Unknown

California Cancer Registry Data Dictionary

Variable Name:	PHASEIDOSEFRACT
Eureka Name:	Phase I Dose Per Fraction
NAACCR Item:	1501
Category:	Treatment, Radiation
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • Phase I Number of Fractions (PHASEINUMFRACT) • Phase I Radiation External Beam Planning Tech (PHASEIBEAMTECH) • Phase I Radiation Primary Treatment Volume (PHASEIPRIMTXVOL) • Phase I Radiation to Draining Lymph Nodes (PHASEIRTTOLN) • Phase I Radiation Treatment Modality (PHASEIRTMODALITY) • Phase I Total Dose (PHASEITOTALDOSE)
Definition:	Records the dose per fraction (treatment session) delivered to the patient in the first phase of radiation during the first course of treatment. The unit of measure is centiGray (cGy).
Values:	<p>00000: Radiation therapy was not administered</p> <p>00001-99997: Actual Phase I dose delivered in cGy</p> <p>99998: Not applicable, brachytherapy or radioisotopes administered to the patient</p> <p>99999: Regional radiation therapy was administered but dose is unknown; it is unknown whether radiation therapy was administered. Death certificate only.</p>

California Cancer Registry Data Dictionary

Variable Name:	PHASEINUMFRACT
Eureka Name:	Phase I Number of Fractions
NAACCR Item:	1503
Category:	Treatment, Radiation
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • Phase I Dose Per Fraction (PHASEIDOSEFRACT) • Phase I Radiation External Beam Planning Tech (PHASEIBEAMTECH) • Phase I Radiation Primary Treatment Volume (PHASEIPRIMTXVOL) • Phase I Radiation to Draining Lymph Nodes (PHASEIRTTOLN) • Phase I Radiation Treatment Modality (PHASEIRTMODALITY) • Phase I Total Dose (PHASEITOTALDOSE)
Definition:	Records the total number of fractions (treatment sessions) delivered to the patient in the first phase of radiation during the first course of treatment.
Values:	<p>000: Radiation therapy was not administered to the patient</p> <p>001-998: Number of fractions administered to the patient during the first phase of radiation therapy</p> <p>999: Phase I Radiation therapy was administered, but the number of fractions is unknown; It is unknown whether radiation therapy was administered</p>

California Cancer Registry Data Dictionary

Variable Name: PHASEIPRIMTXVOL

Eureka Name: Phase I Radiation Primary Treatment Volume

NAACCR Item: 1504

Category: Treatment, Radiation

Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables:

- Phase I Dose Per Fraction (PHASEIDOSEFRACT)
- Phase I Number of Fractions (PHASEINUMFRACT)
- Phase I Radiation External Beam Planning Tech (PHASEIBEAMTECH)
- Phase I Radiation to Draining Lymph Nodes (PHASEIRTTOLN)
- Phase I Radiation Treatment Modality (PHASEIRTMODALITY)
- Phase I Total Dose (PHASEITOTALDOSE)

Definition: Identifies the primary treatment volume or primary anatomic target treated during the first phase of radiation therapy during the first course of treatment.

Values:

- 00: No radiation treatment
- 01: Neck lymph node regions
- 02: Thoracic lymph node regions
- 03: Neck and thoracic lymph node regions
- 04: Breast/Chest wall lymph node regions
- 05: Abdominal lymph nodes
- 06: Pelvic lymph nodes
- 07: Abdominal and pelvic lymph nodes
- 09: Lymph node region, NOS
- 10: Eye/orbit/optic nerve
- 11: Pituitary
- 12: Brain
- 13: Brain (Limited)
- 14: Spinal cord
- 20: Nasopharynx
- 21: Oral Cavity
- 22: Oropharynx
- 23: Larynx (glottis) or hypopharynx
- 24: Sinuses/Nasal tract
- 25: Parotid or other salivary glands
- 26: Thyroid
- 29: Head and neck (NOS)
- 30: Lung or bronchus
- 31: Mesothelium
- 32: Thymus
- 39: Chest/lung (NOS)
- 40: Breast - whole

California Cancer Registry Data Dictionary

- 41: Breast - partial
- 42: Chest wall
- 50: Esophagus
- 51: Stomach
- 52: Small bowel
- 53: Colon
- 54: Rectum
- 55: Anus
- 56: Liver
- 57: Biliary tree or gallbladder
- 58: Pancreas or hepatopancreatic ampulla
- 59: Abdomen (NOS)
- 60: Bladder - whole
- 61: Bladder - partial
- 62: Kidney
- 63: Ureter
- 64: Prostate - whole
- 65: Prostate - partial
- 66: Urethra
- 67: Penis
- 68: Testicle or scrotum
- 70: Ovaries or fallopian tubes
- 71: Uterus or Cervix
- 72: Vagina
- 73: Vulva
- 80: Skull
- 81: Spine/vertebral bodies
- 82: Shoulder
- 83: Ribs
- 84: Hip
- 85: Pelvic bones
- 86: Pelvis (NOS, non-visceral)
- 88: Extremity bone, NOS
- 90: Skin
- 91: Soft tissue
- 92: Hemibody
- 93: Whole body
- 94: Mantle, mini-mantle (obsolete after 2017)
- 95: Lower extended field (obsolete after 2017)
- 96: Inverted Y (obsolete after 2017)
- 97: Invalid historical **FORDS** value
- 98: Other
- 99: Unknown

California Cancer Registry Data Dictionary

Variable Name:	PHASEIRTMODALITY
Eureka Name:	Phase I Radiation Treatment Modality
NAACCR Item:	1506
Category:	Treatment, Radiation
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • Phase I Dose Per Fraction (PHASEIDOSEFRACT) • Phase I Number of Fractions (PHASEINUMFRACT) • Phase I Radiation External Beam Planning Tech (PHASEIBEAMTECH) • Phase I Radiation Primary Treatment Volume (PHASEIPRIMTXVOL) • Phase I Radiation to Draining Lymph Nodes (PHASEIRTTOLN) • Phase I Total Dose (PHASEITOTALDOSE)
Definition:	Identifies the radiation modality administered during the first phase of radiation treatment delivered during the first course of treatment.
Values:	00: No radiation treatment 01: External beam, NOS 02: External beam, photons 03: External beam, protons 04: External beam, electrons 05: External beam, neutrons 06: External beam, carbon ions 07: Brachytherapy, NOS 08: Brachytherapy, intracavitary, LDR 09: Brachytherapy, intracavitary, HDR 10: Brachytherapy, Interstitial, LDR 11: Brachytherapy, Interstitial, HDR 12: Brachytherapy, electronic 13: Radioisotopes, NOS 14: Radioisotopes, Radium-232 15: Radioisotopes, Strontium-89 16: Radioisotopes, Strontium-90 99: Treatment radiation modality unknown; Unknown if radiation treatment administered

California Cancer Registry Data Dictionary

Variable Name:	PHASEIRTTOLN
Eureka Name:	Phase I Radiation to Draining Lymph Nodes
NAACCR Item:	1505
Category:	Treatment, Radiation
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • Phase I Dose Per Fraction (PHASEIDOSEFRACT) • Phase I Number of Fractions (PHASEINUMFRACT) • Phase I Radiation External Beam Planning Tech (PHASEIBEAMTECH) • Phase I Radiation Primary Treatment Volume (PHASEIPRIMTXVOL) • Phase I Radiation Treatment Modality (PHASEIRTMODALITY) • Phase I Total Dose (PHASEITOTALDOSE)
Definition:	Identifies the draining lymph nodes treated (if any) during the first phase of radiation therapy delivered to the patient during the first course of treatment.
Values:	<p>00: No radiation treatment</p> <p>01: Neck lymph node regions</p> <p>02: Thoracic lymph node regions</p> <p>03: Neck and thoracic lymph node regions</p> <p>04: Breast/Chest wall lymph node regions</p> <p>05: Abdominal lymph nodes</p> <p>06: Pelvic lymph nodes</p> <p>07: Abdominal and pelvic lymph nodes</p> <p>08: Lymph node region, NOS</p> <p>88: Not applicable; Phase I Radiation Primary Treatment Volume is lymph nodes</p> <p>99: Unknown if any radiation treatment to draining lymph nodes; Unknown if radiation treatment administered</p>

California Cancer Registry Data Dictionary

Variable Name: PHASEITOTALDOSE

Eureka Name: Phase I Total Dose

NAACCR Item: 1507

Category: Treatment, Radiation

Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables:

- Phase I Dose Per Fraction (PHASEIDOSEFRACT)
- Phase I Number of Fractions (PHASEINUMFRACT)
- Phase I Radiation External Beam Planning Tech (PHASEIBEAMTECH)
- Phase I Radiation Primary Treatment Volume (PHASEIPRIMTXVOL)
- Phase I Radiation to Draining Lymph Nodes (PHASEIRTTOLN)
- Phase I Radiation Treatment Modality (PHASEIRTMODALITY)

Definition: Identifies the total radiation dose delivered to the patient in the first phase of radiation treatment during the first course of treatment. The unit of measure is centiGray (cGy).

Values:

000000:	No radiation treatment administered
000001-999997:	Actual total dose delivered in cGy
999998:	Not applicable, radioisotopes administered to the patient
999999:	Radiation therapy was administered but dose is unknown; it is unknown whether radiation therapy was administered.

California Cancer Registry Data Dictionary

Variable Name: PHASEIIBEAMTECH

Eureka Name: Phase II Radiation External Beam Planning Tech

NAACCR Item: 1512

Category: Treatment, Radiation

Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables:

- Phase II Dose Per Fraction (PHASEIIDOSEFRACT)
- Phase II Number of Fractions (PHASEIINUMFRACT)
- Phase II Radiation Primary Treatment Volume (PHASEIIPRIMTXVOL)
- Phase II Radiation to Draining Lymph Nodes (PHASEIIRTTOLN)
- Phase II Radiation Treatment Modality (PHASEIIRTMODALITY)
- Phase II Total Dose (PHASEIITOTALDOSE)

Definition: Identifies the external beam radiation planning technique used to administer the second phase of radiation treatment during the first course of treatment.

Values:

- 00: No radiation treatment
- 01: External beam, NOS
- 02: Low energy x-ray/photon therapy
- 03: 2-D therapy
- 04: Conformal or 3-D conformal therapy
- 05: Intensity modulated therapy
- 06: Stereotactic radiotherapy or radiosurgery, NOS
- 07: Stereotactic radiotherapy or radiosurgery, robotic
- 08: Stereotactic radiotherapy or radiosurgery, Gamma Knife®
- 09: CT-guided online adaptive therapy
- 10: MR-guided online adaptive therapy
- 88: Not applicable
- 98: Other, NOS
- 99: Unknown
- Blank: No Phase II radiation treatment administered or year of diagnosis prior to 2018

California Cancer Registry Data Dictionary

Variable Name: PHASEIIDOSEFRACT

Eureka Name: Phase II Dose Per Fraction

NAACCR Item: 1511

Category: Treatment, Radiation

Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables:

- Phase II Number of Fractions (PHASEIINUMFRACT)
- Phase II Radiation External Beam Planning Tech (PHASEIIBEAMTECH)
- Phase II Radiation Primary Treatment Volume (PHASEIIPRIMTXVOL)
- Phase II Radiation to Draining Lymph Nodes (PHASEIIRTTOLN)
- Phase II Radiation Treatment Modality (PHASEIIRTMODALITY)
- Phase II Total Dose (PHASEIITOTALDOSE)

Definition: Records the dose per fraction (treatment session) delivered to the patient in the second phase of radiation during the first course of treatment. The unit of measure is centiGray (cGy).

Values:

00000:	Radiation therapy was not administered
00001-99997:	Actual Phase II dose delivered in cGy
99998:	Not applicable, brachytherapy or radioisotopes administered to the patient
99999:	Phase II (Boost) radiation therapy was administered but dose is unknown; It is unknown whether Phase II radiation therapy was administered; Death certificate only.
Blank:	No Phase II radiation treatment administered or year of diagnosis prior to 2018

California Cancer Registry Data Dictionary

Variable Name:	PHASEIINUMFRACT
Eureka Name:	Phase II Number of Fractions
NAACCR Item:	1513
Category:	Treatment, Radiation
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • Phase II Dose Per Fraction (PHASEIIDOSEFRACT) • Phase II Radiation External Beam Planning Tech (PHASEIIBEAMTECH) • Phase II Radiation Primary Treatment Volume (PHASEIIPRIMTXVOL) • Phase II Radiation to Draining Lymph Nodes (PHASEIIRTTOLN) • Phase II Radiation Treatment Modality (PHASEIIRTMODALITY) • Phase II Total Dose (PHASEIITOTALDOSE)
Definition:	Records the total number of fractions (treatment sessions) administered to the patient in the second phase of radiation during the first course of treatment.
Values:	<p>000: Radiation therapy was not administered to the patient</p> <p>001-998: Number of fractions administered to the patient during the second phase of radiation therapy</p> <p>999: Phase II Radiation therapy was administered, but the number of fractions is unknown; It is unknown whether radiation therapy was administered</p> <p>Blank: No Phase II radiation treatment administered or year of diagnosis prior to 2018</p>

California Cancer Registry Data Dictionary

Variable Name:	PHASEIIPRIMTXVOL
Eureka Name:	Phase II Radiation Primary Treatment Volume
NAACCR Item:	1514
Category:	Treatment, Radiation
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • Phase II Dose Per Fraction (PHASEIIDOSEFRACT) • Phase II Number of Fractions (PHASEIINUMFRACT) • Phase II Radiation External Beam Planning Tech (PHASEIIBEAMTECH) • Phase II Radiation to Draining Lymph Nodes (PHASEIIRTTOLN) • Phase II Radiation Treatment Modality (PHASEIIRTMODALITY) • Phase II Total Dose (PHASEIITOTALDOSE)
Definition:	Identifies the primary treatment volume or primary anatomic target treated during the second phase of radiation therapy during the first course of treatment.
Values:	<p>00: No phase II radiation treatment</p> <p>01: Neck lymph node regions</p> <p>02: Thoracic lymph node regions</p> <p>03: Neck and thoracic lymph node regions</p> <p>04: Breast/Chest wall lymph node regions</p> <p>05: Abdominal lymph nodes</p> <p>06: Pelvic lymph nodes</p> <p>07: Abdominal and pelvic lymph nodes</p> <p>09: Lymph node region, NOS</p> <p>10: Eye/orbit/optic nerve</p> <p>11: Pituitary</p> <p>12: Brain</p> <p>13: Brain (Limited)</p> <p>14: Spinal cord</p> <p>20: Nasopharynx</p> <p>21: Oral Cavity</p> <p>22: Oropharynx</p> <p>23: Larynx (glottis) or hypopharynx</p> <p>24: Sinuses/Nasal tract</p> <p>25: Parotid or other salivary glands</p> <p>26: Thyroid</p> <p>29: Head and neck (NOS)</p> <p>30: Lung or bronchus</p> <p>31: Mesothelium</p> <p>32: Thymus</p> <p>39: Chest/lung (NOS)</p> <p>40: Breast - whole</p>

California Cancer Registry Data Dictionary

41:	Breast - partial
42:	Chest wall
50:	Esophagus
51:	Stomach
52:	Small bowel
53:	Colon
54:	Rectum
55:	Anus
56:	Liver
57:	Biliary tree or gallbladder
58:	Pancreas or hepatopancreatic ampulla
59:	Abdomen (NOS)
60:	Bladder - whole
61:	Bladder - partial
62:	Kidney
63:	Ureter
64:	Prostate - whole
65:	Prostate - partial
66:	Urethra
67:	Penis
68:	Testicle or scrotum
70:	Ovaries or fallopian tubes
71:	Uterus or cervix
72:	Vagina
73:	Vulva
80:	Skull
81:	Spine/vertebral bodies
82:	Shoulder
83:	Ribs
84:	Hip
85:	Pelvic bones
86:	Pelvis (NOS, non-visceral)
88:	Extremity bone, NOS
90:	Skin
91:	Soft tissue
92:	Hemibody
93:	Whole body
94:	Mantle, mini-mantle (obsolete after 2017)
95:	Lower extended field (obsolete after 2017)
96:	Inverted Y (obsolete after 2017)
97:	Invalid historical FORDS value
98:	Other
99:	Unknown
Blank:	No Phase II radiation treatment administered or year of diagnosis prior to 2018

California Cancer Registry Data Dictionary

Variable Name:	PHASEIIRTMODALITY
Eureka Name:	Phase II Radiation Treatment Modality
NAACCR Item:	1516
Category:	Treatment, Radiation
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • Phase II Dose Per Fraction (PHASEIIDOSEFRACT) • Phase II Number of Fractions (PHASEIINUMFRACT) • Phase II Radiation External Beam Planning Tech (PHASEIIBEAMTECH) • Phase II Radiation Primary Treatment Volume (PHASEIIPRIMTXVOL) • Phase II Radiation to Draining Lymph Nodes (PHASEIIRTTOLN) • Phase II Total Dose (PHASEIITOTALDOSE)
Definition:	Identifies the radiation modality administered during the second phase of radiation treatment delivered during the first course of treatment.
Values:	<p>00: No radiation treatment</p> <p>01: External beam, NOS</p> <p>02: External beam, photons</p> <p>03: External beam, protons</p> <p>04: External beam, electrons</p> <p>05: External beam, neutrons</p> <p>06: External beam, carbon ions</p> <p>07: Brachytherapy, NOS</p> <p>08: Brachytherapy, intracavitary, LDR</p> <p>09: Brachytherapy, intracavitary, HDR</p> <p>10: Brachytherapy, Interstitial, LDR</p> <p>11: Brachytherapy, Interstitial, HDR</p> <p>12: Brachytherapy, electronic</p> <p>13: Radioisotopes, NOS</p> <p>14: Radioisotopes, Radium-232</p> <p>15: Radioisotopes, Strontium-89</p> <p>16: Radioisotopes, Strontium-90</p> <p>99: Treatment radiation modality unknown; Unknown if radiation treatment administered</p> <p>Blank: No Phase II radiation treatment administered or year of diagnosis prior to 2018</p>

California Cancer Registry Data Dictionary

Variable Name:	PHASEIIRTTOLN
Eureka Name:	Phase II Radiation to Draining Lymph Nodes
NAACCR Item:	1515
Category:	Treatment, Radiation
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • Phase II Dose Per Fraction (PHASEIIDOSEFRACT) • Phase II Number of Fractions (PHASEIINUMFRACT) • Phase II Radiation External Beam Planning Tech (PHASEIIBEAMTECH) • Phase II Radiation Primary Treatment Volume (PHASEIIPRIMTXVOL) • Phase II Radiation Treatment Modality (PHASEIIRTMODALITY) • Phase II Total Dose (PHASEIITOTALDOSE)
Definition:	Identifies the draining lymph nodes treated (if any) during the second phase of radiation therapy delivered to the patient during the first course of treatment.
Values:	<p>00: No radiation treatment to draining lymph nodes</p> <p>01: Neck lymph node regions</p> <p>02: Thoracic lymph node regions</p> <p>03: Neck and thoracic lymph node regions</p> <p>04: Breast/Chest wall lymph node regions</p> <p>05: Abdominal lymph nodes</p> <p>06: Pelvic lymph nodes</p> <p>07: Abdominal and pelvic lymph nodes</p> <p>08: Lymph node region, NOS</p> <p>88: Not applicable; Phase II Radiation Primary Treatment Volume is lymph nodes</p> <p>99: Unknown if any radiation treatment to draining lymph nodes; Unknown if radiation treatment administered</p> <p>Blank: No Phase II radiation treatment administered or year of diagnosis prior to 2018</p>

California Cancer Registry Data Dictionary

Variable Name: PHASEIITOTALDOSE

Eureka Name: Phase II Total Dose

NAACCR Item: 1517

Category: Treatment, Radiation

Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables:

- Phase II Dose Per Fraction (PHASEIIDOSEFRACT)
- Phase II Number of Fractions (PHASEIINUMFRACT)
- Phase II Radiation External Beam Planning Tech (PHASEIIBEAMTECH)
- Phase II Radiation Primary Treatment Volume (PHASEIIPRIMTXVOL)
- Phase II Radiation to Draining Lymph Nodes (PHASEIIRTOLN)
- Phase II Radiation Treatment Modality (PHASEIIRTMODALITY)

Definition: Identifies the total radiation dose delivered to the patient in the second phase of radiation treatment during the first course of treatment. The unit of measure is centiGray (cGy).

Values:

000000:	No radiation treatment administered
000001-999997:	Actual total dose delivered in cGy
999998:	Not applicable, brachytherapy or radioisotopes administered to the patient
999999:	Radiation therapy was administered, but dose is unknown; It is unknown whether radiation therapy was administered.
Blank:	No Phase II radiation treatment administered or year of diagnosis prior to 2018

California Cancer Registry Data Dictionary

Variable Name:	PHASEIIIBEAMTECH
Eureka Name:	Phase III Radiation External Beam Planning Tech
NAACCR Item:	1522
Category:	Treatment, Radiation
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • Phase III Dose Per Fraction (PHASEIIIDOSEFRACT) • Phase III Number of Fractions (PHASEIIINUMFRACT) • Phase III Radiation Primary Treatment Volume (PHASEIIIPRIMTXVOL) • Phase III Radiation to Draining Lymph Nodes (PHASEIIIRTOLN) • Phase III Radiation Treatment Modality (PHASEIIIRTMODALITY) • Phase III Total Dose (PHASEIIITOTALDOSE)

Definition: Identifies the external beam radiation planning technique used to administer the third phase of radiation treatment during the first course of treatment.

Values:	00:	No radiation treatment
	01:	External beam, NOS
	02:	Low energy x-ray/photon therapy
	03:	2-D therapy
	04:	Conformal or 3-D conformal therapy
	05:	Intensity modulated therapy
	06:	Stereotactic radiotherapy or radiosurgery, NOS
	07:	Stereotactic radiotherapy or radiosurgery, robotic
	08:	Stereotactic radiotherapy or radiosurgery, Gamma Knife®
	09:	CT-guided online adaptive therapy
	10:	MR-guided online adaptive therapy
	88:	Not applicable
	98:	Other, NOS
	99:	Unknown
	Blank:	No Phase III radiation treatment administered or year of diagnosis prior to 2018

California Cancer Registry Data Dictionary

Variable Name:	PHASEIIIDOSEFRACT
Eureka Name:	Phase III Dose Per Fraction
NAACCR Item:	1521
Category:	Treatment, Radiation
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • Phase III Number of Fractions (PHASEIIINUMFRACT) • Phase III Radiation External Beam Planning Tech (PHASEIIIBEAMTECH) • Phase III Radiation Primary Treatment Volume (PHASEIIIPRIMTXVOL) • Phase III Radiation to Draining Lymph Nodes (PHASEIIIRTOLN) • Phase III Radiation Treatment Modality (PHASEIIIRTMODALITY) • Phase III Total Dose (PHASEIIITOTALDOSE)
Definition:	Records the dose per fraction (treatment session) delivered to the patient in the third phase of radiation during the first course of treatment. The unit of measure is centiGray (cGy).
Values:	<p>00000: No radiation treatment</p> <p>00001-99997: Actual Phase III dose delivered in cGy</p> <p>99998: Not applicable, radioisotopes administered to the patient</p> <p>99999: Phase III radiation therapy was administered but dose is unknown; it is unknown whether Phase III radiation therapy was administered; death certificate only.</p> <p>Blank: No Phase III radiation treatment administered or year of diagnosis prior to 2018</p>

California Cancer Registry Data Dictionary

Variable Name:	PHASEIIINUMFRACT
Eureka Name:	Phase III Number of Fractions
NAACCR Item:	1523
Category:	Treatment, Radiation
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • Phase III Dose Per Fraction (PHASEIIIDOSEFRACT) • Phase III Radiation External Beam Planning Tech (PHASEIIIBEAMTECH) • Phase III Radiation Primary Treatment Volume (PHASEIIIPRIMTXVOL) • Phase III Radiation to Draining Lymph Nodes (PHASEIIIRTOLN) • Phase III Radiation Treatment Modality (PHASEIIIRTMODALITY) • Phase III Total Dose (PHASEIIITOTALDOSE)
Definition:	Records the total number of fractions (treatment sessions) administered to the patient in the third phase of radiation during the first course of treatment.
Values:	<p>000: No radiation treatment</p> <p>001-998: Number of fractions administered to the patient during the third phase of radiation therapy</p> <p>999: Phase III Radiation therapy was administered, but the number of fractions is unknown; It is unknown whether radiation therapy was administered</p> <p>Blank: No Phase III radiation treatment administered or year of diagnosis prior to 2018</p>

California Cancer Registry Data Dictionary

Variable Name:	PHASEIIIPRIMTXVOL
Eureka Name:	Phase III Radiation Primary Treatment Volume
NAACCR Item:	1524
Category:	Treatment, Radiation
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • Phase III Dose Per Fraction (PHASEIIIDOSEFRACT) • Phase III Number of Fractions (PHASEIIINUMFRACT) • Phase III Radiation External Beam Planning Tech (PHASEIIIBEAMTECH) • Phase III Radiation to Draining Lymph Nodes (PHASEIIIRTOLN) • Phase III Radiation Treatment Modality (PHASEIIIRTMODALITY) • Phase III Total Dose (PHASEIIITOTALDOSE)

Definition: Identifies the primary treatment volume or primary anatomic target treated during the third phase of radiation therapy during the first course of treatment.

Values:	00:	No phase III radiation treatment
	01:	Neck lymph node regions
	02:	Thoracic lymph node regions
	03:	Neck and thoracic lymph node regions
	04:	Breast/Chest wall lymph node regions
	05:	Abdominal lymph nodes
	06:	Pelvic lymph nodes
	07:	Abdominal and pelvic lymph nodes
	09:	Lymph node region, NOS
	10:	Eye/orbit/optic nerve
	11:	Pituitary
	12:	Brain
	13:	Brain (Limited)
	14:	Spinal cord
	20:	Nasopharynx
	21:	Oral Cavity
	22:	Oropharynx
	23:	Larynx (glottis) or hypopharynx
	24:	Sinuses/Nasal tract
	25:	Parotid or other salivary glands
	26:	Thyroid
	29:	Head and neck (NOS)
	30:	Lung or bronchus
	31:	Mesothelium
	32:	Thymus

California Cancer Registry Data Dictionary

- 39: Chest/lung (NOS)
- 40: Breast - whole
- 41: Breast - partial
- 42: Chest wall
- 50: Esophagus
- 51: Stomach
- 52: Small bowel
- 53: Colon
- 54: Rectum
- 55: Anus
- 56: Liver
- 57: Biliary tree or gallbladder
- 58: Pancreas or hepatopancreatic ampulla
- 59: Abdomen (NOS)
- 60: Bladder - whole
- 61: Bladder - partial
- 62: Kidney
- 63: Ureter
- 64: Prostate - whole
- 65: Prostate - partial
- 66: Urethra
- 67: Penis
- 68: Testicle or scrotum
- 70: Ovaries or fallopian tubes
- 71: Uterus or Cervix
- 72: Vagina
- 73: Vulva
- 80: Skull
- 81: Spine/vertebral bodies
- 82: Shoulder
- 83: Ribs
- 84: Hip
- 85: Pelvic bones
- 86: Pelvis (NOS, non-visceral)
- 88: Extremity bone, NOS
- 90: Skin
- 91: Soft tissue
- 92: Hemibody
- 93: Whole body
- 94: Mantle, mini-mantle (obsolete after 2017)
- 95: Lower extended field (obsolete after 2017)
- 96: Inverted Y (obsolete after 2017)
- 97: Invalid historical **FORDS** value
- 98: Other
- 99: Unknown

Blank: No phase III radiation treatment administered or year of diagnosis prior to 2018

California Cancer Registry Data Dictionary

Variable Name:	PHASEIIIRTMODALITY
Eureka Name:	Phase III Radiation Treatment Modality
NAACCR Item:	1526
Category:	Treatment, Radiation
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • Phase III Dose Per Fraction (PHASEIIIDOSEFRACT) • Phase III Number of Fractions (PHASEIIINUMFRACT) • Phase III Radiation External Beam Planning Tech (PHASEIIIBEAMTECH) • Phase III Radiation Primary Treatment Volume (PHASEIIIPRIMTXVOL) • Phase III Radiation to Draining Lymph Nodes (PHASEIIIRTTOLN) • Phase III Total Dose (PHASEIIITOTALDOSE)
Definition:	Identifies the radiation modality administered during the third phase of radiation treatment delivered during the first course of treatment.
Values:	<p>00: No radiation treatment</p> <p>01: External beam, NOS</p> <p>02: External beam, photons</p> <p>03: External beam, protons</p> <p>04: External beam, electrons</p> <p>05: External beam, neutrons</p> <p>06: External beam, carbon ions</p> <p>07: Brachytherapy, NOS</p> <p>08: Brachytherapy, intracavitary, LDR</p> <p>09: Brachytherapy, intracavitary, HDR</p> <p>10: Brachytherapy, Interstitial, LDR</p> <p>11: Brachytherapy, Interstitial, HDR</p> <p>12: Brachytherapy, electronic</p> <p>13: Radioisotopes, NOS</p> <p>14: Radioisotopes, Radium-232</p> <p>15: Radioisotopes, Strontium-89</p> <p>16: Radioisotopes, Strontium-90</p> <p>99: Treatment radiation modality unknown; Unknown if radiation treatment administered</p> <p>Blank: No Phase III radiation treatment administered or year of diagnosis prior to 2018</p>

California Cancer Registry Data Dictionary

Variable Name:	PHASEIIIRTOLN
Eureka Name:	Phase III Radiation to Draining Lymph Nodes
NAACCR Item:	1525
Category:	Treatment, Radiation
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • Phase III Dose Per Fraction (PHASEIIDOSEFRACT) • Phase III Number of Fractions (PHASEIINUMFRACT) • Phase III Radiation External Beam Planning Tech (PHASEIIBEAMTECH) • Phase III Radiation Primary Treatment Volume (PHASEIIPRIMTXVOL) • Phase III Radiation Treatment Modality (PHASEIIIRTMODALITY) • Phase III Total Dose (PHASEIIITOTALDOSE)
Definition:	Identifies the draining lymph nodes treated (if any) during the third phase of radiation therapy delivered to the patient during the first course of treatment.
Values:	<p>00: No radiation treatment</p> <p>01: Neck lymph node regions</p> <p>02: Thoracic lymph node regions</p> <p>03: Neck and thoracic lymph node regions</p> <p>04: Breast/Chest wall lymph node regions</p> <p>05: Abdominal lymph nodes</p> <p>06: Pelvic lymph nodes</p> <p>07: Abdominal and pelvic lymph nodes</p> <p>08: Lymph node region, NOS</p> <p>88: Not applicable; Phase III Radiation Primary Treatment Volume is lymph nodes</p> <p>99: Unknown if any radiation treatment to draining lymph nodes; Unknown if radiation treatment administered</p> <p>Blank: No Phase III radiation treatment administered or year of diagnosis prior to 2018</p>

California Cancer Registry Data Dictionary

Variable Name: PHASEIIITOTALDOSE

Eureka Name: Phase III Total Dose

NAACCR Item: 1527

Category: Treatment, Radiation

Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables:

- Phase III Dose Per Fraction (PHASEIIIDOSEFRACT)
- Phase III Number of Fractions (PHASEIIINUMFRACT)
- Phase III Radiation External Beam Planning Tech (PHASEIIIBEAMTECH)
- Phase III Radiation Primary Treatment Volume (PHASEIIIPRIMTXVOL)
- Phase III Radiation to Draining Lymph Nodes (PHASEIIIRTOLN)
- Phase III Radiation Treatment Modality (PHASEIIIRTMODALITY)

Definition: Identifies the total radiation dose delivered to the patient in the third phase of radiation treatment during the first course of treatment. The unit of measure is centiGray (cGy).

Values:

000000:	No radiation treatment administered
000001-999997:	Actual total dose delivered in cGy
999998:	Not applicable, radioisotopes administered to the patient
999999:	Radiation therapy was administered but dose is unknown; It is unknown whether radiation therapy was administered
Blank:	No Phase III radiation treatment administered or year of diagnosis prior to 2018

California Cancer Registry Data Dictionary

Variable Name: PHONE
Eureka Name: Telephone
NAACCR Item: 2360
Category: Administrative
Level of Variable: Patient
Time Period Available: 1988 - current year

Related Variables:

Definition: Patient's latest phone number or phone number where patient can be contacted.

Values: 10-digit numerical code, with 3-digit area code and 7-digit number.

0000000000: No phone number

9999999999: Unknown phone number

California Cancer Registry Data Dictionary

Variable Name: PLEURALEFFUSION
Eureka Name: Pleural Effusion
NAACCR Item: 3913
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 - current year
Related Variables: CS Site-Specific Factor 1 (CS_SITE_SPEC_F1)

Definition: Pleural effusion is the accumulation of fluid between the parietal pleura (the pleura covering the chest wall and diaphragm) and the visceral pleura (the pleura covering the lungs). Valid for cases diagnosed January 1, 2018 and forward. For pleura cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F1.

Values:

- 0: Pleural effusion not identified/not present
- 1: Pleural effusion present, non-malignant (negative)
- 2: Pleural effusion present, malignant (positive)
- 3: Pleural effusion, atypical/atypical mesothelial cells
- 4: Pleural effusion, NOS
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Pleural Effusion not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: PLEURALINV
Eureka Name: Visceral and Parietal Pleural Invasion
NAACCR Item: 3937
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 - current year

Related Variables:

Definition: Visceral and Parietal Pleural Invasion is defined as invasion beyond the elastic layer or to the surface of the visceral pleura.

Values:

- 0: No evidence of visceral pleural invasion identified; Tumor does not completely traverse the elastic layer of the pleura; Stated as PL0
- 1: Invasion of visceral elastic layer; Not beyond visceral pleural; Stated as PL1
- 2: Invasion outside surface of the visceral pleura; Invasion through outer surface of the visceral pleura; Stated as PL2
- 3: Tumor invades into or through the parietal pleura OR chest wall; Stated as PL3
- 4: Invasion of visceral pleura present, NOS; not stated if PL1 or PL2
- 6: Tumor extends to pleura, NOS; not stated if visceral or parietal
- 8: Not applicable: Information not collected for this case
- 9: No surgical resection of primary site is performed; Visceral Pleural Invasion not assessed or unknown if assessed or cannot be determined
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: PNODETU
Eureka Name: Regional Nodes Positive
NAACCR Item: 820
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 1988 - current year

Related Variables:

Definition: Number of regional lymph nodes with evidence of involvement (positive).

Values:

- 00: All nodes examined are negative
- 01-89: 1-89 nodes are positive (exact number of nodes positive)
- 90: Ninety or more nodes positive
- 95: Positive aspiration of lymph node(s) was performed
- 97: Positive nodes are documented, but the number is unspecified
- 98: No nodes were examined
- 99: Unknown whether nodes are positive; not applicable; not stated in patient record
- Blank: Not abstracted

California Cancer Registry Data Dictionary

Variable Name: PROSTATEPATHEXT
Eureka Name: Prostate Pathological Extension
NAACCR Item: 3919
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 - current year
Related Variables: CS Site-Specific Factor 3 (CS_SITE_SPEC_F3)

Definition: Pathological extension is used to assign pT category for prostate cancer based on radical prostatectomy specimens. Valid for cases diagnosed January 1, 2018 and forward. For prostate cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F3.

Notes: See the most current version of EOD (Prostate) (<https://staging.seer.cancer.gov/>) for rules and site-specific codes and coding structures.

Values:

- 000: In situ: noninvasive; intraepithelial
- 300: Invasion into (but not beyond) prostatic capsule; Intracapsular involvement only;
No extracapsular extension.
Confined to prostate, NOS
Localized, NOS
- 350: Bladder neck, microscopic invasion
Extraprostatic extension (beyond prostatic capsule), unilateral, bilateral, or NOS
WITHOUT invasion of the seminal vesicles
Extension to periprostatic tissue WITHOUT invasion of the seminal vesicles
- 400: Tumor invades seminal vesicle(s)
- 500: Extraprostatic tumor that is not fixed WITHOUT invasion of adjacent structures
Periprostatic extension, NOS (unknown if seminal vesicle(s) involved)
Extraprostatic extension, NOS (unknown if seminal vesicle(s) involved)
Through capsule, NOS
- 600: Bladder neck, except microscopic bladder neck involvement
Bladder, NOS
External sphincter
Extraprostatic urethra (membranous urethra)
Fixation, NOS
Levator muscles
Rectovesical (Denonvillier's) fascia
Rectum
Skeletal muscle
Ureter(s)
- 700: Extension to or fixation to pelvic wall or pelvic bone
"Frozen pelvis", NOS
Further contiguous extension including: Other organs, penis, sigmoid colon, soft

California Cancer Registry Data Dictionary

tissue other than periprostatic

800: No evidence of primary tumor

900: No prostatectomy or autopsy performed

950: Prostatectomy performed, but not first course of treatment. For example, performed after disease progression.

999: Unknown; extension not stated

Unknown if prostatectomy done

Primary tumor cannot be assessed

Not documented in patient record

California Cancer Registry Data Dictionary

Variable Name: PROTOCOL
Eureka Name: Protocol Participation
NAACCR Item: N/A
Category: Administrative
Level of Variable: Admission
Time Period Available: 2002 - current year

Related Variables:

Definition: Code indicating agency or group that established the protocol in which the patient is participating (i.e., clinical trial or treatment standard). Value taken from the facility with the earliest date of admission.

Values:

00:	Not applicable
01:	NSABP
02:	GOG
03:	RTOG
04:	SWOG
05:	ECOG
06:	POG
07:	CCG
08:	CALGB
09:	NCI
10:	ACS
11:	National protocol, NOS
12:	ACoS-OG
13:	VA (Veterans Admin)
14:	COG (Children's Oncology Group)
15:	CTSU (Clinical Trials Support Unit)
16-50:	National Trials
51-79:	Locally defined
80:	Pharmaceutical
81-84:	Locally defined
85:	In-house trial
86-88:	Locally defined
89:	Other
90-98:	Locally defined
99:	Unknown

California Cancer Registry Data Dictionary

Variable Name:	PRPERCENTPOSORRNG
Eureka Name:	Progesterone Receptor Percent Positive or Range
NAACCR Item:	3914
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	Progesterone Receptor Summary (PRSUMMARY)
Definition:	Progesterone Receptor, Percent Positive or Range is the percent of cells staining progesterone receptor positive measured by IHC.
Values:	<p>000: PR negative, or stated as less than 1%</p> <p>001-100: 1-100 percent</p> <p>R10: Stated as 1-10%</p> <p>R20: Stated as 11-20%</p> <p>R30: Stated as 21-30%</p> <p>R40: Stated as 31-40%</p> <p>R50: Stated as 41-50%</p> <p>R60: Stated as 51-60%</p> <p>R70: Stated as 61-70%</p> <p>R80: Stated as 71-80%</p> <p>R90: Stated as 81-90%</p> <p>R99: Stated as 91-100%</p> <p>XX8: Not applicable: Information not collected for this case</p> <p>XX9: Not documented in medical record; PR (Progesterone Receptor) Percent Positive or Range not assessed or unknown if assessed</p> <p>Blank: Date of Diagnosis pre-2018; Non-required Schema ID</p>

California Cancer Registry Data Dictionary

Variable Name:	PRSUMMARY
Eureka Name:	Progesterone Receptor Summary
NAACCR Item:	3915
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • Progesterone Receptor Percent Positive or Range (PRPERCENTPOSORRNG) • CS Site-Specific Factor 2 (CS_SITE_SPEC_F2)

Definition: PR (Progesterone Receptor) Summary is a summary of results from the progesterone receptor (PR) assay. Valid for breast cancers diagnosed January 1, 2018 and forward. For breast cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F2.

Values:	0:	PR negative
	1:	PR positive
	7:	Test ordered, results not in chart
	9:	Not documented in medical record; Cannot be determined (indeterminate); PR (Progesterone Receptor) Summary status not assessed or unknown if assessed
	Blank:	Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: PRTOTALALLRED
Eureka Name: Progesterone Receptor Total Allred Score
NAACCR Item: 3916
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 - current year
Related Variables:

- Progesterone Receptor Percent Positive or Range (PRPERCENTPOSORRNG)
- Progesterone Receptor Summary (PRSUMMARY)

Definition: Progesterone Receptor, Total Allred Score is based on the percentage of cells that stain by IHC for progesterone receptor (PR) and the intensity of that staining.

Values:

- 00: Total PR Allred score of 0
- 01: Total PR Allred score of 1
- 02: Total PR Allred score of 2
- 03: Total PR Allred score of 3
- 04: Total PR Allred score of 4
- 05: Total PR Allred score of 5
- 06: Total PR Allred score of 6
- 07: Total PR Allred score of 7
- 08: Total PR Allred score of 8
- X8: Not applicable: Information not collected for this case
- X9: Not documented in medical record; PR (Progesterone Receptor)
Total Allred Score not assessed, or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: PSAVALUE
Eureka Name: PSA (Prostatic Specific Antigen) Lab Value
NAACCR Item: 3920
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 - current year
Related Variables: CS Site-Specific Factor 1 (CS_SITE_SPEC_F1)

Definition: PSA (Prostatic Specific Antigen) is a protein produced by cells of the prostate gland and is elevated in patients with prostate cancer. This data item pertains to PSA lab value. Valid for cases diagnosed January 1, 2018 and forward. For prostate cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F1.

Values:

0.1:	0.1 or less nanograms/milliliter (ng/ml) (Exact value to nearest tenth of ng/ml)
02-999.9:	0.2–999.9 ng/ml (Exact value to nearest tenth of ng/ml)
XXX.1:	1,000 ng/ml or greater
XXX.7:	Test ordered, results not in chart
XXX.9:	Not documented in medical record; PSA lab value not assessed or unknown if assessed

California Cancer Registry Data Dictionary

Variable Name: PSCLERCHOLANGITIS
Eureka Name: Primary Sclerosing Cholangitis

NAACCR Item: 3917

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables: CS Site-Specific Factor 11 (CSSITESPECIFICFACTOR11)

Definition: Primary sclerosing cholangitis (PSC) denotes a chronic autoimmune inflammation of the bile ducts that leads to scar formation and narrowing of the ducts over time. It is a prognostic factor for intrahepatic bile duct cancer. Valid for cases diagnosed January 1, 2018 and forward. For intrahepatic bile duct cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR11.

Values:

- 0: PSC not identified/not present
- 1: PSC present
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; PSC not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: QME

Eureka Name: N/A

NAACCR Item: N/A

Category: Patient Demographics

Level of Variable: Patient

Time Period Available: 1988 - current year

Related Variables:

- Name -- Last (LNAME)
- Race/ethnicity including Middle Eastern origin (RACEME)
- Source of Middle Eastern surname (SRCSUR)

Definition: Flag indicating whether the patient's last name is on the Middle Eastern surname list. The Middle Eastern surname list was created in 2007. For detailed information see: Nasser, K. (2007). "Construction and validation of a list of common Middle Eastern surnames for epidemiological research." Cancer Detect Prev 31 (5): 424-9.

Notes: For additional information, please see Appendix "Variables Pertaining to Race/Ethnicity in the CCR".

Values:

- 0: No
- 1: Yes

California Cancer Registry Data Dictionary

Variable Name:	QUINYANG
Eureka Name:	N/A
NAACCR Item:	N/A
Category:	Socioeconomic Indicators
Level of Variable:	Tumor
Time Period Available:	2006 – current year
Related Variables	<ul style="list-style-type: none"> • Index of Socioeconomic Status of Block Group (YANGSCL) for cases diagnosed 2006 forward • Index of Socioeconomic Status of Block Group with Missing Values Imputed (YANGSCLIMPUTED) for cases diagnosed 2006 forward • Socioeconomic Status Quintile of Block Group with Missing Values Imputed (QUINYANGIMPUTED) for cases diagnosed 2006 forward • Reliability of SES Indexes YANGSCL and YANGSCLIMPUTED (YANGRELIABILITY) • Index of Socioeconomic Status of Block Group (YOSTSCL) for cases diagnosed 1988 through 2005 • Socioeconomic Status Quintile of Block Group (QUINYOST) for cases diagnosed 1988 through 2005
Definition:	Socioeconomic status (SES) quintile of Juan Yang's index of socioeconomic status (YANGSCL) based on principal components analysis of block group level variables from the American Community Survey. Valid for cases diagnosed 2006 and forward. Also see QUINYANGIMPUTED for cases diagnosed 2006 and forward. For cases diagnosed 1988 through 2005, see QUINYOST.
Notes:	Further documentation on all “Yang” variables is available at https://cancerregistry.ucsf.edu/resources/research-tools
Values:	1: Lowest SES 2: Lower-Middle SES 3: Middle SES 4: Upper-Middle SES 5: Highest SES

California Cancer Registry Data Dictionary

Variable Name:	QUINYANGIMPUTED
Eureka Name:	N/A
NAACCR Item:	N/A
Category:	Socioeconomic Indicators
Level of Variable:	Tumor
Time Period Available:	2006 – current year
Related Variables:	<ul style="list-style-type: none"> • Index of Socioeconomic Status of Block Group with Missing Values Imputed (YANGSCLIMPUTED) for cases diagnosed 2006 and forward • Index of Socioeconomic Status of Block Group (YANGSCL) for cases diagnosed 2006 and forward • Socioeconomic Status Quintile of Block Group (QUINYANG) for cases diagnosed 2006 and forward • Reliability of SES Indexes YANGSCL and YANGSCLIMPUTED (YANGRELIABILITY) • Index of Socioeconomic Status of Block Group (YOSTSCL) for cases diagnosed 1988 through 2005 • Socioeconomic Status Quintile of Block Group (QUINYOST) for cases diagnosed 1988 through 2005
Definition:	Socioeconomic status (SES) quintile of Juan Yang's index of socioeconomic status with missing values imputed (YANGSCLIMPUTED) based on principal components analysis of block group level variables from the American Community Survey. Valid for cases diagnosed 2006 and forward. Also see QUINYANG for cases diagnosed 2006 and forward. For cases diagnosed 1988 through 2005, see QUINYOST.
Notes:	Further documentation is available at https://cancerregistry.ucsf.edu/resources/research-tools
Values:	<ol style="list-style-type: none"> 1: Lowest SES 2: Lower-Middle SES 3: Middle SES 4: Upper-Middle SES 5: Highest SES

California Cancer Registry Data Dictionary

Variable Name: QUINYOST

Eureka Name: N/A

NAACCR Item: N/A

Category: Socioeconomic Indicators

Level of Variable: Tumor

Time Period Available: 1988 - 2005

Related Variables:

- Index of Socioeconomic Status of Block Group (YOSTSCL) for cases diagnosed 1988 through 2005
- Index of Socioeconomic Status of Block Group (YANGSCL) for cases diagnosed 2006 forward
- Socioeconomic Status Quintile of Block Group (QUINYANG) for cases diagnosed 2006 forward
- Index of Socioeconomic Status of Block Group with Missing Values Imputed (YANGSCLIMPUTED) for cases diagnosed 2006 forward
- Socioeconomic Status Quintile of Block Group with Missing Values Imputed (QUINYANGIMPUTED) for cases diagnosed 2006 forward

Definition: Socioeconomic Status (SES) quintile of YOSTSCL based on Census variables at the block group level. This variable applies to cases diagnosed 1988 to 2005. For cases diagnosed 2006 and forward, see QUINYANG and QUINYANGIMPUTED.

Values:

- 1: Lowest SES
- 2: Lower-Middle SES
- 3: Middle SES
- 4: Upper-Middle SES
- 5: Highest SES

California Cancer Registry Data Dictionary

Variable Name:	RACE1
Eureka Name:	Race 1
NAACCR Item:	160
Category:	Patient Demographics
Level of Variable:	Patient
Time Period Available:	1988 - current year
Related Variables:	<ul style="list-style-type: none"> • Race 2 (RACE2) • Race 3 (RACE3) • Race 4 (RACE4) • Race 5 (RACE5) • Race/Ethnicity of Patient (RACEGROUP)

Definition: Race/ethnicity of the patient.

Notes: For additional information, please see Appendix "Variables Pertaining to Race/Ethnicity in the CCR".

Values:	01: White
	02: Black
	03: American Indian, Aleutian, or Eskimo
	04: Chinese
	05: Japanese
	06: Filipino
	07: Hawaiian
	08: Korean
	10: Vietnamese
	11: Laotian
	12: Hmong
	13: Kampuchean (Cambodian)
	14: Thai
	15: Asian Indian or Pakistani, NOS
	16: Asian Indian
	17: Pakistani
	20: Micronesian, NOS
	21: Chamorroan, Chamoru
	22: Guamanian, NOS
	25: Polynesian, NOS
	26: Tahitian
	27: Samoan
	28: Tongan
	30: Melanesian, NOS
	31: Fiji Islander
	32: New Guinean
	90: Other South Asian, Bangladeshi, Bhutanese, Nepalese, Sikkimese, Sri Lankan
	96: Other Asian, including Burmese, Indonesian, Asian, NOS, and Oriental, NOS
	97: Pacific Islander, NOS
	98: Other
	99: Unknown

California Cancer Registry Data Dictionary

Variable Name: RACE2
Eureka Name: Race 2
NAACCR Item: 161
Category: Patient Demographics
Level of Variable: Patient
Time Period Available: 2000 - current year
Related Variables:

- Race 1 (RACE1)
- Race 3 (RACE3)
- Race 4 (RACE4)
- Race 5 (RACE5)

Definition: Race/ethnicity of the patient. This field was added in 2000 to allow for the identification of multiple races.

Notes: For additional information, please see Appendix "Variables Pertaining to Race/Ethnicity in the CCR".

Values:

- 01: White
- 02: Black
- 03: American Indian, Aleutian, or Eskimo
- 04: Chinese
- 05: Japanese
- 06: Filipino
- 07: Hawaiian
- 08: Korean
- 10: Vietnamese
- 11: Laotian
- 12: Hmong
- 13: Kampuchean (Cambodian)
- 14: Thai
- 15: Asian Indian or Pakistani, NOS
- 16: Asian Indian
- 17: Pakistani
- 20: Micronesian, NOS
- 21: Chamorro, Chamoru
- 22: Guamanian, NOS
- 25: Polynesian, NOS
- 26: Tahitian
- 27: Samoan
- 28: Tongan
- 30: Melanesian, NOS
- 31: Fiji Islander
- 32: New Guinean
- 88: No further race documented
- 90: Other South Asian, Bangladeshi, Bhutanese, Nepalese, Sikkimese, Sri Lankan
- 96: Other Asian, including Burmese, Indonesian, Asian, NOS, and Oriental, NOS
- 97: Pacific Islander, NOS
- 98: Other
- 99: Unknown

California Cancer Registry Data Dictionary

Variable Name: RACE3
Eureka Name: Race 3
Category: Level of Variable: Patient Demographics
 Patient

Time Period Available: 2000 - current year

Related Variables:

- Race 1 (RACE1)
- Race 2 (RACE2)
- Race 4 (RACE4)
- Race 5 (RACE5)

Definition: Race/ethnicity of the patient. This field was added in 2000 to allow for the identification of multiple races.

Notes: For additional information, please see Appendix "Variables Pertaining to Race/Ethnicity in the CCR".

Values:

- 01: White
- 02: Black
- 03: American Indian, Aleutian, or Eskimo
- 04: Chinese
- 05: Japanese
- 06: Filipino
- 07: Hawaiian
- 08: Korean
- 10: Vietnamese
- 11: Laotian
- 12: Hmong
- 13: Kampuchean (Cambodian)
- 14: Thai
- 15: Asian Indian or Pakistani, NOS
- 16: Asian Indian
- 17: Pakistani
- 20: Micronesian, NOS
- 21: Chamorran, Chamoru
- 22: Guamanian, NOS
- 25: Polynesian, NOS
- 26: Tahitian
- 27: Samoan
- 28: Tongan
- 30: Melanesian, NOS
- 31: Fiji Islander
- 32: New Guinean
- 88: No further race documented
- 90: Other South Asian, Bangladeshi, Bhutanese, Nepalese, Sikkimese, Sri Lankan
- 96: Other Asian, including Burmese, Indonesian, Asian, NOS, and Oriental, NOS
- 97: Pacific Islander, NOS
- 98: Other
- 99: Unknown

California Cancer Registry Data Dictionary

Variable Name: RACE4
Eureka Name: Race 4
Category: Patient Demographics
Level of Variable: Patient
Time Period Available: 2000 - current year
Related Variables:

- Race 1 (RACE1)
- Race 2 (RACE2)
- Race 3 (RACE3)
- Race 5 (RACE5)

Definition: Race/ethnicity of the patient. This field was added in 2000 to allow for the identification of multiple races.

Notes: For additional information, please see Appendix "Variables Pertaining to Race/Ethnicity in the CCR".

Values:

- 01: White
- 02: Black
- 03: American Indian, Aleutian, or Eskimo
- 04: Chinese
- 05: Japanese
- 06: Filipino
- 07: Hawaiian
- 08: Korean
- 10: Vietnamese
- 11: Laotian
- 12: Hmong
- 13: Kampuchean (Cambodian)
- 14: Thai
- 15: Asian Indian or Pakistani, NOS
- 16: Asian Indian
- 17: Pakistani
- 20: Micronesian, NOS
- 21: Chamorran, Chamoru
- 22: Guamanian, NOS
- 25: Polynesian, NOS
- 26: Tahitian
- 27: Samoan
- 28: Tongan
- 30: Melanesian, NOS
- 31: Fiji Islander
- 32: New Guinean
- 88: No further race documented
- 90: Other South Asian, Bangladeshi, Bhutanese, Nepalese, Sikkimese, Sri Lankan
- 96: Other Asian, including Burmese, Indonesian, Asian, NOS, and Oriental, NOS
- 97: Pacific Islander, NOS
- 98: Other
- 99: Unknown

California Cancer Registry Data Dictionary

Variable Name: RACE5
Eureka Name: Race 5
Category: Patient Demographics
Level of Variable: Patient
Time Period Available: 2000 - current year
Related Variables:

- Race 1 (RACE1)
- Race 2 (RACE2)
- Race 3 (RACE3)
- Race 4 (RACE4)

Definition: Race/ethnicity of the patient. This field was added in 2000 to allow for the identification of multiple races.

Notes: For additional information, please see Appendix "Variables Pertaining to Race/Ethnicity in the CCR".

Values:

- 01: White
- 02: Black
- 03: American Indian, Aleutian, or Eskimo
- 04: Chinese
- 05: Japanese
- 06: Filipino
- 07: Hawaiian
- 08: Korean
- 10: Vietnamese
- 11: Laotian
- 12: Hmong
- 13: Kampuchean (Cambodian)
- 14: Thai
- 15: Asian Indian or Pakistani, NOS
- 16: Asian Indian
- 17: Pakistani
- 20: Micronesian, NOS
- 21: Chamorran, Chamoru
- 22: Guamanian, NOS
- 25: Polynesian, NOS
- 26: Tahitian
- 27: Samoan
- 28: Tongan
- 30: Melanesian, NOS
- 31: Fiji Islander
- 32: New Guinean
- 88: No further race documented
- 90: Other South Asian, Bangladeshi, Bhutanese, Nepalese, Sikkimese, Sri Lankan
- 96: Other Asian, including Burmese, Indonesian, Asian, NOS, and Oriental, NOS
- 97: Pacific Islander, NOS
- 98: Other
- 99: Unknown

California Cancer Registry Data Dictionary

Variable Name: RACEGROUP

Eureka Name: N/A

NAACCR Item: N/A

Category: Patient Demographics

Level of Variable: Patient

Time Period Available: 1988 - current year

Related Variables:

- Race 1 (RACE1)
- NHIA Derived Hisp Origin (NHIA)
- Race--NAPIIA (Derived API) (NAPIIA)
- IHS Link (IHSLINK)

Definition: Race/ethnicity of the patient including Hispanic ethnicity. This variable is not a collected data item but derived from RACE1, NAACCR's Hispanic and Asian Pacific Islander Identification algorithm, and results of the Indian Health Services Linkage.

Notes: The CCR uses RACEGROUP for statistical reports. RACEGROUP replaces older versions of this variable including RACE99 and RACE08. For additional information, please see Appendix "Variables Pertaining to Race/Ethnicity in the CCR".

Values:

- 1: Non-Hispanic White
- 2: Non-Hispanic Black
- 3: Hispanic
- 4: Asian/Pacific Islander
- 5: American Indian
- 9: Other/Unknown

California Cancer Registry Data Dictionary

Variable Name: RACEME
Eureka Name: N/A
NAACCR Item: N/A
Category: Patient Demographics
Level of Variable: Patient
Time Period Available: 1988 - current year
Related Variables: This variable is not a collected data item but derived from race (RACEGROUP) and a Middle Eastern Surname list (QME). SRCSUR is also a related variable.

Definition: Race/ethnicity of the patient including Middle Eastern origin.

Notes: For additional information, please see Appendix "Variables Pertaining to Race/Ethnicity in the CCR".

Values:

- 1: Non-Hispanic White
- 2: Non-Hispanic Black
- 3: Hispanic
- 4: Asian/Pacific Islander
- 5: Non-Hispanic American Indian
- 6: Middle Eastern
- 9: Other/Unknown

California Cancer Registry Data Dictionary

Variable Name: RADBSTMOD
Eureka Name: Rad Boost RX Modality
NAACCR Item: 3200
Category: Treatment, Radiation
Level of Variable: Tumor
Time Period Available: 2003 - 2017
Related Variables: Rad--Regional RX Modality (RADREGMOD)

Definition: Records the dominant modality of radiation therapy used to deliver the most clinically significant boost dose to the primary volume of interest during the first course of treatment. This is accomplished with external beam fields of reduced size (relative to the regional treatment fields), implants, stereotactic radiosurgery, conformal therapy, or intensity-modulated radiation therapy. External beam boosts may consist of two or more successive phases with progressively smaller fields, and they are generally coded as a single entity. This field is used with Rad--Regional RX Modality (RADREGMOD).

Values:

- 00: No boost treatment
- 20: External beam, NOS
- 21: Orthovoltage
- 22: Cobolt-60 & Cesium-137
- 23: Photons (2-5 MV)
- 24: Photons (6-10 MV)
- 25: Photons (11-19 MV)
- 26: Photons (>19 MV)
- 27: Photons (mixed energies)
- 28: Electrons
- 29: Photons and electrons mixed
- 30: Neutrons with or w/o photons/electrons
- 31: IMRT
- 32: Conformal or 3-D therapy
- 40: Protons
- 41: Stereotactic radiosurgery, NOS
- 42: Linac radiosurgery
- 43: Gamma Knife®
- 50: Brachytherapy, NOS
- 51: Brachytherapy, intracavitary, LDR
- 52: Brachytherapy, intracavitary, HDR
- 53: Brachytherapy, interstitial, LDR
- 54: Brachytherapy, interstitial, HDR
- 55: Radium
- 60: Radioisotopes, NOS
- 61: Strontium-89
- 62: Strontium-90
- 98: Other, NOS (Radiation therapy administered, but the treatment modality is not specified or is unknown)
- 99: Unknown, death certificate only (DCO)
- Blank: Diagnosed prior to January 1, 2003 or after December 31, 2017

California Cancer Registry Data Dictionary

Variable Name: RADREGMOD
Eureka Name: Rad--Regional RX Modality
NAACCR Item: 1570
Category: Treatment, Radiation
Level of Variable: Tumor
Time Period Available: 2003 - 2017
Related Variables: Rad Boost RX Modality (RADBSTMOD)

Definition: Records the dominant modality of radiation therapy used to deliver the most clinically significant regional dose to the primary volume of interest during the first course of treatment. Radiation treatment is frequently delivered in two or more phases which can be summarized as “regional” and “boost” treatments. To evaluate patterns of radiation oncology care, it is necessary to know which radiation resources were employed in the delivery of therapy. For outcomes analysis, the modalities used for each of these phases can be very important.

Values:

- 00: None, diagnosed at autopsy
- 20: External beam, NOS
- 21: Orthovoltage
- 22: Cobolt-60 & Cesium-137
- 23: Photons (2-5 MV)
- 24: Photons (6-10 MV)
- 25: Photons (11-19 MV)
- 26: Photons (>19 MV)
- 27: Photons (mixed energies)
- 28: Electrons
- 29: Photons and electrons mixed
- 30: Neutrons with or w/o photons/electrons
- 31: IMRT
- 32: Conformal or 3-D therapy
- 40: Protons
- 41: Stereotactic radiosurgery, NOS
- 42: Linac radiosurgery
- 43: Gamma Knife®
- 50: Brachytherapy, NOS
- 51: Brachytherapy, intracavitary, LDR
- 52: Brachytherapy, intracavitary, HDR
- 53: Brachytherapy, interstitial, LDR
- 54: Brachytherapy, interstitial, HDR
- 55: Radium
- 60: Radioisotopes, NOS
- 61: Strontium-89
- 62: Strontium-90
- 80*: Combination modality, specified*
- 85*: Combination modality, NOS*
- 98: Other, NOS (Radiation therapy administered, but the treatment modality is not specified or is unknown)
- 99: Unknown, death certificate only (DCO)

Blank: Diagnosed prior to January 1, 2003 or after December 31, 2017

* Codes 80 and 85 describe specific converted descriptions of radiation therapy coded according to Volume II ROADS and DAM rules and should only be used to record regional radiation for tumors diagnosed prior to January 1, 2003.

California Cancer Registry Data Dictionary

Variable Name:	RADSEQ
Eureka Name:	RX Summ--Surg/Rad Seq
NAACCR Item:	1380
Category:	Treatment
Level of Variable:	Tumor
Time Period Available:	1988 - current year
Related Variables:	<ul style="list-style-type: none"> • RX Summ--Radiation (RADSUM) • RX Summ--Surg Prim Site (SURGPRIM)

Definition: A code indicating the sequence of radiation therapy given with surgery (pre-op, post-op, etc.) during the first course of treatment.

Values:	0: No radiation and/or no surgery; unknown if surgery and/or radiation given
	2: Radiation before surgery
	3: Radiation after surgery
	4: Radiation both before and after surgery
	5: Intraoperative radiation
	6: Intraoperative radiation with other radiation given before and/or after surgery
	7: Surgery both before and after radiation
	9: Sequence unknown, but both surgery and radiation were given

California Cancer Registry Data Dictionary

Variable Name: RADSUM

Eureka Name: RX Summ--Radiation

NAACCR Item: 1360

Category: Treatment, Radiation

Level of Variable: Tumor

Time Period Available: 1988 - 2017

Related Variables:

- RX Date Radiation (RXDATER)
- Rad--Regional RX Modality (RADREGMOD)
- Rad Boost RX Modality (RADBSTMOD)

Definition: Summary of radiation therapy given as first course of treatment. RXDATER identifies the date radiation therapy started.

Notes: For cases diagnosed after 2003, RADSUM is created using a CCR conversion program which uses values recorded in RADBSTMOD and RADREGMOD. Radiation to brain and central nervous system for leukemia and lung cases is coded as radiation in this field.

Values:

- 0: None, diagnosed at autopsy
- 1: Beam
- 2: Implants
- 3: Isotopes
- 4: Combination of 1 with 2 or 3
- 5: Radiation, NOS
- 6: Implants/Isotopes, NOS
- 9: Unknown
- Blank: Cases diagnosed 2018 and forward

California Cancer Registry Data Dictionary

Variable Name:	RANDOM
Eureka Name:	N/A
NAACCR Item:	N/A
Category:	Geographical Information
Level of Variable:	Tumor
Time Period Available:	1988 - current year
Related Variables:	<ul style="list-style-type: none"> • Census Tract Certainty 1970/80/90 (CENTRD90) • Census Tract Certainty 2000 (CENTRD00) • Census Tract Certainty 2010 (CENSUSTRCERTAINTY2010) • Census Tract Certainty 2020 (CENSUSTRTRACTCERT2020) • Population Living Below 200% of Poverty Line in Block Group 1988 through 2005 (BELOW200) • Population Living Below 200% of Poverty Line in Census Tract 1988 through 2005 (BELOW200CT) • Population Living Below 200% of Poverty Line in Census Tract 2006 forward (BELOW200CTACS2011) • Proportion of Population with Blue Collar Job in Block Group 1988 through 2005 (BLUECOLR) • Proportion of Population with Blue Collar Job in Census Tract 1988 through 2005 (BLUECOLRCT) • Proportion of Population with Blue Collar Job in Census Tract 2006 forward (BLUECOLRCTACS2011) • Proportion of Population with a College Degree in Block Group 1988 through 2005 (COLLEGE) • Proportion of Population with a College Degree in Census Tract 1988 through 2005 (COLLEGECT) • Proportion of Population with a College Degree in Census Tract 2006 forward (COLLEGECTACS2011) • Average Years of Schooling of Persons in Block Group 1988 through 2005 (EDINDEX) • Average Years of Schooling of Persons in Census Tract 1988 through 2005 (EDINDEXCT) • Average Years of Schooling of Persons in Census Tract 2006 forward (EDINDEXCTACS2011) • Median Household Income in Block Group 1988 through 2005 (MDINC) • Median Household Income in Census Tract 1988 through 2005 (MDINCCT) • Median Household Income in Census Tract 2006 forward (MDINCCTACS2011) • Median Rent in Block Group 1988 through 2005 (MEDRENT) • Median Rent in Census Tract 1988 through 2005 (MEDRENTCT) • Median Rent in Census Tract 2006 forward (MEDRENTCTACS2011)

California Cancer Registry Data Dictionary

- Median Value of Homes in Block Group 1988 through 2005 (MEDVALUE)
- Median Value of Homes in Census Tract 1988 through 2005 (MEDVALUECT)
- Median Value of Homes in Census Tract 2006 forward (MEDVALUECTACS2011)
- Proportion of Population without a High School Diploma in Block Group 1988 through 2005 (NOEDUC)
- Proportion of Population without a High School Diploma in Census Tract 1988 through 2005 (NOEDUCCT)
- Proportion of Population without a High School Diploma in Census Tract 2006 and forward (NOEDUCCTACS2011)
- Proportion of Population in Block Group Unemployed 1988 through 2005 (NOJOB)
- Proportion of Population in Census Tract Unemployed 1988 through 2005 (NOJOBCT)
- Proportion of Population in Census Tract Unemployed 2006 forward (NOJOBCTACS2011)
- Index of Socioeconomic Status of Block Group (YOSTSCL) for cases diagnosed 1988 through 2005
- Socioeconomic Status Quintile of Block Group (QUINYOST) for cases diagnosed 1988 through 2005
- Index of Socioeconomic Status of Block Group (YANGSCL) for cases diagnosed 2006 forward
- Socioeconomic Status Quintile of Block Group (QUINYANG) for cases diagnosed 2006 forward
- Index of Socioeconomic Status of Block Group with Missing Values Imputed (YANGSCLIMPUTED) for cases diagnosed 2006 forward
- Socioeconomic Status Quintile of Block Group with Missing Values Imputed (QUINYANGIMPUTED) for cases diagnosed 2006 forward

Definition: Indicator of whether the U.S. Census-based variables (see 'Related Variables' section) were assigned based on a randomly assigned census tract/block group combination or on the census tract/block group combination for an address at time of diagnosis that was geocoded at the street level or the ZIP+4 centroid level. When an address at time of diagnosis is geocoded with high accuracy (i.e., at a street match level or at the centroid of the 5-digit ZIP), the U.S. Census-based variables correspond to the geocoded census tract/block group combination. However, when an address at time of diagnosis is geocoded with less accuracy (i.e., at a ZIP+2 or 5-digit ZIP centroid) or if the address is a PO Box, it is given a randomly assigned census tract/block group combination within the county of diagnosis. This randomly assigned census tract/block group is used to assign the Census-based variables. The randomly assigned census tract/block group combination is not retained in the dataset; only the geocoded census tract and block group is retained and available for reference.

Values:

- 0: Census tract and block group are based on the address at time of DX being geocoded at a street level match or the ZIP+4 centroid.
- 1: Census tract and block group were randomly assigned within the country for the purpose of assigning U.S. Census-based variables.

California Cancer Registry Data Dictionary

Variable Name: RECORD_ORDER
Eureka Name: Record Number Recode
NAACCR Item: 1775
Category: Administrative
Level of Variable: Tumor
Time Period Available: 1988 - current year

Related Variables:

- Date of Diagnosis (DATEDX)
- Sequence Number -- Central (SEQNOCEN)
- Surv-Date DX Recode (SURV_DATEDX_RECODE)
- Surv-Date Active Follow-up (SURV_DATELC_ACT)
- Surv-Date Presumed Alive (SURV_DATELC_PSU)
- Surv-Flag Active Follow-up (SURV_FLAG_ACT)
- Surv-Flag Presumed Alive (SURV_FLAG_PSU)
- Surv-Mos Active Follow-up (SURV_MON_ACT)
- Surv-Mos Presumed Alive (SURV_MON_PSU)

Definition: This variable sequentially numbers a person's tumors within each dataset. The ordered values are based on date of diagnosis and sequence number central. It is used as part of the algorithm for calculating the survival time recode variables and is used for survival, prevalence, and multiple primary - standardized incidence ratio analysis in SEER*Stat.

Values:

- 00: Record number 01 for patient in database
- 01: Record number 02 for patient in database
- 99: Record number 99 for patient in database

California Cancer Registry Data Dictionary

Variable Name: RELIGION
Eureka Name: Religion
NAACCR Item: N/A
Category: Patient Demographics
Level of Variable: Tumor
Time Period Available: 1988 - current year

Related Variables:

Definition: Patient's religion at time of diagnosis.

Values: 01-94, 98, 99

For definitions, refer to [Calif. Cancer Reporting System Standards, Vol. I, Appendix E.](#)

California Cancer Registry Data Dictionary

Variable Name: RESIDPOSTCYTOREDU
Eureka Name: Residual Tumor Volume Post Cytoreduction
NAACCR Item: 3921
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 - current year
Related Variables: CS Site-Specific Factor 3 (CS_SITE_SPEC_F3)

Definition: Gross residual tumor after primary cytoreductive surgery is a prognostic factor for ovarian cancer and residual tumor volume after cytoreductive surgery is a prognostic factor for late stage ovarian cancers. Valid for cases diagnosed January 1, 2018 and forward. For ovarian cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F3.

Values:

- 00: No gross residual tumor nodules
- 10: Residual tumor nodule(s) 1 centimeter (cm) or less AND neoadjuvant chemotherapy not given or unknown if given
- 20: Residual tumor nodule(s) 1 cm or less AND neoadjuvant chemotherapy given (before surgery)
- 30: Residual tumor nodule(s) greater than 1 cm AND neoadjuvant chemotherapy not given or unknown if given
- 40: Residual tumor nodule(s) greater than 1 cm AND neoadjuvant chemotherapy given (before surgery)
- 90: Macroscopic residual tumor, size not stated AND neoadjuvant chemotherapy not given or unknown if given
- 91: Macroscopic residual tumor nodule(s), size not stated AND neoadjuvant chemotherapy given (before surgery)
- 92: Procedure described as optimal debulking and size of residual tumor nodule(s) not given AND neoadjuvant chemotherapy not given or unknown if given
- 93: Procedure described as optimal debulking and size of residual tumor nodule(s) not given AND neoadjuvant chemotherapy given (before surgery)
- 97: No cytoreductive surgery performed
- 98: Not applicable: Information not collected for this case
- 99: Not documented in medical record; Residual tumor status after cytoreductive surgery not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: RESREG
Eureka Name: N/A
NAACCR Item: N/A
Category: Geographical Information
Level of Variable: Tumor
Time Period Available: 1988 - current year

Related Variables:

Definition: Patient's region of residence at time of diagnosis as assigned by the California Cancer Registry.

Values:

- 1: Monterey, San Benito, Santa Clara, and Santa Cruz counties
- 2: Fresno, Kern, Kings, Madera, Mariposa, Merced, Stanislaus, Tulare, and Tuolumne counties
- 3: Alpine, Amador, Calaveras, El Dorado, Nevada, Placer, Sacramento, San Joaquin, Sierra, Solano, Sutter, Yolo, and Yuba counties
- 4: San Luis Obispo, Santa Barbara, and Ventura counties
- 5: Inyo, Mono, Riverside, and San Bernardino counties
- 6: Butte, Colusa, Del Norte, Glenn, Humboldt, Lake, Lassen, Mendocino, Modoc, Napa, Plumas, Shasta, Siskiyou, Sonoma, Tehama, and Trinity counties
- 7: San Diego and Imperial counties
- 8: Alameda, Contra Costa, Marin, San Francisco, and San Mateo counties
- 9: Los Angeles County
- 10: Orange County

California Cancer Registry Data Dictionary

Variable Name: RSPNSTONEOADJUVT
Eureka Name: Response to Neoadjuvant Therapy
NAACCR Item: 3922
Category: Treatment, Systemic
Level of Variable: Tumor
Time Period Available: 2018 - current year
Related Variables: CS Site-Specific Factor 21 (CSSITESPECIFICFACTOR21)

Definition: This data item records the physician's statement of response to neoadjuvant chemotherapy. Valid for cases diagnosed January 1, 2018 and forward. For breast cancers diagnosed 2010 through 2017, this information was recorded in the field CS_SITE_SPEC_F21.

Values:

- 0: Neoadjuvant therapy not given
- 1: Stated as complete response (CR)
- 2: Stated as partial response (PR)
- 3: Stated as response to treatment, but not noted if complete or partial
- 4: Stated as no response (NR)
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Response to neoadjuvant therapy not assessed or unknown if assessed

Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: RTDISCONTEARLY
Eureka Name: Radiation Treatment Discontinued Early
NAACCR Item: 1531
Category: Treatment, Radiation
Level of Variable: Tumor
Time Period Available: 2018 - current year

Related Variables:

Definition: Identifies patients/tumors whose radiation treatment course was discontinued earlier than initially planned. That is the patient/tumor received fewer treatment fractions (sessions) than originally intended by the treating physician.

Values:

- 00: No radiation treatment
- 01: Radiation treatment completed as prescribed
- 02: Radiation treatment discontinued early - toxicity
- 03: Radiation treatment discontinued early - contraindicated due to other patient risk factors (comorbid conditions, advanced age, progression of tumor prior to planned radiation etc.)
- 04: Radiation treatment discontinued early - patient decision
- 05: Radiation discontinued early - family decision
- 06: Radiation discontinued early - patient expired
- 07: Radiation discontinued early - reason not documented
- 99: Unknown if radiation treatment discontinued; Unknown whether radiation therapy administered

California Cancer Registry Data Dictionary

Variable Name: RUCA
Eureka Name: N/A
NAACCR Item: N/A
Category: Geographical Information
Level of Variable: Tumor
Time Period Available: 1988 - current year

Related Variables:

Definition: Rural-Urban Commuting Area (RUCA) codes published by the U.S. Department of Agriculture for each census tract. The RUCA codes are appended to CCR cases using the census tract of the patient's residence at time of diagnosis. The 1990 RUCA codes were appended to cases diagnosed 1988 through 1995, the 2000 RUCA codes were appended to cases diagnosed 1996 through 2005, and the 2010 RUCA codes were appended to cases diagnosed 2006 and forward.

Notes: For more detailed information go to:
<https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes/documentation/>

Values: 1-10.6: Refer to U.S. Department of Agriculture for RUCA codes
 99: Not coded

California Cancer Registry Data Dictionary

Variable Name: RURALMSSA90

Eureka Name: N/A

NAACCR Item: N/A

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: 1988 - 1995

Related Variables:

- Medical Service Study Area Identification Number (MSSAID)
- Medical Service Study Area Name (MSSANAME)
- Rural/Urban Designation of Year 2000 Medical Service Study Areas (RURALMSSA00)
- Rural/Urban Designation of Year 2010 Medical Service Study Areas (RURALMSSA10)

Definition: Designation of rural/urban for a Medical Service Study Area (MSSA) by the California Health Manpower Policy Commission based on the 1990 U.S. Census. RURALMSSA90 applies to cases diagnosed 1988 through 1995, RURALMSSA00 applies to cases diagnosed 1996 through 2005, and RURALMSSA10 applies to cases diagnosed 2006 and forward.

Values:

R: Rural. Defined as a geographic area with a population density of less than 250 persons per square mile and has no census-defined place within the area with a population in excess of 50,000.

9: Unknown

Blank: Urban

California Cancer Registry Data Dictionary

Variable Name: RURALMSSA00

Eureka Name: N/A

NAACCR Item: N/A

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: 1996 - 2005

Related Variables:

- Medical Service Study Area Identification Number (MSSAID)
- Medical Service Study Area Name (MSSANAME)
- Rural/Urban Designation of Year 1990 Medical Service Study Areas (RURALMSSA90)
- Rural/Urban Designation of Year 2010 Medical Service Study Areas (RURALMSSA10)

Definition: Designation of rural/urban for a Medical Service Study Area (MSSA) by the California Health Manpower Policy Commission, based on the 2000 U.S. Census. RURALMSSA00 applies to cases diagnosed 1996 through 2005, RURALMSSA90 applies to cases diagnosed 1988 through 1995, and RURALMSSA10 applies to cases diagnosed 2006 and forward.

Values:

- U: Urban. Any MSSA that is not rural or frontier is urban
- F: Frontier. A frontier MSSA is a rural MSSA that has a population density of less than 11 person per square mile.
- R: Rural. A rural MSSA has a population density of less than 250 persons per square mile and has no census-defined place within the area with a population in excess of 50,000.
- 9: Unknown

California Cancer Registry Data Dictionary

Variable Name: RURALMSSA10

Eureka Name: N/A

NAACCR Item: N/A

Category: Geographical Information

Level of Variable: Tumor

Time Period Available: 2006 - current year

Related Variables:

- Medical Service Study Area Identification Number (MSSAID)
- Medical Service Study Area Name (MSSANAME)
- Rural/Urban Designation of Year 1990 Medical Service Study Areas (RURALMSSA90)
- Rural/Urban Designation of Year 2000 Medical Service Study Areas (RURALMSSA00)

Definition: Designation of rural/urban for a Medical Service Study Area (MSSA) by the California Health Manpower Policy Commission, based on the 2010 U.S. Census. RURALMSSA10 applies to cases diagnosed 2006 and forward, RURALMSSA90 applies to cases diagnosed 1988 through 1995, and RURALMSSA00 applies to cases diagnosed 1996 through 2005.

Values:

- U: Urban. Any MSSA that is not rural or frontier is urban
- F: Frontier. A frontier MSSA is a rural MSSA that has a population density of less than 11 person per square mile.
- R: Rural. A rural MSSA has a population density of less than 250 persons per square mile and has no census-defined place within the area with a population in excess of 50,000.
- 9: Unknown

California Cancer Registry Data Dictionary

Variable Name: RXDATE
Eureka Name: Date Initial RX SEER
NAACCR Item: 1260
Category: Treatment
Level of Variable: Tumor
Time Period Available: 1988 - current year

Related Variables:

Definition: Date first course of definitive treatment started for this tumor. Based on earliest date reported for surgery, radiation, chemotherapy, hormone therapy, immunotherapy, or transplant/endocrine procedure.

Values: Any date: YYYYMMDD format
 0's: No treatment or unknown if treated.
 9's: Death certificate only case or treatment performed but the date is unknown

California Cancer Registry Data Dictionary

Variable Name: RXDATEBRMFLAG

Eureka Name: RX Date BRM Flag

NAACCR Item: 1241

Category: Treatment, Systemic

Level of Variable: Tumor

Time Period Available: 2010 - current year

Related Variables: RX Date BRM (RXDATEI)

Definition: Explains why there is no appropriate value in the corresponding date field, RX Date BRM (RXDATEI).

Values:

- 10: No information whatsoever can be inferred from this exceptional value (e.g., unknown if immunotherapy administered)
- 11: No proper value is applicable in this context (e.g., no immunotherapy administered; autopsy only case)
- 12: A value is applicable but not known. This event occurred, but the date is unknown (e.g., immunotherapy administered but date is unknown)
- 15: Information is not available at this time, but it is expected that it will be available later (e.g., immune therapy is planned as part of the first course of therapy, but had not been started at the time of the most recent follow-up)
- Blank: A valid date value is provided in item RX Date--BRM, or the date was not expected to have been transmitted

California Cancer Registry Data Dictionary

Variable Name:	RXDATEC
Eureka Name:	RX Date Chemo
NAACCR Item:	1220
Category:	Treatment, Systemic
Level of Variable:	Tumor
Time Period Available:	1988 - current year
Related Variables:	RX Summ--Chemo (CHEMOSUM)
Definition:	Date chemotherapy started. CHEMOSUM identifies the type of chemotherapy given as first course of treatment.
Values:	Any date: YYYYMMDD format
	0's: No chemotherapy or unknown if ever treated
	8's: Treatment planned but not started within 6 months of the date of first admission
	9's: Death certificate only case or chemotherapy given but the date is unknown

California Cancer Registry Data Dictionary

Variable Name: RXDATECHEMOFLAG

Eureka Name: RX Date Chemo Flag

NAACCR Item: 1221

Category: Treatment, Systemic

Level of Variable: Tumor

Time Period Available: 2010 - current year

Related Variables: RX Date Chemo (RXDATEC)

Definition: Explains why there is no appropriate value in the corresponding date field, RX Date Chemo (RXDATEC).

Values:

- 10: No information whatsoever can be inferred from this exceptional value (e.g., unknown if chemotherapy administered)
- 11: No proper value is applicable in this context (e.g., no chemotherapy administered; autopsy only case)
- 12: A value is applicable but not known. This event occurred, but the date is unknown (e.g., chemotherapy administered but date is unknown)
- 15: Information is not available at this time, but it is expected that it will be available later (e.g., chemotherapy is planned as part of the first course of therapy, but had not been started at the time of the most recent follow-up)
- Blank: A valid date value is provided in item RX Date--Chemo, or the date was not expected to have been transmitted

California Cancer Registry Data Dictionary

Variable Name:	RXDATEDXSTGPROCFLAG
Eureka Name:	RX Date DX/Stg Proc Flag
NAACCR Item:	1281
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2010 - current year
Related Variables:	RX Date DX/Stg Proc (RXDATESN)
Definition:	Explains why there is no appropriate value in the corresponding date field, RXDATESN.
Values:	<p>10: No information whatsoever can be inferred from this exceptional value (e.g., unknown if any diagnostic or staging procedure performed)</p> <p>11: No proper value is applicable in this context (e.g., no diagnostic or staging procedure performed; autopsy only case)</p> <p>12: Proper value is applicable but not known. This event occurred, but the date is unknown (e.g., diagnostic or staging procedure performed but date is unknown)</p> <p>Blank: A valid date value is provided in item RX Date DX/Stg Proc, or the date was not expected to have been transmitted</p>

California Cancer Registry Data Dictionary

Variable Name:	RXDATEH
Eureka Name:	RX Date Hormone
NAACCR Item:	1230
Category:	Treatment, Systemic
Level of Variable:	Tumor
Time Period Available:	1988 - current year
Related Variables:	RX Summ—Hormone (HORMSUM)
Definition:	Date hormone therapy started. HORMSUM identifies the type of hormone therapy given as first course of treatment.
Values:	Any date: YYYYMMDD format
	0's: No hormone therapy or unknown if ever treated
	8's: Treatment planned but not started within 6 months of the date of first admission
	9's: Death certificate only case or hormone therapy given but the date is unknown

California Cancer Registry Data Dictionary

Variable Name: RXDATEHORMONEFLAG

Eureka Name: RX Date Hormone Flag

NAACCR Item: 1231

Category: Treatment, Systemic

Level of Variable: Tumor

Time Period Available: 2010 - current year

Related Variables: RX Date Hormone (RXDATEH)

Definition: Explains why there is no appropriate value in the corresponding date field, RX Date Hormone (RXDATEH).

Values:

- 10: No information whatsoever can be inferred from this exceptional value (e.g., unknown if hormone therapy administered)
- 11: No proper value is applicable in this context (e.g., no hormone therapy administered; autopsy only case)
- 12: A value is applicable but not known. This event occurred, but the date is unknown (e.g., hormone therapy administered but date is unknown)
- 15: Information is not available at this time, but it is expected that it will be available later (e.g., hormone therapy is planned as part of the first course of therapy, but had not been started at the time of the most recent follow-up)
- Blank: A valid date value is provided in item RX Date Hormone, or the date was not expected to have been transmitted

California Cancer Registry Data Dictionary

Variable Name:	RXDATEI
Eureka Name:	RX Date BRM
NAACCR Item:	1240
Category:	Treatment, Systemic
Level of Variable:	Tumor
Time Period Available:	1988 - current year
Related Variables:	RX Summ--BRM (IMMUSUM)
Definition:	Date of initiation for immunotherapy (a.k.a. biological response modifier) that is part of the first course of treatment. IMMUSUM identifies the type of immunotherapy given as first course of treatment.
Values:	Any date: YYYYMMDD format
	0's: No immunotherapy or unknown if ever treated
	8's: Treatment planned but not started within 6 months of the date of first admission
	9's: Death certificate only case or immunotherapy given but the date is unknown

California Cancer Registry Data Dictionary

Variable Name: RXDATEMSTDEFNSRGFLAG

Eureka Name: RX Date Mst Defn Srg Flag

NAACCR Item: 3171

Category: Treatment, Surgical

Level of Variable: Tumor

Time Period Available: 2010 – current year

Related Variables: Date Def Surg (DTDEFSURG)

Definition: Explains why there is no appropriate value in the corresponding date field, DTDEFSURG (date of the most definitive surgery).

Values:

- 10: Unknown if any surgical procedure of the primary site was performed
- 11: No surgical procedure of the primary site was performed; autopsy only case
- 12: Surgery to the primary site was administered but date is unknown
- Blank: A valid date is provided in item Date Def Surg, or the date was not expected to have been transmitted

California Cancer Registry Data Dictionary

Variable Name: RXDATEO

Eureka Name: RX Date Other

NAACCR Item: 1250

Category: Treatment

Level of Variable: Tumor

Time Period Available: 1988 - current year

Related Variables: RX Summ--Other (OTHSUM)

Definition: Date other therapy started. OTHSUM identifies the 'other' type of therapy given as first course of treatment.

Values:

- Any date: YYYYMMDD format
- 0's: No other treatment or unknown if ever treated
- 9's: Death certificate only case or other treatment given but the date is unknown

California Cancer Registry Data Dictionary

Variable Name: RXDATEOTHERFLAG

Eureka Name: RX Date--Other Flag

NAACCR Item: 1251

Category: Treatment

Level of Variable: Tumor

Time Period Available: 2010 - current year

Related Variables: RX Date Other (RXDATEO)

Definition: This flag explains why there is no appropriate value in the corresponding date field, RX Date Other (RXDATEO).

Values:

- 10: No information whatsoever can be inferred from this exceptional value (e.g., unknown if other therapy administered)
- 11: No proper value is applicable in this context (e.g., no other therapy administered; autopsy only case)
- 12: A value is applicable but not known. This event occurred, but the date is unknown (e.g., other therapy administered but date is unknown)
- 15: Information is not available at this time, but it is expected that it will be available later (e.g., other therapy is planned as part of the first course of therapy, but had not been started at the time of the most recent follow-up)
- Blank: A valid date value is provided in item RX Date Other, or the date was not expected to have been transmitted

California Cancer Registry Data Dictionary

Variable Name:	RXDATER
Eureka Name:	RX Date Radiation
NAACCR Item:	1210
Category:	Treatment, Radiation
Level of Variable:	Tumor
Time Period Available:	1988 - current year
Related Variables:	RX Summ--Radiation (RADSUM)
Definition:	Date radiation therapy started (including radiation to central nervous system). RADSUM identifies the type of radiation therapy used for first course of treatment.
Values:	<p>Any date: YYYYMMDD format</p> <p>0's: No radiation or unknown if ever treated</p> <p>8's: Treatment planned but not started within 6 months of the date of first admission</p> <p>9's: Death certificate only case or radiation performed but the date is unknown</p>

California Cancer Registry Data Dictionary

Variable Name: RXDATERADIATIONFLAG
Eureka Name: RX Date Radiation Flag
NAACCR Item: 1211
Category: Treatment, Radiation
Level of Variable: Tumor
Time Period Available: 2010 - current year
Related Variables: RX Date Radiation (RXDATER)

Definition: This flag explains why there is no appropriate value in the corresponding date field, RX Date Radiation (RXDATER).

Values:

- 10: No information whatsoever can be inferred from this exceptional value (e.g., unknown if radiation therapy administered)
- 11: No proper value is applicable in this context (e.g., no radiation therapy administered; autopsy only case)
- 12: A value is applicable but not known. This event occurred, but the date is unknown (e.g., radiation therapy administered but date is unknown)
- 15: Information is not available at this time, but it is expected that it will be available later (e.g., radiation therapy is planned as part of the first course of therapy, but had not been started at the time of the most recent follow-up)
- Blank: A valid date value is provided in item RX Date Radiation, or the date was not expected to have been transmitted

California Cancer Registry Data Dictionary

Variable Name:	RXDATESN
Eureka Name:	RX Date DX/Stg Proc
NAACCR Item:	1280
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	1988 - current year
Related Variables:	RX Date DX/Stg Proc Flag (RXDATEDXSTGPROCFLAG)
Definition:	Date of diagnostic or staging procedure.
Values:	Any date: YYYYMMDD format
	0's: No procedure or unknown if performed
	9's: Death certificate only case or procedure was done but date is unknown

California Cancer Registry Data Dictionary

Variable Name: RXDATESURGERYFLAG

Eureka Name: RX Date Surgery Flag

NAACCR Item: 1201

Category: Treatment, Surgical

Level of Variable: Tumor

Time Period Available: 2010 – current year

Related Variables: RX Date Surgery (SURGDATE)

Definition: This flag explains why there is no appropriate value in the corresponding date field, RX Date Surgery (SURGDATE).

Values:

- 10: Unknown if any surgical procedure of the primary site was performed
- 11: No surgical procedure of the primary site was performed; autopsy only case
- 12: Surgery to the primary site was administered but date is unknown
- Blank: A valid date is provided in RX Date Surgery, or the date was not expected to have been transmitted

California Cancer Registry Data Dictionary

Variable Name: RXDATESYSTEMICFLAG

Eureka Name: RX Date Systemic Flag

NAACCR Item: 3231

Category: Treatment, Systemic

Level of Variable: Tumor

Time Period Available: 2010 - current year

Related Variables: RX Date Systemic (DTSYSTEMIC)

Definition: This flag explains why there is no appropriate value in the corresponding date field, RX Date Systemic (DTSYSTEMIC).

Values:

- 10: No information whatsoever can be inferred from this exceptional value (e.g., unknown if systemic therapy administered)
- 11: No proper value is applicable in this context (e.g., no systemic therapy administered; autopsy only case)
- 12: A value is applicable but not known. This event occurred, but the date is unknown (e.g., systemic therapy administered but date is unknown)
- 15: Information is not available at this time, but it is expected that it will be available later (e.g., systemic therapy is planned as part of the first course of therapy, but had not been started at the time of the most recent follow-up)
- Blank: A valid date value is provided in item RX Date--Systemic, or the date was not expected to have been transmitted

California Cancer Registry Data Dictionary

Variable Name: RXDATETRANSPLNTENDOCRFLAG

Eureka Name: RX Date Transp Endo Flag

NAACCR Item: N/A

Category: Treatment, Systemic

Level of Variable: Tumor

Time Period Available: 2010 - current year

Related Variables: RX Date Transp Endo (DTTRANSP)

Definition: This flag explains why there is no corresponding date in the related field, Date of Transplant/Endocrine Procedure (DTTRANSP).

Notes: Variable previously named 'datetranspendoflag'

Values:

- 10: Unknown if Transplant/Endocrine Procedure performed (Date of Transplant/Endocrine Procedure is unknown and procedure code is 99)
- 11: Procedure was not performed
- 12: Procedure was performed (codes 10-40) but Date of Transplant/Endocrine procedure is unknown
- 15: Procedure is planned (procedure code is 88)
- Blank: A valid date is provided in item RX Date Transp Endo, or the date was not expected to have been transmitted.

California Cancer Registry Data Dictionary

Variable Name: RXSUMMSURGICALMARGINS

Eureka Name: RX Summ--Surgical Margins

NAACCR Item: 1320

Category: Treatment, Surgical

Level of Variable: Tumor

Time Period Available: 2015 - current year

Related Variables: Rx Summ--Surg Prim Site (SURGPRIM)

Definition: Describes the final status of surgical margins after resection of the primary tumor.

Notes: See also RX Summ--Surg Prim Site (SURGPRIM). This item serves as a quality measure for pathology reports, is used for staging, and may be a prognostic factor in recurrence. This item is not limited to cases that have been staged. It applies to all cases that have a surgical procedure of the primary site.

Values:

- 0: No residual tumor
- 1: Residual tumor, NOS
- 2: Microscopic residual tumor
- 3: Macroscopic residual tumor
- 7: Margins not evaluable
- 8: No primary site surgery
- 9: Unknown or not applicable

California Cancer Registry Data Dictionary

Variable Name: RXSUMMSYSTEMICSURSEQ

Eureka Name: RX Summ--Systemic Sur Seq

NAACCR Item: 1639

Category: Treatment, Systemic

Level of Variable: Tumor

Time Period Available: 2006 - current year

Related Variables:

- RX Summ--Chemo (CHEMOSUM)
- RX Summ--Hormone (HORMSUM)
- RX Summ--BRM (IMMUSUM)
- RX Summ--Transplnt/Endocr (TRANSSUM)
- RX Summ--Surg Prim Site (SRUGPRIM)
- RX Summ--Scope Reg LN Surg (SCOPE)
- RX Summ--Surg Oth Reg/Dis (SURGOTH)

Definition: Records the sequencing of systemic therapy (RX Summ--Chemo (CHEMOSUM), RX Summ--Hormone (HORMSUM), RX Summ--BRM (IMMUSUM), and RX Summ--Transplnt/Endocr (TRANSSUM) and surgical procedures given as part of the first course of treatment -- RX Summ--Surg Prim Site (SRUGPRIM), RX Summ--Scope Reg LN Surg (SCOPE), and RX Summ--Surg Oth Reg/Dis (SURGOTH).

Values:

- 0: No systemic therapy and/or surgical procedures; unknown if surgery and/or systemic therapy given
- 2: Systemic therapy before surgery
- 3: Systemic therapy after surgery
- 4: Systemic therapy before and after surgery
- 5: Intraoperative systemic therapy
- 6: Intraoperative systemic therapy with other therapy administered before or after surgery
- 7: Surgery both before and after systemic therapy (effective 2012)
- 9: Sequence unknown, but both surgery and systemic therapy given

California Cancer Registry Data Dictionary

Variable Name: RXSUMMTREATMENTSTATUS

Eureka Name: RX Summ--Treatment Status

NAACCR Item: 1285

Category: Treatment

Level of Variable: Tumor

Time Period Available: 2010 - current year

Related Variables:

Definition: Summary of the status of all treatment modalities. Provides a yes/no summary of whether treatment has been given, including the option that indicates active surveillance (watchful waiting)

Values:

- 0: No treatment given
- 1: Treatment given
- 2: Watchful waiting; Active surveillance
- 9: Unknown if treatment was given
- Blank: Diagnoses prior to 2010

California Cancer Registry Data Dictionary

Variable Name: SARCOMATOID
Eureka Name: Sarcomatoid Features
NAACCR Item: 3925
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 - current year
Related Variables: CS Site-Specific Factor 4 (CS_SITE_SPEC_F4)

Definition: Sarcomatoid features: present or absent and percentage refers to the observation of sheets and fascicles of malignant spindle cells in a kidney tumor which can occur across all histologic subtypes. The percentage of sarcomatoid component has been shown to correlate with cancer-specific mortality. Valid for cases diagnosed January 1, 2018 and forward. For kidney cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F4.

Values:

- 000: Sarcomatoid features not present/not identified
- 000-100: Sarcomatoid features 1-100%
- R01: Sarcomatoid features stated as less than 10%
- R02: Sarcomatoid features stated as range 10%-30% present
- R03: Sarcomatoid features stated as a range 31% to 50% present
- R04: Sarcomatoid features stated as a range 51% to 80% present
- R05: Sarcomatoid features stated as greater than 80%
- XX6: Sarcomatoid features present, percentage unknown
- XX7: Not applicable: Not a renal cell carcinoma morphology
- XX8: Not applicable: Information not collected for this case
- XX9: Not documented in medical record; Sarcomatoid features not assessed or unknown if assessed; No surgical resection of primary site is performed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: SCATCLIN
Eureka Name: S Category Clinical
NAACCR Item: 3923
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 - current year

Related Variables:

- AFP Pre-Orchiectomy Range (AFPPREORCHVALUE)
- AFP Pre-Orchiectomy Lab Value (AFPPREORCHVALUE)
- hCG Pre-Orchiectomy Range (HCGPREORCHVALUE)
- hCG Pre-Orchiectomy Lab Value (HCGPREORCHVALUE)
- LDH Pre-Orchiectomy Range (LDHPREORCHVALUE)

Definition: S Category Clinical combines the results of pre-orchietomy Alpha Fetoprotein (AFP), Human Chorionic Gonadotropin (hCG) and Lactate Dehydrogenase (LDH) into a summary S value.

Values:

- 0: S0: Marker study levels within normal levels
- 1: S1: At least one of these values is elevated AND LDH less than 1.5 x N* AND hCG (mIU/L) less than 5,000 AND AFP (ng/mL) less than 1,000
- 2: S2: LDH 1.5 x N* to 10 x N* OR hCG (mIU/L) 5,000 to 50,000 OR AFP (ng/mL) 1,000 to 10,000
- 3: S3: Only one elevated test is needed; LDH greater than 10 x N* OR hCG (mIU/mL) greater than 50,000 OR AFP (ng/mL) greater than 10,000
- 9: SX: Not documented in medical record; S Category Clinical not assessed or unknown if assessed

Blank: Date of Diagnosis pre-2018; Non-required Schema ID

*N indicates the upper limit of normal for the LDH assay.

California Cancer Registry Data Dictionary

Variable Name: SCATPATH
Eureka Name: S Category Pathological
NAACCR Item: 3924
Category: Prognostic Factors
Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables:

- AFP Post-Orchiectomy Range (AFPPOSTORCH RANGE)
- AFP Post-Orchiectomy Lab Value (AFPPOSTORCHVALUE)
- hCG Post-Orchiectomy Range (HCGPOSTORCH RANGE)
- hCG Post-Orchiectomy Lab Value (HCGPOSTORCHVALUE)
- LDH Post-Orchiectomy Range (LDHPOSTORCH RANGE)

Definition: S Category Pathological combines the results of post-orchietomy Alpha Fetoprotein (AFP), Human Chorionic Gonadotropin (hCG) and Lactate Dehydrogenase (LDH) into a summary S value.

Values:

- 0: S0: Marker study levels within normal levels
- 1: S1: At least one of these values is elevated AND LDH less than 1.5 x N* AND hCG (mIU/L) less than 5,000 AND AFP (ng/mL) less than 1,000
- 2: S2: LDH 1.5 x N* to 10 x N* OR hCG (mIU/L) 5,000 to 50,000 OR AFP (ng/mL) 1,000 to 10,000
- 3: S3: Only one elevated test is needed; LDH greater than 10 x N* OR hCG (mIU/mL) greater than 50,000 OR AFP (ng/mL) greater than 10,000
- 9: SX: Not documented in medical record; S Category Pathological not assessed or unknown if assessed

Blank: Date of Diagnosis pre-2018; Non-required Schema ID

*N indicates the upper limit of normal for the LDH assay.

California Cancer Registry Data Dictionary

Variable Name:	SCHEMADISC1
Eureka Name:	Schema Discriminator 1
NAACCR Item:	3926
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • AJCC ID (AJCCID) • Schema ID (SCHEMAID)

Definition: Schema discriminators are used when primary site and/or histology are not sufficient to identify the correct AJCC staging algorithm. Due to the complexity of some of the AJCC 8th edition chapters, more than one schema discriminator may be needed to define the correct schema. Three variables (SCHEMADISC1, SCHEMADISC2, and SCHEMADISC3) are available to collect the information needed to define schema, although most chapters that require a schema discriminator need only one. Schema discriminators are used to define both Schema ID, used to link all combinations of sites and histologies with the appropriate stage data collection systems and site-specific data items (SSDIs), and AJCC ID, used to link AJCC staging eligible sites/histologies with the appropriate AJCC chapter and staging algorithm.

Values: The information recorded in each Schema Discriminator differs for each anatomic site. See the SSDI manual for the most current version of the site-specific codes and coding structure (<https://apps.naaccr.org/ssdi/list/>).

California Cancer Registry Data Dictionary

Variable Name:	SCHEMADISC2
Eureka Name:	Schema Discriminator 2
NAACCR Item:	3927
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • AJCC ID (AJCCID) • Schema ID (SCHEMAID)

Definition: Schema discriminators are used when primary site and/or histology are not sufficient to identify the correct AJCC staging algorithm. Due to the complexity of some of the AJCC 8th edition chapters, more than one schema discriminator may be needed to define the correct schema. Three variables (SCHEMADISC1, SCHEMADISC2, and SCHEMADISC3) are available to collect the information needed to define schema, although most chapters that require a schema discriminator need only one. Schema discriminators are used to define both Schema ID, used to link all combinations of sites and histologies with the appropriate stage data collection systems and site-specific data items (SSDIs), and AJCC ID, used to link AJCC staging eligible sites/histologies with the appropriate AJCC chapter and staging algorithm.

Values: The information recorded in each Schema Discriminator differs for each anatomic site. See the SSDI manual for the most current version of the site-specific codes and coding structure (<https://apps.naaccr.org/ssdi/list/>).

California Cancer Registry Data Dictionary

Variable Name:	SCHEMADISC3
Eureka Name:	Schema Discriminator 3
NAACCR Item:	3928
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 - current year
Related Variables:	<ul style="list-style-type: none"> • AJCC ID (AJCCID) • Schema ID (SCHEMAID)

Definition: Schema discriminators are used when primary site and/or histology are not sufficient to identify the correct AJCC staging algorithm. Due to the complexity of some of the AJCC 8th edition chapters, more than one schema discriminator may be needed to define the correct schema. Three variables (SCHEMADISC1, SCHEMADISC2, and SCHEMADISC3) are available to collect the information needed to define schema, although most chapters that require a schema discriminator need only one. Schema discriminators are used to define both Schema ID, used to link all combinations of sites and histologies with the appropriate stage data collection systems and site-specific data items (SSDIs), and AJCC ID, used to link AJCC staging eligible sites/histologies with the appropriate AJCC chapter and staging algorithm.

Values: The information recorded in each Schema Discriminator differs for each anatomic site. See the SSDI manual for the most current version of the site-specific codes and coding structure (<https://apps.naaccr.org/ssdi/list/>).

California Cancer Registry Data Dictionary

Variable Name: SCHEMAID
Eureka Name: Schema ID
NAACCR Item: 3800
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 - current year

Related Variables:

Definition: The derived values in this data item link Site-Specific Data Items (including grade data items) with the appropriate site/histology grouping and accounts for every combination of primary site and histology. The values for this data item are derived based on primary site, histology, and schema discriminator fields (when required). The derived values link Site-Specific Data Items with the appropriate site/histology grouping. The purpose of the derived Schema ID is to link the appropriate Site-Specific Data Items with the patient's primary site/histology. This data item is similar to AJCC ID (AJCCID) but includes additional site/histologies that may not be eligible for TNM staging using the current AJCC Staging Manual. AJCC ID is left blank if a case is not eligible for TNM Staging using the current AJCC Staging Manual. Separating AJCC ID and the Schema ID allows coding of Site-Specific Data Items for site/histology combinations that are not eligible for an AJCC Stage but are eligible for Summary Stage.

Values: For additional information and value definitions, see the SSDI manual (<https://apps.naaccr.org/ssdi/list/>).

California Cancer Registry Data Dictionary

Variable Name: SCOPE
Eureka Name: RX Summ--Scope Reg LN Sur
NAACCR Item: 1292
Category: Treatment, Surgical
Level of Variable: Tumor
Time Period Available: 1988 - current year
Related Variables: Rx Reg LN Examined (NNODES)

Definition: Records surgery removing regional lymph nodes during the first course of treatment. Required for cases diagnosed January 1, 2003 and forward; for earlier diagnoses information was taken from the variable NNODES.

Notes: The American College of Surgeons is responsible for establishing data items, codes, and definitions for the surgical treatment of cancer. Whenever possible, surgical codes for cases diagnosed prior to any changes introduced by the College are converted to reflect current coding rules. However, in some cases the information available may not allow for an accurate conversion. Please keep these changes in mind when evaluating time trends in cancer treatment.

Values:

- 0: None, no regional lymph node surgery; no lymph nodes found in the pathologic specimen; diagnosed at autopsy.
- 1: Biopsy or aspiration of regional lymph node, NOS; biopsy or aspiration of regional lymph node(s) regardless of the extent of involvement of disease.
- 2: Sentinel lymph node biopsy; biopsy of the first lymph node or nodes that drain a defined area of tissue within the body; sentinel node(s) are identified by the injection of a dye or radio label at the site of the primary tumor.
- 3: Number of regional nodes removed unknown or not stated; regional lymph node removed, NOS; sampling or dissection of regional lymph node(s) and the number of nodes is unknown or not stated; the procedure is not specified as sentinel node biopsy.
- 4: 1-3 regional lymph nodes removed; sampling or dissection of regional lymph node(s) with fewer than four lymph nodes found in the specimen; the procedure is not specified as sentinel node biopsy.
- 5: 4 or more regional lymph nodes removed; sampling or dissection of regional lymph nodes with at least four lymph nodes found in the specimen; the procedure is not specified as sentinel node biopsy.
- 6: Sentinel node biopsy and code 3, 4, or 5 at same time, or timing not stated; code 2 was performed in a single surgical event with code 3, 4, or 5; code 2 and 3, 4, or 5 were performed, but timing was not stated in patient record.

California Cancer Registry Data Dictionary

- 7: Sentinel node biopsy and code 3, 4, or 5 at different times; code 2 was followed in a subsequent surgical event by procedures coded as 3, 4, or 5.
- 9: Unknown or not applicable; unknown whether regional lymph node surgery was performed; death certificate only; lymphoma with a lymph node primary site; unknown or ill-defined primary site; hematopoietic, reticuloendothelial, immunoproliferative or myeloproliferative disease.

California Cancer Registry Data Dictionary

Variable Name:	SECONDARYDIAGNOSIS1, SECONDARYDIAGNOSIS2, SECONDARYDIAGNOSIS3, SECONDARYDIAGNOSIS4, SECONDARYDIAGNOSIS5, SECONDARYDIAGNOSIS6, SECONDARYDIAGNOSIS7, SECONDARYDIAGNOSIS8, SECONDARYDIAGNOSIS9, SECONDARYDIAGNOSIS10,
Eureka Name:	Secondary Diagnosis 1, Secondary Diagnosis 2, Secondary Diagnosis 3, Secondary Diagnosis 4, Secondary Diagnosis 5, Secondary Diagnosis 6, Secondary Diagnosis 7, Secondary Diagnosis 8, Secondary Diagnosis 9, Secondary Diagnosis 10
NAACCR Item:	3780, 3782, 3784, 3786, 3788, 3790, 3792, 3794, 3796, 3798
Category:	Clinical, Other
Level of Variable:	Tumor
Time Period Available:	2015 - current year
Related Variables:	Comorbid/Complication 1, Comorbid/Complication 2, Comorbid/Complication 3, Comorbid/Complication 4, Comorbid/Complication 5, Comorbid/Complication 6, Comorbid/Complication 7, Comorbid/Complication 8, Comorbid/Complication 9, Comorbid/Complication 10
Definition:	Records the patient's pre-existing medical conditions, factors influencing health status, and/or complications during the patient's hospital stay for the treatment of this cancer using ICD-10-CM codes. All are considered secondary diagnoses. Pre-existing medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Complications may be related to the quality of care.
Notes:	These data items are required by CCR "when available." However, CoC facilities are required to collect this information. As such, many cases in the CCR may have missing information. Only ICD-10-CM codes are allowed in these fields. ICD-9-CM codes are recorded in Comorbid/Complication 1 through 10 fields. ICD-10-CM was implemented October 1, 2015.
Values:	ICD-10-CM Codes: A0000-BZZZZ E0000-EZZZZ G0000-PZZZZ R0000-SZZZZ T360X-T50Z9 Y6200-Y8490 Z1401-Z2299 Z2301-Z2493 Z6810-Z6854 Z8000-Z8090 Z8500-Z8603 Z8611-Z9989 00000 No secondary diagnosis documented

California Cancer Registry Data Dictionary

Variable Name: SEER_CSDC
Eureka Name: SEER Cause Specific COD
NAACCR Item: 1914
Category: Follow-Up
Level of Variable: Tumor
Time Period Available: 1988 - current year
Related Variables: Cause of Death (CDEATH)

Definition: This data item was created for use in cause-specific survival and designates that the person died of their cancer.

For more information on how this variable is derived see:

<https://seer.cancer.gov/causespecific/>

Notes: **Access to death data variables from the CCR for research purposes requires review by the Health and Human Services Agency Committee for the Protection of Human Subjects (CPHS), the Vital Statistics Advisory Committee (VSAC), and CCR. The Center for Health Statistics and Informatics (CHSI), CCR, and CPHS require requesters to submit their proposals for simultaneous review of research projects by CPHS and VSAC. Please allow sufficient time for review of your application. For more information, send inquiries to research@ccr.ca.gov.**

Values:

- 0: Alive or dead of other cause
- 1: Dead (attributable to this cancer dx)
- 8: Missing/Unknown Cause of Death
- 9: Not applicable/not first tumor

California Cancer Registry Data Dictionary

Variable Name: SEER_OTHDC
Eureka Name: SEER Other COD
NAACCR Item: 1915
Category: Follow-Up
Level of Variable: Tumor
Time Period Available: 1988 - current year
Related Variables: Cause of Death (CDEATH)

Definition: This data item was created for use in cause-specific survival and designates that the person died of causes OTHER than their cancer.

For more information on how this variable is derived see:

<https://seer.cancer.gov/causespecific/>

Notes: Access to death data variables from the CCR for research purposes requires review by the Health and Human Services Agency Committee for the Protection of Human Subjects (CPHS), the Vital Statistics Advisory Committee (VSAC), and CCR. The Center for Health Statistics and Informatics (CHSI), CCR, and CPHS require requesters to submit their proposals for simultaneous review of research projects by CPHS and VSAC. Please allow sufficient time for review of your application. For more information, send inquiries to research@ccr.ca.gov.

Values:

- 0: Alive or dead due to cancer
- 1: Dead (attributable to causes other than this cancer diagnosis)
- 8: Missing/Unknown Cause of Death
- 9: Not applicable/not first tumor

California Cancer Registry Data Dictionary

Variable Name: SEERSSF1
Eureka Name: SEER Site-Specific Fact 1
NAACCR Item: 3700
Category: Prognostic Factors
Level of Variable: Tumor
Time Period Available: 2018 - current year

Related Variables:

Definition: This data item is reserved for human papilloma virus (HPV) Status. This data item only applies to the schemas:

- Oropharynx (p16+): C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C103, C108-C109, C111
- Oropharynx (p16-) and Hypopharynx: C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C103, C108-C109, C111, C129, C130-C132, C138- C139
- Lip and Oral Cavity: C000-C009, C020-C023, C028-C029, C030-C031, C039, C040-C041, C048-C049, C050, C058-C059, C060-C062, C068-C069

There is evidence that human papilloma virus (HPV) plays a role in the pathogenesis of some cancers. HPV testing may be performed for prognostic purposes; testing may also be performed on metastatic sites to aid in determination of the primary site.

Values:

- 0: HPV negative for viral DNA by ISH test
- 1: HPV positive for viral DNA by ISH test
- 2: HPV negative for viral DNA by PCR test
- 3: HPV positive for viral DNA by PCR test
- 4: HPV negative by ISH E6/E7 RNA test
- 5: HPV positive by RT-PCR E6/E7 RNA test
- 6: HPV negative by RT-PCR E6/E7 RNA test
- 7: HPV positive by RT-PCR E6/E7 RNA test
- 8: HPV status reported in medical records as positive or negative, but test type is unknown
- 9: Unknown if HPV test detecting viral DNA and/or RNA was performed
- Blank: Date of Diagnosis pre-2018; or Date of Diagnosis 2018 and greater and Schema ID is NOT listed in step 2 of Source Logic

California Cancer Registry Data Dictionary

Variable Name: SEERWHO
Eureka Name: N/A
NAACCR Item: N/A
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 1988 - current year
Related Variables:

- Primary Site (SITE_02)
- Histologic Type ICD-O-3 (HISTO_T3)

Definition: SEER's site recode variable based on ICD-O-3 and WHO's 'Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008).' This variable is not a collected data item but derived per SEER's standards. This coding scheme separates leukemias and lymphomas from site-specific cancers.

Notes: Refer to SEER's website for value definitions and more detailed information regarding this coding scheme:
http://seer.cancer.gov/siterecode/icdo3_dwho/home/index.html.

California Cancer Registry Data Dictionary

Variable Name: SENTINELNODESEXAM
Eureka Name: Sentinel Lymph Nodes Examined
NAACCR Item: 834
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 - current year

Related Variables:

Definition: Records the total number of lymph nodes sampled during the sentinel node biopsy and examined by the pathologist. This data item is required for CoC-accredited facilities as of cases diagnosed 01/01/2018 and later. **This data item is required for breast and melanoma cases only.**

Values:

- 00: No sentinel nodes were examined
- 01-90: Sentinel nodes were examined (code the exact number of sentinel lymph nodes examined)
- 95: No sentinel nodes were removed, but aspiration of sentinel node(s) was performed
- 98: Sentinel lymph nodes were biopsied, but the number is unknown
- 99: It is unknown whether sentinel nodes were examined; not stated in patient record
- Blank: Date of Diagnosis pre-2018

California Cancer Registry Data Dictionary

Variable Name: SENTINELNODESPOS
Eureka Name: Sentinel Lymph Nodes Positive
NAACCR Item: 835
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 - current year

Related Variables:

Definition: Records the exact number of sentinel lymph nodes biopsied by the pathologist and found to contain metastases. This data item is required for CoC-accredited facilities as of cases diagnosed 01/01/2018 and later. **This data item is required for breast and melanoma cases only.**

Values:

- 00: All sentinel nodes examined are negative
- 01-90: Sentinel nodes are positive (code exact number of nodes positive)
- 95: Positive aspiration of sentinel lymph node(s) was performed
- 97: Positive sentinel nodes are documented, but the number is unspecified;
For breast ONLY: SLN and RLND occurred during the same procedure
- 98: No sentinel nodes were biopsied
- 99: It is unknown whether sentinel nodes are positive; not applicable; not stated in patient record
- Blank: Date of Diagnosis pre-2018

California Cancer Registry Data Dictionary

Variable Name: SEPNODES
Eureka Name: Separate Tumor Nodules
NAACCR Item: 3929
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 - current year
Related Variables: CS Site-Specific Factor 1 (CS_SITE_SPEC_F1)

Definition: "Separate tumor nodules" refers to what is conceptually a single tumor with intrapulmonary metastasis in the ipsilateral (same) lung. Their presence in the same or different lobes of lung from the primary tumor affects the T and M categories. Valid for cases diagnosed January 1, 2018 and forward. For lung cancers diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F1.

Values:

- 0: No separate tumor nodules; single tumor only; Separate tumor nodules of same histologic type not identified/not present; Intrapulmonary metastasis not identified/not present; Multiple nodules described
- 1: Separate tumor nodules of same histologic type in ipsilateral lung, same lobe
- 2: Separate tumor nodules of same histologic type in ipsilateral lung, different lobe
- 3: Separate tumor nodules of same histologic type in ipsilateral lung, same AND different lobes
- 4: Separate tumor nodules of same histologic type in ipsilateral lung, unknown if same or different lobe(s)
- 7: Multiple nodules or foci of tumor present, not classifiable based on notes 3 and 4
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Primary tumor is *in situ*; Separate Tumor Nodules not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: SEQNOCEN
Eureka Name: Sequence Number--Central
NAACCR Item: 380
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 1988 - current year

Related Variables:

Definition: Indicates the sequence of all reportable neoplasms during the patient's lifetime as determined by the central registry. When two or more tumors are diagnosed simultaneously, the tumor with the worse prognosis is assigned the lowest sequence number:

Values:

- 0: One primary only in the patient's lifetime
- 01-59: Actual number of this primary
- 99: Unspecified required sequence number or unknown

State Registry Defined:

- 60: Only one state registry-defined neoplasm
- 61: First of two or more state registry-defined neoplasms
- 62: Second of two or more state registry-defined neoplasms
- 63-87: Actual number of state registry-defined neoplasms
- 88: Unspecified number of state registry-defined neoplasms

California Cancer Registry Data Dictionary

Variable Name: SEX
Eureka Name: Sex
NAACCR Item: 220
Category: Patient Demographics
Level of Variable: Tumor
Time Period Available: 1988 - current year

Related Variables:

Definition: Sex of the patient

Values:

- 1: Male
- 2: Female
- 3: Other (intersex, disorders of sexual development/DSD). The word hermaphrodite formally classified under this code is an outdated term.
- 4: Transsexual, NOS
- 5: Transsexual, natal male
- 6: Transsexual, natal female
- 9: Unknown

California Cancer Registry Data Dictionary

Variable Name: SITE_02
Eureka Name: Primary Site
NAACCR Item: 400
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 1988 - current year

Related Variables:

Definition: Location where this tumor originated in as much detail as is known and for which a code is provided in ICD-O-2 for cases diagnosed 1988 through 2000 and ICD-O-3 for cases diagnosed 2001 forward.

Values: Please refer to ICD-O-2/3 for values

California Cancer Registry Data Dictionary

Variable Name: SITEFLAG
Eureka Name: N/A
NAACCR Item: N/A
Category: Administrative

Level of Variable: Tumor
Time Period Available: 1988 - current year

Related Variables:

- Primary Site (SITE_02)
- Histology (92-00) ICD-O-2 (HISTO_T2)
- Histologic Type ICD-O-3 (HISTO_T3)
- Year of Diagnosis (YEARDX)

Definition: Flags reportable site/histology codes based on year of diagnosis. For benign brain and central nervous system tumors diagnosed after 2004, only a primary site code is required, histology is not taken into account. This variable is not a collected data item, but derived using SITE_02, HISTO_T2, HISTO_T3 and YEARDX.

California Cancer Registry Data Dictionary

Variable Name:	SOURCECOMORBIDITY
Eureka Name:	Source Comorbidity
NAACCR Item:	9970
Category:	Clinical, Other
Level of Variable:	Tumor
Time Period Available:	2011 - current year
Related Variables:	Comorbid/Complication 1, Comorbid/Complication 2, Comorbid/Complication 3, Comorbid/Complication 4, Comorbid/Complication 5, Comorbid/Complication 6, Comorbid/Complication 7, Comorbid/Complication 8, Comorbid/Complication 9, Comorbid/Complication 10
Definition:	Records the data source from which comorbidities/complications were collected.
Values:	<p>0: No comorbid condition or complication identified/Not Applicable</p> <p>1: Collected from facility face sheet</p> <p>2: Linkage to facility/hospital discharge data set</p> <p>3: Linkage to Medicare/Medicaid data set</p> <p>4: Linkage with another claims data set</p> <p>5: Linkage through a combination of two or more sources above</p> <p>9: Other source</p> <p>Blank: A blank is only allowed for cases diagnosed prior to 2011</p>

California Cancer Registry Data Dictionary

Variable Name: SPANISH
Eureka Name: Spanish/Hispanic Origin
NAACCR Item: 190
Category: Patient Demographics
Level of Variable: Patient
Time Period Available: 1988 - current year

Related Variables:

Definition: SPANISH is a collected data item. This field is used to denote persons of Spanish/Hispanic origin or descent. Included are people whose native tongue is Spanish, who are nationals of a Spanish speaking Latin American country or Spain, and/or who identify with Spanish or Hispanic culture. Coding is independent of RACE1 through RACE5. The primary source for coding this variable is an ethnic identifier in the medical record.

Notes: This field is different than computed Spanish surname (SPANSURN). For additional information, please see Appendix "Variables Pertaining to Race/Ethnicity in the CCR".

Values:

- 0: Non-Spanish
- 1: Mexican
- 2: Puerto Rican
- 3: Cuban
- 4: Central or South American (except Brazil)
- 5: Other Spanish
- 6: Spanish, NOS
- 7: Spanish surname
- 8: Dominican Republic (effective with cases diagnosed on or after 01/01/2005)
- 9: Unknown whether Spanish or not

California Cancer Registry Data Dictionary

Variable Name: SPANSURN

Eureka Name: Computed Ethnicity

NAACCR Item: 200

Category: Patient Demographics

Level of Variable: Patient

Time Period Available: 1988 - current year

Related Variables:

- Name--Last (LNAME)
- Name--Maiden (MAIDNAME)
- Sex (SEX)

Definition: Used to denote persons with Spanish surnames as recognized by a computer algorithm comparing names to the 1980 Spanish surname list from the U.S. Census Bureau.

Values:

- 0: No match was run
- 1: Non-Hispanic last name and non-Hispanic maiden name
- 2: Non-Hispanic last name, did not check maiden name or patient was male
- 3: Non-Hispanic last name, missing maiden name
- 4: Hispanic last name, non-Hispanic maiden name
- 5: Hispanic last name, did not check maiden name or patient was male
- 6: Hispanic last name, missing maiden name
- 7: Hispanic Maiden name (females only) (regardless of last name)

California Cancer Registry Data Dictionary

Variable Name:	SRCSUR
Eureka Name:	N/A
NAACCR Item:	N/A
Category:	Patient Demographics
Level of Variable:	Patient
Time Period Available:	1988 - current year
Related Variables:	<ul style="list-style-type: none"> • Patient's Last Name on Middle Eastern Surname List (QME) • Race/Ethnicity of Patient Including Middle Eastern Origin (RACEME)
Definition:	Source of Middle Eastern surname.
Notes:	For additional information, please see Appendix "Variables Pertaining to Race/Ethnicity in the CCR".
Values:	<ol style="list-style-type: none"> 1: Male surname 2: Female surname, no maiden name 3: Female maiden name

California Cancer Registry Data Dictionary

Variable Name: SSNO
Eureka Name: Social Security Number
NAACCR Item: 2320
Category: Administrative
Level of Variable: Patient
Time Period Available: 1988 - current year

Related Variables:

Definition: Patient's Social Security Number, which is used for patient identification and linkage.

Values: 9 digits: Numeric value
999999999: Unknown SSN

California Cancer Registry Data Dictionary

Variable Name: STAGE
Eureka Name: N/A
NAACCR Item: N/A
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 1988 - current year
Related Variables: STAGE_SEER

Definition: Combined AJCC stage group variable derived using Extent of Disease (EOD) variables, Collaborative Stage variables, and T, N, and M variables. For cervical, colon, rectum, ovarian, vulva, vagina, and lung cancers diagnosed 1994-2003 and breast cancers diagnosed 1988-2003, STAGE is derived from EOD staging data items according to AJCC 3rd edition. For all cancer sites diagnosed 2004 through 2009, STAGE is derived from Collaborative Stage data items according to the AJCC 6th edition. For all cancers diagnosed 2010 through 2015, STAGE is derived from Collaborative Stage data items according to AJCC 7th edition. For all cancers diagnosed 2016 through 2017, STAGE is derived from directly coded T, N, M data items according to the Union for International Cancer Control (UICC) 7th edition. For all cancers diagnosed 2018 and forward, STAGE is derived from EOD variables according to the AJCC 8th edition.

Notes: The rules of classification and staging in the UICC 7th edition correspond with those appearing in the seventh edition of the **AJCC Cancer Staging Manual** (2009) and have approval of all national TNM committees. (UICC, 7th edition, pg. 4).

Before 2004, code 90 included unstaged occult or otherwise unknown stage. From 2004 forward, code 90 is reserved for unstaged occult and code 99 for stage unknown.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

- 00: 00 (In situ)
- 10: I
- 11: IA
- 12: IB
- 13: IC
- 19: I, NOS
- 20: II
- 21: IIA
- 22: IIB
- 23: IIC
- 29: II, NOS
- 30: III
- 31: IIIA

California Cancer Registry Data Dictionary

- 32: IIIB
- 33: IIIC
- 34: IIID
- 39: III, NOS
- 40: IV
- 41: IVA
- 42: IVB
- 43: IVC
- 49: IV, NOS
- 90: Unstaged/Occult
- 98: Not applicable
- 99: Error/Unknown

California Cancer Registry Data Dictionary

Variable Name: STAGE_SEER
Eureka Name: N/A
NAACCR Item: N/A
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 1988 - current year
Related Variables: STAGE

Definition: Combined AJCC stage group variable derived using Extent of Disease (EOD) variables, Collaborative Stage variables, and T, N, and M variables. For cervical, colon, rectum, ovarian, vulva, vagina, and lung cancers diagnosed 1994-2003 and breast cancers diagnosed 1988-2003, STAGE_SEER is derived from EOD staging data items according to SEER-Modified AJCC 3rd edition. For all cancer sites diagnosed 2004 through 2009, STAGE_SEER is derived from Collaborative Stage data items according to the AJCC 6th edition. For all cancers diagnosed 2010 through 2015, STAGE_SEER is derived from Collaborative Stage data items according to AJCC 7th edition. For all cancers diagnosed 2016 through 2017, STAGE_SEER is derived from directly coded T, N, M data items according to the Union for International Cancer Control (UICC) 7th edition. For all cancers diagnosed 2018 and forward, STAGE_SEER is derived from EOD variables according to the AJCC 8th edition.

Notes: The rules of classification and staging in the UICC 7th edition correspond with those appearing in the seventh edition of the **AJCC Cancer Staging Manual** (2009) and have approval of all national TNM committees. (UICC, 7th edition, pg. 4).

Before 2004, code 90 included unstaged occult or otherwise unknown stage. From 2004 forward, code 90 is reserved for unstaged occult and code 99 for stage unknown.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

- 00: 00 (In situ)
- 10: I
- 11: IA
- 12: IB
- 13: IC
- 19: I, NOS
- 20: II
- 21: IIA
- 22: IIB
- 23: IIC
- 29: II, NOS
- 30: III

California Cancer Registry Data Dictionary

- 31: IIIA
- 32: IIIB
- 33: IIIC
- 34: IIID
- 39: III, NOS
- 40: IV
- 41: IVA
- 42: IVB
- 43: IVC
- 49: IV, NOS
- 90: Unstaged/Occult
- 98: Not applicable
- 99: Error/Unknown

California Cancer Registry Data Dictionary

Variable Name: STYPEFU
Eureka Name: N/A
NAACCR Item: 2180
Category: Follow-Up
Level of Variable: Tumor
Time Period Available: 1988 - current year

Related Variables:

Definition: Type of follow-up – SEER, identifies the source of information used to code the patient's vital status. This is not a collected data item; it is derived based on reporting source and behavior/site combinations.

Values:

- 1: Not in follow-up -- autopsy only or death certificate only (DCO) case
- 2: Active follow-up case
- 3: Not in follow-up – in situ cancer of the cervix uteri only
- 4: Case not originally in active follow-up, but in active follow-up now (Region 8 only)
- 9: Non-incidence case

California Cancer Registry Data Dictionary

Variable Name: SUMMARYSTAGE2018
Eureka Name: Summary Stage 2018
NAACCR Item: 764
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 - current year

Related Variables:

Definition: This item stores the directly assigned Summary Stage 2018. Valid for cases diagnosed January 1, 2018 and forward.

Notes: *For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."*

Values:

- 0: In situ
- 1: Localized
- 2: Regional by direct extension only
- 3: Regional lymph nodes only
- 4: Regional by BOTH direct extension AND lymph node involvement
- 7: Distant site(s)/node(s) involved
- 8: Benign/borderline; Applicable for the following SS2018 chapters - Brain, CNS Other, Intracranial Gland
- 9: Unknown if extension or metastasis (unstaged, unknown, or unspecified); death certificate only
- Blank: Date of Diagnosis pre-2018

California Cancer Registry Data Dictionary

Variable Name: SUMSTAGE

Eureka Name: N/A

NAACCR Item: N/A

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 1988 - current year

Related Variables:

- SUMSTAGE77 (SEER Summary Stage 1977, collected)
- SUMSTAGE77_SEER (SEER Summary Stage 1977, derived from EOD staging data items)
- SUMSTAGE00_SEER (SEER Summary Stage 2000, derived from EOD staging data items)
- DERIVED_SS2000 (SEER Summary Stage 2000, derived from Collaborative Stage data items)
- SUMSTAGE00 (SEER Summary Stage 2000, collected)
- DERIVEDSUMMARYSTAGE2018 (SEER Summary Stage 2018, derived from EOD staging data item)

Notes: *For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."*

Definition: Summary stage at time of diagnosis. This variable is not a collected data item, but is derived using SEER Summary Stage 1977 (SUMSTAGE77) collected for cases diagnosed 1988 through 1993, SEER Summary Stage 1977 (SUMSTAGE77_SEER) derived from EOD staging data items for cases diagnosed 1994 through 2000, SEER Summary Stage 2000 (SUMSTAGE00_SEER) derived from EOD staging data items for cases diagnosed 2001 through 2003, SEER Summary Stage 2000 (DERIVED_SS2000) derived from Collaborative Stage data items for cases diagnosed 2004-2015, SEER Summary Stage 2000 (SUMSTAGE00) collected for cases diagnosed 2016 through 2017, and Derived Summary Stage 2018 (DERIVEDSUMMARYSTAGE2018) derived from EOD staging data items for cases diagnosed 2018 and forward.

Values:

- 0: In situ
- 1: Localized
- 2: Regional by direct extension
- 3: Regional by lymph nodes
- 4: Regional by direct extension and lymph nodes
- 5: Regional, NOS
- 7: Remote
- 8: Not abstracted
- 9: Unknown or not specified

California Cancer Registry Data Dictionary

Variable Name: SURGDATE
Eureka Name: RX Date Surgery
NAACCR Item: 1200
Category: Treatment, Surgical
Level of Variable: Tumor
Time Period Available: 1988 - current year

Related Variables:

Definition: Date the earliest definitive surgery was performed. Different from DTDEFSURG, which is the date when the most extensive surgery was performed.

Notes: For cases diagnosed prior to 1996, SURGDATE may include surgical procedures to sites other than the primary tumor or organ of origin (such as lymph nodes or distant sites).

Values: Any valid date: YYYYMMDD format
 0's: No surgery or unknown if surgery performed
 9's: Surgery performed but date is unknown, or case reported through death certificate only (DCO).

California Cancer Registry Data Dictionary

Variable Name: SURGOTH
Eureka Name: Rx Summ--Surg Oth Reg/Dis
NAACCR Item: 1294
Category: Treatment, Surgical
Level of Variable: Tumor
Time Period Available: 2003 - current year

Related Variables:

Definition: Surgical removal of tissue other than the primary tumor or organ of origin (other regional site(s), distant site(s) or distant LN(s)) for cases diagnosed January 1, 2003 and forward.

Notes: Variable is intended primarily for cases with ill-defined or unknown primary site, and for hematopoietic malignancies such as lymphoma and leukemia. The American College of Surgeons is responsible for establishing data items, codes, and definitions for the surgical treatment of cancer. Whenever possible, surgery codes for cases diagnosed prior to any changes introduced by the College are converted to reflect current coding rules. However, in some cases the information available may not allow for an accurate conversion. Please keep these changes in mind when evaluating time trends in cancer treatment.

Values:

- 0: None, no surgical procedure of non-primary site; resection of regional site
- 1: Non-primary surgical procedure performed; non-primary surgical resection to other site(s); unknown if whether the site(s) is regional or distant
- 2: Non-primary surgical procedure to other regional sites
- 3: Non-primary surgical procedure to distant lymph node(s); resection of distant lymph node(s)
- 4: Non-primary surgical procedure to distant site, resection of distant site
- 5: Combination of codes, any combination of surgical procedures 2, 3, or 4
- 9: Unknown; it is unknown whether any surgical procedure of a non-primary site was performed; death certificate only

California Cancer Registry Data Dictionary

Variable Name: SURGPRIM
Eureka Name: Rx Summ--Surg Prim Site
NAACCR Item: 1290
Category: Treatment, Surgical
Level of Variable: Tumor
Time Period Available: 2003 - current year

Related Variables: RX Date Mst Defn Surg (DTDEFSURG)

Definition: Most extensive type of surgery performed during the first course of treatment for cases diagnosed January 1, 2003 and forward.

Notes: For current site-specific codes see Appendix K of Volume I:
<https://www.ccrca.org/submit-data/cancer-registrars-hospitals-and-facilities/reporting-by-cancer-registrars/#volumes-anchor>

The American College of Surgeons is responsible for establishing data items, codes, and definitions for the surgical treatment of cancer. Whenever possible, surgery codes for cases diagnosed prior to any changes introduced by the College are converted to reflect current coding rules. However, in some cases the information available may not allow for an accurate conversion. Please keep these changes in mind when evaluating time trends in cancer treatment.

Values:

- 00: No surgery, autopsy only
- 10-90: Definitive surgery to the primary site
- 98: Special codes for hematopoietic/reticuloendothelial/immunoproliferative/myeloproliferative disease, ill-defined site & unknown primaries. Code 98 takes precedence over 00.
- 99: Unknown whether definitive surgery was done; Death certificate only

California Cancer Registry Data Dictionary

Variable Name: SURGRCON

Eureka Name: Rx Summ--Reconstruct 1st

NAACCR Item: 1330

Category: Treatment, Surgical

Level of Variable: Tumor

Time Period Available: 1998 - 2002

Related Variables: Rx Summ--Surg Prim Site (SURGPRIM)

Definition: Most extensive reconstructive surgery performed during first course of treatment, for cases diagnosed prior to January 1, 2003. For cases diagnosed 2003 forward, information was incorporated into SURGPRIM.

Notes: College of Surgeons is responsible for establishing data items, codes, and definitions for the surgical treatment of cancer. Whenever possible, surgery codes for cases diagnosed prior to any changes introduced by the College are converted to reflect current coding rules. However, in some cases the information available may not allow for an accurate conversion. Please keep these changes in mind when evaluating time trends in cancer treatment.

Values:

- 0-9: Codes are site specific; see the 1998 ROADS Manual available at:
(<https://www.facs.org/-/media/files/quality-programs/cancer/coc/roads/roads1998.ashx>)
- Blank: Date of Diagnosis is on or after January 1, 2003

California Cancer Registry Data Dictionary

Variable Name: SURV_DATEDX_RECODE

Eureka Name: Surv-Date DX Recode

NAACCR Item: 1788

Category: Follow-Up

Level of Variable: Tumor

Time Period Available: 1988 - current year

Related Variables:

- Date of Diagnosis (DATEDX)
- Surv-Date Active Followup (SURV_DATELC_ACT)
- Surv-Date Presumed Alive (SURV_DATELC_PSU)
- Surv-Flag Active Followup (SURV_FLAG_ACT)
- Surv-Flag Presumed Alive (SURV_FLAG_PSU)
- Surv-Mos Active Followup (SURV_MON_ACT)
- Surv-Mos Presumed Alive (SURV_MON_PSU)

Definition: Survival Date of Diagnosis Recode (SURV_DATEDX_RECODE) is calculated using the month, day, and year of Date of Diagnosis (DATEDX). If DATEDX has complete month and day information, SURV_DATEDX_RECODE will be the same as DATEDX. If the day or month of DATEDX is unknown or not available, the values are imputed.

Notes: This is one of seven fields derived by a survival program provided by SEER. For additional information about the survival algorithm and what specific values are assigned when dates are missing go to: <http://seer.cancer.gov/survivaltime/>.

Values: A valid date in YYYYMMDD

California Cancer Registry Data Dictionary

Variable Name: SURV_DATELC_ACT
Eureka Name: Surv-Date Active Followup
NAACCR Item: 1782
Category: Follow-Up
Level of Variable: Tumor
Time Period Available: 1988 - current year
Related Variables:

- Date of Last Contact (FUDATE)
- Surv-Mos Active Followup (SURV_MON_ACT)
- Surv-Flag Active Followup (SURV_FLAG_ACT)

Definition: Survival Date of Active Follow-up (SURV_DATELC_ACT) is defined as the earlier of the date of last contact (FUDATE) or the study cutoff date which is the date for which follow-up (or death ascertainment) is complete. The study cut-off date is a pre-determined date based on the year of data submission and is set in the survival program used to derive seven survival variables. If FUDATE is earlier than the study cut-off date and either the day or month is unknown or not available, the values are imputed.

Notes: This is one of seven fields derived by a survival program provided by SEER. For additional information about the survival algorithm and what specific values are assigned when dates are missing go to: <http://seer.cancer.gov/survivaltime/>.

Values: A valid date in YYYYMMDD

California Cancer Registry Data Dictionary

Variable Name:	SURV_DATELC_PSU
Eureka Name:	Surv-Date Presumed Alive
NAACCR Item:	1785
Category:	Follow-Up
Level of Variable:	Tumor
Time Period Available:	1988 - current year
Related Variables:	<ul style="list-style-type: none"> • Vital Status (VITSTAT) • Date of Last Contact (FUDATE) • Surv-Mos Presumed Alive (SURV_MON_PSU) • Surv-Flag Presumed Alive (SURV_FLAG_PSU)

Definition: Survival Date of Presumed Alive (SURV_DATELC_PSU) is the last date for which complete death ascertainment is available in the registry. Because not all central cancer registries conduct active patient follow-up, it is necessary to have an option for calculating survival times based on the assumption that the registry has ascertained all available deaths (state/province and national), and persons not known to be deceased are presumed to be alive as of the last date for which complete death ascertainment is available. The California Cancer Registry does perform active follow-up and therefore, we would only encourage the use of this variable when comparing California survival to survival for registries that do not have active follow-up. This variable is set in the survival program used to derive seven survival variables.

Notes: This is one of seven fields derived by a survival program provided by SEER. For additional information about the survival algorithm and what specific values are assigned when dates are missing go to: <http://seer.cancer.gov/survivaltime/>.

Values: A valid date in YYYYMMDD

California Cancer Registry Data Dictionary

Variable Name:	SURV_FLAG_ACT
Eureka Name:	Surv-Flag Active Followup
NAACCR Item:	1783
Category:	Follow-Up
Level of Variable:	Tumor
Time Period Available:	1988 - current year
Related Variables:	<ul style="list-style-type: none"> • Surv-Date DX Recode (SURV_DATEDX_RECODE) • Surv-Date Active Followup (SURV_DATELC_ACT) • Surv-Mos Active Followup (SURV_MON_ACT)

Definition: This flag is generated by the program that creates Surv-Mos Active Followup (SURV_MON_ACT) and describes how complete the date information used to calculate survival in months was.

Notes: This is one of seven fields derived by a survival program provided by SEER. For additional information about the survival algorithm and what specific values are assigned when dates are missing go to: <http://seer.cancer.gov/survivaltime/>.

Values:	0:	Complete dates are available and there are 0 days of survival
	1:	Complete dates are available and there are more than 0 days of survival
	2:	Incomplete dates are available and there could be zero days of follow-up
	3:	Incomplete dates are available and there cannot be zero days of follow-up
	8:	Not calculated because a death certificate only or autopsy only case
	9:	Unknown
	Blank:	Not coded

California Cancer Registry Data Dictionary

Variable Name: SURV_FLAG_PSU

Eureka Name: Surv-Flag Presumed Alive

NAACCR Item: 1786

Category: Follow-Up

Level of Variable: Tumor

Time Period Available: 1988 - current year

Related Variables:

- Surv-Date DX Recode (SURV_DATEDX_RECODE)
- Surv-Date Presumed Alive (SURV_DATELC_PSU)
- Surv-Mos Presumed Alive (SURV_MON_PSU)

Definition: This flag is generated by the program that creates Surv-Mos Presumed Alive (SURV_MON_PSU) and describes how complete the date information used to calculate survival in months was.

Notes: This is one of seven fields derived by a survival program provided by SEER. For additional information about the survival algorithm and what specific values are assigned when dates are missing go to: <http://seer.cancer.gov/survivaltime/>.

Values:

- 0: Complete dates are available and there are 0 days of survival
- 1: Complete dates are available and there are more than 0 days of survival
- 2: Incomplete dates are available and there could be zero days of follow-up
- 3: Incomplete dates are available and there cannot be zero days of follow-up
- 8: Not calculated because a death certificate only or autopsy only case
- 9: Unknown
- Blank: Not coded

California Cancer Registry Data Dictionary

Variable Name: SURV_MON_ACT

Eureka Name: Surv-Mos Active Follow-up

NAACCR Item: 1784

Category: Follow-Up

Level of Variable: Tumor

Time Period Available: 1988 - current year

Related Variables:

- Surv-Date DX Recode (SURV_DATEDX_RECODE)
- Surv-Date Active Followup (SURV_DATELC_ACT)
- Surv-Flag Active Followup (SURV_FLAG_ACT)

Definition: Survival interval in months calculated using the month, day, and year of Surv-Date DX Recode (SURV_DATEDX_RECODE) and the month, day, and year of Surv-Date Active Followup (SURV_DATELC_ACT).

Notes: This is one of seven fields derived by a survival program provided by SEER. For additional information about the survival algorithm and what specific values are assigned when dates are missing go to: <http://seer.cancer.gov/survivaltime/>.

Values: 9999 for missing and matches the Surv-Flag Active Follow-up value of 9 or blank.

California Cancer Registry Data Dictionary

Variable Name: SURV_MON_PSU

Eureka Name: Surv-Mos Presumed Alive

NAACCR Item: 1787

Category: Follow-Up

Level of Variable: Tumor

Time Period Available: 1988 - current year

Related Variables:

- Surv-Date DX Recode (SURV_DATEDX_RECODE)
- Surv-Date Presumed Alive (SURV_DATELC_PSU)
- Surv-Flag Presumed Alive (SURV_FLAG_PSU)

Definition: Survival interval in months calculated using the month, day, and year of Surv-Date DX Recode (SURV_DATEDX_RECODE) and the month, day, and year of Surv-Date Presumed Alive (SURV_DATELC_PSU). Because not all central cancer registries conduct active patient follow-up, it is necessary to have an option for calculating survival times based on the assumption that the registry has ascertained all available deaths (state/province and national), and persons not known to be deceased are presumed to be alive as of the last date for which complete death ascertainment is available. The California Cancer Registry does perform active follow-up and therefore, we would only suggest using this variable when comparing California survival to survival in states that do not have active follow-up.

Notes: This is one of seven fields derived by a survival program provided by SEER. For additional information about the survival algorithm and what specific values are assigned when dates are missing go to: <http://seer.cancer.gov/survivaltime/>.

Values: 9999 for missing and matches the Surv-Flag Presumed Alive value of 9 or blank.

California Cancer Registry Data Dictionary

Variable Name:	TCODE
Eureka Name:	N/A
NAACCR Item:	N/A
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	1998 - 2003
Related Variables:	<ul style="list-style-type: none"> • EOD--Tumor Size (TSIZETU) • EOD--Extension (DIREXTTU) • Extent of Disease Derived N Code for TNM Staging (NCODE) • Extent of Disease Derived M Code for TNM Staging (MCODE) • Extent of Disease Derived AJCC 3rd Edition Stage Group 1988 through 2003 (STAGE_AJCC) • SEER Modified Extent of Disease Derived AJCC 3rd Edition Stage Group 1988 through 2003 (STAGE_AJCCSEER) • AJCC Stage of Cancer (STAGE) • SEER-Modified AJCC Stage of Cancer (STAGE_SEER) • Derived AJCC-6 T (DERIVED_AJCC_T) • Derived AJCC-7 T (DERIVEDAJCC7T) • TNM Clin T (TNM_T_CODE_CLINICAL) • TNM Path T (TNM_T_CODE_PATH) • Derived SEER Combined T (DERIVEDSEERCOMBINEDT) • Derived EOD 2018 T (DERIVEDEOD18T)

Definition: Extent of Disease (EOD) derived "T" value for TNM staging which provides the size or contiguous extension of the primary tumor. This variable is not a collected data item but derived according to the AJCC third edition using the EOD staging data items for tumor size (TSIZETU) and extension (DIREXTTU). For cases diagnosed 2004 through 2015, this value is derived from collaborative stage data items according to the AJCC sixth edition and is recorded in the field DERIVED_AJCC_T. Additionally, for cases diagnosed 2010 through 2015, this value is derived from collaborative stage data items according to the AJCC seventh edition and is recorded in the field DERIVEDAJCC7T. For cases diagnosed 2016 and 2017, TNM values were directly coded by Certified Tumor Registrars and the AJCC seventh edition T value is recorded in the fields TNM_T_CODE_CLINICAL and TNM_T_CODE_PATH. Or, for the T value used to calculate DERIVEDSEERCMBSTGGRP, see DERIVEDSEERCOMBINEDT. For cases diagnosed 2018 and forward, this value was once again derived from EOD staging data items according to the AJCC eighth edition and is recorded in the field, DERIVEDEOD18T.

California Cancer Registry Data Dictionary

Notes: TCODE only has values for the following sites: breast, cervix, colon, lung, ovarian, rectum, vagina and vulva.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values: T0, Tis, T1, T1a, T1b, T1c, T1x, T2, T2a, T2b, T2c, T2x, T3, T3a, T3b, T3c, T3x, T4, T4a, T4b, T4c, T4d, TX, TXa, TXb, TXc

Values are site-specific; see SEER Program: Comparative Staging Guide For Cancer (https://seer.cancer.gov/archive/manuals/historic/comp_stage1.1.pdf).

California Cancer Registry Data Dictionary

Variable Name:	THICKNESS
Eureka Name:	Measured Thickness
NAACCR Item:	3888
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2018 – current year
Related Variables:	CS Site-Specific Factor 3 (CS_SITE_SPEC_F3)
Definition:	Measured Thickness, or height, of a uveal melanoma, is a prognostic indicator for this tumor.
Values:	<p>0.0: No mass/tumor found</p> <p>0.1-99.9: 0.1–99.9 millimeters (mm) (Exact measurement to nearest tenth of a mm)</p> <p>XX.0: 100 millimeters (mm) or larger</p> <p>XX.1: Described as "less than 3 mm"</p> <p>XX.2: Described as "at least" 3 mm</p> <p>XX.3: Described as "at least" 6 mm</p> <p>XX.4: Described as "at least" 9 mm</p> <p>XX.5: Described as "at least" 12 mm</p> <p>XX.6: Described as "at least" 15 mm</p> <p>XX.8: Not applicable; Information not collected for this case</p> <p>XX.9: Not documented in medical record; Cannot be determined; Measured Thickness not assessed or unknown if assessed</p> <p>Blank: Date of Diagnosis pre-2018; Non-required Schema ID</p>

California Cancer Registry Data Dictionary

Variable Name: THROMBOCYTOPENIA
Eureka Name: Thrombocytopenia
NAACCR Item: 3933
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 - current year

Related Variables:

Definition: Thrombocytopenia is defined by a deficiency of platelets in the blood. In staging of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), thrombocytopenia is defined as Platelets (Plt) less than 100,000/ μ L.

Values:

- 0: Thrombocytopenia not present; Platelets (Plt) = 100,000/ μ L
- 1: Thrombocytopenia present; Platelets (Plt) < 100,000/ μ L
- 6: Lab value unknown, physician states thrombocytopenia is present
- 7: Test ordered, results not in chart
- 9: Not documented in medical record; Thrombocytopenia not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name:	TNM_CODER_CLINICAL
Eureka Name:	TNM Clin Staged By
NAACCR Item:	990
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2016-2017
Related Variables:	<ul style="list-style-type: none"> • TNM CLIN T (TNM_T_CODE_CLINICAL) • TNM CLIN N (TNM_N_CODE_CLINICAL) • TNM CLIN M (TNM_M_CODE_CLINICAL) • TNM CLIN STAGE GROUP (TNM_STAGE_CLINICAL) • TNM CLIN DESCRIPTOR (TNMCLINDESCRIPTOR)

Definition: Identifies the person who documented the clinical AJCC staging elements and the Stage Group in the patient's medical record.

Notes: *For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."*

Values:	00: Not staged
	10: Physician, NOS, or physician type not specified in codes 11-15
	11: Surgeon
	12: Radiation Oncologist
	13: Medical Oncologist
	14: Pathologist
	15: Multiple Physicians; Tumor Board; etc.
	20: Cancer registrar
	30: Cancer registrar and physician
	40: Nurse, physician assistant, or other non-physician medical staff
	50: Staging assigned at another facility
	60: Staging by Central Registry
	88: Case is not eligible for staging
	99: Staged but unknown who assigned stage

California Cancer Registry Data Dictionary

Variable Name:	TNM_CODER_PATH
Eureka Name:	TNM Path Staged By
NAACCR Item:	930
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2016 - 2017
Related Variables:	<ul style="list-style-type: none"> • TNM PATH T (TNM_T_CODE_PATH) • TNM PATH N (TNM_N_CODE_PATH) • TNM PATH M (TNM_M_CODE_PATH) • TNM PATH STAGE GROUP (TNM_STAGE_PATH) • TNM PATH DESCRIPTOR (TNMPATHDESCRIPTOR)

Definition: Identifies the person who recorded the pathologic AJCC staging elements in the patient's medical record.

Notes: *For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."*

Values:	00: Not staged
	10: Physician, NOS, or physician type not specified in codes 11-15
	11: Surgeon
	12: Radiation Oncologist
	13: Medical Oncologist
	14: Pathologist
	15: Multiple Physicians; Tumor Board; etc.
	20: Cancer registrar
	30: Cancer registrar and physician
	40: Nurse, physician assistant, or other non-physician medical staff
	50: Staging assigned at another facility
	60: Staging by Central Registry
	88: Case is not eligible for staging
	99: Staged but unknown who assigned stage

California Cancer Registry Data Dictionary

Variable Name: TNM_M_CODE_CLINICAL
Eureka Name: TNM Clin M
NAACCR Item: 960
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2016 - 2017
Related Variables:

- TNM CLIN T (TNM_T_CODE_CLINICAL)
- TNM CLIN N (TNM_N_CODE_CLINICAL)
- TNM CLIN STAGE GROUP (TNM_STAGE_CLINICAL)
- TNM CLIN DESCRIPTOR (TNMCLINDESCRIPTOR)
- TNM Clin Staged By (TNM_CODER_CLINICAL)

Definition: Identifies the presence or absence of distant metastasis (M) of the tumor known prior to the start of any therapy.

Notes: See the **AJCC Cancer Staging Manual**, current edition for site-specific categories for the TNM elements and stage groups. See the **FORDS** manual for specifications for codes and data entry rules.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

c0:	cM0
c0l+:	cM0(i+)
c1:	cM1
c1A:	cM1a
c1B:	cM1b
c1C:	cM1c
c1D:	cM1d
c1E:	cM1e
p1:	pM1
p1A:	pM1a
p1B:	pM1b
p1C:	pM1c
p1D:	pM1d
p1E:	pM1e
88:	Not applicable, no code assigned for this case in the current AJCC Cancer Staging Manual
Blank:	No information at all is available to code this item

California Cancer Registry Data Dictionary

Variable Name: TNM_M_CODE_PATH
Eureka Name: TNM Path M
NAACCR Item: 900
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2016 - 2017

Related Variables:

- TNM PATH T (TNM_T_CODE_PATH)
- TNM PATH N (TNM_N_CODE_PATH)
- TNM PATH STAGE GROUP (TNM_STAGE_PATH)
- TNM PATH DESCRIPTOR (TNMPATHDESCRIPTOR)
- TNM Path Staged By (TNM_CODER_PATH)

Definition: Identifies the presence or absence of distant metastasis (M) of the tumor known following the completion of surgical therapy.

Notes: See the **AJCC Cancer Staging Manual**, current edition for site-specific categories for the TNM elements and stage groups. See the **FORDS** manual for specifications for codes and data entry rules.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

c0:	cM0
c0I+:	cM0(i+)
p1:	pM1
p1A:	pM1a
p1B:	pM1b
p1C:	pM1c
p1D:	pM1d
p1E:	pM1e
c1:	cM1
c1A:	cM1a
c1B:	cM1b
c1C:	cM1c
c1D:	cM1d
c1E:	cM1e
88:	Not applicable, no code assigned for this case in the current AJCC Cancer Staging Manual
Blank:	No information at all is available to code this item

California Cancer Registry Data Dictionary

Variable Name: TNM_N_CODE_CLINICAL

Eureka Name: TNM Clin N

NAACCR Item: 950

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2016 - 2017

Related Variables:

- TNM CLIN T (TNM_T_CODE_CLINICAL)
- TNM CLIN M (TNM_M_CODE_CLINICAL)
- TNM CLIN STAGE GROUP (TNM_STAGE_CLINICAL)
- TNM CLIN DESCRIPTOR (TNMCLINDESCRIPTOR)
- TNM Clin Staged By (TNM_CODER_CLINICAL)

Definition: Identifies the absence or presence of regional lymph node (N) metastasis and describes the extent of regional lymph node metastasis of the tumor known prior to the start of any therapy.

Notes: See the **AJCC Cancer Staging Manual**, current edition for site-specific categories for the TNM elements and stage groups. See the **FORDS** manual for specifications for codes and data entry rules.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

cX:	cNX
c0:	cN0
c0A:	cN0a
c0B:	cN0b
c1:	cN1
c1A:	cN1a
c1B:	cN1b
c1C:	cN1c
c2:	cN2
c2A:	cN2a
c2B:	cN2b
c2C:	cN2c
c3:	cN3
c3A:	cN3a
c3B:	cN3b
c3C:	cN3c
c4:	cN4
88:	Not applicable, no code assigned for this case in the current AJCC Cancer Staging Manual
Blank:	No information at all is available to code this item

California Cancer Registry Data Dictionary

Variable Name: TNM_N_CODE_PATH

Eureka Name: TNM Path N

NAACCR Item: 890

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2016 - 2017

Related Variables:

- TNM PATH T (TNM_T_CODE_PATH)
- TNM PATH M (TNM_M_CODE_PATH)
- TNM PATH STAGE GROUP (TNM_STAGE_PATH)
- TNM PATH DESCRIPTOR (TNMPATHDESCRIPTOR)
- TNM Path Staged By (TNM_CODER_PATH)

Definition: Identifies the absence or presence of regional lymph node (N) metastasis and describes the extent of regional lymph node metastasis of the tumor known following the completion of surgical therapy.

Notes: See the **AJCC Cancer Staging Manual**, current edition for site-specific categories for the TNM elements and stage groups. See the **FORDS** manual for specifications for codes and data entry rules.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

pX:	pNX
c0:	cN0
p0:	pN0
p0I-:	pN0i-
p0I+:	pN0i+
p0M-:	pN0m-
p0M+:	pN0m+
p1MI:	pN1mi
p0A:	pN0a
p0B:	pN0b
p1:	pN1
p1A:	pN1a
p1B:	pN1b
p1C:	pN1c
p2:	pN2
p2A:	pN2a
p2B:	pN2b
p2C:	pN2c
p3:	pN3
p3A:	pN3a
p3B:	pN3b
p3C:	pN3c

California Cancer Registry Data Dictionary

p4: pN4

88: Not applicable, no code assigned for this case in the current ***AJCC Cancer Staging Manual***

Blank: No information at all is available to code this item

California Cancer Registry Data Dictionary

Variable Name:	TNM_STAGE_CLINICAL
Eureka Name:	TNM Clin Stage Group
NAACCR Item:	970
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2016 - 2017
Related Variables:	<ul style="list-style-type: none"> • TNM CLIN T (TNM_T_CODE_CLINICAL) • TNM CLIN N (TNM_N_CODE_CLINICAL) • TNM CLIN M (TNM_M_CODE_CLINICAL) • TNM CLIN DESCRIPTOR (TNMCLINDESCRIPTOR) • TNM Clin Staged By (TNM_CODER_CLINICAL)

Definition: Identifies the anatomic extent of disease based on the T, N, and M elements known prior to the start of any therapy.

Notes: See the **AJCC Cancer Staging Manual**, current edition, for site-specific categories for the TNM elements and stage groups. See the **FORDS** manual for specifications for codes and data entry rules.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:	0:	Stage 0
	0A:	Stage 0A
	0IS:	Stage 0is
	1:	Stage I
	1A:	Stage IA
	1A1:	Stage IA1
	1A2:	Stage IA2
	1B:	Stage IB
	1B1:	Stage IB1
	1B2:	Stage IB2
	1C:	Stage IC
	1S:	Stage IS
	2:	Stage II
	2A:	Stage IIA
	2A1:	Stage IIA1
	2A2:	Stage IIA2
	2B:	Stage IIB
	2C:	Stage IIC
	3:	Stage III
	3A:	Stage IIIA
	3B:	Stage IIIB
	3C:	Stage IIIC
	3C1:	Stage IIIC1

California Cancer Registry Data Dictionary

3C2:	Stage IIIC2
4:	Stage IV
4A:	Stage IVA
4A1:	Stage IVA1
4A2:	Stage IVA2
4B:	Stage IVB
4C:	Stage IVC
OC:	Occult
88:	Not applicable, no code assigned for this case in the current <i>AJCC Cancer Staging Manual</i>
99:	Unknown

California Cancer Registry Data Dictionary

Variable Name: TNM_STAGE_PATH
Eureka Name: TNM Path Stage Group
NAACCR Item: 910
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2016 - 2017
Related Variables:

- TNM PATH T (TNM_T_CODE_PATH)
- TNM PATH N (TNM_N_CODE_PATH)
- TNM PATH M (TNM_M_CODE_PATH)
- TNM PATH DESCRIPTOR (TNMPATHDESCRIPTOR)
- TNM Path Staged By (TNM_CODER_PATH)

Definition: Identifies the anatomic extent of disease based on the T, N, and M elements known following the completion of surgical therapy.

Notes: See the **AJCC Cancer Staging Manual**, current edition, for site-specific categories for the TNM elements and stage groups. See the **FORDS** manual for specifications for codes and data entry rules.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

0:	Stage 0
0A:	Stage 0A
0IS:	Stage 0is
1:	Stage I
1A:	Stage IA
1A1:	Stage IA1
1A2:	Stage IA2
1B:	Stage IB
1B1:	Stage IB1
1B2:	Stage IB2
1C:	Stage IC
1S:	Stage IS
2:	Stage II
2A:	Stage IIA
2A1:	Stage IIA1
2A2:	Stage IIA2
2B:	Stage IIB
2C:	Stage IIC
3:	Stage III
3A:	Stage IIIA
3B:	Stage IIIB
3C:	Stage IIIC

California Cancer Registry Data Dictionary

3C1:	Stage IIIC1
3C2:	Stage IIIC2
4:	Stage IV
4A:	Stage IVA
4A1:	Stage IVA1
4A2:	Stage IVA2
4B:	Stage IVB
4C:	Stage IVC
OC:	Occult
88:	Not applicable, no code assigned for this case in the current <i>AJCC Cancer Staging Manual</i>
99:	Unknown

California Cancer Registry Data Dictionary

Variable Name:	TNM_T_CODE_CLINICAL
Eureka Name:	TNM Clin T
NAACCR Item:	940
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2016 - 2017
Related Variables:	<ul style="list-style-type: none"> • TNM CLIN N (TNM_N_CODE_CLINICAL) • TNM CLIN M (TNM_M_CODE_CLINICAL) • TNM Clin Stage Group (TNM_STAGE_CLINICAL) • TNM CLIN DESCRIPTOR (TNMCLINDESCRIPTOR) • TNM Clin Staged By (TNM_CODER_CLINICAL)

Definition: Evaluates the primary tumor (T) and reflects the tumor size and/or extension of the tumor prior to the start of any therapy.

Notes: See the **AJCC Cancer Staging Manual**, current edition, for site-specific categories for the TNM elements and stage groups. See the **FORDS** manual for specifications for codes and data entry rules.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:	cX: cTX
	c0: cT0
	pA: pTa
	pIS: pTis
	pISU: pTispu
	pISD: pTispd
	c1MI: cT1mi, cT1mic
	c1: cT1
	c1A: cT1a
	c1A1: cT1a1
	c1A2: cT1a2
	c1B: cT1b
	c1B1: cT1b1
	c1B2: cT1b2
	c1C: cT1c
	c1D: cT1d
	c2: cT2
	c2A: cT2a
	c2A1: cT2a1
	c2A2: cT2a2
	c2B: cT2b
	c2C: cT2c
	c2D: cT2d

California Cancer Registry Data Dictionary

c3:	cT3
c3A:	cT3a
c3B:	cT3b
c3C:	cT3c
c3D:	cT3d
c4:	cT4
c4A:	cT4a
c4B:	cT4b
c4C:	cT4c
c4D:	cT4d
c4E:	cT4e
88:	Not applicable, no code assigned for this case in the current AJCC <i>Cancer Staging Manual</i>
Blank:	No information at all is available to code this item

California Cancer Registry Data Dictionary

Variable Name: TNM_T_CODE_PATH

Eureka Name: TNM Path T

NAACCR Item: 880

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2016 - 2017

Related Variables:

- TNM PATH N (TNM_N_CODE_PATH)
- TNM PATH M (TNM_M_CODE_PATH)
- TNM Path Stage Group (TNM_STAGE_PATH)
- TNM PATH DESCRIPTOR (TNMPATHDESCRIPTOR)
- TNM Path Staged By (TNM_CODER_PATH)

Definition: Evaluates the primary tumor (T) and reflects the tumor size and/or extension of the tumor known following the completion of surgical therapy.

Notes: See the **AJCC Cancer Staging Manual**, current edition, for site-specific categories for the TNM elements and stage groups. See the **FORDS** manual for specifications for codes and data entry rules.

For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."

Values:

pX:	pTX
p0:	pT0
pA:	pTa
pIS:	pTis
pISU:	pTispu
pISD:	pTispd
p1MI:	pT1mi, pT1mic
p1:	pT1
p1A:	pT1a
p1A1:	pT1a1
p1A2:	pT1a2
p1B:	pT1b
p1B1:	pT1b1
p1B2:	pT1b2
p1C:	pT1c
p1D:	pT1d
p2:	pT2
p2A:	pT2a
p2A1:	pT2a1
p2A2:	pT2a2
p2B:	pT2b
p2C:	pT2c
p2D:	pT2d

California Cancer Registry Data Dictionary

p3:	pT3
p3A:	pT3a
p3B:	pT3b
p3C:	pT3c
p3D:	pT3d
p4:	pT4
p4A:	pT4a
p4B:	pT4b
p4C:	pT4c
p4D:	pT4d
p4E:	pT4e
88:	Not applicable, no code assigned for this case in the current AJCC Cancer Staging Manual
Blank:	No information at all is available to code this item

California Cancer Registry Data Dictionary

Variable Name: TNMCLINDESCRIPTOR
Eureka Name: TNM Clin Descriptor
NAACCR Item: 980
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2016 - 2017
Related Variables: TNM Clin Stage Group (TNM_STAGE_CLINICAL)

Definition: Identifies the AJCC clinical stage (prefix/suffix) descriptor of the tumor prior to the start of any therapy. AJCC stage descriptors identify special cases that need separate data analysis. The descriptors are adjuncts to and do not change the stage group.

Notes: *For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."*

Values:

- 0: None
- 1: E (Extranodal, lymphomas only)
- 2: S (Spleen, lymphomas only)
- 3: M (Multiple primary tumor in a single site)
- 5: E & S (Extranodal and spleen, lymphomas only)
- 9: Unknown, not state in patient record
- Blank: No information available to code this item

California Cancer Registry Data Dictionary

Variable Name: TNMPATHDESCRIPTOR
Eureka Name: TNM Path Descriptor
NAACCR Item: 920
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2016 - 2017
Related Variables: TNM Path Stage Group (TNM_STAGE_PATH)

Definition: Identifies the AJCC pathologic stage (prefix/suffix) descriptor known following the completion of surgical therapy. AJCC stage descriptors identify special cases that need separate data analysis. The descriptors are adjuncts to and do not change the stage group.

Notes: *For more information on stage at diagnosis in the CCR, see the Appendix, "CCR Stage at Diagnosis."*

Values:

- 0: None
- 1: E (Extranodal, lymphomas only)
- 2: S (Spleen, lymphomas only)
- 3: M (Multiple primary tumor in a single site)
- 4: Y (Classification during or after initial multimodality therapy)
- pathologic staging only
- 5: E & S (Extranodal and spleen, lymphomas only)
- 6: M & Y (Multiple primary tumor and initial multimodality therapy)
- 9: Unknown, not state in patient record
- Blank: No information available to code this item

California Cancer Registry Data Dictionary

Variable Name: TOBACCOUSECIGARETTES

Eureka Name: Tobacco Use Cigarettes

NAACCR Item: 9965

Category: Clinical, Other

Level of Variable: Tumor

Time Period Available: 2011 - current year

Related Variables:

- Tobacco Use Other Smoke (TOBACCOUSEOTHERSMOKE)
- Tobacco Use Smokeless (TOBACCOUSESMOKELESS)
- Tobacco Use NOS (TOBACCOUSENOS)

Definition: Records patient's past or current use of tobacco in the form of cigarettes. Does not include electronic cigarettes.

Values:

- 0: Never used
- 1: Current user (i.e. "current user" as of date of diagnosis)
- 2: Former user, quit within one year of date of diagnosis
- 3: Former user, quit more than one year prior to the date of diagnosis
- 4: Former user, unknown when quit
- 9: Unknown/not stated, no smoking specifics provided (code 9 is also used if the medical record only indicates "No" rather than "Never used.")

Blank: A blank is only allowed for cases diagnosed prior to 2011

California Cancer Registry Data Dictionary

Variable Name: TOBACCOUSENOS

Eureka Name: Tobacco Use NOS

NAACCR Item: 9968

Category: Clinical, Other

Level of Variable: Tumor

Time Period Available: 2011 - current year

Related Variables:

- Tobacco Use Cigarettes (TOBACCOUSECIGARETTES)
- Tobacco Use Other Smoke (TOBACCOUSEOTHERSMOKE)
- Tobacco Use Smokeless (TOBACCOUSESMOKELESS)

Definition: Records the patient's past or current use of tobacco when the type of tobacco product used was not specified. Does not include electronic cigarettes.

Values:

- 0: Never used
- 1: Current user (i.e. "current user" as of date of diagnosis)
- 2: Former user, quit within one year of date of diagnosis
- 3: Former user, quit more than one year prior to the date of diagnosis
- 4: Former user, unknown when quit
- 9: Unknown/not stated, no smoking specifics provided (code 9 is also used if the medical record only indicates "No" rather than "Never used.")

Blank: A blank is only allowed for cases diagnosed prior to 2011

California Cancer Registry Data Dictionary

Variable Name: TOBACCOUSEOTHERSMOKE

Eureka Name: Tobacco Use Other Smoke

NAACCR Item: 9966

Category: Clinical, Other

Level of Variable: Tumor

Time Period Available: 2011 - current year

Related Variables:

- Tobacco Use Cigarettes (TOBACCOUSECIGARETTES)
- Tobacco Use Smokeless (TOBACCOUSESMOKELESS)
- Tobacco Use NOS (TOBACCOUSENOS)

Definition: Records the patient's past or current use of tobacco in the form of smoking tobacco products other than cigarettes (e.g. pipes, cigars, kreteks). Does not include electronic cigarettes.

Values:

- 0: Never used
- 1: Current user (i.e. "current user" as of date of diagnosis)
- 2: Former user, quit within one year of date of diagnosis
- 3: Former user, quit more than one year prior to the date of diagnosis
- 4: Former user, unknown when quit
- 9: Unknown/not stated, no smoking specifics provided (code 9 is also used if the medical record only indicates "No" rather than "Never used.")

Blank: A blank is only allowed for cases diagnosed prior to 2011

California Cancer Registry Data Dictionary

Variable Name: TOBACCOUSESMOKELESS

Eureka Name: Tobacco Use Smokeless

NAACCR Item: 9967

Category: Clinical, Other

Level of Variable: Tumor

Time Period Available: 2011 - current year

Related Variables:

- Tobacco Use Cigarettes (TOBACCOUSECIGARETTES)
- Tobacco Use Other Smoke (TOBACCOUSEOTHERSMOKE)
- Tobacco Use NOS (TOBACCOUSENOS)

Definition: Records the patient's past or current use of tobacco in the form of smokeless tobacco products (e.g. chewing tobacco, snuff, etc.). Does not include electronic cigarettes.

Values:

- 0: Never used
- 1: Current user (i.e. "current user" as of date of diagnosis)
- 2: Former user, quit within one year of date of diagnosis
- 3: Former user, quit more than one year prior to the date of diagnosis
- 4: Former user, unknown when quit
- 9: Unknown/not stated, no smoking specifics provided (code 9 is also used if the medical record only indicates "No" rather than "Never used.")
- Blank: A blank is only allowed for cases diagnosed prior to 2011

California Cancer Registry Data Dictionary

Variable Name: TOTALDOSE
Eureka Name: Total Dose
NAACCR Item: 1533
Category: Treatment, Radiation
Level of Variable: Tumor
Time Period Available: 2018 - current year

Related Variables:

Definition: Identifies the total radiation dose administered to the patient across all phases during the first course of treatment. The unit of measure is centiGray (cGy).

To evaluate the patterns of radiation care, it is necessary to capture information describing the prescribed total dose of radiation during the first course of treatment. Outcomes are strongly related to the dose delivered.

Values:

000000:	No radiation treatment
000001-999997:	Record the actual dose delivered in cGy
999998:	Not applicable, radioisotopes administered to the patient
999999:	Radiation therapy was administered, but the dose is unknown; it is unknown whether radiation therapy was administered

California Cancer Registry Data Dictionary

Variable Name: TRANSSUM
Eureka Name: RX Summ--Transplnt/Endocr
NAACCR Item: 3250
Category: Treatment, Systemic
Level of Variable: Tumor
Time Period Available: 2003 - current year

Related Variables:

Definition: Identifies systemic therapeutic procedures given as first course of treatment at this facility and all other facilities or the reason they were not used. These include bone marrow transplants, stem cell harvests, and surgical and radiation endocrine therapy.

Notes: Data item required only for cases diagnosed 2003 forward, but if available, information was incorporated for cases diagnosed prior to that year.

Values:

- 00: None; diagnosed at autopsy
- 10: Bone marrow transplant, NOS
- 11: Bone marrow transplant, autologous
- 12: Bone marrow transplant, allogenic
- 20: Stem cell harvest and infusion
- 30: Endocrine surgery and/or endocrine radiation therapy
- 40: Code 30 in combination with 10, 11, 12, or 20
- 82: Contraindicated
- 85: Patient died
- 86: Recommended, not given
- 87: Refused
- 88: Recommended, unknown if given
- 99: Unknown; death certificate only (DCO)

California Cancer Registry Data Dictionary

Variable Name:	TSIZETU
Eureka Name:	EOD--Tumor Size
NAACCR Item:	780
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	1988 - 2003
Related Variables:	<ul style="list-style-type: none"> • Tumor Size (TUMORSIZE) • CS Tumor Size (CS_TUM_SIZE) • Tumor Size Summary (TUMORSIZESUMMARY)

Definition: Extent of Disease (EOD) staging data item that records the size of the tumor in millimeters. Valid for cases diagnosed 1988 through 2003. For cases diagnosed 2004 through 2015, this information is recorded in the field CS_TUM_SIZE. For cases diagnosed 2016 and forward, this information is recorded in the field TUMORSIZESUMMARY.

Note: The variable **TUMORSIZE** is a summary variable that combines TSIZETU, CS_TUM_SIZE, and TUMORSIZESUMMARY to provide a single variable for tumor size across all years of diagnosis.

Values: All numeric values are allowed, including 0's
Blank: Not abstracted; for cases diagnosed after January 1, 2004

California Cancer Registry Data Dictionary

Variable Name: TUMOR_ID

Eureka Name: Tumor ID

NAACCR Item: N/A

Category: Administrative

Level of Variable: Tumor

Time Period Available: 1988 - current year

Related Variables:

Definition: Unique statewide identification number assigned by the CCR to identify each tumor.

Values: Numeric value: up to 8 digits in length (1-99999999)

California Cancer Registry Data Dictionary

Variable Name: TUMORDEPOSITS
Eureka Name: Tumor Deposits
NAACCR Item: 3934
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2018 - current year

Related Variables:

Definition: A tumor deposit is defined as a discrete nodule of cancer in pericolic/perirectal fat or in adjacent mesentery (mesocolic or rectal fat) within the lymph drainage area of the primary carcinoma, without identifiable lymph node tissue or identifiable vascular structure.

Values:

- 00: No tumor deposits
- 01-99: 01-99 Tumor deposits (Exact number of Tumor Deposits)
- X1: 100 or more Tumor Deposits
- X2: Tumor Deposits identified, number unknown
- X8: Not applicable: Information not collected for this case
- X9: Not documented in medical record; Cannot be determined by the pathologist;
Pathology report does not mention tumor deposits; No surgical resection done;
Tumor Deposits not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: TUMORGROWTHPAT

Eureka Name: Tumor Growth Pattern

NAACCR Item: 3935

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables: CS Site-Specific Factor 10 (CSSITESPECIFICFACTOR10)

Definition: Tumor Growth Pattern refers to the growth pattern of intrahepatic cholangiocarcinoma. Valid for cases diagnosed January 1, 2018 and forward. For intrahepatic bile duct cancers diagnosed 2010 through 2017, this information was recorded in the field CSSITESPECIFICFACTOR10

Values:

- 1: Mass-forming
- 2: Periductal infiltrating
- 3: Mixed mass-forming and periductal infiltrating
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Pathology report does not mention tumor growth pattern; Cannot be determined by the pathologist; Tumor growth pattern not assessed or unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: TUMORSIZE

Eureka Name: N/A

NAACCR Item: N/A

Category: Tumor Characteristics/Stage at Diagnosis

Level of Variable: Tumor

Time Period Available: 1988 - current year

Related Variables:

- EOD--Tumor Size (TSIZETU)
- CS Tumor Size (CS_TUM_SIZE)
- Tumor Size Summary (TUMORSIZESUMMARY)

Definition: Size of the tumor at time of diagnosis. Records the largest dimension or diameter of the primary tumor in millimeters.

Notes: This data item is not collected but derived from TSIZETU collected for cases diagnosed 1988-2003 under the Extent of Disease staging system, CS_TUM_SIZE collected for cases diagnosed 2004-2015 under the Collaborative Stage coding system, and TUMORSIZESUMMARY collected for cases diagnosed 2016 and forward.

California Cancer Registry Data Dictionary

Variable Name: TUMORSIZECLINICAL
Eureka Name: Tumor Size Clinical
NAACCR Item: 752
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2016 - current year
Related Variables: Tumor Size Pathologic (TUMORSIZEPATHOLOGIC)
Definition: This data item records the size of a solid primary tumor before any treatment.

Values:

- 000: No mass/tumor found
- 001: 1 mm or described as less than 1 mm
- 002-988: Exact size in millimeters (2 mm to 988 mm)
- 989: 989 mm or larger
- 990: Microscopic focus or foci only and no size of focus is given
- 998: Alternate descriptions of tumor size for specific sites:
 - Familial/multiple polyposis:
 - Rectosigmoid and rectum (C19.9, C20.9)
 - Colon (C18.0, C18.2-C18.9)
 - If no size is documented:**
 - Circumferential:
 - Esophagus (C15.0 C15.5, C15.8 C15.9)
 - Diffuse; widespread: 3/4s or more; linitis plastica:
 - Stomach and Esophagus GE Junction (C16.0 C16.6, C16.8 C16.9)
 - Diffuse, entire lung or NOS:
 - Lung and main stem bronchus (C34.0 C34.3, C34.8 C34.9)
 - Diffuse:
 - Breast (C50.0 C50.6, C50.8 C50.9)
- 999: Unknown; Size not stated; Not documented in patient record; Size of tumor cannot be assessed; Not applicable

California Cancer Registry Data Dictionary

Variable Name:	TUMORSIZEPATHOLOGIC
Eureka Name:	Tumor Size Pathologic
NAACCR Item:	754
Category:	Tumor Characteristics/Stage at Diagnosis
Level of Variable:	Tumor
Time Period Available:	2016 - current year
Related Variables:	Tumor Size Clinical (TUMORSIZECLINICAL)
Definition:	This data item records the size of a solid primary tumor that has been resected.
Values:	<p>000: No mass/tumor found</p> <p>001: 1 mm or described as less than 1 mm</p> <p>002-988: Exact size in millimeters (2 mm to 988 mm)</p> <p>989: 989 mm or larger</p> <p>990: Microscopic focus or foci only and no size of focus is given</p> <p>998: Alternate descriptions of tumor size for specific sites:</p> <p style="padding-left: 40px;">Familial/multiple polyposis:</p> <p style="padding-left: 80px;">Rectosigmoid and rectum (C19.9, C20.9)</p> <p style="padding-left: 80px;">Colon (C18.0, C18.2-C18.9)</p> <p>If no size is documented:</p> <p style="padding-left: 40px;">Circumferential:</p> <p style="padding-left: 80px;">Esophagus (C15.0 C15.5, C15.8 C15.9)</p> <p style="padding-left: 40px;">Diffuse; widespread: 3/4s or more; linitis plastica:</p> <p style="padding-left: 80px;">Stomach and Esophagus GE Junction (C16.0 C16.6, C16.8 C16.9)</p> <p style="padding-left: 40px;">Diffuse, entire lung or NOS:</p> <p style="padding-left: 80px;">Lung and main stem bronchus (C34.0 C34.3, C34.8 C34.9)</p> <p style="padding-left: 40px;">Diffuse:</p> <p style="padding-left: 80px;">Breast (C50.0 C50.6, C50.8 C50.9)</p> <p>999: Unknown; Size not stated; Not documented in patient record; Size of tumor cannot be assessed; Not applicable</p>

California Cancer Registry Data Dictionary

Variable Name: TUMORSIZESUMMARY
Eureka Name: Tumor Size Summary
NAACCR Item: 756
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 2016 - current year
Related Variables:

- **Tumor Size (TUMORSIZE)**
- EOD--Tumor Size (TSIZETU)
- CS Tumor Size (CS_TUM_SIZE)

Definition: This data item records the most accurate measurement of a solid primary tumor, usually measured on the surgical resection specimen.

Notes: The variable **TUMORSIZE** is a summary variable that combines TSIZETU, CS_TUM_SIZE, and TUMORSIZESUMMARY to provide a single variable for tumor size across all years of diagnosis.

Values:

- 000: No mass/tumor found
- 001: 1 mm or described as less than 1 mm
- 002-988: Exact size in millimeters (2 mm to 988 mm)
- 989: 989 mm or larger
- 990: Microscopic focus or foci only and no size of focus is given
- 998: Alternate descriptions of tumor size for specific sites:
 - Familial/multiple polyposis:
 - Rectosigmoid and rectum (C19.9, C20.9)
 - Colon (C18.0, C18.2-C18.9)
 - If no size is documented:**
 - Circumferential:
 - Esophagus (C15.0 C15.5, C15.8 C15.9)
 - Diffuse; widespread: 3/4s or more; linitis plastica:
 - Stomach and Esophagus GE Junction (C16.0 C16.6, C16.8 C16.9)
 - Diffuse, entire lung or NOS:
 - Lung and main stem bronchus (C34.0 C34.3, C34.8 C34.9)
 - Diffuse:
 - Breast (C50.0 C50.6, C50.8 C50.9)
- 999: Unknown; Size not stated; Not documented in patient record; Size of tumor cannot be assessed; Not applicable

California Cancer Registry Data Dictionary

Variable Name: TUSTAT
Eureka Name: Cancer Status
NAACCR Item: 1770
Category: Follow-Up
Level of Variable: Tumor
Time Period Available: 1988 - current year

Related Variables:

Definition: Status of this tumor at time of last tumor follow-up.

Values:

- 1: Free of this tumor
- 2: Not free of this tumor
- 9: Tumor status unknown

California Cancer Registry Data Dictionary

Variable Name: TYPEADM
Eureka Name: Type Admis
NAACCR Item: N/A
Category: Hospital and Physician
Level of Variable: Admission
Time Period Available: 1988 - current year

Related Variables:

Definition: Type of admission at the reporting hospital. Value taken from the facility with the earliest date of admission.

Values:

- 1: Inpatient
- 2: Outpatient
- 3: Tumor Board
- 4: Path
- 5: Inpatient and Outpatient
- 6: Inpatient and Tumor Board
- 7: Outpatient and Tumor Board
- 8: Inpatient, Outpatient, and Tumor Board

California Cancer Registry Data Dictionary

Variable Name: TYPERP
Eureka Name: Type of Reporting Source
NAACCR Item: 500
Category: Administrative
Level of Variable: Tumor
Time Period Available: 1988 - current year

Related Variables:

Definition: Best source of information to prepare this case abstract.

Values:

- 1: Hospital inpatient and clinic
- 2: Radiation treatment centers or medical oncology centers (for cases diagnosed 2006 and later)
- 3: Laboratory only
- 4: Physician's office/private medical practitioner LMD
- 5: Nursing/convalescent home/hospice
- 6: Autopsy only
- 7: Death certificate only (DCO)
- 8: Other hospital outpatient units/surgery centers (for cases diagnosed 2006 and later)

California Cancer Registry Data Dictionary

Variable Name: ULCERATION

Eureka Name: Ulceration

NAACCR Item: 3936

Category: Prognostic Factors

Level of Variable: Tumor

Time Period Available: 2018 - current year

Related Variables: CS Site-Specific Factor 2 (CS_SITE_SPEC_F2)

Definition: Ulceration, the absence of an intact epidermis overlying the primary melanoma based upon histopathological examination, is a prognostic factor for melanoma of the skin. Valid for cases diagnosed January 1, 2018 and forward. For cases of melanoma of the skin diagnosed 2004 through 2017, this information was recorded in the field CS_SITE_SPEC_F2.

Values:

- 0: Ulceration not identified/not present
- 1: Ulceration present
- 8: Not applicable: Information not collected for this case
- 9: Not documented in medical record; Cannot be determined by the pathologist;
Pathology report does not mention ulceration; Ulceration not assessed or
unknown if assessed
- Blank: Date of Diagnosis pre-2018; Non-required Schema ID

California Cancer Registry Data Dictionary

Variable Name: VAHOSP

Eureka Name: N/A

NAACCR Item: N/A

Category: Hospital and Physician

Level of Variable: Admission

Time Period Available: 1988 - current year

Related Variables: Reporting Facility (HOSPNO)

Definition: Flag to identify cases diagnosed at a Veterans' Health Administration Hospital. VAHOSP is based on the facility with the earliest admission date for the tumor.

Values: 0: Not a VA Hospital

1: VA Hospital

California Cancer Registry Data Dictionary

Variable Name: VIETSURN

Eureka Name: N/A

NAACCR Item: N/A

Category: Patient Demographics

Level of Variable: Patient

Time Period Available: 1988 - current year

Related Variables: Name--Last (LNAME)

Definition: This variable indicates whether the patient's last name is on a Vietnamese surname list.

Notes: For additional information, please see Appendix "Variables Pertaining to Race/Ethnicity in the CCR".

Values: 0: No
1: Yes

California Cancer Registry Data Dictionary

Variable Name: VITSTAT
Eureka Name: Vital Status
NAACCR Item: 1760
Category: Follow-Up
Level of Variable: Patient
Time Period Available: 1988 - current year
Related Variables: Date of Last Contact (FUDATE)

Definition: Patient's vital status as of the date of last contact (FUDATE).

Values: 0: Dead
1: Alive

Notes: Access to death data variables from the CCR for research purposes requires review by the Health and Human Services Agency Committee for the Protection of Human Subjects (CPHS), the Vital Statistics Advisory Committee (VSAC), and CCR. The Center for Health Statistics and Informatics (CHSI), CCR, and CPHS require requesters to submit their proposals for simultaneous review of research projects by CPHS and VSAC. Please allow sufficient time for review of your application. For more information, send inquiries to research@ccr.ca.gov.

California Cancer Registry Data Dictionary

Variable Name: WEIGHT

Eureka Name: Weight

NAACCR Item: 9961

Category: Clinical, Other

Level of Variable: Tumor

Time Period Available: 2011 - current year

Related Variables:

Definition: Weight of the patient on or near the date of diagnosis for this tumor.

Values: Numeric values ranging from 000 to 999

California Cancer Registry Data Dictionary

Variable Name: XNODETU
Eureka Name: Regional Nodes Examined
NAACCR Item: 830
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 1988 - current year

Related Variables:

Definition: Records the total number of regional lymph nodes that were removed and examined by the pathologist.

Values:

- 00: No regional lymph nodes examined
- 01-89: Actual number examined
- 90: Ninety or more regional lymph nodes examined
- 95: No regional lymph node(s) removed, but aspiration of regional lymph node(s) was performed
- 96: Regional lymph node removal documented as a sampling and number of lymph nodes unknown/not stated
- 97: Regional lymph node removal documented as dissection and number of lymph nodes unknown/not stated
- 98: Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection
- 99: Unknown; not stated; death certificate only (DCO)

California Cancer Registry Data Dictionary

Variable Name:	YANGRELIABILITY
Eureka Name:	N/A
NAACCR Item:	N/A
Category:	Socioeconomic Indicators
Level of Variable:	Tumor
Time Period Available:	2006 - present
Related Variables:	<ul style="list-style-type: none"> • Index of Socioeconomic Status of Block Group (YANGSCL) for cases diagnosed 2006 forward • Index of Socioeconomic Status of Block Group with Missing Values Imputed (YANGSCLIMPUTED) for cases diagnosed 2006 forward • Socioeconomic Status Quintile of Block Group (QUINYANG) for cases diagnosed 2006 forward • Socioeconomic Status Quintile of Block Group with Missing Values Imputed (QUINYANGIMPUTED) for cases diagnosed 2006 forward
Definition:	Measures the reliability of YANGSCL and YANGSCLIMPUTED based on the reliability of individual components that make up the index. We strongly recommend that any variables related to YANGSCL be excluded from analysis for records where YANGRELIABILITY is 0 or 6.
Notes:	Further documentation of all "Yang" variables is available at https://cancerregistry.ucsf.edu/resources/research-tools
Values:	<p>0: Block group/census tract where population = 0 or median household income=0</p> <p>1: Block group/census tract where all 7 component variables have high or medium reliability (Coefficient of Variation<40%)</p> <p>2: Block group/census tract where 6 component variables have high or medium reliability (Coefficient of Variation<40%) and 1 component variable is missing (which could be imputed based on the 6 reliable component variables)</p> <p>3: Block group/census tract where 6 component variables have high or medium reliability (Coefficient of Variation<40%) and 1 component variable has low reliability (Coefficient of Variation=40%)</p> <p>4: Block group/census tract where 5 component variables have high or medium reliability (Coefficient of Variation<40%) and 2 component variables are missing (which could be imputed based on the 5 reliable component variables)</p> <p>5: Block group/census tract where 5 component variables have high or medium reliability (Coefficient of Variation<40%) and 2 component variables have low reliability (Coefficient of Variation =40%)</p> <p>6: Block group/census tract where 3 or more component variables are missing or have low reliability (Coefficient of Variation=40%)</p>

California Cancer Registry Data Dictionary

Variable Name:	YANGSCL
Eureka Name:	N/A
NAACCR Item:	N/A
Category:	Socioeconomic Indicators
Level of Variable:	Tumor
Time Period Available:	2006 - present
Related Variables:	<ul style="list-style-type: none"> • Socioeconomic Status Quintile of Block Group (QUINYANG) for cases diagnosed 2006 forward • Index of Socioeconomic Status of Block Group with Missing Values Imputed (YANGSCLIMPUTED) for cases diagnosed 2006 forward • Socioeconomic Status Quintile of Block Group with Missing Values Imputed (QUINYANGIMPUTED) for cases diagnosed 2006 forward • Reliability of SES Indexes YANGSCL and YANGSCLIMPUTED (YANGRELIABILITY) • Index of Socioeconomic Status of Block Group (YOSTSCL) for cases diagnosed 1988 through 2005 • Socioeconomic Status Quintile of Block Group (QUINYOST) for cases diagnosed 1988 through 2005

Definition: Juan Yang's index of socioeconomic status (SES) based on principal components analysis of block group level variables. YANGSCL is based on American Community Survey data and is not reliable for all block groups in California. YANGSCL is broadly similar to YOSTSCL with minor differences. Reliability of YANGSCL is measured in the variable YANGRELIABILITY. We strongly recommend that block groups with a value of 0 or 6 for YANGRELIABILITY be excluded from any analysis.

Notes: Further documentation of all "Yang" variables is available at <https://cancerregistry.ucsf.edu/resources/research-tools>

California Cancer Registry Data Dictionary

Variable Name:	YANGSCLIMPUTED
Eureka Name:	N/A
NAACCR Item:	N/A
Category:	Socioeconomic Indicators
Level of Variable:	Tumor
Time Period Available:	2006 - present
Related Variables:	<ul style="list-style-type: none"> • Socioeconomic Status Quintile of Block Group with Missing Values Imputed (QUINYANGIMPUTED) for cases diagnosed 2006 forward • Index of Socioeconomic Status of Block Group (YANGSCL) for cases diagnosed 2006 forward • Socioeconomic Status Quintile of Block Group (QUINYANG) for cases diagnosed 2006 forward • Reliability of SES Indexes YANGSCL and YANGSCLIMPUTED (YANGRELIABILITY) • Index of Socioeconomic Status of Block Group (YOSTSCL) for cases diagnosed 1988 through 2005 • Socioeconomic Status Quintile of Block Group (QUINYOST) for cases diagnosed 1988 through 2005

Definition: For certain block groups, American Community Survey data may be missing for one or more of the components used to calculate YANGSCL. Up to two missing values may be imputed based on other components being sufficiently reliable. Values of YANGSCL calculated using imputed values are found in YANGSCLIMPUTED but not in YANGSCL. Reliability of YANGSCL / YANGSCLIMPUTED is measured in the variable YANGRELIABILITY. We strongly recommend that block groups with a value of 0 or 6 for YANGRELIABILITY be excluded from analysis. Valid for cases diagnosed 2006 and forward. For cases diagnosed 1988 through 2005, see YOSTSCL.

Notes: Further documentation of all "Yang" variables is available at <https://cancerregistry.ucsf.edu/resources/research-tools>

California Cancer Registry Data Dictionary

Variable Name: YEARDX
Eureka Name: N/A
NAACCR Item: N/A
Category: Tumor Characteristics/Stage at Diagnosis
Level of Variable: Tumor
Time Period Available: 1988 - present
Related Variables: Date of Diagnosis (DATEDX)
Definition: Year of Diagnosis
Values: The allowable range is >1949 to <= current date or blank
 9999: Unknown

California Cancer Registry Data Dictionary

Variable Name:	YOSTSCL
Eureka Name:	N/A
NAACCR Item:	N/A
Category:	Socioeconomic Indicators
Level of Variable:	Tumor
Time Period Available:	1988 - 2005
Related Variables:	<ul style="list-style-type: none"> • Socioeconomic Status Quintile of Block Group (QUINYOST) for cases diagnosed 1988 through 2005 • Index of Socioeconomic Status of Block Group (YANGSCL) for cases diagnosed 2006 forward • Socioeconomic Status Quintile of Block Group (QUINYANG) for cases diagnosed 2006 forward • Index of Socioeconomic Status of Block Group with Missing Values Imputed (YANGSCLIMPUTED) for cases diagnosed 2006 forward • Socioeconomic Status Quintile of Block Group with Missing Values Imputed (QUINYANGIMPUTED) for cases diagnosed 2006 forward • Reliability of SES Indexes YANGSCL and YANGSCLIMPUTED (YANGRELIABILITY)
Definition:	Kathleen Yost's index of socioeconomic status (SES) based on principal components analysis of block group level variables from the decennial Census.
Notes:	<p>For more information on how this SES index was created see:</p> <p>Yost, K., et al., "Socioeconomic status and breast cancer incidence in California for different race/ethnic groups." Cancer Causes Control, 2001. 12(8): p. 703-11.</p>

California Cancer Registry Data Dictionary

Variable Name:	YR_SSNISSUED
Eureka Name:	N/A
NAACCR Item:	N/A
Category:	Patient Demographics
Level of Variable:	Patient
Time Period Available:	1988 – current year
Related Variables:	Social Security Number (SSNO) Social Security Number from Death Certificate (DCSSNO)
Definition:	Year the patient's Social Security Number was issued.
Values:	YYYY: Any year from 1936 forward) 9995: No valid year 9996: Not patient's own Social Security Number 9997: No Social Security Number 9998: No Prefix Data 9999: Unknown year

California Cancer Registry Data Dictionary

APPENDIX 1: CCR STAGE AT DIAGNOSIS

CCR uses two major staging systems for most cancers: the SEER Summary Stage and the AJCC - American Joint Committee on Cancer. SEER Summary Stage is a system that classifies cancers as *In Situ*, Localized, Regional, or Distant at the time of diagnosis. The AJCC system assigns a stage based on TNM information (i.e., Tumor, Node, and Metastases), which also matches stages from other specialized systems such as Dukes (colorectal cancer) and FIGO (female genital cancers). Cancers of the brain, blood, and bone marrow are staged according to their cell type, grade, and tumor burden (most types of leukemia, however, do not have a clear-cut staging system). Childhood cancers are staged using either AJCC or the staging criteria of the Children's Oncology Group, which conducts pediatric clinical trials.

SEER Summary Stage was collected by the CCR from 1988-1993. It became no longer required when the Extent of Disease (EOD) codes were introduced for cases diagnosed in 1994 forward. Programs to convert all cancer sites were created for SEER Summary Stage only, based on the 1977 edition rules. These programs were updated when SEER Summary Stage released the 2000 edition (to code cases diagnosed from 2001 forward).

Programs to convert EOD to AJCC were created by SEER for selected sites only. In the CCR, the following cancer sites diagnosed 1994-2003 have AJCC stage converted from EOD: **colon, rectum, lung, cervix, ovary, vulva, and vagina**. **For breast cancers, EOD-converted AJCC is available from 1988 - 2003.**

These programs converted EOD to AJCC 3rd edition and were never updated (conversions are based on the *SEER Program: Comparative Staging Guide for Cancer* manual). AJCC requires complete information on the T, N, and M components. To mitigate the problem of missing data, SEER introduced modifications to the EOD conversion based on certain assumptions. For example, if the medical record stated that nodes were examined but results were not mentioned, SEER assumed nodes were negative (see the Comparative Staging Guide manual for a complete list of SEER rules). Therefore, there are two AJCC summary variables in the CCR: a straight conversion of EOD to the AJCC 3rd edition, and an EOD conversion based on SEER modifications.

For cases diagnosed in 2004-2009, the Collaborative Stage (CS) Data Collection System replaced EOD, and programs were created to convert all cancer sites to both SEER Summary Stage 2000 and AJCC 6th edition. The introduction of the CS system eliminated the need for SEER modifications to AJCC staging.

For cases diagnosed in 2010-2015, additional site-specific factors were introduced by CS version 2, to conform with AJCC 7th edition requirements for staging.

For cases diagnosed in 2016-2017, the Collaborative Stage Data Collection System was replaced by the direct coding of T-N-M components, and a conversion program was developed to code stage groups (although Site-Specific Factors, Nodes Positive, Nodes Examined and lymph-vascular invasion for penis and testis cancer were still collected). Two AJCC stage groups were coded: clinical and pathological. To keep some consistency over time, AJCC staging variables were also derived based on the best information for the case. Stage groups were assigned based on the UICC TNM 7th edition classification, which represents the international approach to cancer staging (but is mostly comparable to AJCC 7th edition). Summary Stage 2000 was also directly coded by all facilities.

California Cancer Registry Data Dictionary

For cases diagnosed in 2018 and forward, the Extent of Disease (EOD) system was reintroduced with revised definitions. The schemas have been developed to be compatible with the AJCC 8th edition (with EOD TNM Stage Groups derived) and Summary Stage 2018. Summary Stage will be directly collected and derived from EOD codes.

Changes in the rules for staging certain cancers may be substantial (reflecting a better understanding of the disease or improvements in diagnostic methods). Therefore, caution should be used when comparing stage at diagnosis over time.

Coding Systems by Time Period

1994 – 2003	EOD
2004 – 2009	CS V1
2010 – 2015	CS V2
2016 – 2017	Direct Coding of TNM and SEER Summary Stage
2018 +	EOD (Summary Stage will be directly coded as well as EOD-derived)

WHAT VARIABLES SHOULD BE USED?

CCR has now a very large number of variables related to stage at diagnosis, reflecting all the detailed information collected on the tumor such as tumor size, lymph nodes, and presence and extent of metastases. However, if what is needed is the stage at diagnosis itself, derived from the best information available for the tumor, these three variables should be used:

SAS Research file	SEER*Stat (under User Specified tab)
SUMSTAGE	SEER summary stage
Combined SEER Summary Stage. Summary stage 1977 collected 1988-1993; summary stage 1977 converted from EOD 1994-2000; summary stage 2000 converted from EOD 2001-2003; summary stage 2000 converted from CS for 2004-2015; directly coded summary stage 2000 for 2016-2017; and EOD-converted summary stage 2018.	
STAGE	Combined Stage
Combined AJCC stage variable. EOD converted to AJCC 3 rd edition stage for cervical, colon, rectum, ovarian, vulva, vagina, and lung cancers for 1994-2003; breast cancer for 1988-2003; CS converted to AJCC 6 th edition stage for 2004-2009; CS converted to AJCC 7 th edition stage for 2010-2015; directly coded TNM converted to UICC TNM 7 th edition for 2016-2017; and EOD converted to AJCC 8 th edition for 2018 forward.	
STAGE_SEER	Combined Stage_Seer
Combined AJCC stage variable, with SEER modifications until 2003. EOD converted to SEER-Modified AJCC 3 rd edition stage for cervical, colon, rectum, ovarian, vulva, vagina, and lung cancers for 1994-2003; breast cancer for 1988-2003; CS converted to AJCC 6 th edition stage for 2004-2009; CS converted to AJCC 7 th edition stage for 2010-2015; directly coded TNM converted to UICC TNM 7 th edition for 2016-2017; and EOD converted to AJCC 8 th edition for 2018 forward.	



California Cancer Registry Data Dictionary

Single Derived Variables for T-N-M components and AJCC Stage Group, by Time Period

	1988 - 2003	2004 - 2009	2010 - 2015	2016-2017	2018 +
T Component	TCODE	DERIVED_AJCC_T	DERIVEDAJCC7T	DERIVEDSEERCOMBINEDT	DERIVEDEOD2018T
N Component	NCODE	DERIVED_AJCC_N	DERIVEDAJCC7N	DERIVEDSEERCOMBINEDN	DERIVEDEOD2018N
M Component	MCODE	DERIVED_AJCC_M	DERIVEDAJCC7M	DERIVEDSEERCOMBINEDM	DERIVEDEOD2018M
AJCC Stage Group	STAGE and STAGE_SEER	DERIVED_AJCC_STG_GRP	DERIVEDAJCC7STAGEGRP	DERIVEDSEERCMBSTGGRP	DERIVEDEOD18STGGP
Note: STAGE and STAGE_SEER variables combine AJCC stage group for all time periods					

California Cancer Registry Data Dictionary

APPENDIX 2: Industry & Occupation Variables in the CCR

Occupational exposures are an important cancer risk factor, exceeded only by tobacco use and diet. The proportion of cancer deaths attributed to occupational exposures has been estimated to range from 4% to 20%. Federal public law requires the collection of information on the industry or occupation history of individuals diagnosed with cancer to the extent such information is available. The Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries (NPCR), which funds population-based cancer registries in many states, mandates collection of industry and occupation (I&O) information on cancer patients. California's instructions for abstractors states that "because the identification of occupational cancer is an important aspect of cancer research, every effort should be made to record the occupation and the industry in which the patient works or worked, regardless of whether the patient was employed at the time of admission"¹. In particular, the Cancer Surveillance Program in Los Angeles has collected text strings of I&O information from medical records since its inception in 1972, and these data have been collected statewide since 1988.

To be usable for research, narrative text must be converted to I&O codes by a trained I&O coder, which for a database the size of the California Cancer Registry (CCR) is a labor-intensive and expensive task. In the early years of the CCR, some coding was conducted by coders at the University of Southern California (USC) and in Sacramento, and an autocoding program was developed that was used until 2002. In 2007, the CDC funded the National Institute for Occupational Safety and Health (NIOSH) to work with the CCR on a pilot study to explore the feasibility of coding industry and occupation (I&O) information contained in CCR records. NIOSH staff converted the earlier CCR autocoding program to SAS. The program utilizes a "look-up" table with I&O codes and text. CCR research staff used the program to evaluate completeness of I&O coding in the CCR database and to identify previously uncoded text strings that were prioritized by frequency and provided to NIOSH for coding. USC and NIOSH staff coded text strings to the Bureau of the Census 1990 I&O codes, the new codes and text strings were added to the SAS program, and the process was repeated.

Through this project, 78.4% of nearly three million records (diagnosed 1988-2007) were coded to 1990 I&O codes. The remaining uncoded cases have unique text strings that will likely take several years to code. A large proportion of patients are coded as "retired," or "unemployed or unknown" making their records unusable for I&O research. Despite these limitations, a large amount of usable coded data has been created and is being updated regularly. Preliminary research at USC suggested that studies utilizing registry-collected I&O data provide results linking cancer and occupation comparable to more intensive (and expensive)

California Cancer Registry Data Dictionary

research studies. NIOSH researchers recently used the data on over 75,000 cancer patients with a construction occupation to analyze lung cancer and leukemia risk among construction workers^{2,3,4}. NIOSH staff also developed a training program for registrars that should increase the proportion of cases with valid text in the I&O text fields that can be coded for research using the autocoding program.

Researchers interested in investigating I&O information for cancer patients in the CCR should use the variables INDUSTRY_CODE and OCCUPATION_CODE. These variables incorporate both historically coded information (originally contained in INDUS80, OCCUP80, INDUS90 and OCCUP90) and the codes incorporated as a result of the NIOSH-funded project. Values for the I&O codes can be found on the census website:

<https://www.census.gov/topics/employment/industry-occupation/guidance/code-lists.html>.

REFERENCES

1. California Cancer Reporting System Standards, Volume I: Abstracting and Coding Procedures, Eighteenth Ed. 2018. Sacramento, CA: California Department of Public Health, Chronic Disease Surveillance and Research Branch. Available from:
http://ccrcal.org/Cancer_Reporting/Registrar_Resources/Reporting_Cancer_Cal.shtml
2. Calvert GM, Luckhaupt S, Lee SJ, Cress R, Schumacher P, Shen R, Tak S, Deapen D. Lung cancer risk among construction workers in California, 1988-2007. *Am J Ind Med*. 2012 May; 55(5): 412-22.
3. Luckhaupt SE, Deapen D, Cress R, Schumacher P, Shen R, Calvert GM. Leukemia among male construction workers in California, 1988-2007. *Leuk Lymphoma*. 2012 Nov; 53(11): 2228-36.
4. Tsai RJ, Luckhaupt SE, Schumacher P, Cress RD, Deapen DM, Calvert GM. Acute myeloid leukemia risk by industry and occupation. *Leuk Lymphoma*. 2014 Nov; 55(11): 2584-91.

California Cancer Registry Data Dictionary

APPENDIX 3: Variables Pertaining to Race/Ethnicity in the CCR

There are several variables in CCR data that capture and classify a patient's race/ethnicity. These variables can be divided into two groups: (1) collected data items and (2) derived variables.

COLLECTED DATA ITEMS

RACE1, RACE2, RACE3, RACE4, and RACE5

Race1 is the patient's primary race as abstracted from the medical record. This variable is valid for all years of diagnoses – 1988 to the current year.

Beginning with cases diagnosed January 1, 2000, four additional race fields (RACE2, RACE3, RACE4, and RACE5) were added to the CCR database so that patients who belong to more than one racial category can be coded with multiple races, consistent with the 2000 Census.

The codes for all five race fields (shown below) are identical except for code 88 (no further race documented). Code 88 is not used to code RACE1 but is used to code RACE2 through RACE5 if the patient is only identified as being one race. Code 99 (unknown) is used for coding RACE2 through RACE5 if RACE1 is also unknown.

The codes for RACE1 through RACE5 are:

- 01 White
- 02 Black
- 03 American Indian, Aleutian, or Eskimo
- 04 Chinese
- 05 Japanese
- 06 Filipino
- 07 Hawaiian
- 08 Korean
- 09 *Retired effective 01/01/2010. Formerly Asian Indian or Pakistani (see replacement codes 15 through 17)
- 10 Vietnamese
- 11 Laotian
- 12 Hmong
- 13 Kampuchean (Cambodian)
- 14 Thai
- 15 Asian Indian or Pakistani, NOS (code 9 prior to 01/01/2010)
- 16 Asian Indian
- 17 Pakistani
- 20 Micronesian, NOS

California Cancer Registry Data Dictionary

- 21 Chamorran/Chamoru
- 22 Guamanian, NOS
- 25 Polynesian, NOS
- 26 Tahitian
- 27 Samoan
- 28 Tongan
- 30 Melanesian, NOS
- 31 Fiji Islander
- 32 New Guinean
- 88 No further race documented (not used for coding RACE1)
- 90 Other South Asian, Bangladeshi, Bhutanese, Nepalese, Sikkimese, Sri Lankan (California-specific code)
- 96 Other Asian including Burmese, Indonesian, Asian, NOS, and Oriental, NOS
- 97 Pacific Islander, NOS
- 98 Other
- 99 Unknown

It is important to understand all the different ethnic groups that are included in the “white (01)” category. Examples of ethnic groups coded “white (01)” are included in the following table.

Examples of Different Ethnic Groups Included in the “White (01)” Category			
Afghan	Albanian	Algerian	Arabian
Armenian	Australian	Austrian	Bulgarian
Caucasian	Central American*	Cuban**	Cypriot
Czechoslovakian	Dominican**	Egyptian	Greek
Gypsy	Hungarian	Iranian	Iraqi
Israeli	Italian	Jordanian	Latino
Lebanese	Mexican*	Moroccan	Palestinian
Polish	Portuguese	Puerto Rican**	Romanian
Russian	Saudi Arabian	Slavic	Slovene
South American*	Spanish	Syrian	Tunisian
Turkish	Yugoslavian		

* Unless specified as Indian (code 03)

** Unless specified as Black (code 02)

California Cancer Registry Data Dictionary

For additional information on how Certified Tumor Registrars (CTRs) are instructed to abstract the RACE1 through RACE5 fields go to California Cancer Registry Volume I, Part III.2.10 ([California Cancer Registry, Volume I](#)).

SPANISH

SPANISH is a collected data item. This field is used to denote persons of Spanish/Hispanic origin or descent. The field corresponds to a question asked in the United States Census. Included are people whose native tongue is Spanish, who are nationals of a Spanish speaking Latin American country or Spain, and/or who identify with Spanish or Hispanic culture (such as Chicanos living in the American Southwest). Coding is independent of the RACE1 through RACE5 fields, since persons of Hispanic origin might be described as white, black, or some other race in the medical record. The primary source for coding this variable is an ethnic identifier stated in the medical record. The codes for this variable are:

- 0: Non-Spanish, non-Hispanic
- 1: Mexican (including Chicano, NOS)
- 2: Puerto Rican
- 3: Cuban
- 4: South or Central American (except Brazilian)
- 5: Other specified Spanish Origin (includes European; excludes Dominican Republic for cases diagnosed January 1, 2005 and forward)
- 6: Spanish, NOS; Hispanic, NOS; Latino, NOS (There is evidence other than surname or maiden name that the person is Hispanic, but he/she cannot be assigned to any category 1 through 5 above.)
- 7: Spanish surname only (The only evidence of person's Hispanic origin is surname or maiden name, and there is no contrary evidence that the person is not Hispanic.)
- 8: Dominican Republic (For cases diagnosed on or after January 1, 2005.)
- 9: Unknown whether Spanish or not

The CCR has adopted the official list of Spanish surnames from the 1980 U.S. Census, and this list should be used to assign code 7 above. The Spanish surname list is available in: Volume I, Appendix J ([California Cancer Registry, Volume I](#)).

For additional information on how Certified Tumor Registrars (CTRs) are instructed to abstract the SPANISH field go to California Cancer Registry Volume I, Part III.2.10.2 ([California Cancer Registry, Volume I](#)).

California Cancer Registry Data Dictionary

DERIVED DATA ITEMS

RACEGROUP

RACEGROUP is a derived variable that classifies a patient's race/ethnicity, including Hispanic ethnicity. The CCR uses RACEGROUP for statistical reports. RACEGROUP replaces older versions of this variable including RACE08 and RACE99.

The codes for this variable are:

- 1: Non-Hispanic white
- 2: Non-Hispanic black
- 3: Hispanic
- 4: Asian/Pacific Islander
- 5: American Indian
- 9: Other/Unknown

RACEGROUP is derived from several variables including the patient's primary race (RACE1), the results of the Indian Health Services linkage (IHSLINK), the results of the NAACCR Hispanic-Latino Identification Algorithm (NHIA), and the results of the NAACCR Asian/Pacific Islander Identification Algorithm (NAPIIA).

The logic used to derive RACEGROUP is as follows:

If a patient has a RACE1 value of 03 (= American Indian, Aleutian, or Eskimo) **or** an IHSLINK value of 1 (= patient matched with the Indian Health Services database), then the patient's RACEGROUP value is 5 (=American Indian).

Else, if a patient has a NAPIIA value of 04 through 97 (see the NAPIIA section of this document for value definitions) **or** was diagnosed 1990 or earlier and has a RACE1 value of 98, the patient's RACEGROUP value is 4 (=Asian/Pacific Islander).

Else, if a patient has a NHIA value of 1, 2, 3, 4, 5, 6, 7, or 8 (see the NHIA section of this document for value definitions) then the patient has a RACEGROUP value of 3 (= Hispanic).

Else, if a patient has a RACE1 value of 01 (= white), then the patient has a RACEGROUP value of 1 (= non-Hispanic white).

Else, if a patient has a RACE1 value of 02 (= black), then the patient has a RACEGROUP value of 2 (= non-Hispanic black).

Else, the patient has a RACEGROUP value of 9 (= other/unknown)

RACE08 and RACE99

Race08 and Race99 are outdated and no longer available. RACEGROUP replaces RACE08 and RACE99. The primary difference between RACEGROUP and RACE08 is that RACEGROUP uses NHIA (NAACCR Hispanic-Latino Identification Algorithm) to identify Hispanics **and** NAPIIA (NAACCR Asian/Pacific Islander Identification Algorithm) to identify Asian/Pacific Islanders. RACE08 used NHIA to identify Hispanics but did not use NAPIIA to identify Asian/Pacific Islanders. RACE99 did not use NHIA or NAPIIA to identify Hispanics and Asian/Pacific Islanders. Please see the sections of this document pertaining to NHIA and NAPIIA for further detail.

California Cancer Registry Data Dictionary

RACEME

RACEME is RACEGROUP with an additional category for Middle Easterners. The codes for this variable are:

- 1: Non-Hispanic white
- 2: Non-Hispanic black
- 3: Hispanic
- 4: Asian/Pacific Islander
- 5: American Indian
- 6: Middle Eastern
- 9: Other/Unknown

Any non-Hispanic white patient with a QME value of 1 (= the patient's last name is on the Middle Eastern surname list[†]) is reclassified to the Middle Eastern category (or RACEME = 6). The Middle Eastern surname list was created by Dr. Kiu Nasseri and he published this work. For detailed information on how the surname list was created, please reference:

Nasseri K. Construction and validation of a list of common Middle Eastern surnames for epidemiological research. Cancer Detect Prev. 2007;31(5):424-9.
PMID: 18023539

****The Middle Eastern surname list is available to researchers upon request.***

Dr. Kiu Nasseri also published data on cancer incidence and mortality among the Middle Eastern population in California. The references for these works are cited below. Please note, the population data used in these published works is no longer maintained by the CCR.

Nasseri K. Breast cancer in the Middle Eastern population of California, 1988-2004. Breast J. 2009;15(2):182-8.
PMID: 19292805

Nasseri K. Thyroid cancer in the Middle Eastern population of California. Cancer Causes Control. 2008;19(10):1183-91.
PMID: 18543070

Nasseri K. Mortality in first generation white immigrants in California, 1989-1999. J Immigr Minor Health. 2008;10(3):197-205.
PMID: 17661176

Nasseri K, Mills PK, Allen M. Cancer Incidence in the Middle Eastern Population of California, 1988-2004. Asian Pacific J Cancer Prev. 2007;8:405-11.

California Cancer Registry Data Dictionary

QME[†]

This variable denotes whether the patient's last name is on a Middle Eastern surname list. For information on the creation of the Middle Eastern surname list, please read the RACEME section of this document. The codes for QME are:

- 0: No, last name is not on the Middle Eastern Surname list
- 1: Yes, last name is on the Middle Eastern Surname list

QME is created by checking the first ten characters of the patient's last name to see if they are on the Middle Eastern surname list. If they are, then QME = 1.

SRCSUR

This variable is related to RACEME and QME. It denotes the source used to determine whether the patient has a Middle Eastern surname. The codes for this variable are:

- 1: Male surname
- 2: Female surname, no maiden name
- 3: Female maiden name

NHIA

NHIA is derived using the NAACCR Hispanic-Latino Identification Algorithm. NHIA uses a combination of variables to directly or indirectly classify cases as Hispanic. These variables include, last name (LNAME), maiden name (MAIDNAME), Spanish/Hispanic Origin (SPANISH), Birthplace--Country (BIRTHPLACECOUNTRY), primary race (RACE1), sex (SEX), and IHS linkage results (IHSLINK). The algorithm assigns one of the following codes to a case:

- 0: Non-Hispanic
- 1: Mexican, by birthplace or other specific identifier
- 2: Puerto Rican, by birthplace or other specific identifier
- 3: Cuban, by birthplace or other specific identifier
- 4: South or Central American (except Brazil), by birthplace or other specific identifier
- 5: Other specified Spanish/Hispanic origin (includes European; excludes Dominican Republican), by birthplace or other specific identifier
- 6: Spanish, NOS (not otherwise specified); Hispanic, NOS; Latino, NOS
- 7: NHIA surname match only
- 8: Dominican Republican, by birthplace or other specific identifier
- Blank: Algorithm has not been run

The CCR uses NHIA to identify Hispanics in our RACEGROUP variable.

For greater detail on NHIA, refer to the technical documentation at:

https://www.naaccr.org/wp-content/uploads/2016/11/NHIA_v2_2_1_09122011.pdf

California Cancer Registry Data Dictionary

NAPIIA

NAPIIA is derived using the NAACCR Asian/Pacific Islander Identification Algorithm. NAPIIA uses a combination of variables to classify cases directly or indirectly to a specific Asian/Pacific Islander group. These variables include: All race fields (RACE1, RACE2, RACE3, RACE4, and RACE5), Spanish/Hispanic Origin (SPANISH), IHS linkage results (IHSLINK), first name (FNAME), last name (LNAME), maiden name (MAIDNAME), Birthplace--Country (BIRTHPLACECOUNTRY), and sex (SEX). The NAPIIA algorithm focuses on coding cases where any race field is coded 96 (Asian, NOS (not otherwise specified)) or 97 (Pacific Islander, NOS) to a more specific Asian or Pacific Islander race category. The algorithm assigns one of the following codes to a case:

- 01: White
- 02: Black
- 03: American Indian, Aleutian, or Eskimo (includes all indigenous populations of the Western Hemisphere)
- 04: Chinese
- 05: Japanese
- 06: Filipino
- 07: Hawaiian
- 08: Korean
- 10: Vietnamese
- 11: Laotian
- 12: Hmong
- 13: Kampuchean (Cambodian)
- 14: Thai
- 15: Asian Indian or Pakistani, NOS
- 16: Asian Indian
- 17: Pakistani
- 20: Micronesian, NOS
- 21: Chamorro/Chamoru
- 22: Guamanian, NOS
- 25: Polynesian, NOS
- 26: Tahitian
- 27: Samoan
- 28: Tongan
- 30: Melanesian, NOS
- 31: Fiji Islander
- 32: New Guinean
- 96: Other Asian, including Asian, NOS and Oriental, NOS
- 97: Pacific Islander, NOS
- 98: Other
- 99: Unknown
- Blank: Algorithm was not run

For greater detail on NAPIIA, refer to the technical documentation at:

https://www.naacr.org/wp-content/uploads/2016/11/NAPIIA_v1_2_1_08122011.pdf

California Cancer Registry Data Dictionary

HMNGSURN[†]

This variable denotes whether the patient's last name is on a Hmong surname list. The codes for this variable are:

0: No, last name is not on the Hmong surname list

1: Yes, last name is on the Hmong surname list

The Hmong surname list includes:

HER	KUE	KHANG
HANG	MOUA	THAO
THOR	THOW	VANG
VUE	XIONG	

VIETSURN[†]

This variable denotes whether the patient's last name is on a Vietnamese surname list. The codes for this variable are:

0: No, last name is not on the Vietnamese surname list

1: Yes, last name is on the Vietnamese surname list

The Vietnamese surname list includes:

CAO	DINH	DO
DOAN	DUONG	NGUYEN
VU	VUONG	HUYNH*
TRAN**	TRINH**	TRUONG88
*Not applied to persons identified as Korean on medical record or death certificate.		
**Not applied to persons identified as Chinese on medical record or death certificate.		

[†]All the surname lists included in this document, except for the 1980 U.S. Census Spanish Surname list, are unique to the CCR and for research purposes only. These surname lists (which include Hmong, Vietnamese, and Middle Eastern) are not part of the NAACCR standard documents.

**APPENDIX 4: CROSSWALK OF CCR VARIALBE NAMES
AND NAACCR DATA ITEM NUMBERS**

VARIABLE NAME	LABEL / DESCRIPTION	NAACCR #
PATIENT_ID	Patient ID Number	20
NAACCR_REG_ID	Registry-ID (per NAACCR)	40
DXCITY	Addr at DX--City	70
DXSTATE	Addr at DX--State	80
DXSTATEGEO708090	State at DX Geocode 1970/80/90	81
DXSTATEGEO2000	State at DX Geocode 2000	82
DXSTATEGEO2010	State at DX Geocode 2010	83
DXSTATEGEO2020	State at DX Geocode 2020	84
COUNTY	County at DX Reported	90
COUNTYATDXGEOCODE1990	County at DX Geocode1970/80/90	94
COUNTYATDXGEOCODE2000	County at DX Geocode2000	95
COUNTYATDXGEOCODE2010	County at DX Geocode2010	96
DXZIP	Addr at DX--Postal Code	100
ADDRATDXCOUNTRY	Addr at DX--Country	102
CENSUS90	Census Tract 1970/80/90	110
CENSUSCODSYS19708090	Census Cod Sys 1970/80/90	120
CENTRACT2020	Census Tract 2020	125
CENSUS00	Census Tract 2000	130
CENSUSTRACT2010	Census Tract 2010	135
MARSTAT	Marital Status at DX	150
RACE1	Race 1	160
RACE2	Race 2	161
RACE3	Race 3	162
RACE4	Race 4	163
RACE5	Race 5	164
SPANISH	Spanish/Hispanic Origin	190
NHIA	NHIA Derived Hisp Origin	191
IHSLINK	Indian Health Services Linkage Flag	192
NAPIIA	Race--NAPIIA	193
COMPUTEDETHNICITY	Computed Ethnicity	200
COMPUTEDETHNICITYSOURCE	Computed Ethnicity Source	210
SEX	Sex	220
AGE	Age at Diagnosis	230
DOB	Date of Birth	240
DATEOFBIRTHFLAG	Date of Birth Flag	241
BIRTHPLACESTATE	Birthplace--State	252

BIRTHPLACECOUNTRY	Birthplace--Country	254
OCCUPATION_CODE	Text—Usual Occupation	310
INDUSTRY_CODE	Text—Usual Industry	320
CENBLOCKGRP2020	Census Block Group 2020	361
CENTRD90	Census Tr Certainty 1970/80/90	364
CENTRD00	Census Tr Certainty 2000	365
GISCOORDINATEQUALITY	GIS Coordinate Quality	366
CENSUSTRCERTAINTY2010	Census Tr Certainty 2010	367
CENTRACTCERT2020	Census Tract Certainty 2020	369
SEQNOCEN	Sequence Number--Central	380
DATEDX	Date of Diagnosis	390
DATEOFDIAGNOSISFLAG	Date of Diagnosis Flag	391
SITE_02	Primary Site	400
LATERAL	Laterality	410
HISTO_T2	Histology (92-00) ICD-O-2	420
HISTO_M2	Behavior (92-00) ICD-O-2	430
DATEOFMULTIPLTUMORSFLAG	Date of Mult Tumors Flag	439
DIFFERN2	Grade	440
GRADEPATHVALUE	Grade Path Value	441
AMBIGUOUSTERMINOLOGY	Ambiguous Terminology DX	442
DATEOFCONCLUSIVEDX	Date Conclusive DX	443
MULTTUMRPTASONEPRIM	Mult Tum Rpt As One Prim	444
DATEOFMULTIPLTUMORS	Date of Mult Tumors	445
MULTIPLICITYCOUNTER	Multiplicity Counter	446
DATECONCLUSIVEDXFLAG	Date Conclusive DX Flag	448
GRADEPATHSYSTEM	Grade Path System	449
DXCONF	Diagnostic Confirmation	490
TYPEREPR	Type of Reporting Source	500
CASEFIND	Casefinding Source	501
HISTO_T3	Histologic Type ICD-O-3	522
HISTO_M3	Behavior Code ICD-O-3	523
HOSPNO	Reporting Facility	540
DATEADM	Date of 1 st Contact	580
DATEIADM	Date of Inpt Adm	590
DATEOFINPTADMFLAG	Date of Inpt Adm Flag	591
DATEDIS	Date of Inpt Disch	600
CLASS	Class of Case	610
PAYER	Primary Payer at DX	630
DATEREGLNDISS	Date Regional Lymph Node Dissection	682

DATEREGLNDISSFLAG	Date Regional Lymph Node Dissection Flag	683
TUMORSIZECLINICAL	Tumor Size Clinical	752
TUMORSIZEPATHOLOGIC	Tumor Size Pathologic	754
TUMORSIZESUMMARY	Tumor Size Summary	756
SEERSUMMARYSTAGE2000	Calculated SEER Summary Stage 2000	759
SUMSTAGE00	Non-calculated SEER Summary Stage 2000	759
SEERSUMMARYSTAGE1977	Calculated SEER Summary Stage 1977	760
SUMSTAGE77	Non-calculated SEER Summary Stage 1977	760
DERIVEDSUMMARYSTAGE2018	Derived Summary Stage 2018	762
SUMMARYSTAGE2018	Summary Stage 2018	764
EODPRIMARYTUMOR	EOD Primary Tumor	772
EODREGNODES	EOD Regional Nodes	774
EODMETS	EOD Mets	776
TSIZETU	EOD--Tumor Size	780
DERIVEEOD18T	Derived EOD 2018 T	785
DIREXTTU	EOD--Extension	790
DERIVEEOD18M	Derived EOD 2018 M	795
DRXTTU_P	EOD--Extension Prost Path	800
LNSUMTU	EOD--Lymph Node Involv	810
DERIVEEOD18N	Derived EOD 2018 N	815
DERIVEEOD18STGGP	Derived EOD 2018 Stage Group	818
PNODETU	Regional Nodes Positive	820
XNODETU	Regional Nodes Examined	830
DATESENTINELNBX	Date of Sentinel Lymph Node Biopsy	832
DATESENTLNBXFLAG	Date of Sentinel Lymph Node Biopsy Flag	833
SENTINELNODESEXAM	Sentinel Lymph Nodes Examined	834
SENTINELNODESPOS	Sentinel Lymph Nodes Positive	835
EOD_SCHEME	CODING SYSTEM FOR EOD	870
TNM_T_CODE_PATH	TNM Path T, Tumor-level, 2015-2017	880
TNM_N_CODE_PATH	TNM Path N, Tumor-level, 2015-2017	890
TNM_M_CODE_PATH	TNM Path M, Tumor-level, 2015-2017	900
TNM_STAGE_PATH	TNM Path Stage Group, Tumor-level, 2015-2017	910
TNMPATHDESCRIPTOR	TNM Path Descriptor, Tumor-level, 2016-2017	920
TNM_CODER_PATH	TNM Path Staged By, Tumor-level, 2015-2017	930
TNM_T_CODE_CLINICAL	TNM Clin T, Tumor-level, 2015-2017	940
TNM_N_CODE_CLINICAL	TNM Clin N, Tumor-level, 2015-2017	950
TNM_M_CODE_CLINICAL	TNM Clin M, Tumor-level, 2015-2017	960
TNM_STAGE_CLINICAL	TNM Clin Stage Group, Tumor-level, 2015-2017	970
TNMCLINDESCRIPTOR	TNM Clin Descriptor, Tumor-level, 2016-2017	980

TNM_CODER_CLINICAL	TNM Clin Staged By, Tumor-level, 2015-2017	990
AJCCID	AJCC ID	995
AJCCTNMPOSTT	AJCC TNM Post Therapy T	1021
AJCCTNMPOSTN	AJCC TNM Post Therapy N	1022
AJCCTNMPOSTM	AJCC TNM Post Therapy M	1023
AJCCTNMPOSTSTGGRP	AJCC TNM Post Therapy Stage Group	1024
AJCCTNMCLINTSFX	AJCC TNM Clin T Suffix, 2018 forward	1031
AJCCTNMPATHTSFX	AJCC TNM Path T Suffix, 2018 forward	1032
AJCCTNMPOSTTSFX	AJCC TNM Post Therapy T Suffix	1033
AJCCTNMCLINNSFX	AJCC TNM Clin N Suffix	1034
AJCCTNMPATHNSFX	AJCC TNM Path N Suffix	1035
AJCCTNMPOSTNSFX	AJCC TNM Post Therapy N Suffix	1036
AJCCED	TNM Edition Number	1060
METSATDXBONE	Mets at DX-Bone	1112
METSATDXBRAIN	Mets at DX-Brain	1113
METSATDXDISTANTLN	Mets at DX-Distant LN	1114
METSATDXLIVER	Mets at DX-Liver	1115
METSATDXLUNG	Mets at DX-Lung	1116
METSATDXOTHER	Mets at DX-Other	1117
PEDSTAGE	Pediatric Stage	1120
PEDSYS	Pediatric Staging System	1130
PEDCODER	Pediatric Staged By	1140
MARKER1	Tum Markers 1	1150
MARKER2	Tum Markers 2	1160
MARKER3	Tum Markers 3	1170
LYMPHVASCULARINVASION	Lymphovascular Invasion	1182
SURGDATE	RX Date Surgery	1200
RXDATESURGERYFLAG	RX Date Surgery Flag	1201
RXDATER	RX Date Radiation	1210
RXDATERADIATIONFLAG	RX Date Radiation Flag	1211
RXDATEC	RX Date Chemo	1220
RXDATECHEMOFLAG	RX Date--Chemo Flag	1221
RXDATEH	RX Date Hormone	1230
RXDATEHORMONEFLAG	RX Date Hormone Flag	1231
RXDATEI	RX Date BRM	1240
RXDATEBRMFLAG	RX Date BRM Flag	1241
RXDATEO	RX Date Other	1250
RXDATEOTHERFLAG	RX Date--Other Flag	1251
RXDATE	Date Initial RX SEER	1260

DATEOFINITIALRXFLAG	Date Initial RX SEER Flag	1261
RXDATESN	RX Date--DX/Stg Proc	1280
RXDATEDXSTGPROCFLAG	RX Date DX/Stg Proc Flag	1281
RXSUMMTREATMENTSTATUS	Rx Summ--Treatment Status	1285
SURGPRIM	Rx Summ--Surg Prim Site	1290
SCOPE	Rx Summ--Scope Reg LN Sur	1292
SURGOTH	Rx Summ--Surg Other Reg/Dis	1294
NNODES	Rx Reg LN Examined	1296
RXSUMMSURGICALMARGINS	RX Summ--Surgical Margins	1320
SURGRCON	Rx Summ--Reconstruct 1 st	1330
NOSURG	Reason for No Surgery	1340
DX_STG_SUM	RX Summ--DX/Stg Proc	1350
RADSUM	RX Summ--Radiation	1360
RADSEQ	RX Summ--Surg/Rad Seq	1380
CHEMOSUM	RX Summ--Chemo	1390
HORMSUM	RX Summ--Hormone	1400
IMMUSUM	RX Summ--BRM	1410
OTHSUM	RX Summ--Other	1420
NORAD	Reason for No Radiation	1430
PHASEIDOSEFRACT	Phase I Dose Per Fraction	1501
PHASEIBEAMTECH	Phase I Radiation External Beam Planning Tech	1502
PHASEINUMFRACT	Phase I Number of Fractions	1503
PHASEIPRIMTXVOL	Phase I Radiation Primary Treatment Volume	1504
PHASEIIRTOLN	Phase I Radiation to Draining Lymph Nodes	1505
PHASEIIRTMODALITY	Phase I Radiation Treatment Modality	1506
PHASEITOTALDOSE	Phase I Total Dose	1507
PHASEIIDOSEFRACT	Phase II Dose Per Fraction	1511
PHASEIIBEAMTECH	Phase II Radiation External Beam Planning Tech	1512
PHASEIINUMFRACT	Phase II Number of Fractions	1513
PHASEIIPRIMTXVOL	Phase II Radiation Primary Treatment Volume	1514
PHASEIIRTOLN	Phase II Radiation to Draining Lymph Nodes	1515
PHASEIIRTMODALITY	Phase II Radiation Treatment Modality	1516
PHASEIITOTALDOSE	Phase II Total Dose	1517
PHASEIIIDOSEFRACT	Phase III Dose Per Fraction	1521
PHASEIIIBEAMTECH	Phase III Radiation External Beam Planning Tech	1522
PHASEIIINUMFRACT	Phase III Number of Fractions	1523
PHASEIIIPRIMTXVOL	Phase III Radiation Primary Treatment Volume	1524
PHASEIIIRTOLN	Phase III Radiation to Draining Lymph Nodes	1525
PHASEIIIRTMODALITY	Phase III Radiation Treatment Modality	1526

PHASEIIITOTALDOSE	Phase III Total Dose	1527
RTDISCONTEARLY	Radiation Treatment Discontinued Early	1531
NUMPHASESRTTOVOL	Number of Phases of Rad Treatment to This Volume	1532
TOTALDOSE	Total Dose	1533
RADREGMOD	Rad--Regional RX Modality	1570
RXSUMMSYSTEMICSURSEQ	RX Summ--Systemic Sur Seq	1639
FUDATE	Date of Last Contact	1750
DATEOFLASTCONTACTFLAG	Date of Last Contact Flag	1751
VITSTAT	Vital Status	1760
TUSTAT	Cancer Status	1770
DATE_LAST_PAT_FU	Date of Last Cancer (Tumor) Status	1772
RECORD_ORDER	Record Number Recode	1775
SURV_DATELC_ACT	Surv-Date Active Followup	1782
SURV_FLAG_ACT	Surv-Flag Active Followup	1783
SURV_MON_ACT	Surv-Mos Active Followup	1784
SURV_DATELC_PSU	Surv-Date Presumed Alive	1785
SURV_FLAG_PSU	Surv-Flag Presumed Alive	1786
SURV_MON_PSU	Surv-Mos Presumed Alive	1787
SURV_DATEDX_RECODE	Surv-Date DX Recode	1788
CONCITY	Addr Current--City	1810
CONSTATE	Addr Current--State	1820
CONZIP	Addr Current--Postal Code	1830
ADDRCURRENTCOUNTRY	Addr Current--Country	1832
FOLLOWUPCONTACTCOUNTRY	Follow-Up Contact--Country	1847
CDEATH	Cause of Death	1910
SEER_CSDC	SEER Cause Specific Death Classification	1914
SEER_OTHDC	SEER Other Cause of Death Classification	1915
ICDREVISIONNUMBER	ICD Revision Number	1920
PLACEOFDEATHSTATE	Place of Death--State	1942
PLACEOFDEATHCOUNTRY	Place of Death--Country	1944
ORSSNODESPOS	Over-ride SS/NodesPos	1981
ORSSTNMN	Over-ride SS/TNM-N	1982
ORSSTNMM	Over-ride SS/TNM-M	1983
ORSITETNMSTGGRP	Over-ride Site/TNM-STGGRP	1989
ORAGST	Over-ride Age/Site/Morph	1990
ORSQDX	Over-ride SeqNo/DxConf	2000
ORSTSQ	Over-ride Site/Lat/SeqNo	2010
ORSUDX	Over-ride Surg/DxConf	2020

ORSTTY	Over-ride Site/Type	2030
ORHIST	Over-ride Histology	2040
ORDCSQ	Over-ride Report Source	2050
ORILDEF	Over-ride Ill-Define Site	2060
ORLLDX	Over-ride Leuk, Lymphoma	2070
ORSTBEH	Over-ride Site/Behavior	2071
ORLATEOD	Over-ride Site/Lat/EOD	2073
ORLATHIS	Over-ride Site/Lat/Morph	2074
ORNMSX	Over-ride Name/Sex	2078
OVRDNAMESEX	Over-ride flag Sex, Name-First, Date of Birth	2078
COCACCREDITEDFLAG	CoC Accredited Flag	2152
STYPEFU	SEER Type of Follow-Up	2180
LNAME	Name--Last	2230
FNAME	Name--First	2240
MIDLNAME	Name--Middle	2250
SUFFIX	Name--Suffix	2270
SSNO	Social Security Number	2320
DXADDR	Addr at DX--No & Street	2330
DXADDR_S	Addr at DX--Supplemental	2335
CONADDR	Address Current--No & Street	2350
LATITUDE	Latitude	2352
LONGITUDE	Longitude	2354
CONADDR_S	Addr Current--Supplemental	2355
PHONE	Telephone	2360
MAIDNAME	Name--Maiden	2390
DRATTEND	Physician--Managing	2460
DRFOLLOW	Physician--Follow-Up	2470
DRSURG	Physician--Primary Surg	2480
DRRADONC	Radiation Oncologist	2490
DRMEDONC	Medical Oncologist	2500
CS_TUM_SIZE	CS Tumor Size	2800
CS_EXT	CS Extension	2810
CS_TS_EXT_EVAL	CS Tumor Size/Ext Eval	2820
CS_LN	CS Lymph Nodes	2830
CS_REG_LN_EVAL	CS Lymph Nodes Eval	2840
CS_METS_DX	CS Mets at DX	2850
CSMETSATDXBONE	CS Mets at Dx-Bone	2851
CSMETSATDXBRAIN	CS Mets at Dx-Brain	2852
CSMETSATDXLIVER	CS Mets at Dx-Liver	2853

CSMETSATDXLUNG	CS Mets at Dx-Lung	2854
CS_METS_EVAL	CS Mets Eval	2860
CSSITESPECIFICFACTOR7	CS Site Specific Factor 7	2861
CSSITESPECIFICFACTOR8	CS Site Specific Factor 8	2862
CSSITESPECIFICFACTOR9	CS Site Specific Factor 9	2863
CSSITESPECIFICFACTOR10	CS Site Specific Factor 10	2864
CSSITESPECIFICFACTOR11	CS Site Specific Factor 11	2865
CSSITESPECIFICFACTOR12	CS Site Specific Factor 12	2866
CSSITESPECIFICFACTOR13	CS Site Specific Factor 13	2867
CSSITESPECIFICFACTOR14	CS Site Specific Factor 14	2868
CSSITESPECIFICFACTOR15	CS Site Specific Factor 15	2869
CSSITESPECIFICFACTOR16	CS Site Specific Factor 16	2870
CSSITESPECIFICFACTOR17	CS Site Specific Factor 17	2871
CSSITESPECIFICFACTOR18	CS Site Specific Factor 18	2872
CSSITESPECIFICFACTOR19	CS Site Specific Factor 19	2873
CSSITESPECIFICFACTOR20	CS Site Specific Factor 20	2874
CSSITESPECIFICFACTOR21	CS Site Specific Factor 21	2875
CSSITESPECIFICFACTOR22	CS Site Specific Factor 22	2876
CSSITESPECIFICFACTOR23	CS Site Specific Factor 23	2877
CSSITESPECIFICFACTOR24	CS Site Specific Factor 24	2878
CSSITESPECIFICFACTOR25	CS Site Specific Factor 25	2879
CS_SITE_SPEC_F1	CS Site Specific Factor 1	2880
CS_SITE_SPEC_F2	CS Site Specific Factor 2	2890
CS_SITE_SPEC_F3	CS Site Specific Factor 3	2900
CS_SITE_SPEC_F4	CS Site Specific Factor 4	2910
CS_SITE_SPEC_F5	CS Site Specific Factor 5	2920
CS_SITE_SPEC_F6	CS Site Specific Factor 6	2930
CSVERSIONINPUTORIGINAL	CS Version Input Original	2935
CSVERSIONDERIVED	CS Version Derived	2936
CSVERSIONINPUTCURRENT	CS Version Input Current	2937
DERIVED_AJCC_T	Derived AJCC-6 T	2940
DERIVED_AJCC_T_DESC	Derived AJCC-6 T Descript	2950
DERIVED_AJCC_N	Derived AJCC-6 N	2960
DERIVED_AJCC_N_DESC	Derived AJCC-6 N Descript	2970
DERIVED_AJCC_M	Derived AJCC-6 M	2980
DERIVED_AJCC_M_DESC	Derived AJCC-6 M Descript	2990
DERIVED_AJCC_STG_GRP	Derived AJCC-6 Stage Grp	3000
DERIVED_SS1977	SEER Summary Stage 1977 Dervied from CS, 2004-2015	3010

DERIVED_SS2000	SEER Summary Stage 2000 Derived from CS	3020
DERIVED_AJCC_FLAG	Derived AJCC Flag	3030
DERIVED_SS1977_FLAG	Was SEER Summary Stage 1977 coded directly or was it derived from CS or EOD?	3040
DERIVED_SS2000_FLAG	Was SEER Summary Stage 2000 coded directly or was it derived from CS or EOD?	3050
COMORBIDCOMPLICATION1	Comorbid/Complication 1	3110
COMORBIDCOMPLICATION2	Comorbid/Complication 2	3120
COMORBIDCOMPLICATION3	Comorbid/Complication 3	3130
COMORBIDCOMPLICATION4	Comorbid/Complication 4	3140
COMORBIDCOMPLICATION5	Comorbid/Complication 5	3150
COMORBIDCOMPLICATION6	Comorbid/Complication 6	3160
COMORBIDCOMPLICATION7	Comorbid/Complication 7	3161
COMORBIDCOMPLICATION8	Comorbid/Complication 8	3162
COMORBIDCOMPLICATION9	Comorbid/Complication 9	3163
COMORBIDCOMPLICATION10	Comorbid/Complication 10	3164
ICDREVISIONCOMORBID	ICD Revision Comorbid	3165
DTDEFSURG	RX Date Mst Defn Surg	3170
RXDATEMSTDEFNSRGFLAG	RX Date Mst Defn Srg Flag	3171
RADBSTMOD	Rad Boost RX Modality	3200
DTSYSTEMIC	RX Date Systemic	3230
RXDATESYSTEMICFLAG	RX Date Systemic Flag	3231
TRANSSUM	RX Summ--Transplnt/Endocr	3250
DERIVEDAJCC7T	Derived AJCC-7 T	3400
DERIVEDAJCC7TDESCRIPT	Derived AJCC-7 T Descript	3402
DERIVEDAJCC7N	Derived AJCC-7 N	3410
DERIVEDAJCC7NDESCRIPT	Derived AJCC-7 N Descript	3412
DERIVEDAJCC7M	Derived AJCC-7 M	3420
DERIVEDAJCC7MDESCRIPT	Derived AJCC-7 M Descript	3422
DERIVEDAJCC7STAGEGRP	Derived AJCC-7 Stage Group	3430
DERIVEDSEERPATHSTGGRP	Derived SEER Path Stg Grp	3605
DERIVEDSEERCLINSTGGRP	Derived SEER Clin Stg Grp	3610
DERIVEDSEERCMBSTGGRP	Derived SEER Cmb Stg Grp	3614
DERIVEDSEERCOMBINEDT	Derived SEER Combined T	3616
DERIVEDSEERCOMBINEDN	Derived SEER Combined N	3618
DERIVEDSEERCOMBINEDM	Derived SEER Combined M	3620
DERIVEDSEERCMBTSRC	Derived SEER Cmb T Src	3622
DERIVEDSEERCMBNSRC	Derived SEER Cmb N Src	3624
DERIVEDSEERCMBMSRC	Derived SEER Cmb M Src	3626
NPCRDERIVEDCLINSTGGRP	NPCR Derived Clin Stg Grp	3650

NPCRDERIVEDPATHSTGGRP	NPCR Derived Path Stg Grp	3655
SEERSSF1	SEER Site-Specific Fact 1	3700
SECONDARYDIAGNOSIS1	Secondary Diagnosis 1	3780
SECONDARYDIAGNOSIS2	Secondary Diagnosis 2	3782
SECONDARYDIAGNOSIS3	Secondary Diagnosis 3	3784
SECONDARYDIAGNOSIS4	Secondary Diagnosis 4	3786
SECONDARYDIAGNOSIS5	Secondary Diagnosis 5	3788
SECONDARYDIAGNOSIS6	Secondary Diagnosis 6	3790
SECONDARYDIAGNOSIS7	Secondary Diagnosis 7	3792
SECONDARYDIAGNOSIS8	Secondary Diagnosis 8	3794
SECONDARYDIAGNOSIS9	Secondary Diagnosis 9	3796
SECONDARYDIAGNOSIS10	Secondary Diagnosis 10	3798
SCHEMAID	Schema ID	3800
CHROMOSOME1PLOH	Chromosome 1p: Loss of Heterozygosity (LOH)	3801
CHROMOSOME19QLOH	Chromosome 19q: Loss of Heterozygosity (LOH)	3802
ADENOIDCYSTICBSLD	Adenoid Cystic Basaloid Pattern	3803
ADENOPATHY	Adenopathy	3804
AFPPOSTORCHVALUE	AFP Post-Orchiectomy Lab Value	3805
AFPPOSTORCHRANGE	AFP Post-Orchiectomy Range	3806
AFPPREORCHVALUE	AFP Pre-Orchiectomy Lab Value	3807
AFPPREORCHRANGE	AFP Pre-Orchiectomy Range	3808
AFPPREINTERP	AFP Pretreatment Interpretation	3809
AFPPREVALUE	AFP Pretreatment Lab Value	3810
ANEMIA	Anemia	3811
BSYMPTOMS	B Symptoms	3812
BILIRUBINPREVALUE	Bilirubin Pretreatment Total Lab Value	3813
BILIRUBINPREUNIT	Bilirubin Pretreatment Unit of Measure	3814
BONEINVASION	Bone Invasion	3815
BRAINMOLMARKERS	Brain Molecular Markers	3816
BRESLOWTHICKNESS	Breslow Tumor Thickness	3817
CA125PREINTERP	CA-125 Pretreatment Interpretation	3818
CEAPREINTERP	CEA Pretreatment Interpretation	3819
CEAPREVALUE	CEA Pretreatment Lab Value	3820
CHROMOSOME3STATUS	Chromosome 3 Status	3821
CHROMOSOME8QSTAT	Chromosome 8q Status	3822
CRMARGIN	Circumferential Resection Margin (CRM)	3823
CREATININEPREVALU	Creatinine Pretreatment Lab Value	3824
CREATININEPREUNIT	Creatinine Pretreatment Unit of Measure	3825
ERPERCENTPOSORRNG	Estrogen Receptor Percent Positive or Range	3826

ERSUMMARY	Estrogen Receptor Summary	3827
ERTOTALALLRED	Estrogen Receptor Total Allred Score	3828
ESOPHEPICENTER	Esophagus and EGJ Tumor Epicenter	3829
ENECLINNOTHN	Extranodal Extension Clin (Non-Head and Neck)	3830
ENECLINHN	Extranodal Extension Head and Neck Clinical	3831
ENEPATHHN	Extranodal Extension Head and Neck Pathological	3832
ENEPATHNOTHN	Extranodal Extension Path (non-Head and Neck)	3833
EXTRAVASCMATRIX	Extravascular Matrix Patterns	3834
FIBROSSCORE	Fibrosis Score	3835
FIGOSTAGE	FIGO Stage	3836
GESTPROGNOSTINDEX	Gestational Trophoblastic Prognostic Scoring Index	3837
GLEASONPATCLIN	Gleason Patterns Clinical	3838
GLEASONPATPATH	Gleason Patterns Pathological	3839
GLEASONSCORECLIN	Gleason Score Clinical	3840
GLEASONSCOREPATH	Gleason Score Pathological	3841
GLEASONTERTIARYPT	Gleason Tertiary Pattern	3842
GRADECLIN	Grade Clinical	3843
GRADEPATH	Grade Pathological	3844
GRADEPOST	Grade Post Therapy	3845
HCGPOSTORCHVALUE	hCG Post-Orchiectomy Lab Value	3846
HCGPOSTORCHRANGE	hCG Post-Orchiectomy Range	3847
HCGPREORCHVALUE	hCG Pre-Orchiectomy Lab Value	3848
HCGPREORCHRANGE	hCG Pre-Orchiectomy Range	3849
HER2IHCSUMMARY	HER2 IHC Summary	3850
HER2ISHDUALNUM	HER2 ISH Dual Probe Copy Number	3851
HER2ISHDUALRATIO	HER2 ISH Dual Probe Ratio	3852
HER2ISHSINGLENUM	HER2 ISH Single Probe Copy Number	3853
HER2ISHSUMMARY	HER2 ISH Summary	3854
HER2OVERALLSUMM	HER2 Overall Summary	3855
HERITABLETRAIT	Heritable Trait	3856
HIGHRISKCYTOGENET	High Risk Cytogenetics	3857
HIGHRISKHISTFEAT	High Risk Histologic Features	3858
HIVSTATUS	HIV Status	3859
INRPROTIME	International Normalized Ratio Prothrombin Time	3860
IPSIADRENALINVOL	Ipsilateral Adrenal Gland Involvement	3861
JAK2	JAK2	3862
KI67	KI-67	3863
BEYONDCAPSULE	Invasion Beyond Capsule	3864
KITGENEIHHC	KIT Gene Immunohistochemistry	3865

KRAS	KRAS	3866
LDHPOSTORCHRANGE	LDH Post-Orchiectomy Range	3867
LDHPREORCHRANGE	LDH Pre-Orchiectomy Range	3868
LDHPRETLEVEL	LDH Pretreatment Level	3869
LDHUPPERNORMAL	LDH Upper Limits of Normal	3870
LNMETHODFEMING	LN Assessment Method Femoral-Inguinal	3871
LNMETHODPARAAORT	LN Assessment Method Para-Aortic	3872
LNMETHODPELVIC	LN Assessment Method Pelvic	3873
LNDISTANTMETHOD	LN Distant Assessment Method	3874
LNDISTMEDIASSCALN	LN Distant, Mediastinal, Scalene	3875
LNHNLEVELSI_III	LN Head and Neck Levels I-III	3876
LNHNLEVELSIV_V	LN Head and Neck Levels IV-V	3877
LNHNLEVELSVI_VII	LN Head and Neck Levels VI-VII	3878
LNHNLEVELSOTHER	LN Head and Neck Other	3879
LN_ITCS	LN Isolated Tumor Cells (ITC)	3880
LNLATERALITY	LN Laterality	3881
LNPOSAXLEVELSI_II	LN Positive Axillary Level I-II	3882
LN_SIZE	LN Size	3883
LN_FEMINGPARAAPELV	LN Status Femoral-Inguinal, Para-Aortic, Pelvic	3884
LYMPHOCYTOSIS	Lymphocytosis	3885
MAJORVEININVOLV	Major Vein Involvement	3886
BASALDIAMETER	Measured Basal Diameter	3887
THICKNESS	Measured Thickness	3888
METHYLATIONO6MGMT	Methylation of O6-Methylguanine-Methyltransferase	3889
MSI	Microsatellite Instability (MSI)	3890
MICROVASC_DENSITY	Microvascular Density	3891
MITOTICCOUNT_UVEA	Mitotic Count Uveal Melanoma	3892
MITOTICRATE_MELANO	Mitotic Rate Melanoma	3893
MULTIGENEMETHOD	Multigene Signature Method	3894
MULTIGENERESULTS	Multigene Signature Results	3895
NCCNIPI	NCCN International Prognostic Index (IPI)	3896
NUMCORESEXAM	Number of Cores Examined	3897
NUMCORESPOS	Number of Cores Positive	3898
NUMNODESEXAMPARAA	Number of Examined Para-Aortic Nodes	3899
NUMNODESEXAMPELV	Number of Examined Pelvic Nodes	3900
NUMNODESPOSPARAA	Number of Positive Para-Aortic Nodes	3901
NUMNODESPOSPELV	Number of Positive Pelvic Nodes	3902
ONCOTYPESCOREDCIS	Oncotype DX Recurrence Score-DCIS	3903

ONCOTYPERISKDCIS	Oncotype DX Risk Level-DCIS	3905
ONCOTYPERISKINVAS	Oncotype DX Risk Level-Invasive	3906
ORGANOMEGALY	Organomegaly	3907
PERCNTNECROSPST	Percent Necrosis Post Neoadjuvant	3908
PERINEURALINV	Perineural Invasion	3909
PERIPHBLOODINV	Peripheral Blood Involvement	3910
PERITONEALCYTOL	Peritoneal Cytology	3911
PLEURALEFFUSION	Pleural Effusion	3913
PRPERCENTPOSORRNG	Progesterone Receptor Percent Positive or Range	3914
PRSUMMARY	Progesterone Receptor Summary	3915
PRTOTALALLRED	Progesterone Receptor Total Allred Score	3916
PSCLERCHOLANGITIS	Primary Sclerosing Cholangitis	3917
IMMUNESUPP	Profound Immune Suppression	3918
PROSTATEPATHEXT	Prostate Pathological Extension	3919
PSAVALUE	PSA (Prostatic Specific Antigen) Lab Value	3920
RESIDPOSTCYTOREDU	Residual Tumor Volume Post Cytoreduction	3921
RSPNSTONEOADJUVT	Response to Neoadjuvant Therapy	3922
SCATCLIN	S Category Clinical	3923
SCATPATH	S Category Pathological	3924
SARCOMATOID	Sarcomatoid Features	3925
SCHEMADISC1	Schema Discriminator 1	3926
SCHEMADISC2	Schema Discriminator 2	3927
SCHEMADISC3	Schema Discriminator 3	3928
SEPNODULES	Separate Tumor Nodules	3929
ALBUMINPRETXLEVL	Serum Albumin Pretreatment Level	3930
BETA2MGPRETXLVL	Serum Beta-2 Microglobulin Pretreatment Level	3931
LDHPRETXVALUE	LDH Pretreatment Lab Value	3932
THROMBOCYTOPENIA	Thrombocytopenia	3933
TUMORDEPOSITS	Tumor Deposits	3934
TUMORGROWTHPAT	Tumor Growth Pattern	3935
ULCERATION	Ulceration	3936
PLEURALINV	Visceral and Parietal Pleural Invasion	3937
TOBACCOUSECIGARETTES	Tobacco Use Cigarettes	9965
TOBACCOUSEOTHERSMOKE	Tobacco Use Other Smoke	9966
TOBACCOUSESMOKELESS	Tobacco Use Smokeless	9967
TOBACCOUSENOS	Tobacco Use NOS	9968
ACOS	ACOS Approved	n/a
AGECAT	Age-Group	n/a
AYARECODE	SEER Site/Histology Recode for AYA(s)	n/a

BEHAVIOR	SEER Behavior Recode Variable	n/a
BELOW200	Percent Below 200% Poverty Line in Block Group, 1988-2005	n/a
BELOW200CT	Percent Below 200% Poverty Line in Census Tract, 1988-2005	n/a
BELOW200CTACS2011	Percent Below 200% Poverty Line in Census Tract, 2006 forward	n/a
BLKGRP00	Census Block 2000 (block and block group)	n/a
BLKGRP90	Census Block Group 1990 (block group only)	n/a
BLUECOLR	Proportion with Blue Color Job in Block Group, 1988-2005	n/a
BLUECOLRCT	Proportion with Blue Color Job in Census Tract, 1988-2005	n/a
BLUECOLRCTACS2011	Proportion with Blue Color Job in Census Tract, 2006 forward	n/a
CENSUSBLOCK2010	Census Block 2010 (block and block group)	n/a
CHRLSON	Charlson Comorbidity Index	n/a
CNTYFIPS	County FIPS Code	n/a
COC_FLAG	Patient seen at COC Accredited Cancer Program	n/a
CODPROC	Coding Proc	n/a
COLLEGE	Proportion in Block Group with College Degree, 1988-2005	n/a
COLLECT	Proportion in Census Tract with College Degree, 1988-2005	n/a
COLLECTACS2011	Proportion in Census Tract with College Degree, 2006 forward	n/a
DATESURGPRIMFIRSTFLAG	Date Surg Prim First Flag	n/a
DC_FATHERS_SURNAME	Father's Surname as Stated on Death Certificate	n/a
DCBIRTHPL	Birthplace on Death Certificate	n/a
DCFILENO	Death Certificate State File Number	n/a
DCRACE	Race on Death Certificate	n/a
DCSPANISH	Spanish Origin on Death Certificate	n/a
DCSSN_FLAG	Was Death Certificate Social Security Number Used to Get Year of Issue Flag	n/a
DCSSNO	Social Security Number on Death Certificate	n/a
DCSTATE	Issuing State of Death Certificate	n/a
DEN	Density of 1990 MSSA	n/a
DROTHER1	Other Physician, Listed First	n/a
DROTHER2	Other Physician, Listed Second	n/a
DRREF	Physician--Referring	n/a

DTTRANSP	RX Date Transp Endo	n/a
EDINDEX	Average Years of Schooling in Block Group, 1988-2005	n/a
EDINDEXACS2011	Average Years of Schooling in Census Tract, 2006 forward	n/a
EDINDEXACS2011MOE	Margin of Error for EDINDEXACS2011	n/a
EDINDEXCT	Average Years of Schooling in Census Tract, 1988-2005	n/a
FNAMEMOM	Mother's first name	n/a
FUTYPPAT	Follow-Up Last Type Patient	n/a
FUTYPTUM	Follow-Up Last Type Tumor	n/a
FUYEAR	Year of Last Contact	n/a
HEIGHT	Height	n/a
HISPSURN	Hispanic Surname Flag	n/a
HMNGSURN	Hmong Surname Flag	n/a
ICCCWHO	SEER Recode of the International Classification of Childhood Cancer	n/a
INDUS80	Industry 80	n/a
INDUS90	Industry 90	n/a
MAIDSURN	Hispanic Maiden Name Flag	n/a
MARKERCA	Tum Marker CA 1	n/a
MCODE	EOD Derived M value for TNM Staging, 1988-2003	n/a
MDINC	Median Household Income in Block Group, 1988-2005	n/a
MDINCCT	Median Household Income in Census Tract, 1988-2005	n/a
MDINCCTACS2011	Median Household Income in Census Tract, 2006 forward	n/a
MEDRENT	Median Gross Rent in Block Group, 1988-2005	n/a
MEDRENTCT	Median Gross Rent, CT-level, 1988-2005	n/a
MEDRENTCTACS2011	Median Gross Rent, CT-level, 2006 forward	n/a
MEDVALUE	Median Value of Homes in Block Group, 1988-2005	n/a
MEDVALUECT	Median Value of Homes in Census Tract, 1988-2005	n/a
MEDVALUECTACS2011	Median Value of Homes in Census Tract, 2006 forward	n/a
MSSAID	Medical Service Study Area ID	n/a
MSSANAME	Medical Service Study Area Name	n/a
NCCN_FLAG	Patient seen at Nat'l Comprehensive Cancer Network Facility	n/a
NCI_FLAG	Patient seen at NCI-Designated Cancer Center	n/a

NCODE	EOD Derived N value for TNM Staging, 1988-2003	n/a
NOCONTAC	Patient No Contact	n/a
NOEDUC	Proportion in Block Group without High School Diploma, 1988-2005	n/a
NOEDUCCT	Proportion in Census Tract without High School Diploma, 1988-2005	n/a
NOEDUCCTACS2011	Proportion in Census Tract without High School Diploma, 2006 forward	n/a
NOJOB	Proportion Unemployed in Block Group, 1988-2005	n/a
NOJOBCT	Proportion Unemployed in Census Tract, 1988-2005	n/a
NOJOBCTACS2011	Proportion Unemployed in Census Tract, 2006 forward	n/a
NONRURAL	Rural/Urban Designation of 1990 MSSA, 1988-1995	n/a
OCCUP80	Occupation 80	n/a
OCCUP90	Occupation 90	n/a
ORADDX	Over-ride Admis DX	n/a
ORRACE	Over-ride Race BPL	n/a
ORSPAN	Over-ride Spanish BPL	n/a
ORSTSTG	Over-ride Site Stage	n/a
PAYER2	Pay Source 2	n/a
PROTOCOL	Protocol Participation	n/a
QME	Middle Eastern Surname Flag	n/a
QUINYANG	SES Quintile of YANGSCL, Block Group-level, 2006 forward	n/a
QUINYANGIMPUTED	SES Quintile of YANGSCLIMPUTED, Block Group-level, 2006 forward	n/a
QUINYOST	SES Quintile of YOSTSCL, Block Group-level, 1988-2005	n/a
RACEGROUP	California's Custom Race Group	n/a
RACEME	California's Custom Race Group with Category for Middle Eastern	n/a
RANDOM	Was Census Tract/Block Group randomly assigned?	n/a
RELIGION	Religion	n/a
RESREG	CCR Region ID	n/a
RUCA	USDA Rural-Urban Commuting Area, CT-level	n/a
RURALMSSA00	Rural/Urban Designation of 2000 MSSA, 1996-2005	n/a
RURALMSSA10	Rural/Urban Designation of 2010 MSSA, 2006 forward	n/a
RURALMSSA90	Rural/Urban Designation of 1990 MSSA, 1988-1995	n/a
RXDATETRANSPLNTENDOCRFLAG	RX Date Transp Endo Flag	n/a

SEERWHO	SEER Site/Histology Recode	n/a
SOURCECOMORBIDITY	Data Source from which Comorbidities/Complications were Collected	n/a
SPANSURN	Spanish Surname on 1980 Census List	n/a
SRCSUR	Source of Middle Eastern Surname	n/a
STAGE	Consolidated AJCC Stage Variable	n/a
STAGE_AJCC	EOD recode to AJCC Stage	n/a
STAGE_AJCCSEER	EOD recode to AJCC stage modified by SEER	n/a
STAGE_ALTERNATE	Any other staging system and value	n/a
STAGE_SEER	Consolidated AJCC Stage Variable, SEER Modified	n/a
SUMSTAGE	Consolidated Summary Stage Variable	n/a
TCODE	EOD Derived T value for TNM Staging, 1988-2003	n/a
TUMOR_ID	Tumor ID	n/a
TUMORSIZE	Consolidated Tumor Size Variable for All Years of Diagnosis	n/a
TYPEADM	Type Admis	n/a
VAHOSP	Flag to Indicate if Report Came from a VA Facility	n/a
VIETSURN	Vietnamese Surname Flag	n/a
WEIGHT	Weight	n/a
YANGRELIABILITY	Reliability of YANGSCL & YANGSCLIMPUTED	n/a
YANGSCL	Index of SES, Block Group-level, 2006 and forward	n/a
YANGSCLIMPUTED	Index of SES with Missing Values Imputed, Block Group-level, 2006 and forward	n/a
YANGSCLMISS	Missingness of Components in YANGSCL	n/a
YEARDX	Year of Diagnosis	n/a
YOSTSCL	Index of SES, Block Group-level, 1988-2005	n/a
YR_SSNISSUED	Year Social Security Number was Issued	n/a